A BILL 
To provide for certain reforms with respect to the Medicare 
program under title XVIII of the Social Security Act, 
the Medicaid program under title XIX of such Act, the 
Food and Drug Administration, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Lower Costs, More 
4
Cures Act of 2019’’. 
5
SEC. 2. TABLE OF CONTENTS. 
6
The table of contents for this Act is as follows: 
7
Sec. 1. Short title. 
Sec. 2. Table of contents. 
TITLE I—MEDICARE PARTS B AND D 
Subtitle A—Medicare Part B Provisions 
Sec. 101. Improvements to Medicare site-of-service transparency. 
Sec. 102. Requiring manufacturers of certain single-dose container or single-use 
package drugs payable under part B of the Medicare program 
to provide refunds with respect to discarded amounts of such 
drugs. 
Sec. 103. Providing for variation in payment for certain drugs covered under 
part B of the Medicare program. 
Sec. 104. Establishment of maximum add-on payment for drugs and 
biologicals. 
Sec. 105. Treatment of drug administration services furnished by certain ex-
cepted off-campus outpatient departments of a provider. 
Subtitle B—Drug Price Transparency 
Sec. 111. Reporting on explanation for drug price increases. 
Sec. 112. Public disclosure of drug discounts. 
04:12 Dec 12, 2019
H19
3 
•HR 19 IH
Sec. 113. Study of pharmaceutical supply chain intermediaries and merger ac-
tivity. 
Sec. 114. Requiring certain manufacturers to report drug pricing information 
with respect to drugs under the Medicare program. 
Sec. 115. Making prescription drug marketing sample information reported by 
manufacturers available to certain individuals and entities. 
Sec. 116. Requiring prescription drug plan sponsors to include real-time benefit 
information as part of such sponsor’s electronic prescription 
program under the Medicare program. 
Sec. 117. Sense of Congress regarding the need to expand commercially avail-
able drug pricing comparison platforms. 
Sec. 118. Technical corrections. 
Subtitle C—Medicare Part D Benefit Redesign 
Sec. 121. Medicare part D benefit redesign. 
Subtitle D—Other Medicare Part D Provisions 
Sec. 131. Transitional coverage and retroactive Medicare part D coverage for 
certain low-income beneficiaries. 
Sec. 132. Allowing the offering of additional prescription drug plans under 
Medicare part D. 
Sec. 133. Allowing certain enrollees of prescription drugs plans and MA–PD 
plans under Medicare program to spread out cost-sharing 
under certain circumstances. 
Sec. 134. Establishing a monthly cap on beneficiary incurred costs for insulin 
products and supplies under a prescription drug plan or MA– 
PD plan. 
Sec. 135. Growth rate of Medicare part D out-of-pocket cost threshold. 
Subtitle E—MedPAC 
Sec. 141. Providing the Medicare Payment Advisory Commission and Medicaid 
and CHIP Payment and Access Commission with access to cer-
tain drug payment information, including certain rebate infor-
mation. 
TITLE II—MEDICAID 
Sec. 201. Sunset of limit on maximum rebate amount for single source drugs 
and innovator multiple source drugs. 
Sec. 202. Medicaid pharmacy and therapeutics committee improvements. 
Sec. 203. GAO report on conflicts of interest in State Medicaid program drug 
use review boards and pharmacy and therapeutics (P&T) com-
mittees. 
Sec. 204. Ensuring the accuracy of manufacturer price and drug product infor-
mation under the Medicaid drug rebate program. 
Sec. 205. Improving transparency and preventing the use of abusive spread 
pricing and related practices in Medicaid. 
Sec. 206. T–MSIS drug data analytics reports. 
Sec. 207. Risk-sharing value-based payment agreements for covered outpatient 
drugs under Medicaid. 
Sec. 208. Applying Medicaid drug rebate requirement to drugs provided as part 
of outpatient hospital services. 
TITLE III—FOOD AND DRUG ADMINISTRATION 
04:12 Dec 12, 2019
H19
4 
•HR 19 IH
Subtitle A—CREATES Act 
Sec. 301. Actions for delays of generic drugs and biosimilar biological products. 
Sec. 302. REMS approval process for subsequent filers. 
Sec. 303. Rule of construction. 
Subtitle B—Pay-for-Delay 
Sec. 311. Unlawful agreements. 
Sec. 312. Notice and certification of agreements. 
Sec. 313. Forfeiture of 180-day exclusivity period. 
Sec. 314. Commission litigation authority. 
Sec. 315. Statute of limitations. 
Subtitle C—BLOCKING Act 
Sec. 321. Change conditions of first generic exclusivity to spur access and com-
petition. 
Subtitle D—Purple Book 
Sec. 331. Public listing. 
Sec. 332. Review and report on types of information to be listed. 
Subtitle E—Orange Book 
Sec. 341. Orange Book. 
Sec. 342. GAO report to Congress. 
Subtitle F—Advancing Education on Biosimilars 
Sec. 351. Education on biological products. 
Subtitle G—Streamlining Transition of Biological Products 
Sec. 361. Streamlining the transition of biological products. 
Subtitle H—Over-the-Counter Monograph Safety, Innovation, and Reform 
Sec. 370. Short title; references in subtitle. 
PART 1—OTC DRUG REVIEW 
Sec. 371. Regulation of certain nonprescription drugs that are marketed with-
out an approved drug application. 
Sec. 372. Misbranding. 
Sec. 373. Drugs excluded from the over-the-counter drug review. 
Sec. 374. Treatment of Sunscreen Innovation Act. 
Sec. 375. Annual update to Congress on appropriate pediatric indication for 
certain OTC cough and cold drugs. 
Sec. 376. Technical corrections. 
PART 2—USER FEES 
Sec. 381. Short title; finding. 
Sec. 382. Fees relating to over-the-counter drugs. 
Subtitle I—Other Provisions 
Sec. 391. Protecting access to biological products. 
04:12 Dec 12, 2019
H19
5 
•HR 19 IH
Sec. 392. Orphan drug clarification. 
Sec. 393. Conditions of use for biosimilar biological products. 
Sec. 394. Clarifying the meaning of new chemical entity. 
TITLE IV—REVENUE PROVISIONS 
Sec. 401. Permanent extension of reduction in medical expense deduction floor. 
Sec. 402. Safe harbor for high deductible health plans without deductible for 
insulin. 
Sec. 403. Inclusion of certain over-the-counter medical products as qualified 
medical expenses. 
TITLE V—MISCELLANEOUS 
Sec. 501. Payment for biosimilar biological products during initial period. 
Sec. 502. GAO study and report on average sales price. 
Sec. 503. Requiring prescription drug plans and MA–PD plans to report poten-
tial fraud, waste, and abuse to the Secretary of HHS. 
Sec. 504. Establishment of pharmacy quality measures under Medicare part D. 
Sec. 505. Improving coordination between the Food and Drug Administration 
and the Centers for Medicare & Medicaid Services. 
Sec. 506. Patient consultation in Medicare national and local coverage deter-
minations in order to mitigate barriers to inclusion of such per-
spectives. 
Sec. 507. MedPAC report on shifting coverage of certain Medicare part B 
drugs to Medicare part D. 
Sec. 508. Requirement that direct-to-consumer advertisements for prescription 
drugs and biological products include truthful and non-mis-
leading pricing information. 
Sec. 509. Chief Pharmaceutical Negotiator at the Office of the United States 
Trade Representative. 
Sec. 510. Waiving Medicare coinsurance for colorectal cancer screening tests. 
TITLE I—MEDICARE PARTS B 
1
AND D 
2
Subtitle A—Medicare Part B 
3
Provisions 
4
SEC. 101. IMPROVEMENTS TO MEDICARE SITE-OF-SERVICE 
5
TRANSPARENCY. 
6
Section 1834(t) of the Social Security Act (42 U.S.C. 
7
1395m(t)) is amended— 
8
(1) in paragraph (1)— 
9
(A) in the heading, by striking ‘‘IN GEN-
10
ERAL’’ and inserting ‘‘SITE PAYMENT’’; 
11
04:12 Dec 12, 2019
H19
6 
•HR 19 IH
(B) in the matter preceding subparagraph 
1
(A)— 
2
(i) by striking ‘‘or to’’ and inserting ‘‘, 
3
to’’; 
4
(ii) by inserting ‘‘, or to a physician 
5
for services furnished in a physician’s of-
6
fice’’ after ‘‘surgical center’’; and 
7
(iii) by inserting ‘‘(or 2021 with re-
8
spect to a physician for services furnished 
9
in a physician’s office)’’ after ‘‘2018’’; and 
10
(C) in subparagraph (A)— 
11
(i) by striking ‘‘and the’’ and insert-
12
ing ‘‘, the’’; and 
13
(ii) by inserting ‘‘, and the physician 
14
fee schedule under section 1848 (with re-
15
spect to the practice expense component of 
16
such payment amount)’’ after ‘‘such sec-
17
tion’’; 
18
(2) by redesignating paragraphs (2) through 
19
(4) as paragraphs (3) through (5), respectively; and 
20
(3) by inserting after paragraph (1) the fol-
21
lowing new paragraph: 
22
‘‘(2) 
PHYSICIAN
PAYMENT.—Beginning 
in 
23
2021, the Secretary shall expand the information in-
24
04:12 Dec 12, 2019
H19
7 
•HR 19 IH
cluded on the Internet website described in para-
1
graph (1) to include— 
2
‘‘(A) the amount paid to a physician under 
3
section 1848 for an item or service for the set-
4
tings described in paragraph (1); and 
5
‘‘(B) the estimated amount of beneficiary 
6
liability applicable to the item or service.’’. 
7
SEC. 102. REQUIRING MANUFACTURERS OF CERTAIN SIN-
8
GLE-DOSE CONTAINER OR SINGLE-USE PACK-
9
AGE DRUGS PAYABLE UNDER PART B OF THE 
10
MEDICARE PROGRAM TO PROVIDE REFUNDS 
11
WITH RESPECT TO DISCARDED AMOUNTS OF 
12
SUCH DRUGS. 
13
Section 1847A of the Social Security Act (42 U.S.C. 
14
1395–3a) is amended by adding at the end the following 
15
new subsection: 
16
‘‘(h) REFUND FOR CERTAIN DISCARDED SINGLE- 
17
DOSE CONTAINER OR SINGLE-USE PACKAGE DRUGS.— 
18
‘‘(1) SECRETARIAL
PROVISION
OF
INFORMA-
19
TION.— 
20
‘‘(A) IN
GENERAL.—For each calendar 
21
quarter beginning on or after July 1, 2021, the 
22
Secretary shall, with respect to a refundable 
23
single-dose container or single-use package drug 
24
(as defined in paragraph (8)), report to each 
25
04:12 Dec 12, 2019
H19
8 
•HR 19 IH
manufacturer 
(as 
defined 
in 
subsection 
1
(c)(6)(A)) of such refundable single-dose con-
2
tainer or single-use package drug the following 
3
for the calendar quarter: 
4
‘‘(i) Subject to subparagraph (C), in-
5
formation on the total number of units of 
6
the billing and payment code of such drug, 
7
if any, that were discarded during such 
8
quarter, as determined using a mechanism 
9
such as the JW modifier used as of the 
10
date of enactment of this subsection (or 
11
any such successor modifier that includes 
12
such data as determined appropriate by 
13
the Secretary). 
14
‘‘(ii) The refund amount that the 
15
manufacturer is liable for pursuant to 
16
paragraph (3). 
17
‘‘(B) 
DETERMINATION
OF
DISCARDED 
18
AMOUNTS.—For 
purposes 
of 
subparagraph 
19
(A)(i), with respect to a refundable single-dose 
20
container or single-use package drug furnished 
21
during a quarter, the amount of such drug that 
22
was discarded shall be determined based on the 
23
amount of such drug that was unused and dis-
24
carded for each drug on the date of service. 
25
04:12 Dec 12, 2019
H19
9 
•HR 19 IH
‘‘(C) EXCLUSION OF UNITS OF PACKAGED 
1
DRUGS.—The total number of units of the bill-
2
ing and payment code of a refundable single- 
3
dose container or single-use package drug of a 
4
manufacturer furnished during a calendar quar-
5
ter for purposes of subparagraph (A)(i), and 
6
the determination of the estimated total allowed 
7
charges for the drug in the quarter for purposes 
8
of paragraph (3)(A)(ii), shall not include such 
9
units that are packaged into the payment 
10
amount for an item or service and are not sepa-
11
rately payable. 
12
‘‘(2) 
MANUFACTURER
REQUIREMENT.—For 
13
each calendar quarter beginning on or after July 1, 
14
2021, the manufacturer of a refundable single-dose 
15
container or single-use package drug shall, for such 
16
drug, provide to the Secretary a refund that is equal 
17
to the amount specified in paragraph (3) for such 
18
drug for such quarter. 
19
‘‘(3) REFUND AMOUNT.— 
20
‘‘(A) IN GENERAL.—The amount of the re-
21
fund specified in this paragraph is, with respect 
22
to a refundable single-dose container or single- 
23
use package drug of a manufacturer assigned to 
24
a billing and payment code for a calendar quar-
25
04:12 Dec 12, 2019
H19
10 
•HR 19 IH
ter beginning on or after July 1, 2021, an 
1
amount equal to the estimated amount (if any) 
2
by which— 
3
‘‘(i) the product of— 
4
‘‘(I) the total number of units of 
5
the billing and payment code for such 
6
drug that were discarded during such 
7
quarter (as determined under para-
8
graph (1)); and 
9
‘‘(II)(aa) in the case of a refund-
10
able single-dose container or single- 
11
use package drug that is a single 
12
source drug or biological, the amount 
13
determined for such drug under sub-
14
section (b)(4); or 
15
‘‘(bb) in the case of a refundable 
16
single-dose container or single-use 
17
package drug that is a biosimilar bio-
18
logical product, the average sales price 
19
determined 
under 
subsection 
20
(b)(8)(A); exceeds 
21
‘‘(ii) an amount equal to the applica-
22
ble percentage (as defined in subparagraph 
23
(B)) of the estimated total allowed charges 
24
for such drug during the quarter. 
25
04:12 Dec 12, 2019
H19
11 
•HR 19 IH
‘‘(B) 
APPLICABLE
PERCENTAGE
DE-
1
FINED.— 
2
‘‘(i) IN
GENERAL.—For purposes of 
3
subparagraph (A)(ii), the term ‘applicable 
4
percentage’ means— 
5
‘‘(I) subject to subclause (II), 10 
6
percent; and 
7
‘‘(II) if applicable, in the case of 
8
a refundable single-dose container or 
9
single-use package drug described in 
10
clause (ii), a percentage specified by 
11
the Secretary pursuant to such clause. 
12
‘‘(ii) TREATMENT
OF
DRUGS
THAT 
13
HAVE
UNIQUE
CIRCUMSTANCES.—In the 
14
case of a refundable single-dose container 
15
or single-use package drug that has unique 
16
circumstances involving similar loss of 
17
product as that described in paragraph 
18
(8)(B), the Secretary, through notice and 
19
comment rulemaking, may increase the ap-
20
plicable percentage otherwise applicable 
21
under clause (i)(I) as determined appro-
22
priate by the Secretary. 
23
‘‘(4) FREQUENCY.—Amounts required to be re-
24
funded pursuant to paragraph (2) shall be paid in 
25
04:12 Dec 12, 2019
H19
12 
•HR 19 IH
regular intervals (as determined appropriate by the 
1
Secretary). 
2
‘‘(5) REFUND DEPOSITS.—Amounts paid as re-
3
funds pursuant to paragraph (2) shall be deposited 
4
into the Federal Supplementary Medical Insurance 
5
Trust Fund established under section 1841. 
6
‘‘(6) ENFORCEMENT.— 
7
‘‘(A) AUDITS.— 
8
‘‘(i) MANUFACTURER AUDITS.—Each 
9
manufacturer of a refundable single-dose 
10
container or single-use package drug that 
11
is required to provide a refund under this 
12
subsection shall be subject to periodic 
13
audit with respect to such drug and such 
14
refunds by the Secretary. 
15
‘‘(ii) PROVIDER
AUDITS.—The Sec-
16
retary shall conduct periodic audits of 
17
claims submitted under this part with re-
18
spect to refundable single-dose container or 
19
single-use package drugs in accordance 
20
with the authority under section 1833(e) to 
21
ensure compliance with the requirements 
22
applicable under this subsection. 
23
‘‘(B) CIVIL MONEY PENALTY.— 
24
04:12 Dec 12, 2019
H19
13 
•HR 19 IH
‘‘(i) IN
GENERAL.—The Secretary 
1
shall impose a civil money penalty on a 
2
manufacturer of a refundable single-dose 
3
container or single-use package drug who 
4
has failed to comply with the requirement 
5
under paragraph (2) for such drug for a 
6
calendar quarter in an amount equal to the 
7
sum of— 
8
‘‘(I) the amount that the manu-
9
facturer would have paid under such 
10
paragraph with respect to such drug 
11
for such quarter; and 
12
‘‘(II) 25 percent of such amount. 
13
‘‘(ii) APPLICATION.—The provisions 
14
of section 1128A (other than subsections 
15
(a) and (b)) shall apply to a civil money 
16
penalty under this subparagraph in the 
17
same manner as such provisions apply to a 
18
penalty 
or 
proceeding 
under 
section 
19
1128A(a). 
20
‘‘(7) IMPLEMENTATION.—The Secretary shall 
21
implement this subsection through notice and com-
22
ment rulemaking. 
23
‘‘(8) DEFINITION
OF
REFUNDABLE
SINGLE- 
24
DOSE CONTAINER OR SINGLE-USE PACKAGE DRUG.— 
25
04:12 Dec 12, 2019
H19
14 
•HR 19 IH
‘‘(A) IN GENERAL.—Except as provided in 
1
subparagraph (B), in this subsection, the term 
2
‘refundable single-dose container or single-use 
3
package drug’ means a single source drug or bi-
4
ological (as defined in section 1847A(c)(6)(D)) 
5
or a biosimilar biological product (as defined in 
6
section 1847A(c)(6)(H)) for which payment is 
7
established under this part and that is fur-
8
nished from a single-dose container or single- 
9
use package. 
10
‘‘(B) EXCLUSIONS.—The term ‘refundable 
11
single-dose container or single-use package 
12
drug’ does not include— 
13
‘‘(i) a drug or biological that is either 
14
a radiopharmaceutical or an imaging 
15
agent; 
16
‘‘(ii) a drug or biological for which 
17
dosage and administration instructions ap-
18
proved by the Commissioner of Food and 
19
Drugs require filtration during the drug 
20
preparation process, prior to dilution and 
21
administration, and require that any un-
22
used portion of such drug after the filtra-
23
tion process be discarded after the comple-
24
tion of such filtration process; or 
25
04:12 Dec 12, 2019
H19
15 
•HR 19 IH
‘‘(iii) a drug or biological approved by 
1
the Food and Drug Administration on or 
2
after the date of enactment of this sub-
3
section and with respect to which payment 
4
has been made under this part for less 
5
than 18 months.’’. 
6
SEC. 103. PROVIDING FOR VARIATION IN PAYMENT FOR 
7
CERTAIN DRUGS COVERED UNDER PART B 
8
OF THE MEDICARE PROGRAM. 
9
(a) IN GENERAL.—Section 1847A(b) of the Social 
10
Security Act (42 U.S.C. 1395w–3a(b)) is amended— 
11
(1) in paragraph (1)— 
12
(A) in subparagraph (A), by inserting after 
13
‘‘or 106 percent’’ the following: ‘‘(or, for a mul-
14
tiple source drug (other than autologous cellular 
15
immunotherapy) furnished on or after January 
16
1, 2021, the applicable percent specified in 
17
paragraph (9)(A) for the drug and quarter in-
18
volved)’’; and 
19
(B) in subparagraph (B) of paragraph (1), 
20
by inserting after ‘‘106 percent’’ the following: 
21
‘‘(or, for a single source drug or biological 
22
(other than autologous cellular immunotherapy) 
23
furnished on or after January 1, 2021, the ap-
24
plicable percent specified in paragraph (9)(A) 
25
04:12 Dec 12, 2019
H19
16 
•HR 19 IH
for the drug or biological and quarter in-
1
volved)’’; and 
2
(2) by adding at the end the following new 
3
paragraph: 
4
‘‘(9) APPLICATION OF VARIABLE PERCENTAGES 
5
BASED
ON
PERCENTILE
RANKING
OF
PER
BENE-
6
FICIARY ALLOWED CHARGES.— 
7
‘‘(A) APPLICABLE
PERCENT
TO
BE
AP-
8
PLIED.— 
9
‘‘(i) IN GENERAL.—Subject to clauses 
10
(ii), with respect to a drug or biological 
11
furnished in a calendar quarter beginning 
12
on or after January 1, 2021, if the Sec-
13
retary determines that the percentile rank 
14
of a drug or biological under subparagraph 
15
(B)(i)(III), with respect to per beneficiary 
16
allowed charges for all such drugs or 
17
biologicals, is— 
18
‘‘(I) at least equal to the 85th 
19
percentile, the applicable percent for 
20
the drug for such quarter under this 
21
subparagraph is 104 percent; 
22
‘‘(II) at least equal to the 70th 
23
percentile, but less than the 85th per-
24
04:12 Dec 12, 2019
H19
17 
•HR 19 IH
centile, such applicable percent is 106 
1
percent; 
2
‘‘(III) at least equal to the 50th 
3
percentile, but less than the 70th per-
4
centile, such applicable percent is 108 
5
percent; or 
6
‘‘(IV) less than the 50th per-
7
centile, such applicable percent is 110 
8
percent. 
9
‘‘(ii) CASES WHERE DATA NOT SUFFI-
10
CIENTLY
AVAILABLE
TO
COMPUTE
PER 
11
BENEFICIARY
ALLOWED
CHARGES.—Sub-
12
ject to clause (iii), in the case of a drug or 
13
biological furnished for which the amount 
14
of payment is determined under subpara-
15
graph (A) or (B) of paragraph (1) and not 
16
under subsection (c)(4), for calendar quar-
17
ters during a period in which data are not 
18
sufficiently available to compute a per ben-
19
eficiary allowed charges for the drug or bi-
20
ological, the applicable percent is 106 per-
21
cent. 
22
‘‘(B) DETERMINATION
OF
PERCENTILE 
23
RANK OF PER BENEFICIARY ALLOWED CHARGES 
24
OF DRUGS.— 
25
04:12 Dec 12, 2019
H19
18 
•HR 19 IH
‘‘(i) IN GENERAL.—With respect to a 
1
calendar quarter beginning on or after 
2
January 1, 2021, for drugs and biologicals 
3
for which the amount of payment is deter-
4
mined under subparagraph (A) or (B) of 
5
paragraph 
(1), 
except 
for 
drugs 
or 
6
biologicals for which data are not suffi-
7
ciently available, the Secretary shall— 
8
‘‘(I) compute the per beneficiary 
9
allowed charges (as defined in sub-
10
paragraph (C)) for each such drug or 
11
biological; 
12
‘‘(II) adjust such per beneficiary 
13
allowed charges for the quarter, to the 
14
extent provided under subparagraph 
15
(D); and 
16
‘‘(III) array such adjusted per 
17
beneficiary allowed charges for all 
18
such drugs or biologicals from high to 
19
low and rank such drugs or biologicals 
20
by percentile of such arrayed per ben-
21
eficiary allowed charges. 
22
‘‘(ii) 
FREQUENCY.—The 
Secretary 
23
shall make the computations under clause 
24
(i)(I) every 6 months (or, if necessary, as 
25
04:12 Dec 12, 2019
H19
19 
•HR 19 IH
determined by the Secretary, every 9 or 12 
1
months) and such computations shall apply 
2
to succeeding calendar quarters until a 
3
new computation has been made. 
4
‘‘(iii) APPLICABLE
DATA
PERIOD.— 
5
For purposes of this paragraph, the term 
6
‘applicable data period’ means the most re-
7
cent period for which the data necessary 
8
for making the computations under clause 
9
(i) are available, as determined by the Sec-
10
retary. 
11
‘‘(C) 
PER
BENEFICIARY
ALLOWED 
12
CHARGES
DEFINED.—In this paragraph, the 
13
term ‘per beneficiary allowed charges’ means, 
14
with respect to a drug or biological for which 
15
the amount of payment is determined under 
16
subparagraph (A) or (B) of paragraph (1)— 
17
‘‘(i) the allowed charges for the drug 
18
or biological for which payment is so made 
19
for the applicable data period, as estimated 
20
by the Secretary; divided by 
21
‘‘(ii) the number of individuals for 
22
whom any payment for the drug or biologi-
23
cal was made under paragraph (1) for the 
24
04:12 Dec 12, 2019
H19
20 
•HR 19 IH
applicable data period, as estimated by the 
1
Secretary. 
2
‘‘(D) ADJUSTMENT TO REFLECT CHANGES 
3
IN
AVERAGE
SALES
PRICE.—In applying this 
4
paragraph for a particular calendar quarter, the 
5
Secretary shall adjust the per beneficiary al-
6
lowed charges for a drug or biological by multi-
7
plying such per beneficiary allowed charges 
8
under subparagraph (C) for the applicable data 
9
period by the ratio of— 
10
‘‘(i) the average sales price for the 
11
drug or biological for the most recent cal-
12
endar quarter used under subsection 
13
(c)(5)(B); to 
14
‘‘(ii) the average sales price for the 
15
drug or biological for the calendar quarter 
16
(or the weighted average for the quarters 
17
involved) included in the applicable data 
18
period.’’. 
19
(b) APPLICATION
OF JUDICIAL REVIEW PROVI-
20
SIONS.—Section 1847A(g) of the Social Security Act is 
21
amended— 
22
(1) by striking ‘‘and’’ at the end of paragraph 
23
(4); 
24
04:12 Dec 12, 2019
H19
21 
•HR 19 IH
(2) by striking the period at the end of para-
1
graph (5) and inserting ‘‘; and’’; and 
2
(3) by adding at the end the following new 
3
paragraph: 
4
‘‘(6) the determination of per beneficiary al-
5
lowed charges of drugs or biologicals and ranking of 
6
such charges under subsection (b)(9).’’. 
7
SEC. 104. ESTABLISHMENT OF MAXIMUM ADD-ON PAYMENT 
8
FOR DRUGS AND BIOLOGICALS. 
9
(a) IN GENERAL.—Section 1847A of the Social Secu-
10
rity Act (42 U.S.C. 1395w–3a), as amended by section 
11
103, is further amended— 
12
(1) in subsection (b)— 
13
(A) in paragraph (1), in the matter pre-
14
ceding subparagraph (A), by striking ‘‘para-
15
graph (7)’’ and inserting ‘‘paragraphs (7) and 
16
(10)’’; and 
17
(B) by adding at the end the following new 
18
paragraph: 
19
‘‘(10) MAXIMUM ADD-ON PAYMENT AMOUNT.— 
20
‘‘(A) IN
GENERAL.—In determining the 
21
payment amount under the provisions of sub-
22
paragraph (A), (B), or (C) of paragraph (1) of 
23
this subsection, subsection (c)(4)(A)(ii), or sub-
24
section (d)(3)(C) for a drug or biological fur-
25
04:12 Dec 12, 2019
H19
22 
•HR 19 IH
nished on or after January 1, 2021, if the ap-
1
plicable add-on payment (as defined in subpara-
2
graph (B)) for each drug or biological on a 
3
claim for a date of service exceeds the max-
4
imum add-on payment amount specified under 
5
subparagraph (C) for the drug or biological, 
6
then the payment amount otherwise determined 
7
for the drug or biological under those provi-
8
sions, as applicable, shall be reduced by the 
9
amount of such excess. 
10
‘‘(B) APPLICABLE ADD-ON PAYMENT DE-
11
FINED.—In this paragraph, the term ‘applicable 
12
add-on payment’ means the following amounts, 
13
determined without regard to the application of 
14
subparagraph (A): 
15
‘‘(i) In the case of a multiple source 
16
drug, an amount equal to the difference 
17
between— 
18
‘‘(I) the amount that would oth-
19
erwise be applied under paragraph 
20
(1)(A); and 
21
‘‘(II) the amount that would be 
22
applied under such paragraph if ‘100 
23
percent’ were substituted for the ap-
24
04:12 Dec 12, 2019
H19
23 
•HR 19 IH
plicable percent (as defined in para-
1
graph (9)) for such drug. 
2
‘‘(ii) In the case of a single source 
3
drug or biological, an amount equal to the 
4
difference between— 
5
‘‘(I) the amount that would oth-
6
erwise be applied under paragraph 
7
(1)(B); and 
8
‘‘(II) the amount that would be 
9
applied under such paragraph if ‘100 
10
percent’ were substituted for the ap-
11
plicable percent (as defined in para-
12
graph (9)) for such drug or biological. 
13
‘‘(iii) In the case of a biosimilar bio-
14
logical product, the amount otherwise de-
15
termined under paragraph (8)(B). 
16
‘‘(iv) In the case of a drug or biologi-
17
cal during the initial period described in 
18
subsection (c)(4)(A), an amount equal to 
19
the difference between— 
20
‘‘(I) the amount that would oth-
21
erwise be applied under subsection 
22
(c)(4)(A)(ii); and 
23
‘‘(II) the amount that would be 
24
applied under such subsection if ‘100 
25
04:12 Dec 12, 2019
H19
24 
•HR 19 IH
percent’ were substituted, as applica-
1
ble, for— 
2
‘‘(aa) ‘103 percent’ in sub-
3
clause (I) of such subsection; or 
4
‘‘(bb) any percent in excess 
5
of 100 percent applied under 
6
subclause (II) of such subsection. 
7
‘‘(v) In the case of a drug or biologi-
8
cal to which subsection (d)(3)(C) applies, 
9
an amount equal to the difference be-
10
tween— 
11
‘‘(I) the amount that would oth-
12
erwise be applied under such sub-
13
section; and 
14
‘‘(II) the amount that would be 
15
applied under such subsection if ‘100 
16
percent’ were substituted, as applica-
17
ble, for— 
18
‘‘(aa) any percent in excess 
19
of 100 percent applied under 
20
clause (i) of such subsection; or 
21
‘‘(bb) ‘103 percent’ in clause 
22
(ii) of such subsection. 
23
‘‘(C) MAXIMUM ADD-ON PAYMENT AMOUNT 
24
SPECIFIED.—For purposes of subparagraph 
25
04:12 Dec 12, 2019
H19
25 
•HR 19 IH
(A), the maximum add-on payment amount 
1
specified in this subparagraph is— 
2
‘‘(i) with respect to a drug or biologi-
3
cal 
(other 
than 
autologous 
cellular 
4
immunotherapy)— 
5
‘‘(I) for each of 2021 through 
6
2028, $1,000; and 
7
‘‘(II) for a subsequent year, the 
8
amount specified in this subparagraph 
9
for the preceding year increased by 
10
the percentage increase in the con-
11
sumer price index for all urban con-
12
sumers (all items; United States city 
13
average) for the 12-month period end-
14
ing with June of the previous year; or 
15
‘‘(ii) with respect to a drug or biologi-
16
cal 
consisting 
of 
autologous 
cellular 
17
immunotherapy— 
18
‘‘(I) for each of 2021 through 
19
2028, $2,000; and 
20
‘‘(II) for a subsequent year, the 
21
amount specified in this subparagraph 
22
for the preceding year increased by 
23
the percentage increase in the con-
24
sumer price index for all urban con-
25
04:12 Dec 12, 2019
H19
26 
•HR 19 IH
sumers (all items; United States city 
1
average) for the 12-month period end-
2
ing with June of the previous year. 
3
Any amount determined under this subpara-
4
graph that is not a multiple of $10 shall be 
5
rounded to the nearest multiple of $10.’’; and 
6
(2) in subsection (c)(4)(A)(ii), by striking ‘‘in 
7
the case’’ and inserting ‘‘subject to subsection 
8
(b)(10), in the case’’. 
9
(b) CONFORMING AMENDMENTS RELATING TO SEPA-
10
RATELY PAYABLE DRUGS.— 
11
(1) OPPS.—Section 1833(t)(14) of the Social 
12
Security Act (42 U.S.C. 1395l(t)(14)) is amended— 
13
(A) in subparagraph (A)(iii)(II), by insert-
14
ing ‘‘, subject to subparagraph (I)’’ after ‘‘are 
15
not available’’; and 
16
(B) by adding at the end the following new 
17
subparagraph: 
18
‘‘(I) APPLICATION
OF
MAXIMUM
ADD-ON 
19
PAYMENT
FOR
SEPARATELY
PAYABLE
DRUGS 
20
AND BIOLOGICALS.—In establishing the amount 
21
of payment under subparagraph (A) for a speci-
22
fied covered outpatient drug that is furnished 
23
as part of a covered OPD service (or group of 
24
services) on or after January 1, 2021, if such 
25
04:12 Dec 12, 2019
H19
27 
•HR 19 IH
payment is determined based on the average 
1
price for the year established under section 
2
1847A pursuant to clause (iii)(II) of such sub-
3
paragraph, the provisions of subsection (b)(10) 
4
of section 1847A shall apply to the amount of 
5
payment so established in the same manner as 
6
such provisions apply to the amount of payment 
7
under section 1847A.’’. 
8
(2) ASC.—Section 1833(i)(2)(D) of the Social 
9
Security Act (42 U.S.C. 1395l(i)(2)(D)) is amend-
10
ed— 
11
(A) by moving clause (v) 6 ems to the left; 
12
(B) by redesignating clause (vi) as clause 
13
(vii); and 
14
(C) by inserting after clause (v) the fol-
15
lowing new clause: 
16
‘‘(vi) If there is a separate payment 
17
under the system described in clause (i) for 
18
a drug or biological furnished on or after 
19
January 1, 2021, the provisions of sub-
20
section (t)(14)(I) shall apply to the estab-
21
lishment of the amount of payment for the 
22
drug or biological under such system in the 
23
same manner in which such provisions 
24
04:12 Dec 12, 2019
H19
28 
•HR 19 IH
apply to the establishment of the amount 
1
of payment under subsection (t)(14)(A).’’. 
2
SEC. 105. TREATMENT OF DRUG ADMINISTRATION SERV-
3
ICES FURNISHED BY CERTAIN EXCEPTED 
4
OFF-CAMPUS OUTPATIENT DEPARTMENTS OF 
5
A PROVIDER. 
6
Section 1833(t)(16) of the Social Security Act (42 
7
12 U.S.C. 1395l(t)(16)) is amended by adding at the end 
8
the following new subparagraph: 
9
‘‘(G) SPECIAL PAYMENT RULE FOR DRUG 
10
ADMINISTRATION SERVICES FURNISHED BY AN 
11
EXCEPTED DEPARTMENT OF A PROVIDER.— 
12
‘‘(i) IN GENERAL.—In the case of a 
13
covered OPD service that is a drug admin-
14
istration service (as defined by the Sec-
15
retary) furnished by a department of a 
16
provider described in clause (ii) or (iv) of 
17
paragraph (21)(B), the payment amount 
18
for such service furnished on or after Jan-
19
uary 1, 2021, shall be the same payment 
20
amount (as determined in paragraph 
21
(21)(C)) that would apply if the drug ad-
22
ministration service was furnished by an 
23
off-campus outpatient department of a pro-
24
vider (as defined in paragraph (21)(B)). 
25
04:12 Dec 12, 2019
H19
29 
•HR 19 IH
‘‘(ii) APPLICATION WITHOUT REGARD 
1
TO BUDGET NEUTRALITY.—The reductions 
2
made under this subparagraph— 
3
‘‘(I) shall not be considered an 
4
adjustment under paragraph (2)(E); 
5
and 
6
‘‘(II) shall not be implemented in 
7
a budget neutral manner.’’. 
8
Subtitle B—Drug Price 
9
Transparency 
10
SEC. 111. REPORTING ON EXPLANATION FOR DRUG PRICE 
11
INCREASES. 
12
(a) IN GENERAL.—Title III of the Public Health 
13
Service Act (42 U.S.C. 241 et seq.) is amended by adding 
14
at the end the following: 
15
‘‘PART W—DRUG PRICE REPORTING; DRUG 
16
VALUE FUND 
17
‘‘SEC. 399OO. REPORTING ON EXPLANATION FOR DRUG 
18
PRICE INCREASES. 
19
‘‘(a) DEFINITIONS.—In this section: 
20
‘‘(1) MANUFACTURER.—The term ‘manufac-
21
turer’ means the person— 
22
‘‘(A) that holds the application for a drug 
23
approved under section 505 of the Federal 
24
04:12 Dec 12, 2019
H19
30 
•HR 19 IH
Food, Drug, and Cosmetic Act or licensed 
1
under section 351 of this Act; or 
2
‘‘(B) who is responsible for setting the 
3
wholesale acquisition cost for the drug. 
4
‘‘(2) QUALIFYING DRUG.—The term ‘qualifying 
5
drug’ means any drug that is approved under sub-
6
section (c) or (j) of section 505 of the Federal Food, 
7
Drug, and Cosmetic Act or licensed under subsection 
8
(a) or (k) of section 351 of this Act— 
9
‘‘(A) that has a wholesale acquisition cost 
10
of $100 or more, adjusted for inflation occur-
11
ring after the date of enactment of this section, 
12
for a month’s supply or a typical course of 
13
treatment that lasts less than a month, and 
14
is— 
15
‘‘(i) subject to section 503(b)(1) of 
16
the Federal Food, Drug, and Cosmetic 
17
Act; 
18
‘‘(ii) administered or otherwise dis-
19
pensed to treat a disease or condition af-
20
fecting more than 200,000 persons in the 
21
United States; and 
22
‘‘(iii) not a vaccine; and 
23
‘‘(B) for which, during the previous cal-
24
endar year, at least 1 dollar of the total amount 
25
04:12 Dec 12, 2019
H19
31 
•HR 19 IH
of sales were for individuals enrolled under the 
1
Medicare program under title XVIII of the So-
2
cial Security Act (42 U.S.C. 1395 et seq.) or 
3
under a State Medicaid plan under title XIX of 
4
such Act (42 U.S.C. 1396 et seq.) or under a 
5
waiver of such plan. 
6
‘‘(3) WHOLESALE
ACQUISITION
COST.—The 
7
term ‘wholesale acquisition cost’ has the meaning 
8
given that term in section 1847A(c)(6)(B) of the So-
9
cial Security Act (42 U.S.C. 1395w–3a(c)(6)(B)). 
10
‘‘(b) REPORT.— 
11
‘‘(1) REPORT REQUIRED.—The manufacturer of 
12
a qualifying drug shall submit a report to the Sec-
13
retary— 
14
‘‘(A) for each increase in the price of a 
15
qualifying drug that results in an increase in 
16
the wholesale acquisition cost of that drug that 
17
is equal to— 
18
‘‘(i) 10 percent or more within a sin-
19
gle calendar year beginning on or after 
20
January 1, 2019; or 
21
‘‘(ii) 25 percent or more within three 
22
consecutive calendar years for which the 
23
first such calendar year begins on or after 
24
January 1, 2019; and 
25
04:12 Dec 12, 2019
H19
32 
•HR 19 IH
‘‘(B) in the case that the qualifying drug 
1
is first covered under title XVIII with respect 
2
to an applicable year, if the estimated cost or 
3
spending under such title per individual or per 
4
user of such drug (as estimated by the Sec-
5
retary) for such applicable year (or per course 
6
of treatment in such applicable year, as defined 
7
by the Secretary) is at least $26,000. 
8
‘‘(2) REPORT
DEADLINE.—Each report de-
9
scribed in paragraph (1) shall be submitted to the 
10
Secretary— 
11
‘‘(A) in the case of a report with respect 
12
to an increase in the price of a qualifying drug 
13
that occurs during the period beginning on Jan-
14
uary 1, 2019, and ending on the day that is 60 
15
days after the date of enactment of this section, 
16
not later than 90 days after such date of enact-
17
ment; 
18
‘‘(B) in the case of a report with respect 
19
to an increase in the price of a qualifying drug 
20
that occurs after the period described in sub-
21
paragraph (A), not later than 30 days prior to 
22
the planned effective date of such price increase 
23
for such qualifying drug; and 
24
04:12 Dec 12, 2019
H19
33 
•HR 19 IH
‘‘(C) in the case of a report with respect 
1
to a qualifying drug that meets the criteria de-
2
scribed in paragraph (1)(B), not later than 30 
3
days after such drug meets such criteria. 
4
‘‘(c) CONTENTS.—A report under subsection (b), con-
5
sistent with the standard for disclosures described in sec-
6
tion 213.3(d) of title 12, Code of Federal Regulations (as 
7
in effect on the date of enactment of this section), shall, 
8
at a minimum, include— 
9
‘‘(1) with respect to the qualifying drug— 
10
‘‘(A) the percentage by which the manufac-
11
turer will raise the wholesale acquisition cost of 
12
the drug within the calendar year or three con-
13
secutive calendar years as described in sub-
14
section (b)(1)(A) or (b)(1)(B), if applicable, and 
15
the effective date of such price increase; 
16
‘‘(B) an explanation for, and description 
17
of, each price increase for such drug that will 
18
occur during the calendar year period described 
19
in subsection (b)(1)(A) or the three consecutive 
20
calendar year period described in subsection 
21
(b)(1)(B), as applicable; 
22
‘‘(C) if known and different from the man-
23
ufacturer of the qualifying drug, the identity 
24
of— 
25
04:12 Dec 12, 2019
H19
34 
•HR 19 IH
‘‘(i) the sponsor or sponsors of any in-
1
vestigational new drug applications under 
2
section 505(i) of the Federal Food, Drug, 
3
and Cosmetic Act for clinical investigations 
4
with respect to such drug, for which the 
5
full reports are submitted as part of the 
6
application— 
7
‘‘(I) for approval of the drug 
8
under section 505 of such Act; or 
9
‘‘(II) for licensure of the drug 
10
under section 351 of this Act; and 
11
‘‘(ii) the sponsor of an application for 
12
the drug approved under such section 505 
13
of the Federal Food, Drug, and Cosmetic 
14
Act or licensed under section 351 of this 
15
Act; 
16
‘‘(D) a description of the history of the 
17
manufacturer’s price increases for the drug 
18
since the approval of the application for the 
19
drug under section 505 of the Federal Food, 
20
Drug, and Cosmetic Act or the issuance of the 
21
license for the drug under section 351 of this 
22
Act, or since the manufacturer acquired such 
23
approved application or license, if applicable; 
24
04:12 Dec 12, 2019
H19
35 
•HR 19 IH
‘‘(E) the current wholesale acquisition cost 
1
of the drug; 
2
‘‘(F) the total expenditures of the manu-
3
facturer on— 
4
‘‘(i) materials and manufacturing for 
5
such drug; and 
6
‘‘(ii) acquiring patents and licensing 
7
for such drug; 
8
‘‘(G) the percentage of total expenditures 
9
of the manufacturer on research and develop-
10
ment for such drug that was derived from Fed-
11
eral funds; 
12
‘‘(H) the total expenditures of the manu-
13
facturer on research and development for such 
14
drug that is necessary to demonstrate that it 
15
meets applicable statutory standards for ap-
16
proval under section 505 of the Federal Food, 
17
Drug, and Cosmetic Act or licensure under sec-
18
tion 351 of this Act, as applicable; 
19
‘‘(I) the total expenditures of the manufac-
20
turer on pursuing new or expanded indications 
21
or dosage changes for such drug under section 
22
505 of the Federal Food, Drug, and Cosmetic 
23
Act or section 351 of this Act; 
24
04:12 Dec 12, 2019
H19
36 
•HR 19 IH
‘‘(J) the total expenditures of the manufac-
1
turer on carrying out postmarket requirements 
2
related to such drug, including under section 
3
505(o)(3) of the Federal Food, Drug, and Cos-
4
metic Act; 
5
‘‘(K) the total revenue and the net profit 
6
generated from the qualifying drug for each cal-
7
endar year since the approval of the application 
8
for the drug under section 505 of the Federal 
9
Food, Drug, and Cosmetic Act or the issuance 
10
of the license for the drug under section 351, 
11
or since the manufacturer acquired such ap-
12
proved application or license; and 
13
‘‘(L) the total costs associated with mar-
14
keting and advertising for the qualifying drug; 
15
‘‘(2) with respect to the manufacturer— 
16
‘‘(A) the total revenue and the net profit 
17
of the manufacturer for each of the 1-year pe-
18
riod described in subsection (b)(1)(A) or the 3- 
19
year period described in subsection (b)(1)(B), 
20
as applicable; 
21
‘‘(B) all stock-based performance metrics 
22
used by the manufacturer to determine execu-
23
tive compensation for each of the 1-year period 
24
described in subsection (b)(1)(A) or the 3-year 
25
04:12 Dec 12, 2019
H19
37 
•HR 19 IH
period described in subsection (b)(1)(B), as ap-
1
plicable; and 
2
‘‘(C) any additional information the manu-
3
facturer chooses to provide related to drug pric-
4
ing decisions, such as total expenditures on— 
5
‘‘(i) drug research and development; 
6
or 
7
‘‘(ii) clinical trials, including on drugs 
8
that failed to receive approval by the Food 
9
and Drug Administration; and 
10
‘‘(3) such other related information as the Sec-
11
retary considers appropriate and as specified by the 
12
Secretary through notice-and-comment rulemaking. 
13
‘‘(d) INFORMATION PROVIDED.—The manufacturer 
14
of a qualifying drug that is required to submit a report 
15
under subsection (b), shall ensure that such report and 
16
any explanation for, and description of, each price increase 
17
described in subsection (c)(1)(B) shall be truthful, not 
18
misleading, and accurate. 
19
‘‘(e) CIVIL MONETARY PENALTY.—Any manufac-
20
turer of a qualifying drug that fails to submit a report 
21
for the drug as required by this section, following notifica-
22
tion by the Secretary to the manufacturer that the manu-
23
facturer is not in compliance with this section, shall be 
24
04:12 Dec 12, 2019
H19
38 
•HR 19 IH
subject to a civil monetary penalty of $75,000 for each 
1
day on which the violation continues. 
2
‘‘(f) FALSE INFORMATION.—Any manufacturer that 
3
submits a report for a drug as required by this section 
4
that knowingly provides false information in such report 
5
is subject to a civil monetary penalty in an amount not 
6
to exceed $75,000 for each item of false information. 
7
‘‘(g) PUBLIC POSTING.— 
8
‘‘(1) IN GENERAL.—Subject to paragraph (3), 
9
the Secretary shall post each report submitted under 
10
subsection (b) on the public website of the Depart-
11
ment of Health and Human Services the day the 
12
price increase of a qualifying drug is scheduled to go 
13
into effect. 
14
‘‘(2) FORMAT.—In developing the format in 
15
which reports will be publicly posted under para-
16
graph (1), the Secretary shall consult with stake-
17
holders, including beneficiary groups, and shall seek 
18
feedback from consumer advocates and readability 
19
experts on the format and presentation of the con-
20
tent of such reports to ensure that such reports 
21
are— 
22
‘‘(A) user-friendly to the public; and 
23
‘‘(B) written in plain language that con-
24
sumers can readily understand. 
25
04:12 Dec 12, 2019
H19
39 
•HR 19 IH
‘‘(3) PROTECTED
INFORMATION.—Nothing in 
1
this section shall be construed to authorize the pub-
2
lic disclosure of information submitted by a manu-
3
facturer that is prohibited from disclosure by appli-
4
cable laws concerning the protection of trade secrets, 
5
commercial information, and other information cov-
6
ered under such laws. 
7
‘‘SEC. 399OO–1. ANNUAL REPORT TO CONGRESS. 
8
‘‘(a) IN GENERAL.—Subject to subsection (b), the 
9
Secretary shall submit to Congress, and post on the public 
10
website of the Department of Health and Human Services 
11
in a way that is user-friendly to the public and written 
12
in plain language that consumers can readily understand, 
13
an annual report— 
14
‘‘(1) summarizing the information reported pur-
15
suant to section 399OO; 
16
‘‘(2) including copies of the reports and sup-
17
porting detailed economic analyses submitted pursu-
18
ant to such section; 
19
‘‘(3) detailing the costs and expenditures in-
20
curred by the Department of Health and Human 
21
Services in carrying out section 399OO; and 
22
‘‘(4) explaining how the Department of Health 
23
and Human Services is improving consumer and 
24
04:12 Dec 12, 2019
H19
40 
•HR 19 IH
provider information about drug value and drug 
1
price transparency. 
2
‘‘(b) PROTECTED INFORMATION.—Nothing in this 
3
section shall be construed to authorize the public disclo-
4
sure of information submitted by a manufacturer that is 
5
prohibited from disclosure by applicable laws concerning 
6
the protection of trade secrets, commercial information, 
7
and other information covered under such laws.’’. 
8
(b) EFFECTIVE DATE.—The amendment made by 
9
subsection (a) takes effect on the date of enactment of 
10
this Act. 
11
SEC. 112. PUBLIC DISCLOSURE OF DRUG DISCOUNTS. 
12
Section 1150A of the Social Security Act (42 U.S.C. 
13
1320b–23) is amended— 
14
(1) in subsection (c), in the matter preceding 
15
paragraph (1), by inserting ‘‘(other than as per-
16
mitted under subsection (e))’’ after ‘‘disclosed by the 
17
Secretary’’; and 
18
(2) by adding at the end the following new sub-
19
section: 
20
‘‘(e) PUBLIC AVAILABILITY OF CERTAIN INFORMA-
21
TION.— 
22
‘‘(1) IN GENERAL.—In order to allow the com-
23
parison of PBMs’ ability to negotiate rebates, dis-
24
counts, direct and indirect remuneration fees, ad-
25
04:12 Dec 12, 2019
H19
41 
•HR 19 IH
ministrative fees, and price concessions and the 
1
amount of such rebates, discounts, direct and indi-
2
rect remuneration fees, administrative fees, and 
3
price concessions that are passed through to plan 
4
sponsors, beginning January 1, 2020, the Secretary 
5
shall make available on the Internet website of the 
6
Department of Health and Human Services the in-
7
formation with respect to the second preceding cal-
8
endar year provided to the Secretary on generic dis-
9
pensing rates (as described in paragraph (1) of sub-
10
section (b)) and information provided to the Sec-
11
retary under paragraphs (2) and (3) of such sub-
12
section that, as determined by the Secretary, is with 
13
respect to each PBM. 
14
‘‘(2) AVAILABILITY OF DATA.—In carrying out 
15
paragraph (1), the Secretary shall ensure the fol-
16
lowing: 
17
‘‘(A) CONFIDENTIALITY.—The information 
18
described in such paragraph is displayed in a 
19
manner that prevents the disclosure of informa-
20
tion, with respect to an individual drug or an 
21
individual plan, on rebates, discounts, direct 
22
and indirect remuneration fees, administrative 
23
fees, and price concessions. 
24
04:12 Dec 12, 2019
H19
42 
•HR 19 IH
‘‘(B) CLASS OF DRUG.—The information 
1
described in such paragraph is made available 
2
by class of drug, using an existing classification 
3
system, but only if the class contains such num-
4
ber of drugs, as specified by the Secretary (but 
5
not fewer than three drugs), to ensure confiden-
6
tiality of proprietary information or other infor-
7
mation that is prevented to be disclosed under 
8
subparagraph (A).’’. 
9
SEC. 113. STUDY OF PHARMACEUTICAL SUPPLY CHAIN 
10
INTERMEDIARIES AND MERGER ACTIVITY. 
11
(a) INITIAL REPORT.—Not later than 1 year after 
12
the date of enactment of this Act, the Commission shall 
13
submit to the appropriate committees of Congress a report 
14
that— 
15
(1) addresses at minimum— 
16
(A) whether pharmacy benefit managers— 
17
(i) charge payers a higher price than 
18
the reimbursement rate at which the phar-
19
macy benefit managers reimburse com-
20
peting pharmacies; 
21
(ii) steer patients for anticompetitive 
22
purposes to any pharmacies, including re-
23
tail, mail-order, or any other type of phar-
24
04:12 Dec 12, 2019
H19
43 
•HR 19 IH
macy, in which the pharmacy benefit man-
1
ager has an ownership interest; 
2
(iii) audit or review proprietary data, 
3
including acquisition costs, patient infor-
4
mation, or dispensing information, of com-
5
peting pharmacies that can be used for 
6
anticompetitive purposes; or 
7
(iv) use formulary designs to increase 
8
the market share of higher cost prescrip-
9
tion drugs and depress the market share of 
10
lower cost prescription drugs (each net of 
11
rebates and discounts); 
12
(B) how companies and payers assess the 
13
benefits, costs, and risks of contracting with 
14
intermediaries, including pharmacy services ad-
15
ministrative organizations, and whether more 
16
information about the roles of intermediaries 
17
should be available to consumers and payers; 
18
and 
19
(C) whether there are any specific legal or 
20
regulatory obstacles the Commission currently 
21
faces in ensuring a competitive and transparent 
22
marketplace in the pharmaceutical supply 
23
chain, including the pharmacy benefit manager 
24
04:12 Dec 12, 2019
H19
44 
•HR 19 IH
marketplace and pharmacy services administra-
1
tive organizations; and 
2
(2) provides— 
3
(A) observations or conclusions drawn 
4
from the November 2017 roundtable entitled 
5
‘‘Understanding Competition in Prescription 
6
Drug Markets: Entry and Supply Chain Dy-
7
namics’’, and any similar efforts; 
8
(B) specific actions the Commission in-
9
tends to take as a result of the November 2017 
10
roundtable, and any similar efforts, including a 
11
detailed description of relevant forthcoming ac-
12
tions, additional research or roundtable discus-
13
sions, consumer education efforts, or enforce-
14
ment actions; and 
15
(C) policy or legislative recommendations 
16
to— 
17
(i) improve transparency and competi-
18
tion in the pharmaceutical supply chain; 
19
(ii) prevent and deter anticompetitive 
20
behavior in the pharmaceutical supply 
21
chain; and 
22
(iii) best ensure that consumers ben-
23
efit from any cost savings or efficiencies 
24
04:12 Dec 12, 2019
H19
45 
•HR 19 IH
that may result from mergers and consoli-
1
dations. 
2
(b) INTERIM REPORT.—Not later than 180 days 
3
after the date of enactment of this Act, the Commission 
4
shall submit to the appropriate committees of Congress 
5
an interim report on the progress of the report required 
6
by subsection (a), along with preliminary findings and 
7
conclusions based on information collected to that date. 
8
(c) DEFINITIONS.—In this section: 
9
(1) 
APPROPRIATE
COMMITTEES
OF
CON-
10
GRESS.—The term ‘‘appropriate committees of Con-
11
gress’’ means— 
12
(A) the Committee on Energy and Com-
13
merce of the House of Representatives; 
14
(B) the Committee on the Judiciary of the 
15
Senate; and 
16
(C) the Committee on the Judiciary of the 
17
House of Representatives. 
18
(2) COMMISSION.—The term ‘‘Commission’’ 
19
means the Federal Trade Commission. 
20
04:12 Dec 12, 2019
H19
46 
•HR 19 IH
SEC. 114. REQUIRING CERTAIN MANUFACTURERS TO RE-
1
2
RESPECT TO DRUGS UNDER THE MEDICARE 
3
PROGRAM. 
4
(a) IN GENERAL.—Section 1847A of the Social Secu-
5
rity Act (42 U.S.C. 1395w–3a) is amended— 
6
(1) in subsection (b)— 
7
(A) in paragraph (2)(A), by inserting ‘‘or 
8
subsection (f)(2), as applicable’’ before the pe-
9
riod at the end; 
10
(B) in paragraph (3), in the matter pre-
11
ceding subparagraph (A), by inserting ‘‘or sub-
12
section (f)(2), as applicable,’’ before ‘‘deter-
13
mined by’’; and 
14
(C) in paragraph (6)(A), in the matter 
15
preceding clause (i), by inserting ‘‘or subsection 
16
(f)(2), as applicable,’’ before ‘‘determined by’’; 
17
and 
18
(2) in subsection (f)— 
19
(A) by striking ‘‘For requirements’’ and 
20
inserting the following: 
21
‘‘(1) IN GENERAL.—For requirements’’; and 
22
(B) by adding at the end the following new 
23
paragraph: 
24
‘‘(2) MANUFACTURERS
WITHOUT
A
REBATE 
25
AGREEMENT UNDER TITLE XIX.— 
26
04:12 Dec 12, 2019
H19
47 
•HR 19 IH
‘‘(A) IN GENERAL.—If the manufacturer 
1
of a drug or biological described in subpara-
2
graph (C), (E), or (G) of section 1842(o)(1) or 
3
in section 1881(b)(14)(B) that is payable under 
4
this part has not entered into and does not 
5
have in effect a rebate agreement described in 
6
subsection (b) of section 1927, for calendar 
7
quarters beginning on or after January 1, 
8
2020, such manufacturer shall report to the 
9
Secretary the information described in sub-
10
section (b)(3)(A)(iii) of such section 1927 with 
11
respect to such drug or biological in a time and 
12
manner specified by the Secretary. For pur-
13
poses of applying this paragraph, a drug or bio-
14
logical described in the previous sentence in-
15
cludes items, services, supplies, and products 
16
that are payable under this part as a drug or 
17
biological. 
18
‘‘(B) AUDIT.—Information reported under 
19
subparagraph (A) is subject to audit by the In-
20
spector General of the Department of Health 
21
and Human Services. 
22
‘‘(C) VERIFICATION.—The Secretary may 
23
survey wholesalers and manufacturers that di-
24
rectly distribute drugs described in subpara-
25
04:12 Dec 12, 2019
H19
48 
•HR 19 IH
graph (A), when necessary, to verify manufac-
1
turer prices and manufacturer’s average sales 
2
prices (including wholesale acquisition cost) if 
3
required to make payment reported under sub-
4
paragraph (A). The Secretary may impose a 
5
civil monetary penalty in an amount not to ex-
6
ceed $100,000 on a wholesaler, manufacturer, 
7
or direct seller, if the wholesaler, manufacturer, 
8
or direct seller of such a drug refuses a request 
9
for information about charges or prices by the 
10
Secretary in connection with a survey under 
11
this subparagraph or knowingly provides false 
12
information. The provisions of section 1128A 
13
(other than subsections (a) (with respect to 
14
amounts of penalties or additional assessments) 
15
and (b)) shall apply to a civil money penalty 
16
under this subparagraph in the same manner as 
17
such provisions apply to a penalty or proceeding 
18
under section 1128A(a). 
19
‘‘(D) 
CONFIDENTIALITY.—Notwith-
20
standing any other provision of law, information 
21
disclosed by manufacturers or wholesalers 
22
under this paragraph (other than the wholesale 
23
acquisition cost for purposes of carrying out 
24
this section) is confidential and shall not be dis-
25
04:12 Dec 12, 2019
H19
49 
•HR 19 IH
closed by the Secretary in a form which dis-
1
closes the identity of a specific manufacturer or 
2
wholesaler or prices charged for drugs by such 
3
manufacturer or wholesaler, except— 
4
‘‘(i) as the Secretary determines to be 
5
necessary to carry out this section (includ-
6
ing the determination and implementation 
7
of the payment amount), or to carry out 
8
section 1847B; 
9
‘‘(ii) to permit the Comptroller Gen-
10
eral of the United States to review the in-
11
formation provided; and 
12
‘‘(iii) to permit the Director of the 
13
Congressional Budget Office to review the 
14
information provided.’’. 
15
(b) ENFORCEMENT.—Section 1847A of such Act (42 
16
U.S.C. 1395w–3a) is further amended— 
17
(1) in subsection (d)(4)— 
18
(A) in subparagraph (A), by striking ‘‘IN 
19
GENERAL’’ and inserting ‘‘MISREPRESENTA-
20
TION’’; 
21
(B) in subparagraph (B), by striking ‘‘sub-
22
paragraph (B)’’ and inserting ‘‘subparagraph 
23
(A), (B), or (C)’’; 
24
04:12 Dec 12, 2019
H19
50 
•HR 19 IH
(C) by redesignating subparagraph (B) as 
1
subparagraph (D); and 
2
(D) by inserting after subparagraph (A) 
3
the following new subparagraphs: 
4
‘‘(B) FAILURE TO PROVIDE TIMELY INFOR-
5
MATION.—If the Secretary determines that a 
6
manufacturer described in subsection (f)(2) has 
7
failed to report on information described in sec-
8
tion 1927(b)(3)(A)(iii) with respect to a drug or 
9
biological in accordance with such subsection, 
10
the Secretary shall apply a civil money penalty 
11
in an amount of $10,000 for each day the man-
12
ufacturer has failed to report such information 
13
and such amount shall be paid to the Treasury. 
14
‘‘(C) FALSE
INFORMATION.—Any manu-
15
facturer required to submit information under 
16
subsection (f)(2) that knowingly provides false 
17
information is subject to a civil money penalty 
18
in an amount not to exceed $100,000 for each 
19
item of false information. Such civil money pen-
20
alties are in addition to other penalties as may 
21
be prescribed by law.’’; and 
22
(2) in subsection (c)(6)(A), by striking the pe-
23
riod at the end and inserting ‘‘, except that, for pur-
24
poses of subsection (f)(2), the Secretary may, if the 
25
04:12 Dec 12, 2019
H19
51 
•HR 19 IH
Secretary determines appropriate, exclude repack-
1
agers of a drug or biological from such term.’’. 
2
(c) MANUFACTURERS
WITH
A
REBATE
AGREE-
3
MENT.— 
4
(1) IN GENERAL.—Section 1927(b)(3)(A) of the 
5
Social Security Act (42 U.S.C. 1396r–8(b)(3)(A)) is 
6
amended by adding at the end the following new 
7
sentence: ‘‘For purposes of applying clause (iii), a 
8
drug or biological described in the flush matter fol-
9
lowing such clause includes items, services, supplies, 
10
and products that are payable under this part as a 
11
drug or biological.’’. 
12
(2) 
TECHNICAL
AMENDMENT.—Section 
13
1927(b)(3)(A)(iii) of the Social Security Act (42 
14
U.S.C. 1396r–8(b)(3)(A)(iii)) is amended by striking 
15
‘‘section 1881(b)(13)(A)(ii)’’ and inserting ‘‘section 
16
1881(b)(14)(B)’’. 
17
(d) REPORT.—Not later than January 1, 2021, the 
18
Inspector General of the Department of Health and 
19
Human Services shall assess and submit to Congress a 
20
report on the accuracy of average sales price information 
21
submitted by manufacturers under section 1847A of the 
22
Social Security Act (42 U.S.C. 1395w–3a). Such report 
23
shall include any recommendations on how to improve the 
24
accuracy of such information. 
25
04:12 Dec 12, 2019
H19
52 
•HR 19 IH
SEC. 115. MAKING PRESCRIPTION DRUG MARKETING SAM-
1
PLE INFORMATION REPORTED BY MANUFAC-
2
TURERS AVAILABLE TO CERTAIN INDIVID-
3
UALS AND ENTITIES. 
4
(a) IN GENERAL.—Section 1128H of the Social Secu-
5
rity Act (42 U.S.C. 1320a–7i) is amended— 
6
(1) by redesignating subsection (b) as sub-
7
section (e); and 
8
(2) by inserting after subsection (a) the fol-
9
lowing new subsections: 
10
‘‘(b) DATA SHARING AGREEMENTS.— 
11
‘‘(1) IN GENERAL.—The Secretary shall enter 
12
into agreements with the specified data sharing indi-
13
viduals and entities described in paragraph (2) 
14
under which— 
15
‘‘(A) upon request of such an individual or 
16
entity, as applicable, the Secretary makes avail-
17
able to such individual or entity the information 
18
submitted under subsection (a) by manufactur-
19
ers and authorized distributors of record; and 
20
‘‘(B) such individual or entity agrees to 
21
not disclose publicly or to another individual or 
22
entity any information that identifies a par-
23
ticular practitioner or health care facility. 
24
‘‘(2) SPECIFIED
DATA
SHARING
INDIVIDUALS 
25
AND ENTITIES.—For purposes of paragraph (1), the 
26
04:12 Dec 12, 2019
H19
53 
•HR 19 IH
specified data sharing individuals and entities de-
1
scribed in this paragraph are the following: 
2
‘‘(A) OVERSIGHT AGENCIES.—Health over-
3
sight agencies (as defined in section 164.501 of 
4
title 45, Code of Federal Regulations), includ-
5
ing the Centers for Medicare & Medicaid Serv-
6
ices, the Office of the Inspector General of the 
7
Department of Health and Human Services, the 
8
Government Accountability Office, the Congres-
9
sional Budget Office, the Medicare Payment 
10
Advisory Commission, and the Medicaid and 
11
CHIP Payment and Access Commission. 
12
‘‘(B) 
RESEARCHERS.—Individuals 
who 
13
conduct scientific research (as defined in sec-
14
tion 164.501 of title 45, Code of Federal Regu-
15
lations) in relevant areas as determined by the 
16
Secretary. 
17
‘‘(C) PAYERS.—Private and public health 
18
care payers, including group health plans, 
19
health insurance coverage offered by health in-
20
surance issuers, Federal health programs, and 
21
State health programs. 
22
‘‘(3) EXEMPTION FROM FREEDOM OF INFORMA-
23
TION ACT.—Except as described in paragraph (1), 
24
the Secretary may not be compelled to disclose the 
25
04:12 Dec 12, 2019
H19
54 
•HR 19 IH
information submitted under subsection (a) to any 
1
individual or entity. For purposes of section 552 of 
2
title 5, United States Code (commonly referred to as 
3
the Freedom of Information Act), this paragraph 
4
shall be considered a statute described in subsection 
5
(b)(3)(B) of such section. 
6
‘‘(c) PENALTIES.— 
7
‘‘(1) DATA SHARING AGREEMENTS.—Subject to 
8
paragraph (3), any specified data sharing individual 
9
or entity described in subsection (b)(2) that violates 
10
the terms of a data sharing agreement the individual 
11
or entity has with the Secretary under subsection 
12
(b)(1) shall be subject to a civil money penalty of 
13
not less than $1,000, but not more than $10,000, 
14
for each such violation. Such penalty shall be im-
15
posed and collected in the same manner as civil 
16
money penalties under subsection (a) of section 
17
1128A are imposed and collected under that section. 
18
‘‘(2) FAILURE TO REPORT.—Subject to para-
19
graph (3), any manufacturer or authorized dis-
20
tributor of record of an applicable drug under sub-
21
section (a) that fails to submit information required 
22
under such subsection in a timely manner in accord-
23
ance with rules or regulations promulgated to carry 
24
out such subsection shall be subject to a civil money 
25
04:12 Dec 12, 2019
H19
55 
•HR 19 IH
penalty of not less than $1,000, but not more than 
1
$10,000, for each such failure. Such penalty shall be 
2
imposed and collected in the same manner as civil 
3
money penalties under subsection (a) of section 
4
1128A are imposed and collected under that section. 
5
‘‘(3) LIMITATION.—The total amount of civil 
6
money penalties imposed under paragraph (1) or (2) 
7
with respect to a year and an individual or entity de-
8
scribed in paragraph (1) or a manufacturer or dis-
9
tributor described in paragraph (2), respectively, 
10
shall not exceed $150,000. 
11
‘‘(d) DRUG SAMPLE DISTRIBUTION INFORMATION.— 
12
‘‘(1) IN GENERAL.—Not later than January 1 
13
of each year (beginning with 2021), the Secretary 
14
shall maintain a list containing information related 
15
to the distribution of samples of applicable drugs. 
16
Such list shall provide the following information with 
17
respect to the preceding year: 
18
‘‘(A) The name of the manufacturer or au-
19
thorized distributor of record of an applicable 
20
drug for which samples were requested or dis-
21
tributed under this section. 
22
‘‘(B) The quantity and class of drug sam-
23
ples requested. 
24
04:12 Dec 12, 2019
H19
56 
•HR 19 IH
‘‘(C) The quantity and class of drug sam-
1
ples distributed. 
2
‘‘(2) PUBLIC
AVAILABILITY.—The Secretary 
3
shall make the information in such list available to 
4
the public on the Internet website of the Food and 
5
Drug Administration.’’. 
6
(b) FDA MAINTENANCE
OF INFORMATION.—The 
7
Food and Drug Administration shall maintain information 
8
available to affected reporting companies to ensure their 
9
ability to fully comply with the requirements of section 
10
1128H of the Social Security Act. 
11
(c) PROHIBITION ON DISTRIBUTION OF SAMPLES OF 
12
OPIOIDS.—Section 503(d) of the Federal Food, Drug, and 
13
Cosmetic Act (21 U.S.C. 353(d)) is amended— 
14
(1) by moving the margin of paragraph (4) 2 
15
ems to the left; and 
16
(2) by adding at the end the following: 
17
‘‘(5) No person may distribute a drug sample of a 
18
drug that is— 
19
‘‘(A) an applicable drug (as defined in section 
20
1128H(e) of the Social Security Act); 
21
‘‘(B) a controlled substance (as defined in sec-
22
tion 102 of the Controlled Substances Act) for which 
23
the findings required under section 202(b)(2) of 
24
such Act have been made; and 
25
04:12 Dec 12, 2019
H19
57 
•HR 19 IH
‘‘(C) approved under section 505 for use in the 
1
management or treatment of pain (other than for 
2
the management or treatment of a substance use 
3
disorder).’’. 
4
(d) MEDPAC REPORT.—Not later than 3 years after 
5
the date of the enactment of this Act, the Medicare Pay-
6
ment Advisory Commission shall conduct a study on the 
7
impact of drug samples on provider prescribing practices 
8
and health care costs and may, as the Commission deems 
9
appropriate, make recommendations on such study. 
10
SEC. 116. REQUIRING PRESCRIPTION DRUG PLAN SPON-
11
SORS TO INCLUDE REAL-TIME BENEFIT IN-
12
FORMATION AS PART OF SUCH SPONSOR’S 
13
ELECTRONIC 
PRESCRIPTION 
PROGRAM 
14
UNDER THE MEDICARE PROGRAM. 
15
Section 1860D–4(e)(2) of the Social Security Act (42 
16
U.S.C. 1395w–104(e)(2)) is amended— 
17
(1) in subparagraph (D), by striking ‘‘To the 
18
extent’’ and inserting ‘‘Except as provided in sub-
19
paragraph (F), to the extent’’; and 
20
(2) by adding at the end the following new sub-
21
paragraph: 
22
‘‘(F) 
REAL-TIME
BENEFIT
INFORMA-
23
TION.— 
24
04:12 Dec 12, 2019
H19
58 
•HR 19 IH
‘‘(i) IN
GENERAL.—Not later than 
1
January 1, 2021, the program shall imple-
2
ment real-time benefit tools that are capa-
3
ble of integrating with a prescribing health 
4
care professional’s electronic prescribing or 
5
electronic health record system for the 
6
transmission of formulary and benefit in-
7
formation in real time to prescribing health 
8
care professionals. With respect to a cov-
9
ered part D drug, such tools shall be capa-
10
ble of transmitting such information spe-
11
cific to an individual enrolled in a prescrip-
12
tion drug plan. Such information shall in-
13
clude the following: 
14
‘‘(I) A list of any clinically-appro-
15
priate alternatives to such drug in-
16
cluded in the formulary of such plan. 
17
‘‘(II) Cost-sharing information 
18
for such drug and such alternatives, 
19
including a description of any vari-
20
ance in cost-sharing based on the 
21
pharmacy dispensing such drug or 
22
such alternatives. 
23
‘‘(III) Information relating to 
24
whether such drug is included in the 
25
04:12 Dec 12, 2019
H19
59 
•HR 19 IH
formulary of such plan and any prior 
1
authorization or other utilization man-
2
agement requirements applicable to 
3
such drug and such alternatives so in-
4
cluded. 
5
‘‘(ii) ELECTRONIC
TRANSMISSION.— 
6
The provisions of subclauses (I) and (II) of 
7
clause (ii) of subparagraph (E) shall apply 
8
to an electronic transmission described in 
9
clause (i) in the same manner as such pro-
10
visions apply with respect to an electronic 
11
transmission described in clause (i) of such 
12
subparagraph. 
13
‘‘(iii) SPECIAL RULE FOR 2021.—The 
14
program shall be deemed to be in compli-
15
ance with clause (i) for 2021 if the pro-
16
gram complies with the provisions of sec-
17
tion 423.160(b)(7) of title 42, Code of 
18
Federal Regulations (or a successor regula-
19
tion), for such year. 
20
‘‘(iv) RULE
OF
CONSTRUCTION.— 
21
Nothing in this subparagraph shall be con-
22
strued as to allow a real-time benefits tool 
23
to steer an individual, without the consent 
24
of the individual, to a particular pharmacy 
25
04:12 Dec 12, 2019
H19
60 
•HR 19 IH
or pharmacy setting over their preferred 
1
pharmacy setting nor prohibit the designa-
2
tion of a preferred pharmacy under such 
3
tool.’’. 
4
SEC. 117. SENSE OF CONGRESS REGARDING THE NEED TO 
5
EXPAND COMMERCIALLY AVAILABLE DRUG 
6
PRICING COMPARISON PLATFORMS. 
7
It is the sense of Congress that— 
8
(1) commercially available drug pricing com-
9
parison platforms can, at no cost, help patients find 
10
the lowest price for their medications at their local 
11
pharmacy; 
12
(2) such platforms should be integrated, to the 
13
maximum extent possible, in the health care delivery 
14
ecosystem; and 
15
(3) pharmacy benefit managers should work to 
16
disclose generic and brand name drug prices to such 
17
platforms to ensure that— 
18
(A) patients can benefit from the lowest 
19
possible price available to them; and 
20
(B) overall drug prices can be reduced as 
21
more educated purchasing decisions are made 
22
based on price transparency. 
23
04:12 Dec 12, 2019
H19
61 
•HR 19 IH
SEC. 118. TECHNICAL CORRECTIONS. 
1
(a) IN GENERAL.—Section 3022(b) of the Public 
2
Health Service Act (42 U.S.C. 300jj–52(b)) is amended 
3
by adding at the end the following new paragraph: 
4
‘‘(4) APPLICATION OF AUTHORITIES UNDER IN-
5
SPECTOR GENERAL ACT OF 1978.—In carrying out 
6
this subsection, the Inspector General shall have the 
7
same authorities as provided under section 6 of the 
8
Inspector General Act of 1978 (5 U.S.C. App.).’’. 
9
(b) EFFECTIVE DATE.—The amendment made by 
10
subsection (a) shall take effect as if included in the enact-
11
ment of the 21st Century Cures Act (Public Law 114– 
12
255). 
13
Subtitle C—Medicare Part D 
14
Benefit Redesign 
15
SEC. 121. MEDICARE PART D BENEFIT REDESIGN. 
16
(a) 
BENEFIT
STRUCTURE
REDESIGN.—Section 
17
1860D–2(b) of the Social Security Act (42 U.S.C. 1395w– 
18
102(b)) is amended— 
19
(1) in paragraph (2)— 
20
(A) in subparagraph (A)— 
21
(i) in the matter preceding clause (i), 
22
by inserting ‘‘for a year preceding 2022 
23
and for costs above the annual deductible 
24
specified in paragraph (1) and up to the 
25
annual out-of-pocket threshold specified in 
26
04:12 Dec 12, 2019
H19
62 
•HR 19 IH
paragraph (4)(B) for 2022 and each subse-
1
quent year’’ after ‘‘paragraph (3)’’; and 
2
(ii) in clause (i), by inserting after 
3
‘‘25 percent’’ the following: ‘‘(or, for 2022 
4
and each subsequent year, 15 percent)’’; 
5
(B) in subparagraph (C)— 
6
(i) in clause (i), in the matter pre-
7
ceding subclause (I), by inserting ‘‘for a 
8
year preceding 2022,’’ after ‘‘paragraph 
9
(4),’’; and 
10
(ii) in clause (ii)(III), by striking 
11
‘‘and each subsequent year’’ and inserting 
12
‘‘and 2021’’; and 
13
(C) in subparagraph (D)— 
14
(i) in clause (i)— 
15
(I) in the matter preceding sub-
16
clause (I), by inserting ‘‘for a year 
17
preceding 2022,’’ after ‘‘paragraph 
18
(4),’’; and 
19
(II) in subclause (I)(bb), by 
20
striking ‘‘a year after 2018’’ and in-
21
serting ‘‘each of years 2018 through 
22
2021’’; and 
23
(ii) in clause (ii)(V), by striking 
24
‘‘2019 and each subsequent year’’ and in-
25
04:12 Dec 12, 2019
H19
63 
•HR 19 IH
serting ‘‘each of years 2019 through 
1
2021’’; 
2
(2) in paragraph (3)(A)— 
3
(A) in the matter preceding clause (i), by 
4
inserting ‘‘for a year preceding 2022,’’ after 
5
‘‘and (4),’’; and 
6
(B) in clause (ii), by striking ‘‘for a subse-
7
quent year’’ and inserting ‘‘for each of years 
8
2007 through 2021’’; and 
9
(3) in paragraph (4)— 
10
(A) in subparagraph (A)— 
11
(i) in clause (i)— 
12
(I) by redesignating subclauses 
13
(I) and (II) as items (aa) and (bb), 
14
respectively, and indenting appro-
15
priately; 
16
(II) in the matter preceding item 
17
(aa), as redesignated by subclause (I), 
18
by striking ‘‘is equal to the greater 
19
of—’’ and inserting ‘‘is equal to— 
20
‘‘(I) for a year preceding 2022, 
21
the greater of—’’; 
22
(III) by striking the period at the 
23
end of item (bb), as redesignated by 
24
04:12 Dec 12, 2019
H19
64 
•HR 19 IH
subclause (I), and inserting ‘‘; and’’; 
1
and 
2
(IV) by adding at the end the fol-
3
lowing: 
4
‘‘(II) for 2022 and each suc-
5
ceeding year, $0.’’; and 
6
(ii) in clause (ii)— 
7
(I) by striking ‘‘clause (i)(I)’’ and 
8
inserting ‘‘clause (i)(I)(aa)’’; and 
9
(II) by adding at the end the fol-
10
lowing new sentence: ‘‘The Secretary 
11
shall continue to calculate the dollar 
12
amounts specified in clause (i)(I)(aa), 
13
including with the adjustment under 
14
this clause, after 2021 for purposes of 
15
section 1860D–14(a)(1)(D)(iii).’’; 
16
(B) in subparagraph (B)— 
17
(i) in clause (i)— 
18
(I) in subclause (V), by striking 
19
‘‘or’’ at the end; 
20
(II) in subclause (VI)— 
21
(aa) by striking ‘‘for a sub-
22
sequent year’’ and inserting ‘‘for 
23
2021’’; and 
24
04:12 Dec 12, 2019
H19
65 
•HR 19 IH
(bb) by striking the period 
1
at the end and inserting a semi-
2
colon; and 
3
(III) by adding at the end the 
4
following new subclauses: 
5
‘‘(VII) for 2022, is equal to 
6
$3,100; or 
7
‘‘(VIII) for a subsequent year, is 
8
equal to the amount specified in this 
9
subparagraph for the previous year, 
10
increased by the annual percentage in-
11
crease described in paragraph (6) for 
12
the year involved.’’; and 
13
(ii) in clause (ii), by striking ‘‘clause 
14
(i)(II)’’ and inserting ‘‘clause (i)’’; 
15
(C) in subparagraph (C)(i), by striking 
16
‘‘and for amounts’’ and inserting ‘‘and for a 
17
year preceding 2022 for amounts’’; and 
18
(D) in subparagraph (E), by striking ‘‘In 
19
applying’’ and inserting ‘‘For each of 2011 
20
through 2021, in applying’’. 
21
(b) 
DECREASING
REINSURANCE
PAYMENT 
22
AMOUNT.—Section 1860D–15(b)(1) of the Social Security 
23
Act (42 U.S.C. 1395w–115(b)(1)) is amended— 
24
04:12 Dec 12, 2019
H19
66 
•HR 19 IH
(1) by striking ‘‘equal to 80 percent’’ and in-
1
serting ‘‘equal to— 
2
‘‘(A) for a year preceding 2022, 80 per-
3
cent’’; 
4
(2) in subparagraph (A), as added by para-
5
graph (1), by striking the period at the end and in-
6
serting ‘‘; and’’; and 
7
(3) by adding at the end the following new sub-
8
paragraph: 
9
‘‘(B) for 2022 and each subsequent year, 
10
the sum of— 
11
‘‘(i) an amount equal to 20 percent of 
12
the allowable reinsurance costs (as speci-
13
fied in paragraph (2)) attributable to that 
14
portion of gross covered prescription drug 
15
costs as specified in paragraph (3) in-
16
curred in the coverage year after such indi-
17
vidual has incurred costs that exceed the 
18
annual out-of-pocket threshold specified in 
19
section 1860D–2(b)(4)(B) with respect to 
20
applicable drugs (as defined in section 
21
1860D–14B(g)(2)); and 
22
‘‘(ii) an amount equal to 30 percent of 
23
the allowable reinsurance costs (as speci-
24
fied in paragraph (2)) attributable to that 
25
04:12 Dec 12, 2019
H19
67 
•HR 19 IH
portion of gross covered prescription drug 
1
costs as specified in paragraph (3) in-
2
curred in the coverage year after such indi-
3
vidual has incurred costs that exceed the 
4
annual out-of-pocket threshold specified in 
5
section 1860D–2(b)(4)(B) with respect to 
6
covered part D drugs that are not applica-
7
ble drugs (as so defined).’’. 
8
(c) MANUFACTURER DISCOUNT PROGRAM.— 
9
(1) IN GENERAL.—Part D of title XVIII of the 
10
Social Security Act is amended by inserting after 
11
section 1860D–14A (42 U.S.C. 1495w–114) the fol-
12
lowing new section: 
13
‘‘SEC. 1860D–14B. MANUFACTURER DISCOUNT PROGRAM. 
14
‘‘(a) ESTABLISHMENT.—The Secretary shall estab-
15
lish a manufacturer discount program (in this section re-
16
ferred to as the ‘program’). Under the program, the Sec-
17
retary shall enter into agreements described in subsection 
18
(b) with manufacturers and provide for the performance 
19
of the duties described in subsection (c). The Secretary 
20
shall establish a model agreement for use under the pro-
21
gram by not later than January 1, 2021, in consultation 
22
with manufacturers, and allow for comment on such model 
23
agreement. 
24
‘‘(b) TERMS OF AGREEMENT.— 
25
04:12 Dec 12, 2019
H19
68 
•HR 19 IH
‘‘(1) IN GENERAL.— 
1
‘‘(A) AGREEMENT.—An agreement under 
2
this section shall require the manufacturer to 
3
provide applicable beneficiaries access to dis-
4
counted prices for applicable drugs of the man-
5
ufacturer that are dispensed on or after Janu-
6
ary 1, 2022. 
7
‘‘(B) PROVISION OF DISCOUNTED PRICES 
8
AT THE POINT-OF-SALE.—The discounted prices 
9
described in subparagraph (A) shall be provided 
10
to the applicable beneficiary at the pharmacy or 
11
by the mail order service at the point-of-sale of 
12
an applicable drug. 
13
‘‘(2) PROVISION OF APPROPRIATE DATA.—Each 
14
manufacturer with an agreement in effect under this 
15
section shall collect and have available appropriate 
16
data, as determined by the Secretary, to ensure that 
17
it can demonstrate to the Secretary compliance with 
18
the requirements under the program. 
19
‘‘(3) COMPLIANCE
WITH
REQUIREMENTS
FOR 
20
ADMINISTRATION
OF
PROGRAM.—Each manufac-
21
turer with an agreement in effect under this section 
22
shall comply with requirements imposed by the Sec-
23
retary or a third party with a contract under sub-
24
section (d)(3), as applicable, for purposes of admin-
25
04:12 Dec 12, 2019
H19
69 
•HR 19 IH
istering the program, including any determination 
1
under subparagraph (A) of subsection (c)(1) or pro-
2
cedures established under such subsection (c)(1). 
3
‘‘(4) LENGTH OF AGREEMENT.— 
4
‘‘(A) IN GENERAL.—An agreement under 
5
this section shall be effective for an initial pe-
6
riod of not less than 12 months and shall be 
7
automatically renewed for a period of not less 
8
than 1 year unless terminated under subpara-
9
graph (B). 
10
‘‘(B) TERMINATION.— 
11
‘‘(i) BY THE SECRETARY.—The Sec-
12
retary may provide for termination of an 
13
agreement under this section for a knowing 
14
and willful violation of the requirements of 
15
the agreement or other good cause shown. 
16
Such termination shall not be effective ear-
17
lier than 30 days after the date of notice 
18
to the manufacturer of such termination. 
19
The Secretary shall provide, upon request, 
20
a manufacturer with a hearing concerning 
21
such a termination, and such hearing shall 
22
take place prior to the effective date of the 
23
termination with sufficient time for such 
24
04:12 Dec 12, 2019
H19
70 
•HR 19 IH
effective date to be repealed if the Sec-
1
retary determines appropriate. 
2
‘‘(ii) BY A MANUFACTURER.—A man-
3
ufacturer may terminate an agreement 
4
under this section for any reason. Any 
5
such termination shall be effective, with re-
6
spect to a plan year— 
7
‘‘(I) if the termination occurs be-
8
fore January 30 of a plan year, as of 
9
the day after the end of the plan year; 
10
and 
11
‘‘(II) if the termination occurs on 
12
or after January 30 of a plan year, as 
13
of the day after the end of the suc-
14
ceeding plan year. 
15
‘‘(iii) EFFECTIVENESS
OF
TERMI-
16
NATION.—Any termination under this sub-
17
paragraph shall not affect discounts for 
18
applicable drugs of the manufacturer that 
19
are due under the agreement before the ef-
20
fective date of its termination. 
21
‘‘(iv) NOTICE TO THIRD PARTY.—The 
22
Secretary shall provide notice of such ter-
23
mination to a third party with a contract 
24
under subsection (d)(3) within not less 
25
04:12 Dec 12, 2019
H19
71 
•HR 19 IH
than 30 days before the effective date of 
1
such termination. 
2
‘‘(5) EFFECTIVE
DATE
OF
AGREEMENT.—An 
3
agreement under this section shall take effect on a 
4
date determined appropriate by the Secretary, which 
5
may be at the start of a calendar quarter. 
6
‘‘(c) DUTIES DESCRIBED.—The duties described in 
7
this subsection are the following: 
8
‘‘(1) ADMINISTRATION OF PROGRAM.—Admin-
9
istering the program, including— 
10
‘‘(A) the determination of the amount of 
11
the discounted price of an applicable drug of a 
12
manufacturer; 
13
‘‘(B) the establishment of procedures 
14
under which discounted prices are provided to 
15
applicable beneficiaries at pharmacies or by 
16
mail order service at the point-of-sale of an ap-
17
plicable drug; 
18
‘‘(C) the establishment of procedures to 
19
ensure that, not later than the applicable num-
20
ber of calendar days after the dispensing of an 
21
applicable drug by a pharmacy or mail order 
22
service, the pharmacy or mail order service is 
23
reimbursed for an amount equal to the dif-
24
ference between— 
25
04:12 Dec 12, 2019
H19
72 
•HR 19 IH
‘‘(i) the negotiated price of the appli-
1
cable drug; and 
2
‘‘(ii) the discounted price of the appli-
3
cable drug; 
4
‘‘(D) the establishment of procedures to 
5
ensure that the discounted price for an applica-
6
ble drug under this section is applied before any 
7
coverage or financial assistance under other 
8
health benefit plans or programs that provide 
9
coverage or financial assistance for the pur-
10
chase or provision of prescription drug coverage 
11
on behalf of applicable beneficiaries as the Sec-
12
retary may specify; and 
13
‘‘(E) providing a reasonable dispute resolu-
14
tion mechanism to resolve disagreements be-
15
tween manufacturers, applicable beneficiaries, 
16
and the third party with a contract under sub-
17
section (d)(3). 
18
‘‘(2) MONITORING COMPLIANCE.— 
19
‘‘(A) IN
GENERAL.—The Secretary shall 
20
monitor compliance by a manufacturer with the 
21
terms of an agreement under this section. 
22
‘‘(B) NOTIFICATION.—If a third party 
23
with a contract under subsection (d)(3) deter-
24
mines that the manufacturer is not in compli-
25
04:12 Dec 12, 2019
H19
73 
•HR 19 IH
ance with such agreement, the third party shall 
1
notify the Secretary of such noncompliance for 
2
appropriate enforcement under subsection (e). 
3
‘‘(3) COLLECTION OF DATA FROM PRESCRIP-
4
TION DRUG PLANS AND MA–PD PLANS.—The Sec-
5
retary may collect appropriate data from prescrip-
6
tion drug plans and MA–PD plans in a timeframe 
7
that allows for discounted prices to be provided for 
8
applicable drugs under this section. 
9
‘‘(d) ADMINISTRATION.— 
10
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
11
the Secretary shall provide for the implementation of 
12
this section, including the performance of the duties 
13
described in subsection (c). 
14
‘‘(2) LIMITATION.—In providing for the imple-
15
mentation of this section, the Secretary shall not re-
16
ceive or distribute any funds of a manufacturer 
17
under the program. 
18
‘‘(3) CONTRACT
WITH
THIRD
PARTIES.—The 
19
Secretary shall enter into a contract with 1 or more 
20
third parties to administer the requirements estab-
21
lished by the Secretary in order to carry out this 
22
section. At a minimum, the contract with a third 
23
party under the preceding sentence shall require 
24
that the third party— 
25
04:12 Dec 12, 2019
H19
74 
•HR 19 IH
‘‘(A) receive and transmit information be-
1
tween the Secretary, manufacturers, and other 
2
individuals or entities the Secretary determines 
3
appropriate; 
4
‘‘(B) receive, distribute, or facilitate the 
5
distribution of funds of manufacturers to ap-
6
propriate individuals or entities in order to 
7
meet the obligations of manufacturers under 
8
agreements under this section; 
9
‘‘(C) provide adequate and timely informa-
10
tion to manufacturers, consistent with the 
11
agreement with the manufacturer under this 
12
section, as necessary for the manufacturer to 
13
fulfill its obligations under this section; and 
14
‘‘(D) permit manufacturers to conduct 
15
periodic audits, directly or through contracts, of 
16
the data and information used by the third 
17
party to determine discounts for applicable 
18
drugs of the manufacturer under the program. 
19
‘‘(4) 
PERFORMANCE
REQUIREMENTS.—The 
20
Secretary shall establish performance requirements 
21
for a third party with a contract under paragraph 
22
(3) and safeguards to protect the independence and 
23
integrity of the activities carried out by the third 
24
party under the program under this section. 
25
04:12 Dec 12, 2019
H19
75 
•HR 19 IH
‘‘(5) ADMINISTRATION.—Chapter 35 of title 44, 
1
United States Code, shall not apply to the program 
2
under this section. 
3
‘‘(e) ENFORCEMENT.— 
4
‘‘(1) AUDITS.—Each manufacturer with an 
5
agreement in effect under this section shall be sub-
6
ject to periodic audit by the Secretary. 
7
‘‘(2) CIVIL MONEY PENALTY.— 
8
‘‘(A) IN
GENERAL.—The Secretary shall 
9
impose a civil money penalty on a manufacturer 
10
that fails to provide applicable beneficiaries dis-
11
counts for applicable drugs of the manufacturer 
12
in accordance with such agreement for each 
13
such failure in an amount the Secretary deter-
14
mines is commensurate with the sum of— 
15
‘‘(i) the amount that the manufac-
16
turer would have paid with respect to such 
17
discounts under the agreement, which will 
18
then be used to pay the discounts which 
19
the manufacturer had failed to provide; 
20
and 
21
‘‘(ii) 25 percent of such amount. 
22
‘‘(B) APPLICATION.—The provisions of 
23
section 1128A (other than subsections (a) and 
24
(b)) shall apply to a civil money penalty under 
25
04:12 Dec 12, 2019
H19
76 
•HR 19 IH
this paragraph in the same manner as such 
1
provisions apply to a penalty or proceeding 
2
under section 1128A(a). 
3
‘‘(f) CLARIFICATION REGARDING AVAILABILITY OF 
4
OTHER COVERED PART D DRUGS.—Nothing in this sec-
5
tion shall prevent an applicable beneficiary from pur-
6
chasing a covered part D drug that is not on the formulary 
7
of the prescription drug plan or MA–PD plan that the 
8
applicable beneficiary is enrolled in. 
9
‘‘(g) DEFINITIONS.—In this section: 
10
‘‘(1) APPLICABLE
BENEFICIARY.—The term 
11
‘applicable beneficiary’ means an individual who, on 
12
the date of dispensing a covered part D drug— 
13
‘‘(A) is enrolled in a prescription drug plan 
14
or an MA–PD plan; 
15
‘‘(B) is not enrolled in a qualified retiree 
16
prescription drug plan; and 
17
‘‘(C) has incurred costs for covered part D 
18
drugs in the year that are equal to or exceed 
19
the annual deductible specified in section 
20
1860D–2(b)(1) for such year. 
21
‘‘(2) APPLICABLE DRUG.—The term ‘applicable 
22
drug’ means, with respect to an applicable bene-
23
ficiary, a covered part D drug— 
24
04:12 Dec 12, 2019
H19
77 
•HR 19 IH
‘‘(A) approved under a new drug applica-
1
tion under section 505(c) of the Federal Food, 
2
Drug, and Cosmetic Act or, in the case of a bio-
3
logic product, licensed under section 351 of the 
4
Public Health Service Act (including a product 
5
licensed under subsection (k) of such section); 
6
and 
7
‘‘(B)(i) if the PDP sponsor of the prescrip-
8
tion drug plan or the MA organization offering 
9
the MA–PD plan uses a formulary, which is on 
10
the formulary of the prescription drug plan or 
11
MA–PD plan that the applicable beneficiary is 
12
enrolled in; 
13
‘‘(ii) if the PDP sponsor of the prescrip-
14
tion drug plan or the MA organization offering 
15
the MA–PD plan does not use a formulary, for 
16
which benefits are available under the prescrip-
17
tion drug plan or MA–PD plan that the appli-
18
cable beneficiary is enrolled in; or 
19
‘‘(iii) is provided through an exception or 
20
appeal. 
21
‘‘(3) APPLICABLE
NUMBER
OF
CALENDAR 
22
DAYS.—The term ‘applicable number of calendar 
23
days’ means— 
24
04:12 Dec 12, 2019
H19
78 
•HR 19 IH
‘‘(A) with respect to claims for reimburse-
1
ment submitted electronically, 14 days; and 
2
‘‘(B) with respect to claims for reimburse-
3
ment submitted otherwise, 30 days. 
4
‘‘(4) DISCOUNTED PRICE.— 
5
‘‘(A) IN GENERAL.—The term ‘discounted 
6
price’ means, with respect to an applicable drug 
7
of a manufacturer furnished during a year to 
8
an applicable beneficiary, 90 percent of the ne-
9
gotiated price of such drug. 
10
‘‘(B) CLARIFICATION.—Nothing in this 
11
section shall be construed as affecting the re-
12
sponsibility of an applicable beneficiary for pay-
13
ment of a dispensing fee for an applicable drug. 
14
‘‘(C) SPECIAL CASE FOR CLAIMS SPANNING 
15
DEDUCTIBLE.—In the case where the entire 
16
amount of the negotiated price of an individual 
17
claim for an applicable drug with respect to an 
18
applicable beneficiary does not fall at or above 
19
the annual deductible specified in section 
20
1860D–2(b)(1) for the year, the manufacturer 
21
of the applicable drug shall provide the dis-
22
counted price under this section on only the 
23
portion of the negotiated price of the applicable 
24
04:12 Dec 12, 2019
H19
79 
•HR 19 IH
drug that falls at or above such annual deduct-
1
ible. 
2
‘‘(5) MANUFACTURER.—The term ‘manufac-
3
turer’ means any entity which is engaged in the pro-
4
duction, preparation, propagation, compounding, 
5
conversion, or processing of prescription drug prod-
6
ucts, either directly or indirectly by extraction from 
7
substances of natural origin, or independently by 
8
means of chemical synthesis, or by a combination of 
9
extraction and chemical synthesis. Such term does 
10
not include a wholesale distributor of drugs or a re-
11
tail pharmacy licensed under State law. 
12
‘‘(6) NEGOTIATED
PRICE.—The term ‘nego-
13
tiated price’ has the meaning given such term in sec-
14
tion 1860D–2(d)(1)(B), except that such negotiated 
15
price shall not include any dispensing fee for an ap-
16
plicable drug. 
17
‘‘(7) QUALIFIED RETIREE PRESCRIPTION DRUG 
18
PLAN.—The term ‘qualified retiree prescription drug 
19
plan’ has the meaning given such term in section 
20
11860D–22(a)(2).’’. 
21
(2) SUNSET OF MEDICARE COVERAGE GAP DIS-
22
COUNT PROGRAM.—Section 1860D–14A of the So-
23
cial Security Act (42 U.S.C. 1395–114a) is amend-
24
ed— 
25
04:12 Dec 12, 2019
H19
80 
•HR 19 IH
(A) in subsection (a), in the first sentence, 
1
by striking ‘‘The Secretary’’ and inserting 
2
‘‘Subject to subsection (h), the Secretary’’; and 
3
(B) by adding at the end the following new 
4
subsection: 
5
‘‘(h) SUNSET OF PROGRAM.— 
6
‘‘(1) IN
GENERAL.—The program shall not 
7
apply to applicable drugs dispensed on or after Jan-
8
uary 1, 2022, and, subject to paragraph (2), agree-
9
ments under this section shall be terminated as of 
10
such date. 
11
‘‘(2) CONTINUED APPLICATION FOR APPLICA-
12
BLE
DRUGS
DISPENSED
PRIOR
TO
SUNSET.—The 
13
provisions of this section (including all responsibil-
14
ities and duties) shall continue to apply after Janu-
15
ary 1, 2022, with respect to applicable drugs dis-
16
pensed prior to such date.’’. 
17
(3) INCLUSION OF ACTUARIAL VALUE OF MANU-
18
FACTURER DISCOUNTS IN BIDS.—Section 1860D–11 
19
of the Social Security Act (42 U.S.C. 1395w–111) 
20
is amended— 
21
(A) in subsection (b)(2)(C)(iii)— 
22
(i) by striking ‘‘assumptions regarding 
23
the reinsurance’’ and inserting ‘‘assump-
24
tions regarding— 
25
04:12 Dec 12, 2019
H19
81 
•HR 19 IH
‘‘(I) the reinsurance’’; and 
1
(ii) by adding at the end the fol-
2
lowing: 
3
‘‘(II) for 2022 and each subse-
4
quent year, the manufacturer dis-
5
counts provided under section 1860D– 
6
14B subtracted from the actuarial 
7
value to produce such bid; and’’; and 
8
(B) in subsection (c)(1)(C)— 
9
(i) by striking ‘‘an actuarial valuation 
10
of the reinsurance’’ and inserting ‘‘an ac-
11
tuarial valuation of— 
12
‘‘(i) the reinsurance’’; 
13
(ii) in clause (i), as added by clause 
14
(i) of this subparagraph, by adding ‘‘and’’ 
15
at the end; and 
16
(iii) by adding at the end the fol-
17
lowing: 
18
‘‘(ii) for 2022 and each subsequent 
19
year, the manufacturer discounts provided 
20
under section 1860D–14B;’’. 
21
(d) DETERMINATION OF ALLOWABLE REINSURANCE 
22
COSTS.—Section 1860D–15(b) of the Social Security Act 
23
(42 U.S.C. 1395w–115(b)) is amended— 
24
(1) in paragraph (2)— 
25
04:12 Dec 12, 2019
H19
82 
•HR 19 IH
(A) by striking ‘‘COSTS.—For purposes’’ 
1
and inserting ‘‘COSTS.— 
2
‘‘(A) IN
GENERAL.—Subject to subpara-
3
graph (B), for purposes’’; and 
4
(B) by adding at the end the following new 
5
subparagraph: 
6
‘‘(B) INCLUSION OF MANUFACTURER DIS-
7
COUNTS ON APPLICABLE DRUGS.—For purposes 
8
of applying subparagraph (A), the term ‘allow-
9
able reinsurance costs’ shall include the portion 
10
of the negotiated price (as defined in section 
11
1860D–14B(g)(6)) of an applicable drug (as 
12
defined in section 1860D–14(g)(2)) that was 
13
paid by a manufacturer under the manufacturer 
14
discount program under section 1860D–14B.’’; 
15
and 
16
(2) in paragraph (3)— 
17
(A) in the first sentence, by striking ‘‘For 
18
purposes’’ and inserting ‘‘Subject to paragraph 
19
(2)(B), for purposes’’; and 
20
(B) in the second sentence, by inserting 
21
‘‘or, in the case of an applicable drug, by a 
22
manufacturer’’ after ‘‘by the individual or 
23
under the plan’’. 
24
04:12 Dec 12, 2019
H19
83 
•HR 19 IH
(e) UPDATING RISK ADJUSTMENT METHODOLOGIES 
1
TO ACCOUNT
FOR PART D MODERNIZATION REDE-
2
SIGN.—Section 1860D–15(c) of the Social Security Act 
3
(42 U.S.C. 1395w–115(c)) is amended by adding at the 
4
end the following new paragraph: 
5
‘‘(3) UPDATING
RISK
ADJUSTMENT
METH-
6
ODOLOGIES TO ACCOUNT FOR PART D MODERNIZA-
7
TION REDESIGN.—The Secretary shall update the 
8
risk adjustment model used to adjust bid amounts 
9
pursuant to this subsection as appropriate to take 
10
into account changes in benefits under this part pur-
11
suant to the amendments made by section 121 of 
12
the Lower Costs, More Cures Act of 2019.’’. 
13
(f) CONDITIONS FOR COVERAGE OF DRUGS UNDER 
14
THIS PART.—Section 1860D–43 of the Social Security 
15
Act (42 U.S.C. 1395w–153) is amended— 
16
(1) in subsection (a)— 
17
(A) in paragraph (2), by striking ‘‘and’’ at 
18
the end; 
19
(B) in paragraph (3), by striking the pe-
20
riod at the end and inserting a semicolon; and 
21
(C) by adding at the end the following new 
22
paragraphs: 
23
‘‘(4) participate in the manufacturer discount 
24
program under section 1860D–14B; 
25
04:12 Dec 12, 2019
H19
84 
•HR 19 IH
‘‘(5) have entered into and have in effect an 
1
agreement described in subsection (b) of such sec-
2
tion 1860D–14B with the Secretary; and 
3
‘‘(6) have entered into and have in effect, under 
4
terms and conditions specified by the Secretary, a 
5
contract with a third party that the Secretary has 
6
entered into a contract with under subsection (d)(3) 
7
of such section 1860D–14B.’’; 
8
(2) by striking subsection (b) and inserting the 
9
following: 
10
‘‘(b) EFFECTIVE DATE.—Paragraphs (1) through (3) 
11
of subsection (a) shall apply to covered part D drugs dis-
12
pensed under this part on or after January 1, 2011, and 
13
before January 1, 2022, and paragraphs (4) through (6) 
14
of such subsection shall apply to covered part D drugs 
15
dispensed on or after January 1, 2022.’’; and 
16
(3) in subsection (c), by striking paragraph (2) 
17
and inserting the following: 
18
‘‘(2) the Secretary determines that in the period 
19
beginning on January 1, 2011, and ending on De-
20
cember 31, 2011 (with respect to paragraphs (1) 
21
through (3) of subsection (a)), or the period begin-
22
ning on January 1, 2022, and ending December 31, 
23
2022 (with respect to paragraphs (4) through (6) of 
24
04:12 Dec 12, 2019
H19
85 
•HR 19 IH
such subsection), there were extenuating cir-
1
cumstances.’’. 
2
(g) CONFORMING AMENDMENTS.— 
3
(1) Section 1860D–2 of the Social Security Act 
4
(42 U.S.C. 1395w–102) is amended— 
5
(A) in subsection (a)(2)(A)(i)(I), by strik-
6
ing ‘‘, or an increase in the initial’’ and insert-
7
ing ‘‘or for a year preceding 2022 an increase 
8
in the initial’’; 
9
(B) in subsection (c)(1)(C)— 
10
(i) in the subparagraph heading, by 
11
striking ‘‘AT
INITIAL
COVERAGE
LIMIT’’; 
12
and 
13
(ii) by inserting ‘‘for a year preceding 
14
2022 or the annual out-of-pocket threshold 
15
specified in subsection (b)(4)(B) for the 
16
year for 2022 and each subsequent year’’ 
17
after ‘‘subsection (b)(3) for the year’’ each 
18
place it appears; and 
19
(C) in subsection (d)(1)(A), by striking ‘‘or 
20
an initial’’ and inserting ‘‘or for a year pre-
21
ceding 2022, an initial’’. 
22
(2) Section 1860D–4(a)(4)(B)(i) of the Social 
23
Security Act (42 U.S.C. 1395w–104(a)(4)(B)(i)) is 
24
04:12 Dec 12, 2019
H19
86 
•HR 19 IH
amended by striking ‘‘the initial’’ and inserting ‘‘for 
1
a year preceding 2022, the initial’’. 
2
(3) Section 1860D–14(a) of the Social Security 
3
Act (42 U.S.C. 1395w–114(a)) is amended— 
4
(A) in paragraph (1)— 
5
(i) in subparagraph (C), by striking 
6
‘‘The continuation’’ and inserting ‘‘For a 
7
year preceding 2022, the continuation’’; 
8
(ii) in subparagraph (D)(iii), by strik-
9
ing ‘‘1860D–2(b)(4)(A)(i)(I)’’ and insert-
10
ing ‘‘1860D–2(b)(4)(A)(i)(I)(aa)’’; and 
11
(iii) in subparagraph (E), by striking 
12
‘‘The elimination’’ and inserting ‘‘For a 
13
year preceding 2022, the elimination’’; and 
14
(B) in paragraph (2)— 
15
(i) in subparagraph (C), by striking 
16
‘‘The continuation’’ and inserting ‘‘For a 
17
year preceding 2022, the continuation’’; 
18
and 
19
(ii) in subparagraph (E)— 
20
(I) by inserting ‘‘for a year pre-
21
ceding 2022,’’ after ‘‘subsection (c)’’; 
22
and 
23
04:12 Dec 12, 2019
H19
87 
•HR 19 IH
(II) 
by 
striking 
‘‘1860D– 
1
2(b)(4)(A)(i)(I)’’ 
and 
inserting 
2
‘‘1860D–2(b)(4)(A)(i)(I)(aa)’’. 
3
(4) Section 1860D–21(d)(7) of the Social Secu-
4
rity Act (42 U.S.C. 1395w–131(d)(7)) is amended 
5
by striking ‘‘section 1860D–2(b)(4)(B)(i)’’ and in-
6
serting ‘‘section 1860D–2(b)(4)(C)(i)’’. 
7
(5) Section 1860D–22(a)(2)(A) of the Social 
8
Security Act (42 U.S.C. 1395w–132(a)(2)(A)) is 
9
amended— 
10
(A) by striking ‘‘the value of any discount’’ 
11
and inserting the following: ‘‘the value of— 
12
‘‘(i) for years prior to 2022, any dis-
13
count’’; 
14
(B) in clause (i), as inserted by subpara-
15
graph (A) of this paragraph, by striking the pe-
16
riod at the end and inserting ‘‘; and’’; and 
17
(C) by adding at the end the following new 
18
clause: 
19
‘‘(ii) for 2022 and each subsequent 
20
year, any discount provided pursuant to 
21
section 1860D–14B.’’. 
22
(6) Section 1860D–41(a)(6) of the Social Secu-
23
rity Act (42 U.S.C. 1395w–151(a)(6)) is amended— 
24
04:12 Dec 12, 2019
H19
88 
•HR 19 IH
(A) by inserting ‘‘for a year before 2022’’ 
1
after ‘‘1860D–2(b)(3)’’; and 
2
(B) by inserting ‘‘for such year’’ before the 
3
period. 
4
(h) EFFECTIVE DATE.—The amendments made by 
5
this section shall apply to plan year 2022 and subsequent 
6
plan years. 
7
Subtitle D—Other Medicare Part D 
8
Provisions 
9
SEC. 131. TRANSITIONAL COVERAGE AND RETROACTIVE 
10
MEDICARE PART D COVERAGE FOR CERTAIN 
11
LOW-INCOME BENEFICIARIES. 
12
Section 1860D–14 of the Social Security Act (42 
13
U.S.C. 1395w–114) is amended— 
14
(1) by redesignating subsection (e) as sub-
15
section (f); and 
16
(2) by adding after subsection (d) the following 
17
new subsection: 
18
‘‘(e) LIMITED INCOME NEWLY ELIGIBLE TRANSI-
19
TION PROGRAM.— 
20
‘‘(1) IN GENERAL.—Beginning not later than 
21
January 1, 2021, the Secretary shall carry out a 
22
program to provide transitional coverage for covered 
23
part D drugs for LI NET eligible individuals in ac-
24
cordance with this subsection. 
25
04:12 Dec 12, 2019
H19
89 
•HR 19 IH
‘‘(2) LI NET ELIGIBLE INDIVIDUAL DEFINED.— 
1
For purposes of this subsection, the term ‘LI NET 
2
eligible individual’ means a part D eligible individual 
3
who— 
4
‘‘(A) meets the requirements of clauses (ii) 
5
and (iii) of subsection (a)(3)(A); and 
6
‘‘(B) has not yet enrolled in a prescription 
7
drug plan or an MA–PD plan, or, who has so 
8
enrolled, but with respect to whom coverage 
9
under such plan has not yet taken effect. 
10
‘‘(3) TRANSITIONAL COVERAGE.—For purposes 
11
of this subsection, the term ‘transitional coverage’ 
12
means, with respect to an LI NET eligible indi-
13
vidual— 
14
‘‘(A) immediate access to covered part D 
15
drugs at the point-of-sale during the period that 
16
begins on the first day of the month such indi-
17
vidual is determined to meet the requirements 
18
of clauses (ii) and (iii) of subsection (a)(3)(A) 
19
and ends on the date that coverage under a pre-
20
scription drug plan or MA–PD plan takes effect 
21
with respect to such individual; and 
22
‘‘(B) in the case of an LI NET eligible in-
23
dividual who is a full-benefit dual eligible indi-
24
vidual (as defined in section 1935(c)(6)) or a 
25
04:12 Dec 12, 2019
H19
90 
•HR 19 IH
recipient of supplemental security income bene-
1
fits under title XVI, retroactive coverage (in the 
2
form of reimbursement of the amounts that 
3
would have been paid under this part had such 
4
individual been enrolled in a prescription drug 
5
plan or MA–PD plan) of covered part D drugs 
6
purchased by such individual during the period 
7
that begins on the date that is the later of— 
8
‘‘(i) the date that such individual was 
9
first eligible for a low-income subsidy 
10
under this part; or 
11
‘‘(ii) the date that is 36 months prior 
12
to the date such individual enrolls in a pre-
13
scription drug plan or MA–PD plan, and 
14
ends on the date that coverage under such 
15
plan takes effect. 
16
‘‘(4) PROGRAM ADMINISTRATION.— 
17
‘‘(A) SINGLE
OF
CONTACT.—The 
18
Secretary shall, to the extent feasible, admin-
19
ister the program under this subsection through 
20
a contract with a single program administrator. 
21
‘‘(B) BENEFIT
DESIGN.—The Secretary 
22
shall ensure that the transitional coverage pro-
23
vided to LI NET eligible individuals under this 
24
subsection— 
25
04:12 Dec 12, 2019
H19
91 
•HR 19 IH
‘‘(i) provides access to all covered part 
1
D drugs under an open formulary; 
2
‘‘(ii) permits all pharmacies deter-
3
mined by the Secretary to be in good 
4
standing to process claims under the pro-
5
gram; 
6
‘‘(iii) is consistent with such require-
7
ments as the Secretary considers necessary 
8
to improve patient safety and ensure ap-
9
propriate dispensing of medication; and 
10
‘‘(iv) meets such other requirements 
11
as the Secretary may establish. 
12
‘‘(5) RELATIONSHIP TO OTHER PROVISIONS OF 
13
THIS TITLE; WAIVER AUTHORITY.— 
14
‘‘(A) IN GENERAL.—The following provi-
15
sions shall not apply with respect to the pro-
16
gram under this subsection: 
17
‘‘(i) Paragraphs (1) and (3)(B) of sec-
18
tion 1860D–4(a) (relating to dissemination 
19
of general information; availability of infor-
20
mation on changes in formulary through 
21
the internet). 
22
‘‘(ii) Subparagraphs (A) and (B) of 
23
section 1860D–4(b)(3) (relating to require-
24
04:12 Dec 12, 2019
H19
92 
•HR 19 IH
ments on development and application of 
1
formularies; formulary development). 
2
‘‘(iii) Paragraphs (1)(C) and (2) of 
3
section 1860D–4(c) (relating to medication 
4
therapy management program). 
5
‘‘(B) WAIVER AUTHORITY.—The Secretary 
6
may waive such other requirements of title XI 
7
and this title as may be necessary to carry out 
8
the purposes of the program established under 
9
this subsection.’’. 
10
SEC. 132. ALLOWING THE OFFERING OF ADDITIONAL PRE-
11
SCRIPTION DRUG PLANS UNDER MEDICARE 
12
PART D. 
13
(a) RESCINDING
AND ISSUANCE
OF NEW GUID-
14
ANCE.—Not later than one year after the date of the en-
15
actment of this Act, the Secretary of Health and Human 
16
Services (in this section referred to as the ‘‘Secretary’’) 
17
shall— 
18
(1) rescind sections of any sub-regulatory guid-
19
ance that limit the number of prescription drug 
20
plans in each PDP region that may be offered by a 
21
PDP sponsor under part D of title XVIII of the So-
22
cial Security Act (42 U.S.C. 1395w–101 et seq.); 
23
and 
24
04:12 Dec 12, 2019
H19
93 
•HR 19 IH
(2) issue new guidance specifying that a PDP 
1
sponsor may offer up to 4 (or a greater number if 
2
determined appropriate by the Secretary) prescrip-
3
tion drug plans in each PDP region, except in cases 
4
where the PDP sponsor may offer up to 2 additional 
5
plans in a PDP region pursuant to section 1860D– 
6
11(d)(4) of the Social Security Act (42 U.S.C. 
7
1395w–111(d)(4)), as added by subsection (b). 
8
(b) OFFERING
OF ADDITIONAL PLANS.—Section 
9
1860D–11(d) of the Social Security Act (42 U.S.C. 
10
1395w–111(d)) is amended by adding at the end the fol-
11
lowing new paragraph: 
12
‘‘(4) OFFERING OF ADDITIONAL PLANS.— 
13
‘‘(A) IN GENERAL.—For plan year 2022 
14
and each subsequent plan year, a PDP sponsor 
15
may offer up to 2 additional prescription drug 
16
plans in a PDP region (in addition to any limit 
17
established by the Secretary under this part) 
18
provided that the PDP sponsor complies with 
19
subparagraph (B) with respect to at least one 
20
such prescription drug plan. 
21
‘‘(B) REQUIREMENTS.—In order to be eli-
22
gible to offer up to 2 additional plans in a PDP 
23
region pursuant to subparagraph (A), a PDP 
24
sponsor must ensure that, with respect to at 
25
04:12 Dec 12, 2019
H19
94 
•HR 19 IH
least one such prescription drug plan, the spon-
1
sor or any entity that provides pharmacy bene-
2
fits management services under a contract with 
3
any such sponsor or plan does not receive direct 
4
or indirect remuneration, as defined in section 
5
423.308 of title 42, Code of Federal Regula-
6
tions (or any successor regulation), unless at 
7
least 25 percent of the aggregate reductions in 
8
price or other remuneration received by the 
9
PDP sponsor or entity from drug manufactur-
10
ers with respect to the plan and plan year— 
11
‘‘(i) are reflected at the point-of-sale 
12
to the enrollee; or 
13
‘‘(ii) are used to reduce total bene-
14
ficiary cost-sharing estimated by the PDP 
15
sponsor for prescription drug coverage 
16
under the plan in the annual bid submitted 
17
by the PDP sponsor under section 1860D– 
18
11(b). 
19
‘‘(C) DEFINITION
OF
REDUCTIONS
IN 
20
PRICE.—For purposes of subparagraph (B), the 
21
term ‘reductions in price’ refers only to collect-
22
ible amounts, as determined by the Secretary, 
23
which excludes amounts which after adjudica-
24
tion and reconciliation with pharmacies and 
25
04:12 Dec 12, 2019
H19
95 
•HR 19 IH
manufacturers are duplicate in nature, contrary 
1
to other contractual clauses, or otherwise ineli-
2
gible (such as due to beneficiary disenrollment 
3
or coordination of benefits).’’. 
4
(c) RULE OF CONSTRUCTION.—Nothing in the provi-
5
sions of, or amendments made by, this section shall be 
6
construed as limiting the ability of the Secretary to in-
7
crease any limit otherwise applicable on the number of 
8
prescription drug plans that a PDP sponsor may offer, 
9
at the discretion of the PDP sponsor, in a PDP region 
10
under part D of title XVIII of the Social Security Act (42 
11
U.S.C. 1395w–101 et seq.). 
12
SEC. 133. ALLOWING CERTAIN ENROLLEES OF PRESCRIP-
13
TION 
DRUGS 
PLANS 
AND 
MA–PD 
PLANS 
14
UNDER MEDICARE PROGRAM TO SPREAD 
15
OUT COST-SHARING UNDER CERTAIN CIR-
16
CUMSTANCES. 
17
(a) STANDARD PRESCRIPTION DRUG COVERAGE.— 
18
Section 1860D–2(b)(2) of the Social Security Act (42 
19
U.S.C. 1395w–102(b)(2)), as amended by section 121, is 
20
further amended— 
21
(1) in subparagraph (A), by striking ‘‘Subject 
22
to subparagraphs (C) and (D)’’ and inserting ‘‘Sub-
23
ject to subparagraphs (C), (D), and (E)’’; and 
24
04:12 Dec 12, 2019
H19
96 
•HR 19 IH
(2) by adding at the end the following new sub-
1
paragraph: 
2
‘‘(E) 
ENROLLEE
OPTION
REGARDING 
3
SPREADING COST-SHARING.— 
4
‘‘(i) IN
GENERAL.—The Secretary 
5
shall establish by regulation a process 
6
under which, with respect to plan year 
7
2022 and subsequent plan years, a pre-
8
scription drug plan or an MA–PD plan 
9
shall, in the case of a part D eligible indi-
10
vidual enrolled with such plan for such 
11
plan year with respect to whom the plan 
12
projects that the dispensing of a covered 
13
part D drug to such individual will result 
14
in the individual incurring costs within a 
15
30-day period that are equal to a signifi-
16
cant percentage (as specified by the Sec-
17
retary pursuant to such regulation) of the 
18
annual out-of-pocket threshold specified in 
19
paragraph (4)(B) for such plan year, pro-
20
vide such individual with the option to 
21
make the coinsurance payment required 
22
under subparagraph (A) for such costs in 
23
the form of equal monthly installments 
24
over the remainder of such plan year. 
25
04:12 Dec 12, 2019
H19
97 
•HR 19 IH
‘‘(ii) SIGNIFICANT PERCENTAGE LIMI-
1
TATIONS.—In specifying a significant per-
2
centage pursuant to the regulation estab-
3
lished by the Secretary under clause (i), 
4
the Secretary may not specify a percentage 
5
that is less than 30 percent or greater 
6
than 100 percent.’’. 
7
(b) 
ALTERNATIVE
PRESCRIPTION
DRUG
COV-
8
ERAGE.—Section 1860D–2(c) of the Social Security Act 
9
(42 U.S.C. 1395w–102(c)) is amended by adding at the 
10
end the following new paragraph: 
11
‘‘(4) SAME
ENROLLEE
OPTION
REGARDING 
12
SPREADING
COST-SHARING.—For plan year 2022 
13
and subsequent plan years, the coverage provides the 
14
enrollee option regarding spreading cost-sharing de-
15
scribed 
in 
and 
required 
under 
subsection 
16
(b)(2)(E).’’. 
17
SEC. 134. ESTABLISHING A MONTHLY CAP ON BENEFICIARY 
18
INCURRED COSTS FOR INSULIN PRODUCTS 
19
AND 
SUPPLIES 
UNDER 
A 
PRESCRIPTION 
20
DRUG PLAN OR MA–PD PLAN. 
21
(a) IN GENERAL.—Section 1860D–2 of the Social 
22
Security Act (42 U.S.C. 1395w–102), as amended by sec-
23
tions 121 and 133, is further amended— 
24
(1) in subsection (b)(2)— 
25
04:12 Dec 12, 2019
H19
98 
•HR 19 IH
(A) in subparagraph (A), by striking ‘‘and 
1
(E)’’ and inserting ‘‘(E), and (F)’’; 
2
(B) in subparagraph (B), by striking ‘‘and 
3
(D)’’ and inserting ‘‘(D), and (F)’’; and 
4
(C) by adding at the end the following new 
5
subparagraph: 
6
‘‘(F) CAP ON INCURRED COSTS FOR INSU-
7
LIN PRODUCTS AND SUPPLIES.— 
8
‘‘(i) IN GENERAL.—The coverage pro-
9
vides benefits, for costs above the annual 
10
deductible specified in paragraph (1) and 
11
up to the annual out-of-pocket threshold 
12
described in paragraph (4)(B) and with re-
13
spect to a month (beginning with January 
14
of 2022), with cost sharing that is equal to 
15
$0 for a specified covered part D drug (as 
16
defined in clause (iii)) furnished to an indi-
17
vidual who has incurred costs during such 
18
month with respect to specified covered 
19
part D drugs equal to— 
20
‘‘(I) for months occurring in 
21
2022, $50; or 
22
‘‘(II) for months occurring in a 
23
subsequent year, the amount applica-
24
ble under this clause for months oc-
25
04:12 Dec 12, 2019
H19
99 
•HR 19 IH
curring in the year preceding such 
1
subsequent year, increased by the an-
2
nual percentage increase specified in 
3
paragraph (6) for such subsequent 
4
year and rounded to the nearest dol-
5
lar. 
6
‘‘(ii) APPLICATION.—The provisions 
7
of clauses (i) through (iii) of paragraph 
8
(4)(C) shall apply with respect to the de-
9
termination of the incurred costs for speci-
10
fied covered part D drugs for purposes of 
11
clause (i) in the same manner as such pro-
12
visions apply with respect to the deter-
13
mination of incurred costs for covered part 
14
D drugs for purposes of paragraph (4)(A). 
15
‘‘(iii) SPECIFIED
COVERED
PART
D 
16
DRUG.—For purposes of this subpara-
17
graph, the term ‘specified covered part D 
18
drug’ means a covered part D drug that 
19
is— 
20
‘‘(I) insulin; or 
21
‘‘(II) a medical supply associated 
22
with the injection of insulin (as de-
23
fined in regulations of the Secretary 
24
04:12 Dec 12, 2019
H19
100 
•HR 19 IH
promulgated pursuant to subsection 
1
(e)(1)(B)).’’; and 
2
(2) in subsection (c), by adding at the end the 
3
following new paragraph: 
4
‘‘(5) SAME PROTECTION WITH RESPECT TO EX-
5
PENDITURES FOR INSULIN AND CERTAIN MEDICAL 
6
SUPPLIES.—The coverage provides the coverage re-
7
quired under subsection (b)(2)(F).’’. 
8
(b) CONFORMING AMENDMENTS.— 
9
(1) IN GENERAL.—Section 1860D–14(a)(1)(D) 
10
of the Social Security Act (42 U.S.C. 1395w– 
11
114(a)(1)(D)), as amended by section 121, is fur-
12
ther amended— 
13
(A) in clause (ii), by striking ‘‘section 
14
1860D–2(b)(2)’’ and inserting ‘‘section 1860D– 
15
2(b)(2)(A)’’; and 
16
(B) in clause (iii), by striking ‘‘section 
17
1860D–2(b)(2)’’ and inserting ‘‘section 1860D– 
18
2(b)(2)(A)’’. 
19
(2) EFFECTIVE DATE.—The amendments made 
20
by paragraph (1) shall apply with respect to plan 
21
year 2022 and each subsequent plan year. 
22
04:12 Dec 12, 2019
H19
101 
•HR 19 IH
SEC. 135. GROWTH RATE OF MEDICARE PART D OUT-OF- 
1
2
(a) PROVIDING MEDICARE PART D BENEFICIARIES 
3
WITH
CERTAIN
2020 OFFSET
PAYMENTS.—Section 
4
1860D–2(b)(4) of the Social Security Act (42 U.S.C. 
5
1395w–102(b)(4)) is amended by adding at the end the 
6
following new subparagraph: 
7
‘‘(F) 2020 OFFSET PAYMENTS.— 
8
‘‘(i) IN GENERAL.—Subject to clause 
9
(iv), the Secretary shall provide for pay-
10
ment from the Medicare Prescription Drug 
11
Account as follows: 
12
‘‘(I) In the case of a specified in-
13
dividual (as defined in clause (ii)(I)) 
14
who as of the last day of a calendar 
15
quarter in 2020 has incurred costs for 
16
covered part D drugs so that the indi-
17
vidual has exceeded the annual out-of- 
18
pocket threshold applied under sub-
19
paragraph (B)(i)(V) for 2020, pay-
20
ment to the individual by not later 
21
than 15th day of the third month fol-
22
lowing the end of such quarter of the 
23
amount by which such threshold so 
24
applied exceeded the target threshold 
25
for 2020. 
26
04:12 Dec 12, 2019
H19
102 
•HR 19 IH
‘‘(II) In the case of a specified 
1
individual who is not described in sub-
2
clause (I) and who as of the last day 
3
of 2020 has incurred costs for covered 
4
part D drugs so that the individual 
5
has exceeded the target threshold for 
6
2020, payment to the individual by 
7
not later than December 31, 2021, of 
8
the amount by which such incurred 
9
costs exceeded the target threshold for 
10
2020. 
11
‘‘(ii) DEFINITIONS.—For purposes of 
12
this subparagraph: 
13
‘‘(I) SPECIFIED
INDIVIDUAL.— 
14
The term ‘specified individual’ means 
15
an individual who— 
16
‘‘(aa) is enrolled in a pre-
17
scription drug plan or an MA– 
18
PD plan; 
19
‘‘(bb) is not enrolled in a 
20
qualified retiree prescription drug 
21
plan; and 
22
‘‘(cc) is not entitled to an in-
23
come-related subsidy under sec-
24
tion 1860D–14(a). 
25
04:12 Dec 12, 2019
H19
103 
•HR 19 IH
‘‘(II) TARGET
THRESHOLD
FOR 
1
2020.—the term ‘target threshold for 
2
2020’ means the annual out-of-pocket 
3
threshold that would have been ap-
4
plied under subparagraph (B)(i) for 
5
2020 if such threshold had been de-
6
termined in accordance with subclause 
7
(IV) of such subparagraph instead of 
8
subclause (V) of such subparagraph. 
9
‘‘(iii) NOTIFICATION.—In the case of 
10
any specified individual who during 2020 
11
has incurred costs for covered part D 
12
drugs so that the individual has exceeded 
13
the target threshold for 2020, the Sec-
14
retary shall, not later than September 30, 
15
2021, provide to such individual a notifica-
16
tion informing such individual of such indi-
17
vidual’s right to a payment described in 
18
clause (i) and the estimated timing of such 
19
payment. 
20
‘‘(iv) CLARIFICATION.—The Secretary 
21
shall provide only 1 payment under this 
22
subparagraph with respect to any indi-
23
vidual. 
24
04:12 Dec 12, 2019
H19
104 
•HR 19 IH
‘‘(v) 
IMPLEMENTATION.—The 
Sec-
1
retary may implement this subparagraph 
2
by program instruction or otherwise.’’. 
3
(b) REDUCED GROWTH RATE FOR 2021 OF MEDI-
4
CARE PART D OUT-OF-POCKET COST THRESHOLD.—Sec-
5
tion 1860D–2(b)(4)(B)(i) of the Social Security Act (42 
6
U.S.C. 1395w–102(b)(4)(B)(i)) is amended— 
7
(1) in subclause (V), by striking at the end 
8
‘‘or’’; 
9
(2) by redesignating subclause (VI) as sub-
10
clause (VIII); and 
11
(3) by inserting after subclause (V) the fol-
12
lowing new subclauses: 
13
‘‘(VI) for 2021, is equal to the 
14
amount that would have been applied 
15
under this subparagraph for 2020 if 
16
such amount had been determined in 
17
accordance with subclause (IV) in-
18
stead of subclause (V), increased by 
19
the lesser of— 
20
‘‘(aa) the annual percentage 
21
increase described in paragraph 
22
(7) for 2021, plus 2 percentage 
23
points; or 
24
04:12 Dec 12, 2019
H19
105 
•HR 19 IH
‘‘(bb) the annual percentage 
1
increase described in paragraph 
2
(6) for 2021; 
3
‘‘(VII) for 2022, is equal to the 
4
amount that would have been applied 
5
under this subparagraph for 2022 if 
6
the amendments made by section 
7
1101(d)(1) of the Health Care and 
8
Education Reconciliation Act of 2010 
9
and by section 135 of the Lower 
10
Costs, More Cures Act of 2019 had 
11
not been enacted; or’’. 
12
Subtitle E—MedPAC 
13
SEC. 141. PROVIDING THE MEDICARE PAYMENT ADVISORY 
14
COMMISSION AND MEDICAID AND CHIP PAY-
15
MENT AND ACCESS COMMISSION WITH AC-
16
CESS TO CERTAIN DRUG PAYMENT INFORMA-
17
TION, INCLUDING CERTAIN REBATE INFOR-
18
MATION. 
19
(a) ACCESS TO CERTAIN PART D PAYMENT DATA.— 
20
Section 1860D–15(f) of the Social Security Act (42 
21
U.S.C. 1395w–115(f)) is amended— 
22
(1) in paragraph (2)— 
23
(A) in subparagraph (A)(ii), by striking 
24
‘‘and’’ at the end; 
25
04:12 Dec 12, 2019
H19
106 
•HR 19 IH
(B) in subparagraph (B), by striking the 
1
period at the end and inserting ‘‘; and’’; and 
2
(C) by inserting at the end the following 
3
new subparagraph: 
4
‘‘(C) by the Executive Director of the 
5
Medicare Payment Advisory Commission for 
6
purposes of monitoring, making recommenda-
7
tions, and analysis of the program under this 
8
title and by the Executive Director of the Med-
9
icaid and CHIP Payment and Access Commis-
10
sion for purposes of monitoring, making rec-
11
ommendations, and analysis of the Medicaid 
12
program established under title XIX and the 
13
Children’s Health Insurance Program under 
14
title XXI.’’; and 
15
(2) by adding at the end the following new 
16
paragraph: 
17
‘‘(3) ADDITIONAL
RESTRICTIONS
ON
DISCLO-
18
SURE OF INFORMATION.—The Executive Directors 
19
described in paragraph (2)(C) shall not disclose any 
20
of the following information disclosed to such Execu-
21
tive Directors or obtained by such Executive Direc-
22
tors pursuant to such paragraph, with respect to a 
23
prescription drug plan offered by a PDP sponsor: 
24
04:12 Dec 12, 2019
H19
107 
•HR 19 IH
‘‘(A) The specific amounts or the identity 
1
of the source of any rebates, price concessions, 
2
or other forms of direct or indirect remunera-
3
tion under such prescription drug plan. 
4
‘‘(B) Information submitted with the bid 
5
submitted under section 1860D–11 by such 
6
PDP sponsor. 
7
‘‘(C) In the case of such information from 
8
prescription drug event records, in a form that 
9
would 
not 
be 
permitted 
under 
section 
10
423.505(m) of title 42, Code of Federal Regula-
11
tions, or any successor regulation, if made by 
12
the Centers for Medicare & Medicaid Services.’’. 
13
(b) ACCESS TO CERTAIN REBATE AND PAYMENT 
14
DATA
UNDER
MEDICARE
AND
MEDICAID.—Section 
15
1927(b)(3)(D) of the Social Security Act (42 U.S.C. 
16
1396r–8(b)(3)(D)) is amended— 
17
(1) in the matter before clause (i), by striking 
18
‘‘subsection (a)(6)(A)(ii)’’ and inserting ‘‘subsection 
19
(a)(6)(A)’’; 
20
(2) in clause (v), by striking ‘‘and’’ at the end; 
21
(3) in clause (vi), by striking the period at the 
22
end and inserting ‘‘, and’’; 
23
(4) by inserting after clause (vi) the following 
24
new clause: 
25
04:12 Dec 12, 2019
H19
108 
•HR 19 IH
‘‘(vii) to permit the Executive Direc-
1
tor of the Medicare Payment Advisory 
2
Commission and the Executive Director of 
3
the Medicaid and CHIP Payment and Ac-
4
cess Commission to review the information 
5
provided.’’; 
6
(5) in the matter at the end, by striking 
7
‘‘1860D–4(c)(2)(E)’’ 
and 
inserting 
‘‘1860D– 
8
4(c)(2)(G)’’; and 
9
(6) by adding at the end the following new sen-
10
tence: ‘‘Any information disclosed to the Executive 
11
Director of the Medicare Payment Advisory Commis-
12
sion or the Executive Director of the Medicaid and 
13
CHIP Payment and Access Commission pursuant to 
14
this subparagraph shall not be disclosed by either 
15
such Executive Director in a form which discloses 
16
the identity of a specific manufacturer or wholesaler 
17
or prices charged for drugs by such manufacturer or 
18
wholesaler.’’. 
19
TITLE II—MEDICAID 
20
SEC. 201. SUNSET OF LIMIT ON MAXIMUM REBATE AMOUNT 
21
FOR SINGLE SOURCE DRUGS AND INNO-
22
VATOR MULTIPLE SOURCE DRUGS. 
23
Section 1927(c)(2)(D) of the Social Security Act (42 
24
U.S.C. 1396r–8(c)(2)(D)) is amended by inserting after 
25
04:12 Dec 12, 2019
H19
109 
•HR 19 IH
‘‘December 31, 2009,’’ the following: ‘‘and before January 
1
1, 2023,’’. 
2
SEC. 202. MEDICAID PHARMACY AND THERAPEUTICS COM-
3
MITTEE IMPROVEMENTS. 
4
(a) IN GENERAL.—Subparagraph (A) of section 
5
1927(d)(4) of the Social Security Act (42 U.S.C. 1396r– 
6
8(d)(4)) is amended to read as follows: 
7
‘‘(A)(i) The formulary is developed and re-
8
viewed by a pharmacy and therapeutics com-
9
mittee consisting of physicians, pharmacists, 
10
and other appropriate individuals appointed by 
11
the Governor of the State. 
12
‘‘(ii) Subject to clause (vi), the State estab-
13
lishes and implements a conflict of interest pol-
14
icy for the pharmacy and therapeutics com-
15
mittee that— 
16
‘‘(I) is publicly accessible; 
17
‘‘(II) requires all committee members 
18
to complete, on at least an annual basis, a 
19
disclosure of relationships, associations, 
20
and financial dealings that may affect their 
21
independence of judgement in committee 
22
matters; and 
23
‘‘(III) contains clear processes, such 
24
as recusal from voting or discussion, for 
25
04:12 Dec 12, 2019
H19
110 
•HR 19 IH
those members who report a conflict of in-
1
terest, along with appropriate processes to 
2
address any instance where a member fails 
3
to report a conflict of interest. 
4
‘‘(iii) The membership of the pharmacy 
5
and therapeutics committee— 
6
‘‘(I) includes at least 1 actively prac-
7
ticing physician and at least 1 actively 
8
practicing pharmacist, each of whom— 
9
‘‘(aa) is independent and free of 
10
conflict with respect to manufacturers 
11
and Medicaid participating plans or 
12
subcontractors, including pharmacy 
13
benefit managers; and 
14
‘‘(bb) has expertise in the care of 
15
1 or more Medicaid-specific popu-
16
lations such as elderly or disabled in-
17
dividuals, children with complex med-
18
ical needs, or low-income individuals 
19
with chronic illnesses; and 
20
‘‘(II) is made publicly available. 
21
‘‘(iv) At the option of the State, the 
22
State’s drug use review board established under 
23
subsection (g)(3) may serve as the pharmacy 
24
and therapeutics committee provided the State 
25
04:12 Dec 12, 2019
H19
111 
•HR 19 IH
ensures that such board meets the requirements 
1
of clauses (ii) and (iii). 
2
‘‘(v) The State reviews and has final ap-
3
proval of the formulary established by the phar-
4
macy and therapeutics committee. 
5
‘‘(vi) If the Secretary determines it appro-
6
priate or necessary based on the findings and 
7
recommendations of the Comptroller General of 
8
the United States in the report submitted to 
9
Congress under section 203 of the Lower Costs, 
10
More Cures Act of 2019, the Secretary shall 
11
issue guidance that States must follow for es-
12
tablishing conflict of interest policies for the 
13
pharmacy and therapeutics committee in ac-
14
cordance with the requirements of clause (ii), 
15
including appropriate standards and require-
16
ments for identifying, addressing, and reporting 
17
on conflicts of interest.’’. 
18
(b) APPLICATION TO MEDICAID MANAGED CARE OR-
19
GANIZATIONS.—Clause (xiii) of section 1903(m)(2)(A) of 
20
the Social Security Act (42 U.S.C. 1396b(m)(2)(A)) is 
21
amended— 
22
(1) by striking ‘‘and (III)’’ and inserting 
23
‘‘(III)’’; 
24
04:12 Dec 12, 2019
H19
112 
•HR 19 IH
(2) by striking the period at the end and insert-
1
ing ‘‘, and (IV) any formulary used by the entity for 
2
covered outpatient drugs dispensed to individuals eli-
3
gible for medical assistance who are enrolled with 
4
the entity is developed and reviewed by a pharmacy 
5
and therapeutics committee that meets the require-
6
ments 
of 
clauses 
(ii) 
and 
(iii) 
of 
section 
7
1927(d)(4)(A).’’; and 
8
(3) by moving the left margin 2 ems to the left. 
9
(c) EFFECTIVE DATE.—The amendments made by 
10
this section shall take effect on the date that is 1 year 
11
after the date of enactment of this Act. 
12
SEC. 203. GAO REPORT ON CONFLICTS OF INTEREST IN 
13
STATE MEDICAID PROGRAM DRUG USE RE-
14
VIEW BOARDS AND PHARMACY AND THERA-
15
PEUTICS (P&T) COMMITTEES. 
16
(a) INVESTIGATION.—The Comptroller General of the 
17
United States shall conduct an investigation of potential 
18
or existing conflicts of interest among members of State 
19
Medicaid program State drug use review boards (in this 
20
section referred to as ‘‘DUR Boards’’) and pharmacy and 
21
therapeutics committees (in this section referred to as 
22
‘‘P&T Committees’’). 
23
(b) REPORT.—Not later than 24 months after the 
24
date of enactment of this Act, the Comptroller General 
25
04:12 Dec 12, 2019
H19
113 
•HR 19 IH
shall submit to Congress a report on the investigation con-
1
ducted under subsection (a) that includes the following: 
2
(1) A description outlining how DUR Boards 
3
and P&T Committees operate in States, including 
4
details with respect to— 
5
(A) the structure and operation of DUR 
6
Boards and statewide P&T Committees; 
7
(B) States that operate separate P&T 
8
Committees for their fee-for-service Medicaid 
9
program and their Medicaid managed care or-
10
ganizations or other Medicaid managed care ar-
11
rangements (collectively referred to in this sec-
12
tion as ‘‘Medicaid MCOs)’’; and 
13
(C) States that allow Medicaid MCOs to 
14
have their own P&T Committees and the extent 
15
to which pharmacy benefit managers administer 
16
or participate in such P&T Committees. 
17
(2) A description outlining the differences be-
18
tween DUR Boards established in accordance with 
19
section 1927(g)(3) of the Social Security Act (42 
20
U.S.C. 1396r(g)(3)) and P&T Committees. 
21
(3) A description outlining the tools P&T Com-
22
mittees may use to determine Medicaid drug cov-
23
erage and utilization management policies. 
24
04:12 Dec 12, 2019
H19
114 
•HR 19 IH
(4) An analysis of whether and how States or 
1
P&T Committees establish participation and inde-
2
pendence requirements for DUR Boards and P&T 
3
Committees, including with respect to entities with 
4
connections with drug manufacturers, State Med-
5
icaid programs, managed care organizations, and 
6
other entities or individuals in the pharmaceutical 
7
industry. 
8
(5) A description outlining how States, DUR 
9
Boards, or P&T Committees define conflicts of inter-
10
est. 
11
(6) A description of how DUR Boards and P&T 
12
Committees address conflicts of interest, including 
13
who is responsible for implementing such policies. 
14
(7) A description of the tools, if any, States use 
15
to ensure that there are no conflicts of interest on 
16
DUR Boards and P&T Committees. 
17
(8) An analysis of the effectiveness of tools 
18
States use to ensure that there are no conflicts of 
19
interest on DUR Boards and P&T Committees and, 
20
if applicable, recommendations as to how such tools 
21
could be improved. 
22
(9) A review of strategies States may use to 
23
guard against conflicts of interest on DUR Boards 
24
and P&T Committees and to ensure compliance with 
25
04:12 Dec 12, 2019
H19
115 
•HR 19 IH
the requirements of titles XI and XIX of the Social 
1
Security Act (42 U.S.C. 1301 et seq., 1396 et seq.) 
2
and access to effective, clinically appropriate, and 
3
medically necessary drug treatments for Medicaid 
4
beneficiaries, including recommendations for such 
5
legislative and administrative actions as the Comp-
6
troller General determines appropriate. 
7
SEC. 204. ENSURING THE ACCURACY OF MANUFACTURER 
8
PRICE AND DRUG PRODUCT INFORMATION 
9
UNDER THE MEDICAID DRUG REBATE PRO-
10
GRAM. 
11
(a) AUDIT OF MANUFACTURER PRICE AND DRUG 
12
PRODUCT INFORMATION.— 
13
(1) IN GENERAL.—Subparagraph (B) of section 
14
1927(b)(3) of the Social Security Act (42 U.S.C. 
15
1396r–8(b)(3)) is amended to read as follows: 
16
‘‘(B) AUDITS AND SURVEYS OF MANUFAC-
17
TURER PRICE AND DRUG PRODUCT INFORMA-
18
TION.— 
19
‘‘(i) AUDITS.—The Secretary shall 
20
conduct ongoing audits of the price and 
21
drug product information reported by man-
22
ufacturers under subparagraph (A) for the 
23
most recently ended rebate period to en-
24
sure the accuracy and timeliness of such 
25
04:12 Dec 12, 2019
H19
116 
•HR 19 IH
information. In conducting such audits, the 
1
Secretary may employ evaluations, surveys, 
2
statistical sampling, predictive analytics 
3
and other relevant tools and methods. 
4
‘‘(ii) VERIFICATIONS SURVEYS OF AV-
5
ERAGE MANUFACTURER PRICE AND MANU-
6
FACTURER’S
AVERAGE
SALES
PRICE.—In 
7
addition to the audits required under 
8
clause (i), the Secretary may survey whole-
9
salers and manufacturers (including manu-
10
facturers that directly distribute their cov-
11
ered outpatient drugs (in this subpara-
12
graph referred to as ‘direct sellers’)), when 
13
necessary, to verify manufacturer prices 
14
and manufacturer’s average sales prices 
15
(including wholesale acquisition cost) to 
16
make payment reported under subpara-
17
graph (A). 
18
‘‘(iii) PENALTIES.—In addition to 
19
other penalties as may be prescribed by 
20
law, including under subparagraph (C) of 
21
this paragraph, the Secretary may impose 
22
a civil monetary penalty in an amount not 
23
to exceed $185,000 on an annual basis on 
24
a wholesaler, manufacturer, or direct sell-
25
04:12 Dec 12, 2019
H19
117 
•HR 19 IH
er, if the wholesaler, manufacturer, or di-
1
rect seller of a covered outpatient drug re-
2
fuses a request for information about 
3
charges or prices by the Secretary in con-
4
nection with an audit or survey under this 
5
subparagraph or knowingly provides false 
6
information. The provisions of section 
7
1128A (other than subsections (a) (with 
8
respect to amounts of penalties or addi-
9
tional assessments) and (b)) shall apply to 
10
a civil money penalty under this clause in 
11
the same manner as such provisions apply 
12
to a penalty or proceeding under section 
13
1128A(a). 
14
‘‘(iv) REPORTS.— 
15
‘‘(I) REPORT
TO
CONGRESS.— 
16
The Secretary shall, not later than 18 
17
months after date of enactment of 
18
this subparagraph, submit a report to 
19
the Committee on Energy and Com-
20
merce of the House of Representatives 
21
and the Committee on Finance of the 
22
Senate regarding additional regulatory 
23
or statutory changes that may be re-
24
quired in order to ensure accurate and 
25
04:12 Dec 12, 2019
H19
118 
•HR 19 IH
timely reporting and oversight of 
1
manufacturer price and drug product 
2
information, 
including 
whether 
3
changes should be made to reasonable 
4
assumption requirements to ensure 
5
such assumptions are reasonable and 
6
accurate or whether another method-
7
ology for ensuring accurate and timely 
8
reporting of price and drug product 
9
information should be considered to 
10
ensure the integrity of the drug rebate 
11
program under this section. 
12
‘‘(II) ANNUAL
REPORTS.—The 
13
Secretary shall, on at least an annual 
14
basis, submit a report to the Com-
15
mittee on Energy and Commerce of 
16
the House of Representatives and the 
17
Committee on Finance of the Senate 
18
summarizing the results of the audits 
19
and surveys conducted under this sub-
20
paragraph during the period that is 
21
the subject of the report. 
22
‘‘(III) CONTENT.—Each report 
23
submitted under subclause (II) shall, 
24
with respect to the period that is the 
25
04:12 Dec 12, 2019
H19
119 
•HR 19 IH
subject of the report, include sum-
1
maries of— 
2
‘‘(aa) error rates in the 
3
price, drug product, and other 
4
relevant information supplied by 
5
manufacturers under subpara-
6
graph (A); 
7
‘‘(bb) the timeliness with 
8
which 
manufacturers, 
whole-
9
salers, and direct sellers provide 
10
information required under sub-
11
paragraph (A) or under clause (i) 
12
or (ii) of this subparagraph; 
13
‘‘(cc) the number of manu-
14
facturers, wholesalers, and direct 
15
sellers and drug products audited 
16
under this subparagraph; 
17
‘‘(dd) the types of price and 
18
drug product information re-
19
viewed under the audits con-
20
ducted under this subparagraph; 
21
‘‘(ee) the tools and meth-
22
odologies employed in such au-
23
dits; 
24
04:12 Dec 12, 2019
H19
120 
•HR 19 IH
‘‘(ff) the findings of such 
1
audits, including which manufac-
2
turers, if any, were penalized 
3
under this subparagraph; and 
4
‘‘(gg) such other relevant in-
5
formation as the Secretary shall 
6
deem appropriate. 
7
‘‘(IV) PROTECTION OF INFORMA-
8
TION.—In preparing a report required 
9
under subclause (II), the Secretary 
10
shall redact such proprietary informa-
11
tion as the Secretary determines ap-
12
propriate to prevent disclosure of, and 
13
to safeguard, such information. 
14
‘‘(v) APPROPRIATIONS.—Out of any 
15
funds in the Treasury not otherwise appro-
16
priated, there is appropriated to the Sec-
17
retary $2,000,000 for fiscal year 2020 and 
18
each fiscal year thereafter to carry out this 
19
subparagraph.’’. 
20
(2) EFFECTIVE DATE.—The amendments made 
21
by this subsection shall take effect on the first day 
22
of the first fiscal quarter that begins after the date 
23
of enactment of this Act. 
24
04:12 Dec 12, 2019
H19
121 
•HR 19 IH
(b) INCREASED PENALTIES
FOR NONCOMPLIANCE 
1
WITH REPORTING REQUIREMENTS.— 
2
(1) INCREASED PENALTY FOR LATE REPORTING 
3
OF INFORMATION.—Section 1927(b)(3)(C)(i) of the 
4
Social Security Act (42 U.S.C. 1396r–8(b)(3)(C)(i)) 
5
is amended by striking ‘‘increased by $10,000 for 
6
each day in which such information has not been 
7
provided and such amount shall be paid to the 
8
Treasury’’ and inserting ‘‘, for each covered out-
9
patient drug with respect to which such information 
10
is not provided, $50,000 for the first day that such 
11
information is not provided on a timely basis and 
12
$19,000 for each subsequent day that such informa-
13
tion is not provided’’. 
14
(2) INCREASED PENALTY FOR KNOWINGLY RE-
15
FALSE
INFORMATION.—Section 
16
1927(b)(3)(C)(ii) of the Social Security Act (42 
17
U.S.C. 1396r–8(b)(3)(C)(ii)) is amended by striking 
18
‘‘$100,000’’ and inserting ‘‘$500,000’’. 
19
(3) EFFECTIVE DATE.—The amendments made 
20
by this subsection shall take effect on the first day 
21
of the first fiscal quarter that begins after the date 
22
of enactment of this Act. 
23
04:12 Dec 12, 2019
H19
122 
•HR 19 IH
SEC. 205. IMPROVING TRANSPARENCY AND PREVENTING 
1
THE USE OF ABUSIVE SPREAD PRICING AND 
2
RELATED PRACTICES IN MEDICAID. 
3
(a) PASS-THROUGH PRICING REQUIRED.— 
4
(1) IN GENERAL.—Section 1927(e) of the So-
5
cial Security Act (42 U.S.C. 1396r–8(e)) is amended 
6
by adding at the end the following: 
7
‘‘(6) PASS-THROUGH
PRICING
REQUIRED.—A 
8
contract between the State and a pharmacy benefit 
9
manager (referred to in this paragraph as a ‘PBM’), 
10
or a contract between the State and a managed care 
11
entity or other specified entity (as such terms are 
12
defined in section 1903(m)(9)(D)) that includes pro-
13
visions making the entity responsible for coverage of 
14
covered outpatient drugs dispensed to individuals en-
15
rolled with the entity, shall require that payment for 
16
such drugs and related administrative services (as 
17
applicable), including payments made by a PBM on 
18
behalf of the State or entity, is based on a pass- 
19
through pricing model under which— 
20
‘‘(A) any payment made by the entity of 
21
the PBM (as applicable) for such a drug— 
22
‘‘(i) is limited to— 
23
‘‘(I) ingredient cost; and 
24
‘‘(II) a professional dispensing 
25
fee that is not less than the profes-
26
04:12 Dec 12, 2019
H19
123 
•HR 19 IH
sional dispensing fee that the State 
1
plan or waiver would pay if the plan 
2
or waiver was making the payment di-
3
rectly; 
4
‘‘(ii) is passed through in its entirety 
5
by the entity or PBM to the pharmacy 
6
that dispenses the drug; and 
7
‘‘(iii) is made in a manner that is con-
8
sistent with section 1902(a)(30)(A) and 
9
sections 447.512, 447.514, and 447.518 of 
10
title 42, Code of Federal Regulations (or 
11
any successor regulation), as if such re-
12
quirements applied directly to the entity or 
13
the PBM; 
14
‘‘(B) payment to the entity or the PBM 
15
(as applicable) for administrative services per-
16
formed by the entity or PBM is limited to a 
17
reasonable administrative fee that covers the 
18
reasonable cost of providing such services; 
19
‘‘(C) the entity or the PBM (as applicable) 
20
shall make available to the State, and the Sec-
21
retary upon request, all costs and payments re-
22
lated to covered outpatient drugs and accom-
23
panying administrative services incurred, re-
24
ceived, or made by the entity or the PBM, in-
25
04:12 Dec 12, 2019
H19
124 
•HR 19 IH
cluding ingredient costs, professional dispensing 
1
fees, administrative fees, post-sale and post-in- 
2
voice fees. Discounts, or related adjustments 
3
such as direct and indirect remuneration fees, 
4
and any and all remuneration; and 
5
‘‘(D) any form of spread pricing whereby 
6
any amount charged or claimed by the entity or 
7
the PBM (as applicable) is in excess of the 
8
amount paid to the pharmacies on behalf of the 
9
entity, including any post-sale or post-invoice 
10
fees, discounts, or related adjustments such as 
11
direct and indirect remuneration fees or assess-
12
ments (after allowing for a reasonable adminis-
13
trative fee as described in subparagraph (B)) is 
14
not allowable for purposes of claiming Federal 
15
matching payments under this title.’’. 
16
(2) CONFORMING
AMENDMENT.—Clause (xiii) 
17
of section 1903(m)(2)(A) of such Act (42 U.S.C. 
18
1396b(m)(2)(A)), as amended by section 202, is fur-
19
ther amended— 
20
(A) by striking ‘‘and (IV)’’ and inserting 
21
‘‘(IV)’’; and 
22
(B) by inserting before the period at the 
23
end the following: ‘‘, and (V) pharmacy benefit 
24
management services provided by the entity, or 
25
04:12 Dec 12, 2019
H19
125 
•HR 19 IH
provided by a pharmacy benefit manager on be-
1
half of the entity under a contract or other ar-
2
rangement between the entity and the phar-
3
macy benefit manager, shall comply with the re-
4
quirements of section 1927(e)(6)’’. 
5
(3) EFFECTIVE DATE.—The amendments made 
6
by this subsection apply to contracts between States 
7
and managed care entities, other specified entities, 
8
or pharmacy benefits managers that are entered into 
9
or renewed on or after the date that is 18 months 
10
after the date of enactment of this Act. 
11
(b) SURVEY OF RETAIL PRICES.— 
12
(1) IN GENERAL.—Section 1927(f) of the Social 
13
Security Act (42 U.S.C. 1396r–8(f)) is amended— 
14
(A) by striking ‘‘and’’ after the semicolon 
15
at the end of paragraph (1)(A)(i) and all that 
16
precedes it through ‘‘(1)’’ and inserting the fol-
17
lowing: 
18
‘‘(1) SURVEY
OF
RETAIL
PRICES.—The Sec-
19
retary shall conduct a survey of retail community 
20
drug prices, to include at least the national average 
21
drug acquisition cost, as follows: 
22
‘‘(A) USE
OF
VENDOR.—The Secretary 
23
may contract services for— 
24
04:12 Dec 12, 2019
H19
126 
•HR 19 IH
‘‘(i) with respect to retail community 
1
pharmacies, the determination on a month-
2
ly basis of retail survey prices of the na-
3
tional average drug acquisition cost for 
4
covered outpatient drugs for such phar-
5
macies, net of all discounts and rebates (to 
6
the extent any information with respect to 
7
such discounts and rebates is available), 
8
the average reimbursement received for 
9
such drugs by such pharmacies from all 
10
sources of payment, including third par-
11
ties, and, to the extent available, the usual 
12
and customary charges to consumers for 
13
such drugs; and’’; 
14
(B) by adding at the end of paragraph (1) 
15
the following: 
16
‘‘(F) SURVEY
REPORTING.—In order to 
17
meet the requirement of section 1902(a)(54), a 
18
State shall require that any retail community 
19
pharmacy in the State that receives any pay-
20
ment, administrative fee, discount, or rebate re-
21
lated to the dispensing of covered outpatient 
22
drugs to individuals receiving benefits under 
23
this title, regardless of whether such payment, 
24
fee, discount, or rebate is received from the 
25
04:12 Dec 12, 2019
H19
127 
•HR 19 IH
State or a managed care entity directly or from 
1
a pharmacy benefit manager or another entity 
2
that has a contract with the State or a man-
3
aged care entity, shall respond to surveys of re-
4
tail prices conducted under this subsection. 
5
‘‘(G) SURVEY INFORMATION.—Information 
6
on retail community prices obtained under this 
7
paragraph shall be made publicly available and 
8
shall include at least the following: 
9
‘‘(i) The monthly response rate of the 
10
survey including a list of pharmacies not in 
11
compliance with subparagraph (F). 
12
‘‘(ii) The sampling frame and number 
13
of pharmacies sampled monthly. 
14
‘‘(iii) 
Characteristics 
of 
reporting 
15
pharmacies, including type (such as inde-
16
pendent or chain), geographic or regional 
17
location, and dispensing volume. 
18
‘‘(iv) Reporting of a separate national 
19
average drug acquisition cost for each drug 
20
for independent retail pharmacies and 
21
chain operated pharmacies. 
22
‘‘(v) Information on price concessions 
23
including on and off invoice discounts, re-
24
bates, and other price concessions. 
25
04:12 Dec 12, 2019
H19
128 
•HR 19 IH
‘‘(vi) Information on average profes-
1
sional dispensing fees paid. 
2
‘‘(H) PENALTIES.— 
3
‘‘(i) FAILURE TO PROVIDE TIMELY IN-
4
FORMATION.—A retail community phar-
5
macy that fails to respond to a survey con-
6
ducted under this subsection on a timely 
7
basis may be subject to a civil monetary 
8
penalty in the amount of $10,000 for each 
9
day in which such information has not 
10
been provided. 
11
‘‘(ii) FALSE INFORMATION.—A retail 
12
community pharmacy that knowingly pro-
13
vides false information in response to a 
14
survey conducted under this subsection 
15
may be subject to a civil money penalty in 
16
an amount not to exceed $100,000 for 
17
each item of false information. 
18
‘‘(iii) OTHER
PENALTIES.—Any civil 
19
money penalties imposed under this sub-
20
paragraph shall be in addition to other 
21
penalties as may be prescribed by law. The 
22
provisions of section 1128A (other than 
23
subsections (a) and (b)) shall apply to a 
24
civil money penalty under this subpara-
25
04:12 Dec 12, 2019
H19
129 
•HR 19 IH
graph in the same manner as such provi-
1
sions apply to a penalty or proceedings 
2
under section 1128A(a). 
3
‘‘(I) 
REPORT
ON
SPECIALTY
PHAR-
4
MACIES.— 
5
‘‘(i) IN GENERAL.—Not later than 1 
6
year after the effective date of this sub-
7
paragraph, the Secretary shall submit a re-
8
port to Congress examining specialty drug 
9
coverage and reimbursement under this 
10
title. 
11
‘‘(ii) CONTENT OF REPORT.—Such re-
12
port shall include a description of how 
13
State Medicaid programs define specialty 
14
drugs, how much State Medicaid programs 
15
pay for specialty drugs, how States and 
16
managed care plans determine payment for 
17
specialty drugs, the settings in which spe-
18
cialty drugs are dispensed (such as retail 
19
community pharmacies or specialty phar-
20
macies), whether acquisition costs for spe-
21
cialty drugs are captured in the national 
22
average drug acquisition cost survey, and 
23
recommendations as to whether specialty 
24
pharmacies should be included in the sur-
25
04:12 Dec 12, 2019
H19
130 
•HR 19 IH
vey of retail prices to ensure national aver-
1
age drug acquisition costs capture drugs 
2
sold at specialty pharmacies and how such 
3
specialty pharmacies should be defined.’’; 
4
(C) in paragraph (2)— 
5
(i) in subparagraph (A), by inserting 
6
‘‘, including payments rates under Med-
7
icaid managed care plans,’’ after ‘‘under 
8
this title’’; and 
9
(ii) in subparagraph (B), by inserting 
10
‘‘and the basis for such dispensing fees’’ 
11
before the semicolon; and 
12
(D) in paragraph (4), by inserting ‘‘, and 
13
$5,000,000 for fiscal year 2020 and each fiscal 
14
year thereafter,’’ after ‘‘2010’’. 
15
(2) EFFECTIVE DATE.—The amendments made 
16
by this subsection take effect on the 1st day of the 
17
1st quarter that begins on or after the date that is 
18
18 months after the date of enactment of this Act. 
19
(c) MANUFACTURER REPORTING
OF WHOLESALE 
20
ACQUISITION COST.—Section 1927(b)(3) of such Act (42 
21
U.S.C. 1396r–8(b)(3)), as amended by section 141, is fur-
22
ther amended— 
23
(1) in subparagraph (A)(i)— 
24
04:12 Dec 12, 2019
H19
131 
•HR 19 IH
(A) in subclause (I), by striking ‘‘and’’ 
1
after the semicolon; 
2
(B) in subclause (II), by adding ‘‘and’’ 
3
after the semicolon; 
4
(C) by moving the left margins of sub-
5
clauses (I) and (II) 2 ems to the right; and 
6
(D) by adding at the end the following: 
7
‘‘(III) in the case of rebate peri-
8
ods that begin on or after the date of 
9
enactment of this subclause, on the 
10
wholesale acquisition cost (as defined 
11
in section 1847A(c)(6)(B)) for cov-
12
ered outpatient drugs for the rebate 
13
period under the agreement (including 
14
for all such drugs that are sold under 
15
a new drug application approved 
16
under section 505(c) of the Federal 
17
Food, Drug, and Cosmetic Act);’’; and 
18
(2) in subparagraph (D)— 
19
(A) in the matter preceding clause (i), by 
20
inserting ‘‘and clause (vii) of this subpara-
21
graph’’ after ‘‘1847A’’; 
22
(B) in clause (vi), by striking ‘‘and’’ after 
23
the comma; 
24
04:12 Dec 12, 2019
H19
132 
•HR 19 IH
(C) in clause (vii), by striking the period 
1
and inserting ‘‘, and’’; and 
2
(D) by inserting after clause (vii) the fol-
3
lowing: 
4
‘‘(viii) to the Secretary to disclose 
5
(through a website accessible to the public) 
6
the most recently reported wholesale acqui-
7
sition 
cost 
(as 
defined 
in 
section 
8
1847A(c)(6)(B)) for each covered out-
9
patient drug (including for all such drugs 
10
that are sold under a new drug application 
11
approved under section 505(c) of the Fed-
12
eral Food, Drug, and Cosmetic Act), as re-
13
ported under subparagraph (A)(i)(III).’’. 
14
SEC. 206. T–MSIS DRUG DATA ANALYTICS REPORTS. 
15
(a) IN GENERAL.—Not later than May 1 of each cal-
16
endar year beginning with calendar year 2021, the Sec-
17
retary of Health and Human Services (in this section re-
18
ferred to as the ‘‘Secretary’’) shall publish on a website 
19
of the Centers for Medicare & Medicaid Services that is 
20
accessible to the public a report of the most recently avail-
21
able data on provider prescribing patterns under the Med-
22
icaid program. 
23
(b) CONTENT OF REPORT.— 
24
04:12 Dec 12, 2019
H19
133 
•HR 19 IH
(1) REQUIRED
CONTENT.—Each report re-
1
quired under subsection (a) for a calendar year shall 
2
include the following information with respect to 
3
each State (and, to the extent available, with respect 
4
to Puerto Rico, the United States Virgin Islands, 
5
Guam, the Northern Mariana Islands, and American 
6
Samoa): 
7
(A) A comparison of covered outpatient 
8
drug (as defined in section 1927(k)(2) of the 
9
Social Security Act (42 U.S.C. 1396r–8(k)(2))) 
10
prescribing patterns under the State Medicaid 
11
plan or waiver of such plan (including drugs 
12
prescribed on a fee-for-service basis and drugs 
13
prescribed under managed care arrangements 
14
under such plan or waiver)— 
15
(i) across all forms or models of reim-
16
bursement used under the plan or waiver; 
17
(ii) within specialties and subspecial-
18
ties, as defined by the Secretary; 
19
(iii) by episodes of care for— 
20
(I) each chronic disease category, 
21
as defined by the Secretary, that is 
22
represented in the 10 conditions that 
23
accounted for the greatest share of 
24
total spending under the plan or waiv-
25
04:12 Dec 12, 2019
H19
134 
•HR 19 IH
er during the year that is the subject 
1
of the report; 
2
(II) procedural groupings; and 
3
(III) rare disease diagnosis codes; 
4
(iv) by patient demographic character-
5
istics, including race (to the extent that 
6
the Secretary determines that there is suf-
7
ficient data available with respect to such 
8
characteristic in a majority of States), gen-
9
der, and age; 
10
(v) by patient high-utilizer or risk sta-
11
tus; and 
12
(vi) by high and low resource settings 
13
by facility and place of service categories, 
14
as determined by the Secretary. 
15
(B) In the case of medical assistance for 
16
covered outpatient drugs (as so defined) pro-
17
vided under a State Medicaid plan or waiver of 
18
such plan in a managed care setting, an anal-
19
ysis of the differences in managed care pre-
20
scribing patterns when a covered outpatient 
21
drug is prescribed in a managed care setting as 
22
compared to when the drug is prescribed in a 
23
fee-for-service setting. 
24
04:12 Dec 12, 2019
H19
135 
•HR 19 IH
(2) ADDITIONAL CONTENT.—A report required 
1
under subsection (a) for a calendar year may include 
2
State-specific information about prescription utiliza-
3
tion management tools under State Medicaid plans 
4
or waivers of such plans, including— 
5
(A) a description of prescription utilization 
6
management tools under State programs to pro-
7
vide long-term services and supports under a 
8
State Medicaid plan or a waiver of such plan; 
9
(B) a comparison of prescription utilization 
10
management tools applicable to populations cov-
11
ered under a State Medicaid plan waiver under 
12
section 1115 of the Social Security Act (42 
13
U.S.C. 1315) and the models applicable to pop-
14
ulations that are not covered under the waiver; 
15
(C) a comparison of the prescription utili-
16
zation management tools employed by different 
17
Medicaid managed care organizations, phar-
18
macy benefit managers, and related entities 
19
within the State; 
20
(D) a comparison of the prescription utili-
21
zation management tools applicable to each en-
22
rollment category under a State Medicaid plan 
23
or waiver; and 
24
04:12 Dec 12, 2019
H19
136 
•HR 19 IH
(E) a comparison of the prescription utili-
1
zation management tools applicable under the 
2
State Medicaid plan or waiver by patient high- 
3
utilizer or risk status. 
4
(3) ADDITIONAL
ANALYSIS.—To the extent 
5
practicable, the Secretary shall include in each re-
6
port published under subsection (a)— 
7
(A) analyses of national, State, and local 
8
patterns of Medicaid population-based pre-
9
scribing behaviors; and 
10
(B) recommendations for administrative or 
11
legislative action to improve the effectiveness of, 
12
and reduce costs for, covered outpatient drugs 
13
under Medicaid while ensuring timely bene-
14
ficiary access to medically necessary covered 
15
outpatient drugs. 
16
(c) USE OF T–MSIS DATA.—Each report required 
17
under subsection (a) shall— 
18
(1) be prepared using data and definitions from 
19
the Transformed Medicaid Statistical Information 
20
System (T–MSIS) data set (or a successor data set) 
21
that is not more than 24 months old on the date 
22
that the report is published; and 
23
(2) as appropriate, include a description with 
24
respect to each State of the quality and complete-
25
04:12 Dec 12, 2019
H19
137 
•HR 19 IH
ness of the data, as well as any necessary caveats 
1
describing the limitations of the data reported to the 
2
Secretary by the State that are sufficient to commu-
3
nicate the appropriate uses for the information. 
4
(d) PREPARATION
OF REPORT.—Each report re-
5
quired under subsection (a) shall be prepared by the Ad-
6
ministrator for the Centers for Medicare & Medicaid Serv-
7
ices. 
8
(e) APPROPRIATION.—For fiscal year 2020 and each 
9
fiscal year thereafter, there is appropriated to the Sec-
10
retary $2,000,000 to carry out this section. 
11
SEC. 207. RISK-SHARING VALUE-BASED PAYMENT AGREE-
12
MENTS FOR COVERED OUTPATIENT DRUGS 
13
UNDER MEDICAID. 
14
(a) IN GENERAL.—Section 1927 of the Social Secu-
15
rity Act (42 U.S.C. 1396r–8) is amended by adding at 
16
the end the following new subsection: 
17
‘‘(l) STATE OPTION TO PAY FOR COVERED OUT-
18
PATIENT DRUGS THROUGH RISK-SHARING VALUE-BASED 
19
AGREEMENTS.— 
20
‘‘(1) IN
GENERAL.—Beginning January 1, 
21
2022, a State shall have the option to pay (whether 
22
on a fee-for-service or managed care basis) for cov-
23
ered outpatient drugs that are potentially curative 
24
treatments intended for one-time use that are ad-
25
04:12 Dec 12, 2019
H19
138 
•HR 19 IH
ministered to individuals under this title by entering 
1
into a risk-sharing value-based payment agreement 
2
with the manufacturer of the drug in accordance 
3
with the requirements of this subsection. 
4
‘‘(2) SECRETARIAL APPROVAL.— 
5
‘‘(A) IN GENERAL.—A State shall submit a 
6
request to the Secretary to enter into a risk- 
7
sharing value based payment agreement, and 
8
the Secretary shall not approve a proposed risk- 
9
sharing value-based payment agreement be-
10
tween a State and a manufacturer for payment 
11
for a covered outpatient drug of the manufac-
12
turer unless the following requirements are met: 
13
‘‘(i) MANUFACTURER IS PARTY TO RE-
14
BATE
AGREEMENT
AND
IN
COMPLIANCE 
15
WITH REQUIREMENTS.—The manufacturer 
16
has a rebate agreement in effect as re-
17
quired under subsections (a) and (b) of 
18
this section and is in compliance with all 
19
applicable requirements under this title. 
20
‘‘(ii) NO
INCREASE
TO
PROJECTED 
21
NET FEDERAL SPENDING.— 
22
‘‘(I) IN
GENERAL.—The Chief 
23
Actuary certifies that the projected 
24
payments for each covered outpatient 
25
04:12 Dec 12, 2019
H19
139 
•HR 19 IH
drug under such proposed agreement 
1
would not result in greater estimated 
2
Federal spending under this title than 
3
the net Federal spending that would 
4
result in the absence of the agree-
5
ment. 
6
‘‘(II) NET
FEDERAL
SPENDING 
7
DEFINED.—For purposes of this sub-
8
section, the term ‘net Federal spend-
9
ing’ means the amount of Federal 
10
payments the Chief Actuary estimates 
11
would be made under this title for ad-
12
ministering a covered outpatient drug 
13
to an individual eligible for medical 
14
assistance under a State plan or a 
15
waiver of such plan, reduced by the 
16
amount of all rebates the Chief Actu-
17
ary estimates would be paid with re-
18
spect to the administering of such 
19
drug, including all rebates under this 
20
title and any supplemental or other 
21
additional rebates, in the absence of 
22
such an agreement. 
23
‘‘(III) INFORMATION.—The Chief 
24
Actuary shall make the certifications 
25
04:12 Dec 12, 2019
H19
140 
•HR 19 IH
required under this clause based on 
1
the most recently available and reli-
2
able drug pricing and product infor-
3
mation. The State and manufacturer 
4
shall provide the Secretary and the 
5
Chief Actuary with all necessary infor-
6
mation required to make the estimates 
7
needed for such certifications. 
8
‘‘(iii) LAUNCH AND LIST PRICE JUS-
9
TIFICATIONS.—The manufacturer submits 
10
all relevant information and supporting 
11
documentation necessary for pricing deci-
12
sions as deemed appropriate by the Sec-
13
retary, which shall be truthful and non- 
14
misleading, including manufacturer infor-
15
mation and supporting documentation for 
16
launch price or list price increases, and 
17
any applicable justification required under 
18
section 1128L. 
19
‘‘(iv) CONFIDENTIALITY OF INFORMA-
20
TION; PENALTIES.—The provisions of sub-
21
paragraphs (C) and (D) of subsection 
22
(b)(3) shall apply to a manufacturer that 
23
fails to submit the information and docu-
24
mentation required under clauses (ii) and 
25
04:12 Dec 12, 2019
H19
141 
•HR 19 IH
(iii) on a timely basis, or that knowingly 
1
provides false or misleading information, in 
2
the same manner as such provisions apply 
3
to a manufacturer with a rebate agreement 
4
under this section. 
5
‘‘(B) CONSIDERATION OF STATE REQUEST 
6
FOR APPROVAL.— 
7
‘‘(i) IN
GENERAL.—The Secretary 
8
shall treat a State request for approval of 
9
a risk-sharing value-based payment agree-
10
ment in the same manner that the Sec-
11
retary treats a State plan amendment, and 
12
subpart B of part 430 of title 42, Code of 
13
Federal Regulations, including, subject to 
14
clause (ii), the timing requirements of sec-
15
tion 430.16 of such title (as in effect on 
16
the date of enactment of this subsection), 
17
shall apply to a request for approval of a 
18
risk-sharing value-based payment agree-
19
ment in the same manner as such subpart 
20
applies to a State plan amendment. 
21
‘‘(ii) TIMING.—The Secretary shall 
22
consult with the Commissioner of Food 
23
and Drugs as required under subpara-
24
graph (C) and make a determination on 
25
04:12 Dec 12, 2019
H19
142 
•HR 19 IH
whether to approve a request from a State 
1
for approval of a proposed risk-sharing 
2
value-based payment agreement (or request 
3
additional information necessary to allow 
4
the Secretary to make a determination 
5
with respect to such request for approval) 
6
within the time period, to the extent prac-
7
ticable, specified in section 430.16 of title 
8
42, Code of Federal Regulations (as in ef-
9
fect on the date of enactment of this sub-
10
section), but in no case shall the Secretary 
11
take more than 180 days after the receipt 
12
of such request for approval or response to 
13
such request for additional information to 
14
make such a determination (or request ad-
15
ditional information). 
16
‘‘(C) CONSULTATION WITH THE COMMIS-
17
SIONER OF FOOD AND DRUGS.—In considering 
18
whether to approve a risk-sharing value-based 
19
payment agreement, the Secretary, to the ex-
20
tent necessary, shall consult with the Commis-
21
sioner of Food and Drugs to determine whether 
22
the relevant clinical parameters specified in 
23
such agreement are appropriate. 
24
04:12 Dec 12, 2019
H19
143 
•HR 19 IH
‘‘(3) INSTALLMENT-BASED
PAYMENT
STRUC-
1
TURE.— 
2
‘‘(A) IN GENERAL.—A risk-sharing value- 
3
based payment agreement shall provide for a 
4
payment structure under which, for every in-
5
stallment year of the agreement (subject to sub-
6
paragraph (B)), the State shall pay the total in-
7
stallment year amount in equal installments to 
8
be paid at regular intervals over a period of 
9
time that shall be specified in the agreement. 
10
‘‘(B) REQUIREMENTS
FOR
INSTALLMENT 
11
PAYMENTS.— 
12
‘‘(i) TIMING
OF
FIRST
PAYMENT.— 
13
The State shall make the first of the in-
14
stallment payments described in subpara-
15
graph (A) for an installment year not later 
16
than 30 days after the end of such year. 
17
‘‘(ii) LENGTH OF INSTALLMENT PE-
18
RIOD.—The period of time over which the 
19
State shall make the installment payments 
20
described in subparagraph (A) for an in-
21
stallment year shall not be longer than 5 
22
years. 
23
‘‘(iii) NONPAYMENT
OR
REDUCED 
24
PAYMENT OF INSTALLMENTS FOLLOWING 
25
04:12 Dec 12, 2019
H19
144 
•HR 19 IH
A
FAILURE
TO
MEET
CLINICAL
PARAM-
1
ETER.—If, prior to the payment date (as 
2
specified in the agreement) of any install-
3
ment payment described in subparagraph 
4
(A) or any other alternative date or time 
5
frame (as otherwise specified in the agree-
6
ment), the covered outpatient drug which 
7
is subject to the agreement fails to meet a 
8
relevant clinical parameter of the agree-
9
ment, the agreement shall provide that— 
10
‘‘(I) the installment payment 
11
shall not be made; or 
12
‘‘(II) the installment payment 
13
shall be reduced by a percentage spec-
14
ified in the agreement that is based 
15
on the outcome achieved by the drug 
16
relative to the relevant clinical param-
17
eter. 
18
‘‘(4) NOTICE OF INTENT.— 
19
‘‘(A) IN
GENERAL.—Subject to subpara-
20
graph (B), a manufacturer of a covered out-
21
patient drug shall not be eligible to enter into 
22
a risk-sharing value-based payment agreement 
23
under this subsection with respect to such drug 
24
unless the manufacturer notifies the Secretary 
25
04:12 Dec 12, 2019
H19
145 
•HR 19 IH
that the manufacturer is interested in entering 
1
into such an agreement with respect to such 
2
drug. The decision to submit and timing of a 
3
request to enter into a proposed risk-sharing 
4
value-based payment agreement shall remain 
5
solely within the discretion of the State and 
6
shall only be effective upon Secretarial approval 
7
as required under this subsection. 
8
‘‘(B) TREATMENT OF SUBSEQUENTLY AP-
9
PROVED DRUGS.— 
10
‘‘(i) IN GENERAL.—In the case of a 
11
manufacturer of a covered outpatient drug 
12
approved under section 505 of the Federal 
13
Food, Drug, and Cosmetic Act or licensed 
14
under section 351 of the Public Health 
15
Service Act after the date of enactment of 
16
this subsection, not more than 90 days 
17
after meeting with the Food and Drug Ad-
18
ministration following phase II clinical 
19
trials for such drug (or, in the case of a 
20
drug described in clause (ii), not later than 
21
March 31, 2022), the manufacturer must 
22
notify the Secretary of the manufacturer’s 
23
intent to enter into a risk-sharing value- 
24
based payment agreement under this sub-
25
04:12 Dec 12, 2019
H19
146 
•HR 19 IH
section with respect to such drug. If no 
1
such meeting has occurred, the Secretary 
2
may use discretion as to whether a poten-
3
tially curative treatment intended for one- 
4
time use may qualify for a risk-sharing 
5
value-based payment agreement under this 
6
section. A manufacturer notification of in-
7
terest shall not have any influence on a de-
8
cision for approval by the Food and Drug 
9
Administration. 
10
‘‘(ii) APPLICATION TO CERTAIN SUB-
11
SEQUENTLY
APPROVED
DRUGS.—A drug 
12
described in this clause is a covered out-
13
patient drug of a manufacturer— 
14
‘‘(I) that is approved under sec-
15
tion 505 of the Federal Food, Drug, 
16
and Cosmetic Act or licensed under 
17
section 351 of the Public Health Serv-
18
ice Act after the date of enactment of 
19
this subsection; and 
20
‘‘(II) with respect to which, as of 
21
January 1, 2022, more than 90 days 
22
have passed after the manufacturer’s 
23
meeting with the Food and Drug Ad-
24
04:12 Dec 12, 2019
H19
147 
•HR 19 IH
ministration following phase II clinical 
1
trials for such drug. 
2
‘‘(iii) 
PARALLEL
APPROVAL.—The 
3
Secretary, in coordination with the Admin-
4
istrator of the Centers for Medicare & 
5
Medicaid Services and the Commissioner of 
6
Food and Drugs, shall, to the extent prac-
7
ticable, approve a State’s request to enter 
8
into a proposed risk-sharing value-based 
9
payment agreement that otherwise meets 
10
the requirements of this subsection at the 
11
time that such a drug is approved by the 
12
Food and Drug Administration to help 
13
provide that no State that wishes to enter 
14
into such an agreement is required to pay 
15
for the drug in full at one time if the State 
16
is seeking to pay over a period of time as 
17
outlined in the proposed agreement. 
18
‘‘(iv) RULE
OF
CONSTRUCTION.— 
19
Nothing in this paragraph shall be applied 
20
or construed to modify or affect the time-
21
frames or factors involved in the Sec-
22
retary’s determination of whether to ap-
23
prove or license a drug under section 505 
24
of the Federal Food, Drug, and Cosmetic 
25
04:12 Dec 12, 2019
H19
148 
•HR 19 IH
Act or section 351 of the Public Health 
1
Service Act. 
2
‘‘(5) SPECIAL PAYMENT RULES.— 
3
‘‘(A) IN GENERAL.—Except as otherwise 
4
provided in this paragraph, with respect to an 
5
individual who is administered a unit of a cov-
6
ered outpatient drug that is purchased under a 
7
State plan by a State Medicaid agency under a 
8
risk-sharing value-based payment agreement in 
9
an installment year, the State shall remain lia-
10
ble to the manufacturer of such drug for pay-
11
ment for such unit without regard to whether 
12
the individual remains enrolled in the State 
13
plan under this title (or a waiver of such plan) 
14
for each installment year for which the State is 
15
to make installment payments for covered out-
16
patient drugs purchased under the agreement 
17
in such year. 
18
‘‘(B) DEATH.—In the case of an individual 
19
described in subparagraph (A) who dies during 
20
the period described in such subparagraph, the 
21
State plan shall not be liable for any remaining 
22
payment for the unit of the covered outpatient 
23
drug administered to the individual which is 
24
04:12 Dec 12, 2019
H19
149 
•HR 19 IH
owed under the agreement described in such 
1
subparagraph. 
2
‘‘(C) WITHDRAWAL OF APPROVAL.—In the 
3
case of a covered outpatient drug that is the 
4
subject of a risk-sharing value-based agreement 
5
between a State and a manufacturer under this 
6
subsection, including a drug approved in ac-
7
cordance with section 506(c) of the Federal 
8
Food, Drug, and Cosmetic Act, and such drug 
9
is the subject of an application that has been 
10
withdrawn by the Secretary, the State plan 
11
shall not be liable for any remaining payment 
12
that is owed under the agreement. 
13
‘‘(D) ALTERNATIVE ARRANGEMENT UNDER 
14
AGREEMENT.—Subject to approval by the Sec-
15
retary, the terms of a proposed risk-sharing 
16
value-based payment agreement submitted for 
17
approval by a State may provide that subpara-
18
graph (A) shall not apply. 
19
‘‘(E) GUIDANCE.—Not later than January 
20
1, 2022, the Secretary shall issue guidance to 
21
States establishing a process for States to no-
22
tify the Secretary when an individual who is ad-
23
ministered a unit of a covered outpatient drug 
24
that is purchased by a State plan under a risk- 
25
04:12 Dec 12, 2019
H19
150 
•HR 19 IH
sharing value-based payment agreement ceases 
1
to be enrolled under the State plan under this 
2
title (or a waiver of such plan) or dies before 
3
the end of the installment period applicable to 
4
such unit under the agreement. 
5
‘‘(6) TREATMENT OF PAYMENTS UNDER RISK- 
6
SHARING
VALUE-BASED
AGREEMENTS
FOR
PUR-
7
8
PRICE.—The Secretary shall treat any payments 
9
made to the manufacturer of a covered outpatient 
10
drug under a risk-sharing value-based payment 
11
agreement under this subsection during a rebate pe-
12
riod in the same manner that the Secretary treats 
13
payments made under a State supplemental rebate 
14
agreement 
under 
sections 
447.504(c)(19) 
and 
15
447.505(c)(7) of title 42, Code of Federal Regula-
16
tions (or any successor regulations), for purposes of 
17
determining average manufacturer price and best 
18
price under this section with respect to the covered 
19
outpatient drug and a rebate period and for pur-
20
poses of offsets required under subsection (b)(1)(B). 
21
‘‘(7) ASSESSMENTS
AND
REPORT
TO
CON-
22
GRESS.— 
23
‘‘(A) ASSESSMENTS.— 
24
04:12 Dec 12, 2019
H19
151 
•HR 19 IH
‘‘(i) IN
GENERAL.—Not later than 
1
180 days after the end of each assessment 
2
period of any risk-sharing value-based pay-
3
ment agreement for a State approved 
4
under this subsection, the Secretary shall 
5
conduct an evaluation of such agreement 
6
which shall include an evaluation by the 
7
Chief Actuary to determine whether pro-
8
gram spending under the risk-sharing 
9
value-based payment agreement aligned 
10
with the projections for the agreement 
11
made under paragraph (2)(A)(ii), including 
12
an assessment of whether actual Federal 
13
spending under this title under the agree-
14
ment was less or more than net Federal 
15
spending would have been in the absence 
16
of the agreement. 
17
‘‘(ii) ASSESSMENT PERIOD.—For pur-
18
poses of clause (i)— 
19
‘‘(I) the first assessment period 
20
for a risk-sharing value-based pay-
21
ment agreement shall be the period of 
22
time over which payments are sched-
23
uled to be made under the agreement 
24
for the first 10 individuals who are 
25
04:12 Dec 12, 2019
H19
152 
•HR 19 IH
administered covered outpatient drugs 
1
under the agreement except that such 
2
period shall not exceed the 5-year pe-
3
riod after the date on which the Sec-
4
retary approves the agreement; and 
5
‘‘(II) each subsequent assessment 
6
period for a risk-sharing value-based 
7
payment agreement shall be the 5- 
8
year period following the end of the 
9
previous assessment period. 
10
‘‘(B) RESULTS OF ASSESSMENTS.— 
11
‘‘(i) TERMINATION
OPTION.—If the 
12
Secretary determines as a result of the as-
13
sessment by the Chief Actuary under sub-
14
paragraph (A) that the actual Federal 
15
spending under this title for any covered 
16
outpatient drug that was the subject of the 
17
State’s risk-sharing value-based payment 
18
agreement was greater than the net Fed-
19
eral spending that would have resulted in 
20
the absence of the agreement, the Sec-
21
retary may terminate approval of such 
22
agreement and shall immediately conduct 
23
an assessment under this paragraph of any 
24
other ongoing risk-sharing value-based 
25
04:12 Dec 12, 2019
H19
153 
•HR 19 IH
payment agreement to which the same 
1
manufacturer is a party. 
2
‘‘(ii) REPAYMENT REQUIRED.— 
3
‘‘(I) IN
GENERAL.—If the Sec-
4
retary determines as a result of the 
5
assessment by the Chief Actuary 
6
under subparagraph (A) that the Fed-
7
eral spending under the risk-sharing 
8
value-based agreement for a covered 
9
outpatient drug that was subject to 
10
such agreement was greater than the 
11
net Federal spending that would have 
12
resulted in the absence of the agree-
13
ment, the manufacturer shall repay 
14
the difference to the State and Fed-
15
eral governments in a timely manner 
16
as determined by the Secretary. 
17
‘‘(II) TERMINATION
FOR
FAIL-
18
URE TO PAY.—The failure of a manu-
19
facturer to make repayments required 
20
under subclause (I) in a timely man-
21
ner shall result in immediate termi-
22
nation of all risk-sharing value-based 
23
agreements to which the manufacturer 
24
is a party. 
25
04:12 Dec 12, 2019
H19
154 
•HR 19 IH
‘‘(III) 
ADDITIONAL
PEN-
1
ALTIES.—In the case of a manufac-
2
turer that fails to make repayments 
3
required under subclause (I), the Sec-
4
retary may treat such manufacturer 
5
in the same manner as a manufac-
6
turer that fails to pay required re-
7
bates under this section, and the Sec-
8
retary may— 
9
‘‘(aa) suspend or terminate 
10
the manufacturer’s rebate agree-
11
ment under this section; and 
12
‘‘(bb) pursue any other rem-
13
edy that would be available if the 
14
manufacturer had failed to pay 
15
required rebates under this sec-
16
tion. 
17
‘‘(C) REPORT
TO
CONGRESS.—Not later 
18
than 5 years after the first risk-sharing value- 
19
based payment agreement is approved under 
20
this subsection, the Secretary shall submit to 
21
Congress and make available to the public a re-
22
port that includes— 
23
‘‘(i) an assessment of the impact of 
24
risk-sharing value-based payment agree-
25
04:12 Dec 12, 2019
H19
155 
•HR 19 IH
ments on access for individuals who are eli-
1
gible for benefits under a State plan or 
2
waiver under this title to medically nec-
3
essary covered outpatient drugs and re-
4
lated treatments; 
5
‘‘(ii) an analysis of the impact of such 
6
agreements on overall State and Federal 
7
spending under this title; 
8
‘‘(iii) an assessment of the impact of 
9
such agreements on drug prices, including 
10
launch price and price increases; and 
11
‘‘(iv) such recommendations to Con-
12
gress as the Secretary deems appropriate. 
13
‘‘(8) GUIDANCE AND REGULATIONS.— 
14
‘‘(A) IN GENERAL.—Not later than Janu-
15
ary 1, 2022, the Secretary shall issue guidance 
16
to States seeking to enter into risk-sharing 
17
value-based payment agreements under this 
18
subsection that includes a model template for 
19
such agreements. The Secretary may issue any 
20
additional guidance or promulgate regulations 
21
as necessary to implement and enforce the pro-
22
visions of this subsection. 
23
‘‘(B) MODEL AGREEMENTS.— 
24
04:12 Dec 12, 2019
H19
156 
•HR 19 IH
‘‘(i) IN
GENERAL.—If a State ex-
1
presses an interest in pursuing a risk-shar-
2
ing value-based payment agreement under 
3
this subsection with a manufacturer for 
4
the purchase of a covered outpatient drug, 
5
the Secretary may share with such State 
6
any risk-sharing value-based agreement be-
7
tween a State and the manufacturer for 
8
the purchase of such drug that has been 
9
approved under this subsection. While such 
10
shared agreement may serve as a template 
11
for a State that wishes to propose, the use 
12
of a previously approved agreement shall 
13
not affect the submission and approval 
14
process for approval of a proposed risk- 
15
sharing value-based payment agreement 
16
under this subsection, including the re-
17
quirements under paragraph (2)(A). 
18
‘‘(ii) CONFIDENTIALITY.—In the case 
19
of a risk-sharing value-based payment 
20
agreement that is disclosed to a State by 
21
the Secretary under this subparagraph and 
22
that is only in effect with respect to a sin-
23
gle State, the confidentiality of information 
24
04:12 Dec 12, 2019
H19
157 
•HR 19 IH
provisions 
described 
in 
subsection 
1
(b)(3)(D) shall apply to such information. 
2
‘‘(C) OIG CONSULTATION.— 
3
‘‘(i) IN
GENERAL.—The Secretary 
4
shall consult with the Office of the Inspec-
5
tor General of the Department of Health 
6
and Human Services to determine whether 
7
there are potential program integrity con-
8
cerns with agreement approvals or tem-
9
plates and address accordingly. 
10
‘‘(ii) OIG POLICY UPDATES AS NEC-
11
ESSARY.—The Inspector General of the 
12
Department of Health and Human Serv-
13
ices shall review and update, as necessary, 
14
any policies or guidelines of the Office of 
15
the Inspector General of the Department 
16
of Human Services (including policies re-
17
lated to the enforcement of section 1128B) 
18
to accommodate the use of risk-sharing 
19
value-based payment agreements in accord-
20
ance with this section. 
21
‘‘(9) RULES OF CONSTRUCTION.— 
22
‘‘(A) MODIFICATIONS.—Nothing in this 
23
subsection or any regulations promulgated 
24
under this subsection shall prohibit a State 
25
04:12 Dec 12, 2019
H19
158 
•HR 19 IH
from requesting a modification from the Sec-
1
retary to the terms of a risk-sharing value- 
2
based payment agreement. A modification that 
3
is expected to result in any increase to pro-
4
jected net State or Federal spending under the 
5
agreement shall be subject to recertification by 
6
the Chief Actuary as described in paragraph 
7
(2)(A)(ii) before the modification may be ap-
8
proved. 
9
‘‘(B) REBATE AGREEMENTS.—Nothing in 
10
this subsection shall be construed as requiring 
11
a State to enter into a risk-sharing value-based 
12
payment agreement or as limiting or super-
13
seding the ability of a State to enter into a sup-
14
plemental rebate agreement for a covered out-
15
patient drug. 
16
‘‘(C) FFP FOR PAYMENTS UNDER RISK- 
17
SHARING
VALUE-BASED
PAYMENT
AGREE-
18
MENTS.—Federal financial participation shall 
19
be available under this title for any payment 
20
made by a State to a manufacturer for a cov-
21
ered outpatient drug under a risk-sharing 
22
value-based payment agreement in accordance 
23
with this subsection, except that no Federal fi-
24
nancial participation shall be available for any 
25
04:12 Dec 12, 2019
H19
159 
•HR 19 IH
payment made by a State to a manufacturer 
1
under such an agreement on and after the ef-
2
fective date of a disapproval of such agreement 
3
by the Secretary. 
4
‘‘(D) CONTINUED APPLICATION OF OTHER 
5
PROVISIONS.—Except as expressly provided in 
6
this subsection, nothing in this subsection or in 
7
any regulations promulgated under this sub-
8
section shall affect the application of any other 
9
provision of this Act. 
10
‘‘(10) APPROPRIATIONS.—For fiscal year 2020 
11
and each fiscal year thereafter, there are appro-
12
priated to the Secretary $5,000,000 for the purpose 
13
of carrying out this subsection. 
14
‘‘(11) DEFINITIONS.—In this subsection: 
15
‘‘(A) CHIEF ACTUARY.—The term ‘Chief 
16
Actuary’ means the Chief Actuary of the Cen-
17
ters for Medicare & Medicaid Services. 
18
‘‘(B) INSTALLMENT YEAR.—The term ‘in-
19
stallment year’ means, with respect to a risk- 
20
sharing value-based payment agreement, a 12- 
21
month period during which a covered outpatient 
22
drug is administered under the agreement. 
23
‘‘(C) POTENTIALLY CURATIVE TREATMENT 
24
INTENDED FOR ONE-TIME USE.—The term ‘po-
25
04:12 Dec 12, 2019
H19
160 
•HR 19 IH
tentially curative treatment intended for one- 
1
time use’ means a treatment that consists of 
2
the administration of a covered outpatient drug 
3
that— 
4
‘‘(i) is a form of gene therapy for a 
5
rare disease, as defined by the Commis-
6
sioner of Food and Drugs, designated 
7
under section 526 of the Federal Food, 
8
Drug, and Cosmetics Act, and approved 
9
under section 505 of such Act or licensed 
10
under subsection (a) or (k) of section 351 
11
of the Public Health Service Act to treat 
12
a serious or life-threatening disease or con-
13
dition; 
14
‘‘(ii) if administered in accordance 
15
with the labeling of such drug, is expected 
16
to result in either— 
17
‘‘(I) the cure of such disease or 
18
condition; or 
19
‘‘(II) a reduction in the symp-
20
toms of such disease or condition to 
21
the extent that such disease or condi-
22
tion is not expected to lead to early 
23
mortality; and 
24
04:12 Dec 12, 2019
H19
161 
•HR 19 IH
‘‘(iii) is expected to achieve a result 
1
described in clause (ii), which may be 
2
achieved over an extended period of time, 
3
after not more than 3 administrations. 
4
‘‘(D) RELEVANT CLINICAL PARAMETER.— 
5
The term ‘relevant clinical parameter’ means, 
6
with respect to a covered outpatient drug that 
7
is the subject of a risk-sharing value-based pay-
8
ment agreement— 
9
‘‘(i) a clinical endpoint specified in the 
10
drug’s labeling or supported by one or 
11
more of the compendia described in section 
12
1861(t)(2)(B)(ii)(I) that— 
13
‘‘(I) is able to be measured or 
14
evaluated on an annual basis for each 
15
year of the agreement on an inde-
16
pendent basis by a provider or other 
17
entity; and 
18
‘‘(II) is required to be achieved 
19
(based on observed metrics in patient 
20
populations) under the terms of the 
21
agreement; or 
22
‘‘(ii) a surrogate endpoint (as defined 
23
in section 507(e)(9) of the Federal Food, 
24
Drug, and Cosmetic Act), including those 
25
04:12 Dec 12, 2019
H19
162 
•HR 19 IH
developed by patient-focused drug develop-
1
ment tools, that— 
2
‘‘(I) is able to be measured or 
3
evaluated on an annual basis for each 
4
year of the agreement on an inde-
5
pendent basis by a provider or other 
6
entity; and 
7
‘‘(II) has been qualified by the 
8
Food and Drug Administration. 
9
‘‘(E) RISK-SHARING
VALUE-BASED
PAY-
10
MENT
AGREEMENT.—The term ‘risk-sharing 
11
value-based payment agreement’ means an 
12
agreement between a State plan and a manu-
13
facturer— 
14
‘‘(i) for the purchase of a covered out-
15
patient drug of the manufacturer that is a 
16
potentially curative treatment intended for 
17
one-time use; 
18
‘‘(ii) under which payment for such 
19
drug shall be made pursuant to an install-
20
ment-based payment structure that meets 
21
the requirements of paragraph (3); 
22
‘‘(iii) which conditions payment on the 
23
achievement of at least 2 relevant clinical 
24
04:12 Dec 12, 2019
H19
163 
•HR 19 IH
parameters (as defined in subparagraph 
1
(C)); 
2
‘‘(iv) which provides that— 
3
‘‘(I) the State plan will directly 
4
reimburse the manufacturer for the 
5
drug; or 
6
‘‘(II) a third party will reimburse 
7
the manufacture in a manner ap-
8
proved by the Secretary; and 
9
‘‘(v) is approved by the Secretary in 
10
accordance with paragraph (2). 
11
‘‘(F) 
TOTAL
INSTALLMENT
YEAR 
12
AMOUNT.—The term ‘total installment year 
13
amount’ means, with respect to a risk-sharing 
14
value-based payment agreement for the pur-
15
chase of a covered outpatient drug and an in-
16
stallment year, an amount equal to the product 
17
of— 
18
‘‘(i) the unit price of the drug charged 
19
under the agreement; and 
20
‘‘(ii) the number of units of such drug 
21
administered under the agreement during 
22
such installment year.’’. 
23
(b) CONFORMING AMENDMENTS.— 
24
04:12 Dec 12, 2019
H19
164 
•HR 19 IH
(1) Section 1903(i)(10)(A) of the Social Secu-
1
rity Act (42 U.S.C. 1396b(i)(10)(A)) is amended by 
2
striking ‘‘or unless section 1927(a)(3) applies’’ and 
3
inserting ‘‘, section 1927(a)(3) applies with respect 
4
to such drugs, or such drugs are the subject of a 
5
risk-sharing value-based payment agreement under 
6
section 1927(l)’’. 
7
(2) Section 1927(b) of the Social Security Act 
8
(42 U.S.C. 1396r–8(b)) is amended— 
9
(A) in paragraph (1)(A), by inserting ‘‘(ex-
10
cept for drugs for which payment is made by a 
11
State under a risk-sharing value-based payment 
12
agreement under subsection (l))’’ after ‘‘under 
13
the State plan for such period’’; and 
14
(B) in paragraph (3)— 
15
(i) in subparagraph (C)(i), by insert-
16
ing ‘‘or subsection (l)(2)(A)’’ after ‘‘sub-
17
paragraph (A)’’; and 
18
(ii) in subparagraph (D), in the mat-
19
ter preceding clause (i), by inserting ‘‘, 
20
under subsection (l)(2)(A),’’ after ‘‘under 
21
this paragraph’’. 
22
04:12 Dec 12, 2019
H19
165 
•HR 19 IH
SEC. 208. APPLYING MEDICAID DRUG REBATE REQUIRE-
1
MENT TO DRUGS PROVIDED AS PART OF OUT-
2
PATIENT HOSPITAL SERVICES. 
3
(a) IN GENERAL.—Section 1927(k)(3) of the Social 
4
Security Act (42 U.S.C. 1396r–8(k)(3)) is amended to 
5
read as follows: 
6
‘‘(3) LIMITING DEFINITION.— 
7
‘‘(A) IN
GENERAL.—The term ‘covered 
8
outpatient drug’ does not include any drug, bio-
9
logical product, or insulin provided as part of, 
10
or as incident to and in the same setting as, 
11
any of the following (and for which payment 
12
may be made under this title as part of pay-
13
ment for the following and not as direct reim-
14
bursement for the drug): 
15
‘‘(i) Inpatient hospital services. 
16
‘‘(ii) Hospice services. 
17
‘‘(iii) Dental services, except that 
18
drugs for which the State plan authorizes 
19
direct reimbursement to the dispensing 
20
dentist are covered outpatient drugs. 
21
‘‘(iv) Physicians’ services. 
22
‘‘(v) Outpatient hospital services. 
23
‘‘(vi) Nursing facility services and 
24
services provided by an intermediate care 
25
facility for the mentally retarded. 
26
04:12 Dec 12, 2019
H19
166 
•HR 19 IH
‘‘(vii) Other laboratory and x-ray serv-
1
ices. 
2
‘‘(viii) Renal dialysis. 
3
‘‘(B) OTHER
EXCLUSIONS.—Such term 
4
also does not include any such drug or product 
5
for which a National Drug Code number is not 
6
required by the Food and Drug Administration 
7
or a drug or biological used for a medical indi-
8
cation which is not a medically accepted indica-
9
tion. 
10
‘‘(C) STATE OPTION.—At the option of a 
11
State, such term may include any drug, biologi-
12
cal product, or insulin for which the State is 
13
the primary payer under this title or a dem-
14
onstration project concerning this title, and that 
15
is provided on an outpatient basis as part of, or 
16
as incident to and in the same setting as, de-
17
scribed in clause (iv) or (v) of subparagraph (A) 
18
and for which payment is made as part of pay-
19
ment for such services. 
20
‘‘(D) NO EFFECT ON BEST PRICE.—Any 
21
drug, biological product, or insulin excluded 
22
from the definition of such term as a result of 
23
this paragraph shall be treated as a covered 
24
outpatient drug for purposes of determining the 
25
04:12 Dec 12, 2019
H19
167 
•HR 19 IH
best price (as defined in subsection (c)(1)(C)) 
1
for such drug, biological product, or insulin.’’. 
2
(b) EFFECTIVE
DATE; IMPLEMENTATION
GUID-
3
ANCE.— 
4
(1) IN
GENERAL.—The amendment made by 
5
subsection (a) shall take effect on the date that is 
6
1 year after the date of enactment of this Act. 
7
(2) IMPLEMENTATION
AND
GUIDANCE.—Not 
8
later than 1 year after the date of enactment of this 
9
Act, the Secretary of Health and Human Services 
10
shall issue guidance and relevant informational bul-
11
letins for States, manufacturers (as defined in sec-
12
tion 1927(k)(5) of the Social Security Act (42 
13
U.S.C. 1396r–8(k)(5))), and other relevant stake-
14
holders, including health care providers, regarding 
15
implementation of the amendment made by sub-
16
section (a). 
17
TITLE III—FOOD AND DRUG 
18
ADMINISTRATION 
19
Subtitle A—CREATES Act 
20
SEC. 301. ACTIONS FOR DELAYS OF GENERIC DRUGS AND 
21
BIOSIMILAR BIOLOGICAL PRODUCTS. 
22
(a) DEFINITIONS.—In this section— 
23
(1) the term ‘‘commercially reasonable, market- 
24
based terms’’ means— 
25
04:12 Dec 12, 2019
H19
168 
•HR 19 IH
(A) a nondiscriminatory price for the sale 
1
of the covered product at or below, but not 
2
greater than, the most recent wholesale acquisi-
3
tion cost for the drug, as defined in section 
4
1847A(c)(6)(B) of the Social Security Act (42 
5
U.S.C. 1395w–3a(c)(6)(B)); 
6
(B) a schedule for delivery that results in 
7
the transfer of the covered product to the eligi-
8
ble product developer consistent with the timing 
9
under subsection (b)(2)(A)(iv); and 
10
(C) no additional conditions are imposed 
11
on the sale of the covered product; 
12
(2) the term ‘‘covered product’’— 
13
(A) means— 
14
(i) any drug approved under sub-
15
section (c) or (j) of section 505 of the Fed-
16
eral Food, Drug, and Cosmetic Act (21 
17
U.S.C. 355) or biological product licensed 
18
under subsection (a) or (k) of section 351 
19
of the Public Health Service Act (42 
20
U.S.C. 262); 
21
(ii) any combination of a drug or bio-
22
logical product described in clause (i); or 
23
(iii) when reasonably necessary to 
24
support approval of an application under 
25
04:12 Dec 12, 2019
H19
169 
•HR 19 IH
section 505 of the Federal Food, Drug, 
1
and Cosmetic Act (21 U.S.C. 355), or sec-
2
tion 351 of the Public Health Service Act 
3
(42 U.S.C. 262), as applicable, or other-
4
wise meet the requirements for approval 
5
under either such section, any product, in-
6
cluding any device, that is marketed or in-
7
tended for use with such a drug or biologi-
8
cal product; and 
9
(B) does not include any drug or biological 
10
product that appears on the drug shortage list 
11
in effect under section 506E of the Federal 
12
Food, Drug, and Cosmetic Act (21 U.S.C. 
13
356e), unless— 
14
(i) the drug or biological product has 
15
been on the drug shortage list in effect 
16
under such section 506E continuously for 
17
more than 6 months; or 
18
(ii) the Secretary determines that in-
19
clusion of the drug or biological product as 
20
a covered product is likely to contribute to 
21
alleviating or preventing a shortage; 
22
(3) the term ‘‘device’’ has the meaning given 
23
the term in section 201 of the Federal Food, Drug, 
24
and Cosmetic Act (21 U.S.C. 321); 
25
04:12 Dec 12, 2019
H19
170 
•HR 19 IH
(4) the term ‘‘eligible product developer’’ means 
1
a person that seeks to develop a product for ap-
2
proval pursuant to an application for approval under 
3
subsection (b)(2) or (j) of section 505 of the Federal 
4
Food, Drug, and Cosmetic Act (21 U.S.C. 355) or 
5
for licensing pursuant to an application under sec-
6
tion 351(k) of the Public Health Service Act (42 
7
U.S.C. 262(k)); 
8
(5) the term ‘‘license holder’’ means the holder 
9
of an application approved under subsection (c) or 
10
(j) of section 505 of the Federal Food, Drug, and 
11
Cosmetic Act (21 U.S.C. 355) or the holder of a li-
12
cense under subsection (a) or (k) of section 351 of 
13
the Public Health Service Act (42 U.S.C. 262) for 
14
a covered product; 
15
(6) the term ‘‘REMS’’ means a risk evaluation 
16
and mitigation strategy under section 505–1 of the 
17
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
18
355–1); 
19
(7) the term ‘‘REMS with ETASU’’ means a 
20
REMS that contains elements to assure safe use 
21
under section 505–1(f) of the Federal Food, Drug, 
22
and Cosmetic Act (21 U.S.C. 355–1(f)); 
23
(8) the term ‘‘Secretary’’ means the Secretary 
24
of Health and Human Services; 
25
04:12 Dec 12, 2019
H19
171 
•HR 19 IH
(9) the term ‘‘single, shared system of elements 
1
to assure safe use’’ means a single, shared system 
2
of elements to assure safe use under section 505– 
3
1(f) of the Federal Food, Drug, and Cosmetic Act 
4
(21 U.S.C. 355–1(f)); and 
5
(10) the term ‘‘sufficient quantities’’ means an 
6
amount of a covered product that the eligible prod-
7
uct developer determines allows it to— 
8
(A) conduct testing to support an applica-
9
tion under— 
10
(i) subsection (b)(2) or (j) of section 
11
505 of the Federal Food, Drug, and Cos-
12
metic Act (21 U.S.C. 355); or 
13
(ii) section 351(k) of the Public 
14
Health Service Act (42 U.S.C. 262(k)); 
15
and 
16
(B) fulfill any regulatory requirements re-
17
lating to approval of such an application. 
18
(b) CIVIL ACTION FOR FAILURE TO PROVIDE SUFFI-
19
CIENT QUANTITIES OF A COVERED PRODUCT.— 
20
(1) IN GENERAL.—An eligible product developer 
21
may bring a civil action against the license holder 
22
for a covered product seeking relief under this sub-
23
section in an appropriate district court of the United 
24
States alleging that the license holder has declined 
25
04:12 Dec 12, 2019
H19
172 
•HR 19 IH
to provide sufficient quantities of the covered prod-
1
uct to the eligible product developer on commercially 
2
reasonable, market-based terms. 
3
(2) ELEMENTS.— 
4
(A) IN GENERAL.—To prevail in a civil ac-
5
tion brought under paragraph (1), an eligible 
6
product developer shall prove, by a preponder-
7
ance of the evidence— 
8
(i) that— 
9
(I) the covered product is not 
10
subject to a REMS with ETASU; or 
11
(II) if the covered product is sub-
12
ject to a REMS with ETASU— 
13
(aa) the eligible product de-
14
veloper has obtained a covered 
15
product authorization from the 
16
Secretary in accordance with sub-
17
paragraph (B); and 
18
(bb) the eligible product de-
19
veloper has provided a copy of 
20
the covered product authorization 
21
to the license holder; 
22
(ii) that, as of the date on which the 
23
civil action is filed, the product developer 
24
has not obtained sufficient quantities of 
25
04:12 Dec 12, 2019
H19
173 
•HR 19 IH
the covered product on commercially rea-
1
sonable, market-based terms; 
2
(iii) that the eligible product developer 
3
has submitted a written request to pur-
4
chase sufficient quantities of the covered 
5
product to the license holder and such re-
6
quest— 
7
(I) was sent to a named cor-
8
porate officer of the license holder; 
9
(II) was made by certified or reg-
10
istered mail with return receipt re-
11
quested; 
12
(III) specified an individual as 
13
the point of contact for the license 
14
holder to direct communications re-
15
lated to the sale of the covered prod-
16
uct to the eligible product developer 
17
and a means for electronic and writ-
18
ten communications with that indi-
19
vidual; and 
20
(IV) specified an address to 
21
which the covered product was to be 
22
shipped upon reaching an agreement 
23
to transfer the covered product; and 
24
04:12 Dec 12, 2019
H19
174 
•HR 19 IH
(iv) that the license holder has not de-
1
livered to the eligible product developer 
2
sufficient quantities of the covered product 
3
on commercially reasonable, market-based 
4
terms— 
5
(I) for a covered product that is 
6
not subject to a REMS with ETASU, 
7
by the date that is 31 days after the 
8
date on which the license holder re-
9
ceived the request for the covered 
10
product; and 
11
(II) for a covered product that is 
12
subject to a REMS with ETASU, by 
13
31 days after the later of— 
14
(aa) the date on which the 
15
license holder received the re-
16
quest for the covered product; or 
17
(bb) the date on which the 
18
license holder received a copy of 
19
the covered product authorization 
20
issued by the Secretary in ac-
21
cordance with subparagraph (B). 
22
(B) AUTHORIZATION FOR COVERED PROD-
23
UCT SUBJECT TO A REMS WITH ETASU.— 
24
04:12 Dec 12, 2019
H19
175 
•HR 19 IH
(i) REQUEST.—An eligible product de-
1
veloper may submit to the Secretary a 
2
written request for the eligible product de-
3
veloper to be authorized to obtain suffi-
4
cient quantities of an individual covered 
5
product subject to a REMS with ETASU. 
6
(ii) AUTHORIZATION.—Not later than 
7
120 days after the date on which a request 
8
under clause (i) is received, the Secretary 
9
shall, by written notice, authorize the eligi-
10
ble product developer to obtain sufficient 
11
quantities of an individual covered product 
12
subject to a REMS with ETASU for pur-
13
poses of— 
14
(I) development and testing that 
15
does not involve human clinical trials, 
16
if the eligible product developer has 
17
agreed to comply with any conditions 
18
the Secretary determines necessary; or 
19
(II) development and testing that 
20
involves human clinical trials, if the 
21
eligible product developer has— 
22
(aa)(AA) submitted proto-
23
cols, 
informed 
consent 
docu-
24
ments, and informational mate-
25
04:12 Dec 12, 2019
H19
176 
•HR 19 IH
rials for testing that include pro-
1
tections that provide safety pro-
2
tections comparable to those pro-
3
vided by the REMS for the cov-
4
ered product; or 
5
(BB) otherwise satisfied the 
6
Secretary that such protections 
7
will be provided; and 
8
(bb) met any other require-
9
ments the Secretary may estab-
10
lish. 
11
(iii) NOTICE.—A covered product au-
12
thorization issued under this subparagraph 
13
shall state that the provision of the covered 
14
product by the license holder under the 
15
terms of the authorization will not be a 
16
violation of the REMS for the covered 
17
product. 
18
(3) AFFIRMATIVE DEFENSE.—In a civil action 
19
brought under paragraph (1), it shall be an affirma-
20
tive defense, on which the defendant has the burden 
21
of persuasion by a preponderance of the evidence— 
22
(A) that, on the date on which the eligible 
23
product developer requested to purchase suffi-
24
04:12 Dec 12, 2019
H19
177 
•HR 19 IH
cient quantities of the covered product from the 
1
license holder— 
2
(i) neither the license holder nor any 
3
of its agents, wholesalers, or distributors 
4
was engaged in the manufacturing or com-
5
mercial marketing of the covered product; 
6
and 
7
(ii) neither the license holder nor any 
8
of its agents, wholesalers, or distributors 
9
otherwise had access to inventory of the 
10
covered product to supply to the eligible 
11
product developer on commercially reason-
12
able, market-based terms; 
13
(B) that— 
14
(i) the license holder sells the covered 
15
product through agents, distributors, or 
16
wholesalers; 
17
(ii) the license holder has placed no 
18
restrictions, explicit or implicit, on its 
19
agents, distributors, or wholesalers to sell 
20
covered products to eligible product devel-
21
opers; and 
22
(iii) the covered product can be pur-
23
chased by the eligible product developer in 
24
sufficient quantities on commercially rea-
25
04:12 Dec 12, 2019
H19
178 
•HR 19 IH
sonable, market-based terms from the 
1
agents, distributors, or wholesalers of the 
2
license holder; or 
3
(C) that the license holder made an offer 
4
to the individual specified pursuant to para-
5
graph (2)(A)(iii)(III), by a means of commu-
6
nication (electronic, written, or both) specified 
7
pursuant to such paragraph, to sell sufficient 
8
quantities of the covered product to the eligible 
9
product developer at commercially reasonable 
10
market-based terms— 
11
(i) for a covered product that is not 
12
subject to a REMS with ETASU, by the 
13
date that is 14 days after the date on 
14
which the license holder received the re-
15
quest for the covered product, and the eli-
16
gible product developer did not accept such 
17
offer by the date that is 7 days after the 
18
date on which the eligible product devel-
19
oper received such offer from the license 
20
holder; or 
21
(ii) for a covered product that is sub-
22
ject to a REMS with ETASU, by the date 
23
that is 20 days after the date on which the 
24
license holder received the request for the 
25
04:12 Dec 12, 2019
H19
179 
•HR 19 IH
covered product, and the eligible product 
1
developer did not accept such offer by the 
2
date that is 10 days after the date on 
3
which the eligible product developer re-
4
ceived such offer from the license holder. 
5
(4) REMEDIES.— 
6
(A) IN GENERAL.—If an eligible product 
7
developer prevails in a civil action brought 
8
under paragraph (1), the court shall— 
9
(i) order the license holder to provide 
10
to the eligible product developer without 
11
delay sufficient quantities of the covered 
12
product on commercially reasonable, mar-
13
ket-based terms; 
14
(ii) award to the eligible product de-
15
veloper reasonable attorney’s fees and costs 
16
of the civil action; and 
17
(iii) award to the eligible product de-
18
veloper a monetary amount sufficient to 
19
deter the license holder from failing to pro-
20
vide eligible product developers with suffi-
21
cient quantities of a covered product on 
22
commercially 
reasonable, 
market-based 
23
terms, if the court finds, by a preponder-
24
ance of the evidence— 
25
04:12 Dec 12, 2019
H19
180 
•HR 19 IH
(I) that the license holder delayed 
1
providing sufficient quantities of the 
2
covered product to the eligible product 
3
developer without a legitimate busi-
4
ness justification; or 
5
(II) that the license holder failed 
6
to comply with an order issued under 
7
clause (i). 
8
(B) MAXIMUM
MONETARY
AMOUNT.—A 
9
monetary amount awarded under subparagraph 
10
(A)(iii) shall not be greater than the revenue 
11
that the license holder earned on the covered 
12
product during the period— 
13
(i) beginning on— 
14
(I) for a covered product that is 
15
not subject to a REMS with ETASU, 
16
the date that is 31 days after the date 
17
on which the license holder received 
18
the request; or 
19
(II) for a covered product that is 
20
subject to a REMS with ETASU, the 
21
date that is 31 days after the later 
22
of— 
23
04:12 Dec 12, 2019
H19
181 
•HR 19 IH
(aa) the date on which the 
1
license holder received the re-
2
quest; or 
3
(bb) the date on which the 
4
license holder received a copy of 
5
the covered product authorization 
6
issued by the Secretary in ac-
7
cordance with paragraph (2)(B); 
8
and 
9
(ii) ending on the date on which the 
10
eligible product developer received suffi-
11
cient quantities of the covered product. 
12
(C) AVOIDANCE
OF
DELAY.—The court 
13
may issue an order under subparagraph (A)(i) 
14
before conducting further proceedings that may 
15
be necessary to determine whether the eligible 
16
product developer is entitled to an award under 
17
clause (ii) or (iii) of subparagraph (A), or the 
18
amount of any such award. 
19
(c) LIMITATION OF LIABILITY.—A license holder for 
20
a covered product shall not be liable for any claim under 
21
Federal, State, or local law arising out of the failure of 
22
an eligible product developer to follow adequate safeguards 
23
to assure safe use of the covered product during develop-
24
ment or testing activities described in this section, includ-
25
04:12 Dec 12, 2019
H19
182 
•HR 19 IH
ing transportation, handling, use, or disposal of the cov-
1
ered product by the eligible product developer. 
2
(d) NO VIOLATION OF REMS.—Section 505–1 of the 
3
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355– 
4
1) is amended by adding at the end the following new sub-
5
section: 
6
‘‘(l) PROVISION OF SAMPLES NOT A VIOLATION OF 
7
STRATEGY.—The provision of samples of a covered prod-
8
uct to an eligible product developer (as those terms are 
9
defined in section 301(a) of the Lower Costs, More Cures 
10
Act of 2019) shall not be considered a violation of the 
11
requirements of any risk evaluation and mitigation strat-
12
egy that may be in place under this section for such 
13
drug.’’. 
14
(e) RULE OF CONSTRUCTION.— 
15
(1) DEFINITION.—In this subsection, the term 
16
‘‘antitrust laws’’— 
17
(A) has the meaning given the term in 
18
subsection (a) of the first section of the Clayton 
19
Act (15 U.S.C. 12); and 
20
(B) includes section 5 of the Federal 
21
Trade Commission Act (15 U.S.C. 45) to the 
22
extent that such section applies to unfair meth-
23
ods of competition. 
24
04:12 Dec 12, 2019
H19
183 
•HR 19 IH
(2) ANTITRUST LAWS.—Nothing in this section 
1
shall be construed to limit the operation of any pro-
2
vision of the antitrust laws. 
3
SEC. 302. REMS APPROVAL PROCESS FOR SUBSEQUENT 
4
FILERS. 
5
Section 505–1 of the Federal Food, Drug, and Cos-
6
metic Act (21 U.S.C. 355–1), as amended by section 301, 
7
is further amended— 
8
(1) in subsection (g)(4)(B)— 
9
(A) in clause (i) by striking ‘‘or’’ after the 
10
semicolon; 
11
(B) in clause (ii) by striking the period at 
12
the end and inserting ‘‘; or’’; and 
13
(C) by adding at the end the following: 
14
‘‘(iii) accommodate different, com-
15
parable aspects of the elements to assure 
16
safe use for a drug that is the subject of 
17
an application under section 505(j), and 
18
the applicable listed drug.’’; 
19
(2) in subsection (i)(1), by striking subpara-
20
graph (C) and inserting the following: 
21
‘‘(C)(i) Elements to assure safe use, if re-
22
quired under subsection (f) for the listed drug, 
23
which, subject to clause (ii), for a drug that is 
24
04:12 Dec 12, 2019
H19
184 
•HR 19 IH
the subject of an application under section 
1
505(j) may use— 
2
‘‘(I) a single, shared system with the 
3
listed drug under subsection (f); or 
4
‘‘(II) a different, comparable aspect of 
5
the elements to assure safe use under sub-
6
section (f). 
7
‘‘(ii) The Secretary may require a drug 
8
that is the subject of an application under sec-
9
tion 505(j) and the listed drug to use a single, 
10
shared system under subsection (f), if the Sec-
11
retary determines that no different, comparable 
12
aspect of the elements to assure safe use could 
13
satisfy the requirements of subsection (f).’’; 
14
(3) in subsection (i), by adding at the end the 
15
following: 
16
‘‘(3) SHARED
REMS.—If the Secretary ap-
17
proves, in accordance with paragraph (1)(C)(i)(II), a 
18
different, comparable aspect of the elements to as-
19
sure safe use under subsection (f) for a drug that 
20
is the subject of an abbreviated new drug application 
21
under section 505(j), the Secretary may require that 
22
such different comparable aspect of the elements to 
23
assure safe use can be used with respect to any 
24
other drug that is the subject of an application 
25
04:12 Dec 12, 2019
H19
185 
•HR 19 IH
under section 505(j) or 505(b) that references the 
1
same listed drug.’’; and 
2
(4) by adding at the end the following: 
3
‘‘(m) SEPARATE REMS.—When used in this section, 
4
the terms ‘different, comparable aspect of the elements to 
5
assure safe use’ or ‘different, comparable approved risk 
6
evaluation and mitigation strategies’ means a risk evalua-
7
tion and mitigation strategy for a drug that is the subject 
8
of an application under section 505(j) that uses different 
9
methods or operational means than the strategy required 
10
under subsection (a) for the applicable listed drug, or 
11
other application under section 505(j) with the same such 
12
listed drug, but achieves the same level of safety as such 
13
strategy.’’. 
14
SEC. 303. RULE OF CONSTRUCTION. 
15
(a) IN GENERAL.—Nothing in this subtitle, the 
16
amendments made by this subtitle, or in section 505–1 
17
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
18
355–1), shall be construed as— 
19
(1) prohibiting a license holder from providing 
20
an eligible product developer access to a covered 
21
product in the absence of an authorization under 
22
this subtitle; or 
23
(2) in any way negating the applicability of a 
24
REMS with ETASU, as otherwise required under 
25
04:12 Dec 12, 2019
H19
186 
•HR 19 IH
such section 505–1, with respect to such covered 
1
product. 
2
(b) DEFINITIONS.—In this section, the terms ‘‘cov-
3
ered product’’, ‘‘eligible product developer’’, ‘‘license hold-
4
er’’, and ‘‘REMS with ETASU’’ have the meanings given 
5
such terms in section 301(a). 
6
Subtitle B—Pay-for-Delay 
7
SEC. 311. UNLAWFUL AGREEMENTS. 
8
(a) AGREEMENTS PROHIBITED.—Subject to sub-
9
sections (b) and (c), it shall be unlawful for an NDA or 
10
BLA holder and a subsequent filer (or for two subsequent 
11
filers) to enter into, or carry out, an agreement resolving 
12
or settling a covered patent infringement claim on a final 
13
or interim basis if under such agreement— 
14
(1) a subsequent filer directly or indirectly re-
15
ceives from such holder (or in the case of such an 
16
agreement between two subsequent filers, the other 
17
subsequent filer) anything of value, including a li-
18
cense; and 
19
(2) the subsequent filer agrees to limit or fore-
20
go research on, or development, manufacturing, 
21
marketing, or sales, for any period of time, of the 
22
covered product that is the subject of the application 
23
described in subparagraph (A) or (B) of subsection 
24
(g)(8). 
25
04:12 Dec 12, 2019
H19
187 
•HR 19 IH
(b) EXCLUSION.—It shall not be unlawful under sub-
1
section (a) if a party to an agreement described in such 
2
subsection demonstrates by clear and convincing evidence 
3
that the value described in subsection (a)(1) is compensa-
4
tion solely for other goods or services that the subsequent 
5
filer has promised to provide. 
6
(c) LIMITATION.—Nothing in this section shall pro-
7
hibit an agreement resolving or settling a covered patent 
8
infringement claim in which the consideration granted by 
9
the NDA or BLA holder to the subsequent filer (or from 
10
one subsequent filer to another) as part of the resolution 
11
or settlement includes only one or more of the following: 
12
(1) The right to market the covered product 
13
that is the subject of the application described in 
14
subparagraph (A) or (B) of subsection (g)(8) in the 
15
United States before the expiration of— 
16
(A) any patent that is the basis of the cov-
17
ered patent infringement claim; or 
18
(B) any patent right or other statutory ex-
19
clusivity that would prevent the marketing of 
20
such covered product. 
21
(2) A payment for reasonable litigation ex-
22
penses not to exceed $7,500,000 in the aggregate. 
23
(3) A covenant not to sue on any claim that 
24
such covered product infringes a patent. 
25
04:12 Dec 12, 2019
H19
188 
•HR 19 IH
(d) ENFORCEMENT BY FEDERAL TRADE COMMIS-
1
SION.— 
2
(1) GENERAL APPLICATION.—The requirements 
3
of this section apply, according to their terms, to an 
4
NDA or BLA holder or subsequent filer that is— 
5
(A) a person, partnership, or corporation 
6
over which the Commission has authority pur-
7
suant to section 5(a)(2) of the Federal Trade 
8
Commission Act (15 U.S.C. 45(a)(2)); or 
9
(B) a person, partnership, or corporation 
10
over which the Commission would have author-
11
ity pursuant to such section but for the fact 
12
that such person, partnership, or corporation is 
13
not organized to carry on business for its own 
14
profit or that of its members. 
15
(2) UNFAIR OR DECEPTIVE ACTS OR PRACTICES 
16
ENFORCEMENT AUTHORITY.— 
17
(A) IN GENERAL.—A violation of this sec-
18
tion shall be treated as an unfair or deceptive 
19
act or practice in violation of section 5(a)(1) of 
20
the Federal Trade Commission Act (15 U.S.C. 
21
45(a)(1)). 
22
(B) POWERS OF COMMISSION.—Except as 
23
provided in subparagraph (C) and paragraphs 
24
(1)(B) and (3)— 
25
04:12 Dec 12, 2019
H19
189 
•HR 19 IH
(i) the Commission shall enforce this 
1
section in the same manner, by the same 
2
means, and with the same jurisdiction, 
3
powers, and duties as though all applicable 
4
terms and provisions of the Federal Trade 
5
Commission Act (15 U.S.C. 41 et seq.) 
6
were incorporated into and made a part of 
7
this section; and 
8
(ii) any NDA or BLA holder or subse-
9
quent filer that violates this section shall 
10
be subject to the penalties and entitled to 
11
the privileges and immunities provided in 
12
the Federal Trade Commission Act. 
13
(C) JUDICIAL REVIEW.—In the case of a 
14
cease and desist order issued by the Commis-
15
sion under section 5 of the Federal Trade Com-
16
mission Act (15 U.S.C. 45) for violation of this 
17
section, a party to such order may obtain judi-
18
cial review of such order as provided in such 
19
section 5, except that— 
20
(i) such review may only be obtained 
21
in— 
22
(I) the United States Court of 
23
Appeals for the District of Columbia 
24
Circuit; 
25
04:12 Dec 12, 2019
H19
190 
•HR 19 IH
(II) the United States Court of 
1
Appeals for the circuit in which the 
2
ultimate parent entity, as defined in 
3
section 801.1(a)(3) of title 16, Code 
4
of Federal Regulations, or any suc-
5
cessor thereto, of the NDA or BLA 
6
holder (if any such holder is a party 
7
to such order) is incorporated as of 
8
the date that the application described 
9
in subparagraph (A) or (B) of sub-
10
section (g)(8) or an approved applica-
11
tion that is deemed to be a license for 
12
a biological product under section 
13
351(k) of the Public Health Service 
14
Act (42 U.S.C. 262(k)) pursuant to 
15
section 7002(e)(4) of the Biologics 
16
Price Competition and Innovation Act 
17
of 2009 (Public Law 111–148; 124 
18
Stat. 817) is submitted to the Com-
19
missioner of Food and Drugs; or 
20
(III) the United States Court of 
21
Appeals for the circuit in which the 
22
ultimate parent entity, as so defined, 
23
of any subsequent filer that is a party 
24
to such order is incorporated as of the 
25
04:12 Dec 12, 2019
H19
191 
•HR 19 IH
date that the application described in 
1
subparagraph (A) or (B) of subsection 
2
(g)(8) is submitted to the Commis-
3
sioner of Food and Drugs; and 
4
(ii) the petition for review shall be 
5
filed in the court not later than 30 days 
6
after such order is served on the party 
7
seeking review. 
8
(3) ADDITIONAL ENFORCEMENT AUTHORITY.— 
9
(A) CIVIL
PENALTY.—The Commission 
10
may commence a civil action to recover a civil 
11
penalty in a district court of the United States 
12
against any NDA or BLA holder or subsequent 
13
filer that violates this section. 
14
(B) SPECIAL
RULE
FOR
RECOVERY
OF 
15
PENALTY
IF
CEASE
AND
DESIST
ORDER 
16
ISSUED.— 
17
(i) IN GENERAL.—If the Commission 
18
has issued a cease and desist order in a 
19
proceeding under section 5 of the Federal 
20
Trade Commission Act (15 U.S.C. 45) for 
21
violation of this section— 
22
(I) the Commission may com-
23
mence a civil action under subpara-
24
graph (A) to recover a civil penalty 
25
04:12 Dec 12, 2019
H19
192 
•HR 19 IH
against any party to such order at 
1
any time before the expiration of the 
2
1-year period beginning on the date 
3
on which such order becomes final 
4
under section 5(g) of such Act (15 
5
U.S.C. 45(g)); and 
6
(II) in such civil action, the find-
7
ings of the Commission as to the ma-
8
terial facts in such proceeding shall be 
9
conclusive, unless— 
10
(aa) the terms of such order 
11
expressly provide that the Com-
12
mission’s findings shall not be 
13
conclusive; or 
14
(bb) such order became final 
15
by reason of section 5(g)(1) of 
16
such Act (15 U.S.C. 45(g)(1)), in 
17
which case such findings shall be 
18
conclusive if supported by evi-
19
dence. 
20
(ii) RELATIONSHIP TO PENALTY FOR 
21
VIOLATION
OF
AN
ORDER.—The penalty 
22
provided in clause (i) for violation of this 
23
section is separate from and in addition to 
24
any penalty that may be incurred for viola-
25
04:12 Dec 12, 2019
H19
193 
•HR 19 IH
tion of an order of the Commission under 
1
section 5(l) of the Federal Trade Commis-
2
sion Act (15 U.S.C. 45(l)). 
3
(C) AMOUNT OF PENALTY.— 
4
(i) IN GENERAL.—The amount of a 
5
civil penalty imposed in a civil action under 
6
subparagraph (A) on a party to an agree-
7
ment described in subsection (a) shall be 
8
sufficient to deter violations of this section, 
9
but in no event greater than— 
10
(I) if such party is the NDA or 
11
BLA holder (or, in the case of an 
12
agreement between two subsequent fil-
13
ers, the subsequent filer who gave the 
14
value described in subsection (a)(1)), 
15
the greater of— 
16
(aa) 3 times the value re-
17
ceived by such NDA or BLA 
18
holder (or by such subsequent 
19
filer) that is reasonably attrib-
20
utable to the violation of this sec-
21
tion; or 
22
(bb) 3 times the value given 
23
to the subsequent filer (or to the 
24
other subsequent filer) reason-
25
04:12 Dec 12, 2019
H19
194 
•HR 19 IH
ably attributable to the violation 
1
of this section; and 
2
(II) if such party is the subse-
3
quent filer (or, in the case of an 
4
agreement between two subsequent fil-
5
ers, the subsequent filer who received 
6
the value described in subsection 
7
(a)(1)), 3 times the value received by 
8
such subsequent filer that is reason-
9
ably attributable to the violation of 
10
this section. 
11
(ii) FACTORS FOR CONSIDERATION.— 
12
In determining such amount, the court 
13
shall take into account— 
14
(I) the nature, circumstances, ex-
15
tent, and gravity of the violation; 
16
(II) with respect to the violator, 
17
the degree of culpability, any history 
18
of violations, the ability to pay, any 
19
effect on the ability to continue doing 
20
business, profits earned by the NDA 
21
or BLA holder (or, in the case of an 
22
agreement between two subsequent fil-
23
ers, the subsequent filer who gave the 
24
value described in subsection (a)(1)), 
25
04:12 Dec 12, 2019
H19
195 
•HR 19 IH
compensation received by the subse-
1
quent filer (or, in the case of an 
2
agreement between two subsequent fil-
3
ers, the subsequent filer who received 
4
the value described in subsection 
5
(a)(1)), and the amount of commerce 
6
affected; and 
7
(III) other matters that justice 
8
requires. 
9
(D) INJUNCTIONS AND OTHER EQUITABLE 
10
RELIEF.—In a civil action under subparagraph 
11
(A), the United States district courts are em-
12
powered to grant mandatory injunctions and 
13
such other and further equitable relief as they 
14
deem appropriate. 
15
(4) REMEDIES
IN
ADDITION.—Remedies pro-
16
vided in this subsection are in addition to, and not 
17
in lieu of, any other remedy provided by Federal 
18
law. 
19
(5) PRESERVATION OF AUTHORITY OF COMMIS-
20
SION.—Nothing in this section shall be construed to 
21
affect any authority of the Commission under any 
22
other provision of law. 
23
(e) FEDERAL TRADE COMMISSION RULEMAKING.— 
24
The Commission may, in its discretion, by rule promul-
25
04:12 Dec 12, 2019
H19
196 
•HR 19 IH
gated under section 553 of title 5, United States Code, 
1
exempt from this section certain agreements described in 
2
subsection (a) if the Commission finds such agreements 
3
to be in furtherance of market competition and for the 
4
benefit of consumers. 
5
(f) ANTITRUST LAWS.—Nothing in this section shall 
6
modify, impair, limit, or supersede the applicability of the 
7
antitrust laws as defined in subsection (a) of the first sec-
8
tion of the Clayton Act (15 U.S.C. 12(a)), and of section 
9
5 of the Federal Trade Commission Act (15 U.S.C. 45) 
10
to the extent that such section 5 applies to unfair methods 
11
of competition. Nothing in this section shall modify, im-
12
pair, limit, or supersede the right of a subsequent filer 
13
to assert claims or counterclaims against any person, 
14
under the antitrust laws or other laws relating to unfair 
15
competition. 
16
(g) DEFINITIONS.—In this section: 
17
(1) AGREEMENT
RESOLVING
OR
SETTLING
A 
18
COVERED
PATENT
INFRINGEMENT
CLAIM.—The 
19
term ‘‘agreement resolving or settling a covered pat-
20
ent infringement claim’’ means any agreement 
21
that— 
22
(A) resolves or settles a covered patent in-
23
fringement claim; or 
24
04:12 Dec 12, 2019
H19
197 
•HR 19 IH
(B) is contingent upon, provides for a con-
1
tingent condition for, or is otherwise related to 
2
the resolution or settlement of a covered patent 
3
infringement claim. 
4
(2) COMMISSION.—The term ‘‘Commission’’ 
5
means the Federal Trade Commission. 
6
(3) COVERED PATENT INFRINGEMENT CLAIM.— 
7
The term ‘‘covered patent infringement claim’’ 
8
means an allegation made by the NDA or BLA hold-
9
er to a subsequent filer (or, in the case of an agree-
10
ment between two subsequent filers, by one subse-
11
quent filer to another), whether or not included in 
12
a complaint filed with a court of law, that— 
13
(A) the submission of the application de-
14
scribed in subparagraph (A) or (B) of para-
15
graph (9), or the manufacture, use, offering for 
16
sale, sale, or importation into the United States 
17
of a covered product that is the subject of such 
18
an application— 
19
(i) in the case of an agreement be-
20
tween an NDA or BLA holder and a sub-
21
sequent filer, infringes any patent owned 
22
by, or exclusively licensed to, the NDA or 
23
BLA holder of the covered product; or 
24
04:12 Dec 12, 2019
H19
198 
•HR 19 IH
(ii) in the case of an agreement be-
1
tween two subsequent filers, infringes any 
2
patent owned by the subsequent filer; or 
3
(B) in the case of an agreement between 
4
an NDA or BLA holder and a subsequent filer, 
5
the covered product to be manufactured under 
6
such application uses a covered product as 
7
claimed in a published patent application. 
8
(4) COVERED
PRODUCT.—The term ‘‘covered 
9
product’’ means a drug (as defined in section 201(g) 
10
of the Federal Food, Drug, and Cosmetic Act (21 
11
U.S.C. 321(g))), including a biological product (as 
12
defined in section 351(i) of the Public Health Serv-
13
ice Act (42 U.S.C. 262(i))). 
14
(5) NDA OR BLA HOLDER.—The term ‘‘NDA 
15
or BLA holder’’ means— 
16
(A) the holder of— 
17
(i) an approved new drug application 
18
filed under section 505(b)(1) of the Fed-
19
eral Food, Drug, and Cosmetic Act (21 
20
U.S.C. 355(b)(1)) for a covered product; 
21
or 
22
(ii) a biologics license application filed 
23
under section 351(a) of the Public Health 
24
04:12 Dec 12, 2019
H19
199 
•HR 19 IH
Service Act (42 U.S.C. 262(a)) with re-
1
spect to a biological product; 
2
(B) a person owning or controlling enforce-
3
ment of the patent on— 
4
(i) the list published under section 
5
505(j)(7) of the Federal Food, Drug, and 
6
Cosmetic Act (21 U.S.C. 355(j)(7)) in con-
7
nection with the application described in 
8
subparagraph (A)(i); or 
9
(ii) any list published under section 
10
351 of the Public Health Service Act (42 
11
U.S.C. 262) comprised of patents associ-
12
ated with biologics license applications filed 
13
under section 351(a) of such Act (42 
14
U.S.C. 262(a)); or 
15
(C) the predecessors, subsidiaries, divi-
16
sions, groups, and affiliates controlled by, con-
17
trolling, or under common control with any en-
18
tity described in subparagraph (A) or (B) (such 
19
control to be presumed by direct or indirect 
20
share ownership of 50 percent or greater), as 
21
well as the licensees, licensors, successors, and 
22
assigns of each of the entities. 
23
04:12 Dec 12, 2019
H19
200 
•HR 19 IH
(6) PATENT.—The term ‘‘patent’’ means a pat-
1
ent issued by the United States Patent and Trade-
2
mark Office. 
3
(7) 
STATUTORY
EXCLUSIVITY.—The 
term 
4
‘‘statutory exclusivity’’ means those prohibitions on 
5
the submission or approval of drug applications 
6
under 
clauses 
(ii) 
through 
(iv) 
of 
section 
7
505(c)(3)(E) (5- and 3-year exclusivity), clauses (ii) 
8
through (iv) of section 505(j)(5)(F) (5-year and 3- 
9
year exclusivity), section 505(j)(5)(B)(iv) (180-day 
10
exclusivity), section 527 (orphan drug exclusivity), 
11
section 505A (pediatric exclusivity), or section 505E 
12
(qualified infectious disease product exclusivity) of 
13
the Federal Food, Drug, and Cosmetic Act (21 
14
U.S.C. 355(c)(3)(E), 355(j)(5)(B)(iv), 355(j)(5)(F), 
15
360cc, 355a, 355f), or prohibitions on the submis-
16
sion or licensing of biologics license applications 
17
under section 351(k)(6) (interchangeable biological 
18
product exclusivity) or section 351(k)(7) (biological 
19
product reference product exclusivity) of the Public 
20
Health Service Act (42 U.S.C. 262(k)(6), (7)). 
21
(8) SUBSEQUENT
FILER.—The term ‘‘subse-
22
quent filer’’ means— 
23
(A) in the case of a drug, a party that 
24
owns or controls an abbreviated new drug appli-
25
04:12 Dec 12, 2019
H19
201 
•HR 19 IH
cation submitted pursuant to section 505(j) of 
1
the Federal Food, Drug, and Cosmetic Act (21 
2
U.S.C. 355(j)) or a new drug application sub-
3
mitted pursuant to section 505(b)(2) of the 
4
Federal Food, Drug, and Cosmetic Act (21 
5
U.S.C. 355(b)(2)) and filed under section 
6
505(b)(1) of such Act (21 U.S.C. 355(b)(1)) or 
7
has the exclusive rights to distribute the cov-
8
ered product that is the subject of such applica-
9
tion; or 
10
(B) in the case of a biological product, a 
11
party that owns or controls an application filed 
12
with the Food and Drug Administration under 
13
section 351(k) of the Public Health Service Act 
14
(42 U.S.C. 262(k)) or has the exclusive rights 
15
to distribute the biological product that is the 
16
subject of such application. 
17
(h) EFFECTIVE DATE.—This section applies with re-
18
spect to agreements described in subsection (a) entered 
19
into on or after the date of the enactment of this Act. 
20
SEC. 312. NOTICE AND CERTIFICATION OF AGREEMENTS. 
21
(a) NOTICE OF ALL AGREEMENTS.—Section 1111(7) 
22
of the Medicare Prescription Drug, Improvement, and 
23
Modernization Act of 2003 (21 U.S.C. 355 note) is 
24
amended by inserting ‘‘or the owner of a patent for which 
25
04:12 Dec 12, 2019
H19
202 
•HR 19 IH
a claim of infringement could reasonably be asserted 
1
against any person for making, using, offering to sell, sell-
2
ing, or importing into the United States a biological prod-
3
uct that is the subject of a biosimilar biological product 
4
application’’ before the period at the end. 
5
(b) CERTIFICATION OF AGREEMENTS.—Section 1112 
6
of such Act (21 U.S.C. 355 note) is amended by adding 
7
at the end the following: 
8
‘‘(d) CERTIFICATION.—The Chief Executive Officer 
9
or the company official responsible for negotiating any 
10
agreement under subsection (a) or (b) that is required to 
11
be filed under subsection (c) shall, within 30 days of such 
12
filing, execute and file with the Assistant Attorney General 
13
and the Commission a certification as follows: ‘I declare 
14
that the following is true, correct, and complete to the best 
15
of my knowledge: The materials filed with the Federal 
16
Trade Commission and the Department of Justice under 
17
section 1112 of the Medicare Prescription Drug, Improve-
18
ment, and Modernization Act of 2003, with respect to the 
19
agreement referenced in this certification— 
20
‘‘ ‘(1) represent the complete, final, and exclu-
21
sive agreement between the parties; 
22
‘‘ ‘(2) include any ancillary agreements that are 
23
contingent upon, provide a contingent condition for, 
24
04:12 Dec 12, 2019
H19
203 
•HR 19 IH
were entered into within 30 days of, or are otherwise 
1
related to, the referenced agreement; and 
2
‘‘ ‘(3) include written descriptions of any oral 
3
agreements, representations, commitments, or prom-
4
ises between the parties that are responsive to sub-
5
section (a) or (b) of such section 1112 and have not 
6
been reduced to writing.’.’’. 
7
SEC. 313. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD. 
8
Section 505(j)(5)(D)(i)(V) of the Federal Food, 
9
Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)(V)) 
10
is amended by inserting ‘‘section 311 of the Lower Costs, 
11
More Cures Act of 2019 or’’ after ‘‘that the agreement 
12
has violated’’. 
13
SEC. 314. COMMISSION LITIGATION AUTHORITY. 
14
Section 16(a)(2) of the Federal Trade Commission 
15
Act (15 U.S.C. 56(a)(2)) is amended— 
16
(1) in subparagraph (D), by striking ‘‘or’’ after 
17
the semicolon; 
18
(2) in subparagraph (E), by inserting ‘‘or’’ 
19
after the semicolon; and 
20
(3) by inserting after subparagraph (E) the fol-
21
lowing: 
22
‘‘(F) under section 311(d)(3)(A) of the 
23
Lower Costs, More Cures Act of 2019;’’. 
24
04:12 Dec 12, 2019
H19
204 
•HR 19 IH
SEC. 315. STATUTE OF LIMITATIONS. 
1
(a) IN GENERAL.—Except as provided in subsection 
2
(b), the Commission shall commence any administrative 
3
proceeding or civil action to enforce section 311 of this 
4
Act not later than 6 years after the date on which the 
5
parties to the agreement file the Notice of Agreement as 
6
provided by section 1112(c)(2) and (d) of the Medicare 
7
Prescription Drug, Improvement, and Modernization Act 
8
of 2003 (21 U.S.C. 355 note). 
9
(b) CIVIL ACTION AFTER ISSUANCE OF CEASE AND 
10
DESIST ORDER.—If the Commission has issued a cease 
11
and desist order under section 5 of the Federal Trade 
12
Commission Act (15 U.S.C. 45) for violation of section 
13
311 of this Act and the proceeding for the issuance of 
14
such order was commenced within the period required by 
15
subsection (a) of this section, such subsection does not 
16
prohibit the commencement, after such period, of a civil 
17
action under section 311(d)(3)(A) against a party to such 
18
order or a civil action under subsection (l) of such section 
19
5 for violation of such order. 
20
Subtitle C—BLOCKING Act 
21
SEC. 321. CHANGE CONDITIONS OF FIRST GENERIC EXCLU-
22
SIVITY TO SPUR ACCESS AND COMPETITION. 
23
(a) IN GENERAL.—Section 505(j)(5)(B)(iv) of the 
24
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
25
355(j)(5)(B)(iv)) is amended— 
26
04:12 Dec 12, 2019
H19
205 
•HR 19 IH
(1) in subclause (I), by striking ‘‘180 days 
1
after’’ and all that follows through the period at the 
2
end and inserting the following: ‘‘180 days after the 
3
earlier of— 
4
‘‘(aa) the date of the first com-
5
mercial marketing of the drug (includ-
6
ing the commercial marketing of the 
7
listed drug) by any first applicant; or 
8
‘‘(bb) the applicable date speci-
9
fied in subclause (III).’’; and 
10
(2) by adding at the end the following new sub-
11
clause: 
12
‘‘(III) APPLICABLE DATE.—The appli-
13
cable date specified in this subclause, with 
14
respect to an application for a drug de-
15
scribed in subclause (I), is the date on 
16
which each of the following conditions is 
17
first met: 
18
‘‘(aa) The approval of such an 
19
application could be made effective, 
20
but for the eligibility of a first appli-
21
cant for 180-day exclusivity under 
22
this clause. 
23
‘‘(bb) At least 30 months have 
24
passed since the date of submission of 
25
04:12 Dec 12, 2019
H19
206 
•HR 19 IH
an application for the drug by at least 
1
one first applicant. 
2
‘‘(cc) Approval of an application 
3
for the drug submitted by at least one 
4
first applicant is not precluded under 
5
clause (iii). 
6
‘‘(dd) No application for the drug 
7
submitted by any first applicant is ap-
8
proved at the time the conditions 
9
under items (aa), (bb), and (cc) are 
10
all met, regardless of whether such an 
11
application 
is 
subsequently 
ap-
12
proved.’’. 
13
(b) INFORMATION.—The Secretary of Health and 
14
Human Services shall— 
15
(1) not later than 120 days after the date of 
16
enactment of this Act, publish, as appropriate and 
17
available, information sufficient to allow applicants 
18
to assess whether the conditions described in section 
19
505(j)(5)(B)(iv)(III) of the Federal Food, Drug, and 
20
Cosmetic Act (as added by subsection (a)) are satis-
21
fied for all applications where the exclusivity period 
22
under clause (iv)(I) of section 505(j)(5)(B) of the 
23
Federal Food, Drug, and Cosmetic Act (as amended 
24
by such subsection) has not expired; and 
25
04:12 Dec 12, 2019
H19
207 
•HR 19 IH
(2) publish updates to such information to re-
1
flect the most recent information available to the 
2
Secretary. 
3
Subtitle D—Purple Book 
4
SEC. 331. PUBLIC LISTING. 
5
Section 351(k) of the Public Health Service Act (42 
6
U.S.C. 262(k)) is amended by adding at the end the fol-
7
lowing: 
8
‘‘(9) PUBLIC LISTING.— 
9
‘‘(A) IN GENERAL.— 
10
‘‘(i) INITIAL PUBLICATION.—Not later 
11
than 180 days after the date of enactment 
12
of the Lower Costs, More Cures Act of 
13
2019, the Secretary shall publish and 
14
make available to the public in a search-
15
able, electronic format— 
16
‘‘(I) a list in alphabetical order of 
17
the nonproprietary or proper name of 
18
each biological product for which a 
19
biologics license under subsection (a) 
20
or this subsection is in effect, or that 
21
has been deemed to be licensed under 
22
this 
section 
pursuant 
to 
section 
23
7002(e)(4) of the Biologics Price 
24
04:12 Dec 12, 2019
H19
208 
•HR 19 IH
Competition and Innovation Act of 
1
2009, as of such date of enactment; 
2
‘‘(II) the date of approval of the 
3
marketing application and the applica-
4
tion number; and 
5
‘‘(III) the marketing or licensure 
6
status of the biological product for 
7
which a biologics license under sub-
8
section (a) or this subsection is in ef-
9
fect or that has been deemed to be li-
10
censed under this section pursuant to 
11
section 7002(e)(4) of the Biologics 
12
Price Competition and Innovation Act 
13
of 2009. 
14
‘‘(ii) 
REVISIONS.—Every 
30 
days 
15
after the publication of the first list under 
16
clause (i), the Secretary shall revise the list 
17
to include each biological product which 
18
has been licensed under subsection (a) or 
19
this subsection during the 30-day period. 
20
‘‘(iii) PATENT
INFORMATION.—Not 
21
later than 30 days after a list of patents 
22
under subsection (l)(3)(A), or a supple-
23
ment to such list under subsection (l)(7), 
24
has been provided by the reference product 
25
04:12 Dec 12, 2019
H19
209 
•HR 19 IH
sponsor to the subsection (k) applicant re-
1
specting a biological product included on 
2
the list published under this subparagraph, 
3
the reference product sponsor shall provide 
4
such list of patents (or supplement there-
5
to) and their corresponding expiry dates to 
6
the Secretary, and the Secretary shall, in 
7
revisions made under clause (ii), include 
8
such information for such biological prod-
9
uct. Within 30 days of providing any sub-
10
sequent or supplemental list of patents to 
11
any subsequent subsection (k) applicant 
12
under subsection (l)(3)(A) or (l)(7), the 
13
reference product sponsor shall update the 
14
information provided to the Secretary 
15
under this clause with any additional pat-
16
ents from such subsequent or supplemental 
17
list and their corresponding expiry dates. 
18
‘‘(iv) LISTING
OF
EXCLUSIVITIES.— 
19
For each biological product included on the 
20
list published under this subparagraph, the 
21
Secretary shall specify each exclusivity pe-
22
riod that is applicable and has not con-
23
cluded under paragraph (6) or paragraph 
24
(7). 
25
04:12 Dec 12, 2019
H19
210 
•HR 19 IH
‘‘(B) WITHDRAWAL OR SUSPENSION OF LI-
1
CENSURE.—If the licensing of a biological prod-
2
uct was withdrawn or suspended for safety, pu-
3
rity, or potency reasons, it may not be pub-
4
lished in the list under subparagraph (A). If the 
5
withdrawal or suspension occurred after its 
6
publication in such list, the reference product 
7
sponsor shall notify the Secretary that— 
8
‘‘(i) the biological product shall be im-
9
mediately removed from such list— 
10
‘‘(I) for the same period as the 
11
withdrawal or suspension; or 
12
‘‘(II) if the biological product has 
13
been withdrawn from sale, for the pe-
14
riod of withdrawal from sale or, if ear-
15
lier, the period ending on the date the 
16
Secretary determines that the with-
17
drawal from sale is not for safety, pu-
18
rity, or potency reasons; and 
19
‘‘(ii) a notice of the removal shall be 
20
published in the Federal Register.’’. 
21
04:12 Dec 12, 2019
H19
211 
•HR 19 IH
SEC. 332. REVIEW AND REPORT ON TYPES OF INFORMA-
1
TION TO BE LISTED. 
2
Not later than 3 years after the date of enactment 
3
of this Act, the Secretary of Health and Human Services 
4
shall— 
5
(1) solicit public comment regarding the type of 
6
information, if any, that should be added to or re-
7
moved from the list required by paragraph (9) of 
8
section 351(k) of the Public Health Service Act (42 
9
U.S.C. 262(k)), as added by section 331; and 
10
(2) transmit to Congress an evaluation of such 
11
comments, including any recommendations about the 
12
types of information that should be added to or re-
13
moved from the list. 
14
Subtitle E—Orange Book 
15
SEC. 341. ORANGE BOOK. 
16
(a) SUBMISSION
OF PATENT INFORMATION
FOR 
17
BRAND NAME DRUGS.—Paragraph (1) of section 505(b) 
18
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
19
355(b)) is amended to read as follows: 
20
‘‘(b)(1) Any person may file with the Secretary an 
21
application with respect to any drug subject to the provi-
22
sions of subsection (a). Such persons shall submit to the 
23
Secretary as part of the application— 
24
04:12 Dec 12, 2019
H19
212 
•HR 19 IH
‘‘(A) full reports of investigations which have 
1
been made to show whether or not such drug is safe 
2
for use and whether such drug is effective in use; 
3
‘‘(B) a full list of the articles used as compo-
4
nents of such drug; 
5
‘‘(C) a full statement of the composition of such 
6
drug; 
7
‘‘(D) a full description of the methods used in, 
8
and the facilities and controls used for, the manufac-
9
ture, processing, and packing of such drug; 
10
‘‘(E) such samples of such drug and of the arti-
11
cles used as components thereof as the Secretary 
12
may require; 
13
‘‘(F) specimens of the labeling proposed to be 
14
used for such drug; 
15
‘‘(G) any assessments required under section 
16
505B; and 
17
‘‘(H) patent information, with respect to each 
18
patent for which a claim of patent infringement 
19
could reasonably be asserted if a person not licensed 
20
by the owner engaged in the manufacture, use, or 
21
sale of the drug, and consistent with the following 
22
requirements: 
23
04:12 Dec 12, 2019
H19
213 
•HR 19 IH
‘‘(i) The applicant shall file with the appli-
1
cation the patent number and the expiration 
2
date of— 
3
‘‘(I) any patent which claims the drug 
4
for which the applicant submitted the ap-
5
plication and is a drug substance (includ-
6
ing active ingredient) patent or a drug 
7
product (including formulation and com-
8
position) patent; and 
9
‘‘(II) any patent which claims the 
10
method of using such drug. 
11
‘‘(ii) If an application is filed under this 
12
subsection for a drug and a patent of the type 
13
described in clause (i) which claims such drug 
14
or a method of using such drug is issued after 
15
the filing date but before approval of the appli-
16
cation, the applicant shall amend the applica-
17
tion to include such patent information. 
18
Upon approval of the application, the Secretary shall pub-
19
lish the information submitted under subparagraph (H). 
20
The Secretary shall, in consultation with the Director of 
21
the National Institutes of Health and with representatives 
22
of the drug manufacturing industry, review and develop 
23
guidance, as appropriate, on the inclusion of women and 
24
04:12 Dec 12, 2019
H19
214 
•HR 19 IH
minorities in clinical trials required by subparagraph 
1
(A).’’. 
2
(b) CONFORMING CHANGES TO REQUIREMENTS FOR 
3
SUBSEQUENT SUBMISSION OF PATENT INFORMATION.— 
4
Section 505(c)(2) of the Federal Food, Drug, and Cos-
5
metic Act (21 U.S.C. 355(j)(7)) is amended— 
6
(1) by inserting after ‘‘the patent number and 
7
the expiration date of any patent which’’ the fol-
8
lowing: ‘‘fulfills the criteria in subsection (b) and’’; 
9
(2) by inserting after the first sentence the fol-
10
lowing: ‘‘Patent information that is not the type of 
11
patent information required by subsection (b) shall 
12
not be submitted.’’; and 
13
(3) by inserting after ‘‘could not file patent in-
14
formation under subsection (b) because no patent’’ 
15
the following: ‘‘of the type required to be submitted 
16
in subsection (b)’’. 
17
(c) LISTING OF EXCLUSIVITIES.—Subparagraph (A) 
18
of section 505(j)(7) of the Federal Food, Drug, and Cos-
19
metic Act (21 U.S.C. 355(j)(7)) is amended by adding at 
20
the end the following: 
21
‘‘(iv) For each drug included on the list, the Sec-
22
retary shall specify each exclusivity period that is applica-
23
ble and has not concluded under— 
24
04:12 Dec 12, 2019
H19
215 
•HR 19 IH
‘‘(I) clause (ii), (iii), or (iv) of subsection 
1
(c)(3)(E) of this section; 
2
‘‘(II) clause (iv) or (v) of paragraph (5)(B) of 
3
this subsection; 
4
‘‘(III) clause (ii), (iii), or (iv) of paragraph 
5
(5)(F) of this subsection; 
6
‘‘(IV) section 505A; 
7
‘‘(V) section 505E; or 
8
‘‘(VI) section 527(a).’’. 
9
(d) REMOVAL OF INVALID PATENTS.— 
10
(1) IN
GENERAL.—Section 505(j)(7) of the 
11
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
12
355(j)(7)) is amended by adding at the end the fol-
13
lowing: 
14
‘‘(D)(i) The holder of an application approved under 
15
subsection (c) for a drug on the list shall notify within 
16
14 days the Secretary in writing if either of the following 
17
occurs: 
18
‘‘(I) The Patent Trial and Appeals Board issues 
19
a decision from which no appeal has been or can be 
20
taken that a patent for such drug is invalid. 
21
‘‘(II) A court issues a decision from which no 
22
appeal has been or can be taken that a patent for 
23
such drug is invalid. 
24
04:12 Dec 12, 2019
H19
216 
•HR 19 IH
‘‘(ii) The holder of an approved application shall in-
1
clude in any notification under clause (i) a copy of the 
2
decision described in subclause (I) or (II) of clause (i). 
3
‘‘(iii) The Secretary shall remove from the list any 
4
patent that is determined to be invalid in a decision de-
5
scribed in subclause (I) or (II) of clause (i)— 
6
‘‘(I) promptly; but 
7
‘‘(II) not before the expiration of any 180-day 
8
exclusivity period under paragraph (5)(B)(iv) that 
9
relies on a certification described in paragraph 
10
(2)(A)(vii)(IV) that such patent was invalid.’’. 
11
(2) APPLICABILITY.—Subparagraph (D) of sec-
12
tion 505(j)(7) of the Federal Food, Drug, and Cos-
13
metic Act (21 U.S.C. 355(j)(7)), as added by para-
14
graph (1), applies only with respect to a decision de-
15
scribed in such subparagraph that is issued on or 
16
after the date of enactment of this Act. 
17
(e) REVIEW AND REPORT.—Not later than one year 
18
after the date of enactment of this Act, the Secretary of 
19
Health and Human Services, acting through the Commis-
20
sioner of Food and Drugs, shall— 
21
(1) solicit public comment regarding the types 
22
of patent information that should be included on the 
23
list under section 507(j)(7) of the Federal Food, 
24
Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)); and 
25
04:12 Dec 12, 2019
H19
217 
•HR 19 IH
(2) transmit to the Congress an evaluation of 
1
such comments, including any recommendations 
2
about the types of patent information that should be 
3
included on or removed from such list. 
4
SEC. 342. GAO REPORT TO CONGRESS. 
5
(a) IN GENERAL.—Not later than one year after the 
6
date of enactment of this Act, the Comptroller General 
7
of the United States (referred to in this section as the 
8
‘‘Comptroller General’’) shall submit to the Committee on 
9
Energy and Commerce of the House of Representatives 
10
a report on the patents included in the list published under 
11
section 505(j)(7) of the Federal Food, Drug and Cosmetic 
12
Act (21 U.S.C. 355(j)(7)), including an analysis and eval-
13
uation of the types of patents included in such list and 
14
the claims such patents make about the products they 
15
claim. 
16
(b) CONTENTS.—The Comptroller General shall in-
17
clude in the report under subsection (a)— 
18
(1) data on the number of— 
19
(A) patents included in the list published 
20
under paragraph (7) of section 505(j) of the 
21
Federal Food, Drug and Cosmetic Act (21 
22
U.S.C. 355(j)), that claim the active ingredient 
23
or formulation of a drug in combination with a 
24
device that is used for delivery of the drug, to-
25
04:12 Dec 12, 2019
H19
218 
•HR 19 IH
gether comprising the finished dosage form of 
1
the drug; and 
2
(B) claims in each patent that claim a de-
3
vice that is used for the delivery of the drug, 
4
but do not claim such device in combination 
5
with an active ingredient or formulation of a 
6
drug; 
7
(2) data on the date of inclusion in the list 
8
under paragraph (7) of such section 505(j) for all 
9
patents under such list, as compared to patents that 
10
claim a method of using the drug in combination 
11
with a device; 
12
(3) an analysis regarding the impact of includ-
13
ing on the list under paragraph (7) of such section 
14
505(j) certain types of patent information for drug 
15
product applicants and approved application holders, 
16
including an analysis of whether— 
17
(A) the listing of the patents described in 
18
paragraph (1)(A) delayed the market entry of 
19
one or more drugs approved under such section 
20
505(j); and 
21
(B) not listing the patents described in 
22
paragraph (1)(A) would delay the market entry 
23
of one or more such drugs; and 
24
04:12 Dec 12, 2019
H19
219 
•HR 19 IH
(4) recommendations about which kinds of pat-
1
ents relating to devices described in paragraph 
2
(1)(A) should be submitted to the Secretary of 
3
Health and Human Services for inclusion on the list 
4
under paragraph (7) of such section 505(j) and 
5
which patents should not be required to be so sub-
6
mitted. 
7
Subtitle F—Advancing Education 
8
on Biosimilars 
9
SEC. 351. EDUCATION ON BIOLOGICAL PRODUCTS. 
10
(a) WEBSITE; CONTINUING EDUCATION.—Subpart 1 
11
of part F of title III of the Public Health Service Act (42 
12
U.S.C. 262 et seq.) is amended by adding at the end the 
13
following: 
14
‘‘SEC. 352A. EDUCATION ON BIOLOGICAL PRODUCTS. 
15
‘‘(a) INTERNET WEBSITE.— 
16
‘‘(1) IN GENERAL.—The Secretary shall main-
17
tain and operate an internet website to provide edu-
18
cational materials for health care providers, patients, 
19
and caregivers, regarding the meaning of the terms, 
20
and the standards for review and licensing of, bio-
21
logical products, including biosimilar biological prod-
22
ucts and interchangeable biosimilar biological prod-
23
ucts. 
24
04:12 Dec 12, 2019
H19
220 
•HR 19 IH
‘‘(2) CONTENT.—Educational materials pro-
1
vided under paragraph (1) may include— 
2
‘‘(A) explanations of key statutory and 
3
regulatory terms, including ‘biosimilar’ and 
4
‘interchangeable’, and clarification regarding 
5
the use of interchangeable biosimilar biological 
6
products; 
7
‘‘(B) information related to development 
8
programs for biological products, including bio-
9
similar biological products and interchangeable 
10
biosimilar biological products and relevant clin-
11
ical considerations for prescribers, which may 
12
include, as appropriate and applicable, informa-
13
tion related to the comparability of such biologi-
14
cal products; 
15
‘‘(C) an explanation of the process for re-
16
porting adverse events for biological products, 
17
including biosimilar biological products and 
18
interchangeable biosimilar biological products; 
19
and 
20
‘‘(D) an explanation of the relationship be-
21
tween biosimilar biological products and inter-
22
changeable biosimilar biological products li-
23
censed under section 351(k) and reference 
24
products (as defined in section 351(i)), includ-
25
04:12 Dec 12, 2019
H19
221 
•HR 19 IH
ing the standards for review and licensing of 
1
each such type of biological product. 
2
‘‘(3) FORMAT.—The educational materials pro-
3
vided under paragraph (1) may be— 
4
‘‘(A) in formats such as webinars, con-
5
tinuing medical education modules, videos, fact 
6
sheets, infographics, stakeholder toolkits, or 
7
other formats as appropriate and applicable; 
8
and 
9
‘‘(B) tailored for the unique needs of 
10
health care providers, patients, caregivers, and 
11
other audiences, as the Secretary determines 
12
appropriate. 
13
‘‘(4) OTHER INFORMATION.—In addition to the 
14
information described in paragraph (2), the Sec-
15
retary shall continue to publish the following infor-
16
mation: 
17
‘‘(A) The action package of each biological 
18
product licensed under subsection (a) or (k). 
19
‘‘(B) The summary review of each biologi-
20
cal product licensed under subsection (a) or (k). 
21
‘‘(5) CONFIDENTIAL AND TRADE SECRET IN-
22
FORMATION.—This subsection does not authorize 
23
the disclosure of any trade secret, confidential com-
24
04:12 Dec 12, 2019
H19
222 
•HR 19 IH
mercial or financial information, or other matter de-
1
scribed in section 552(b) of title 5. 
2
‘‘(b) CONTINUING EDUCATION.—The Secretary shall 
3
advance education and awareness among health care pro-
4
viders regarding biological products, including biosimilar 
5
biological products and interchangeable biosimilar biologi-
6
cal products, as appropriate, including by developing or 
7
improving continuing education programs that advance 
8
the education of such providers on the prescribing of, and 
9
relevant clinical considerations with respect to, biological 
10
products, including biosimilar biological products and 
11
interchangeable biosimilar biological products.’’. 
12
(b) APPLICATION UNDER THE MEDICARE MERIT- 
13
BASED
INCENTIVE
PAYMENT
SYSTEM.—Section 
14
1848(q)(5)(C) of the Social Security Act (42 U.S.C. 
15
1395w–4(q)(5)(C)) is amended by adding at the end the 
16
following new clause: 
17
‘‘(iv) CLINICAL MEDICAL EDUCATION 
18
PROGRAM
ON
BIOSIMILAR
BIOLOGICAL 
19
PRODUCTS.—Completion of a clinical med-
20
ical education program developed or im-
21
proved under section 352A(b) of the Public 
22
Health Service Act by a MIPS eligible pro-
23
fessional during a performance period shall 
24
earn such eligible professional one-half of 
25
04:12 Dec 12, 2019
H19
223 
•HR 19 IH
the highest potential score for the perform-
1
ance category described in paragraph 
2
(2)(A)(iii) for such performance period. A 
3
MIPS eligible professional may only count 
4
the completion of such a program for pur-
5
poses of such category one time during the 
6
eligible professional’s lifetime.’’. 
7
Subtitle G—Streamlining 
8
Transition of Biological Products 
9
SEC. 361. STREAMLINING THE TRANSITION OF BIOLOGICAL 
10
PRODUCTS. 
11
Section 7002(e)(4) of the Biologics Price Competition 
12
and Innovation Act of 2009 (Public Law 111–148) is 
13
amended— 
14
(1) by striking ‘‘An approved application’’ and 
15
inserting the following: 
16
‘‘(A) IN GENERAL.—An approved applica-
17
tion’’; 
18
(2) by adding at the end the following: 
19
‘‘(B) TREATMENT OF CERTAIN APPLICA-
20
TIONS.— 
21
‘‘(i) IN GENERAL.—With respect to an 
22
application for a biological product sub-
23
mitted under subsection (b) or (j) of sec-
24
tion 505 of the Federal Food, Drug, and 
25
04:12 Dec 12, 2019
H19
224 
•HR 19 IH
Cosmetic Act (21 U.S.C. 355) that is filed 
1
not later than March 23, 2019, the Sec-
2
retary shall continue to review such appli-
3
cation under such section 505, even if such 
4
review continues after March 23, 2020. 
5
‘‘(ii) EFFECT
ON
LISTED
DRUGS.— 
6
Only for purposes of carrying out clause 
7
(i), with respect to any applicable listed 
8
drug with respect to such application, the 
9
following shall apply: 
10
‘‘(I) Any drug that is a biological 
11
product that has been deemed licensed 
12
under section 351 of the Public 
13
Health Service Act (42 U.S.C. 262) 
14
pursuant to subparagraph (A) and 
15
that is referenced in an application 
16
described in clause (i), shall continue 
17
to be identified as a listed drug on the 
18
list published pursuant to section 
19
505(j)(7) of the Federal Food, Drug, 
20
and Cosmetic Act, and the informa-
21
tion for such drug on such list shall 
22
not be revised after March 20, 2020, 
23
until— 
24
04:12 Dec 12, 2019
H19
225 
•HR 19 IH
‘‘(aa) such drug is removed 
1
from such list in accordance with 
2
subclause (III) or subparagraph 
3
(C) of such section 505(j)(7); or 
4
‘‘(bb) this subparagraph no 
5
longer has force or effect. 
6
‘‘(II) Any drug that is a biologi-
7
cal product that has been deemed li-
8
censed under section 351 of the Pub-
9
lic Health Service Act (42 U.S.C. 
10
262) pursuant to subparagraph (A) 
11
and that is referenced in an applica-
12
tion described in clause (i) shall be 
13
subject only to requirements applica-
14
ble to biological products licensed 
15
under such section. 
16
‘‘(III) Upon approval under sub-
17
section (c) or (j) of section 505 of the 
18
Federal Food, Drug, and Cosmetic 
19
Act of an application described in 
20
clause (i), the Secretary shall remove 
21
from the list published pursuant to 
22
section 505(j)(7) of the Federal Food, 
23
Drug, and Cosmetic Act any listed 
24
drug that is a biological product that 
25
04:12 Dec 12, 2019
H19
226 
•HR 19 IH
has been deemed licensed under sec-
1
tion 351 of the Public Health Service 
2
Act pursuant to subparagraph (A) 
3
and that is referenced in such ap-
4
proved application, unless such listed 
5
drug is referenced in one or more ad-
6
ditional 
applications 
described 
in 
7
clause (i). 
8
‘‘(iii) 
DEEMED
LICENSURE.—Upon 
9
approval of an application described in 
10
clause (i), such approved application shall 
11
be deemed to be a license for the biological 
12
product under section 351 of the Public 
13
Health Service Act, pursuant to subpara-
14
graph (A), and any period of exclusivity, as 
15
applicable, shall be determined in accord-
16
ance with such section. 
17
‘‘(iv) RULE OF CONSTRUCTION.— 
18
‘‘(I) APPLICATION
OF
CERTAIN 
19
PROVISIONS.— 
20
‘‘(aa) 
PATENT
CERTIFI-
21
CATION OR STATEMENT.—An ap-
22
plication described in clause (i) 
23
shall contain a patent certifi-
24
cation or statement described in, 
25
04:12 Dec 12, 2019
H19
227 
•HR 19 IH
as applicable, section 505(b)(2) 
1
of the Federal Food, Drug, and 
2
Cosmetic Act or clauses (vii) and 
3
(viii) of section 505(j)(2)(A) of 
4
such Act and, with respect to any 
5
listed drug referenced in such ap-
6
plication, comply with related re-
7
quirements concerning any timely 
8
filed patent information listed 
9
pursuant to section 505(j)(7). 
10
‘‘(bb) 
DATE
OF
AP-
11
PROVAL.—The earliest possible 
12
date on which any pending appli-
13
cation described in clause (i) may 
14
be approved shall be determined 
15
based on— 
16
‘‘(AA) the last expira-
17
tion date of any applicable 
18
period of exclusivity that 
19
would prevent such approval 
20
and that is described in sec-
21
tion 
505(c)(3)(E), 
22
505(j)(5)(B)(iv), 
23
505(j)(5)(F), 505A, 505E, 
24
or 527 of the Federal Food, 
25
04:12 Dec 12, 2019
H19
228 
•HR 19 IH
Drug, and Cosmetic Act; 
1
and 
2
‘‘(BB) if the application 
3
was submitted under section 
4
505(b)(2) of the Federal 
5
Food, Drug, and Cosmetic 
6
Act and references any list-
7
ed drug, the last applicable 
8
date determined under sub-
9
paragraph (A), (B), or (C) 
10
of section 505(c)(3) of such 
11
Act, or, if the application 
12
was submitted under section 
13
505(j) of such Act, the last 
14
applicable date determined 
15
under clause (i), (ii), or (iii) 
16
of section 505(j)(5)(B). 
17
‘‘(II) RULE
OF
CONSTRUCTION 
18
WITH
RESPECT
TO
EXCLUSIVITY.— 
19
Nothing in this subparagraph shall be 
20
construed 
to 
affect 
section 
21
351(k)(7)(D) of the Public Health 
22
Service Act. 
23
‘‘(v) AUTHORIZED DISCLOSURE.—The 
24
Secretary may continue to review an appli-
25
04:12 Dec 12, 2019
H19
229 
•HR 19 IH
cation after March 23, 2020, pursuant to 
1
clause (i), and continue to identify any ap-
2
plicable listed drug pursuant to clause (ii) 
3
on the list published pursuant to section 
4
505(j)(7) of the Federal Food, Drug, and 
5
Cosmetic Act, even if such review or listing 
6
may reveal the existence of such applica-
7
tion and the identity of any listed drug for 
8
which the investigations described in sec-
9
tion 505(b)(1)(A) of the Federal Food, 
10
Drug, and Cosmetic Act are relied upon by 
11
the applicant for approval of the pending 
12
application. Nothing in this subparagraph 
13
shall be construed as authorizing the Sec-
14
retary to disclose any other information 
15
that is a trade secret or confidential infor-
16
mation described in section 552(b)(4) of 
17
title 5, United States Code. 
18
‘‘(vi) SUNSET.—Beginning on October 
19
1, 2022, this subparagraph shall have no 
20
force or effect and any applications de-
21
scribed in clause (i) that have not been ap-
22
proved shall be deemed withdrawn.’’. 
23
04:12 Dec 12, 2019
H19
230 
•HR 19 IH
Subtitle 
H—Over-the-Counter 
1
Monograph Safety, Innovation, 
2
and Reform 
3
SEC. 370. SHORT TITLE; REFERENCES IN SUBTITLE. 
4
(a) SHORT TITLE.—This subtitle may be cited as the 
5
‘‘Over-the-Counter Monograph Safety, Innovation, and 
6
Reform Act of 2019’’. 
7
(b) REFERENCES.—Except as otherwise specified, 
8
any reference to ‘‘this Act’’ contained in this subtitle shall 
9
be treated as referring only to the provisions of this sub-
10
title. 
11
PART 1—OTC DRUG REVIEW 
12
SEC. 371. REGULATION OF CERTAIN NONPRESCRIPTION 
13
DRUGS THAT ARE MARKETED WITHOUT AN 
14
APPROVED DRUG APPLICATION. 
15
(a) IN GENERAL.—Chapter V of the Federal Food, 
16
Drug, and Cosmetic Act is amended by inserting after sec-
17
tion 505F of such Act (21 U.S.C. 355g) the following: 
18
‘‘SEC. 505G. REGULATION OF CERTAIN NONPRESCRIPTION 
19
DRUGS THAT ARE MARKETED WITHOUT AN 
20
APPROVED DRUG APPLICATION. 
21
‘‘(a) NONPRESCRIPTION DRUGS MARKETED WITH-
22
OUT
AN
APPROVED
APPLICATION.—Nonprescription 
23
drugs marketed without an approved drug application 
24
under section 505, as of the date of the enactment of this 
25
04:12 Dec 12, 2019
H19
231 
•HR 19 IH
section, shall be treated in accordance with this sub-
1
section. 
2
‘‘(1) DRUGS SUBJECT TO A FINAL MONOGRAPH; 
3
CATEGORY
I
DRUGS
SUBJECT
TO
A
TENTATIVE 
4
FINAL MONOGRAPH.—A drug is deemed to be gen-
5
erally recognized as safe and effective under section 
6
201(p)(1), not a new drug under section 201(p), and 
7
not subject to section 503(b)(1), if— 
8
‘‘(A) the drug is— 
9
‘‘(i) in conformity with the require-
10
ments for nonprescription use of a final 
11
monograph issued under part 330 of title 
12
21, Code of Federal Regulations (except as 
13
provided in paragraph (2)), the general re-
14
quirements for nonprescription drugs, and 
15
conditions or requirements under sub-
16
sections (b), (c), and (k); and 
17
‘‘(ii) except as permitted by an order 
18
issued under subsection (b) or, in the case 
19
of a minor change in the drug, in con-
20
formity with an order issued under sub-
21
section (c), in a dosage form that, imme-
22
diately prior to the date of the enactment 
23
of this section, has been used to a material 
24
04:12 Dec 12, 2019
H19
232 
•HR 19 IH
extent and for a material time under sec-
1
tion 201(p)(2); or 
2
‘‘(B) the drug is— 
3
‘‘(i) classified in category I for safety 
4
and effectiveness under a tentative final 
5
monograph that is the most recently appli-
6
cable proposal or determination issued 
7
under part 330 of title 21, Code of Federal 
8
Regulations; 
9
‘‘(ii) in conformity with the proposed 
10
requirements for nonprescription use of 
11
such tentative final monograph, any appli-
12
cable subsequent determination by the Sec-
13
retary, the general requirements for non-
14
prescription drugs, and conditions or re-
15
quirements under subsections (b), (c), and 
16
(k); and 
17
‘‘(iii) except as permitted by an order 
18
issued under subsection (b) or, in the case 
19
of a minor change in the drug, in con-
20
formity with an order issued under sub-
21
section (c), in a dosage form that, imme-
22
diately prior to the date of the enactment 
23
of this section, has been used to a material 
24
04:12 Dec 12, 2019
H19
233 
•HR 19 IH
extent and for a material time under sec-
1
tion 201(p)(2). 
2
‘‘(2) TREATMENT
OF
SUNSCREEN
DRUGS.— 
3
With respect to sunscreen drugs subject to this sec-
4
tion, the applicable requirements in terms of con-
5
formity with a final monograph, for purposes of 
6
paragraph (1)(A)(i), shall be the requirements speci-
7
fied in part 352 of title 21, Code of Federal Regula-
8
tions, as published on May 21, 1999, beginning on 
9
page 27687 of volume 64 of the Federal Register, 
10
except that the applicable requirements governing ef-
11
fectiveness and labeling shall be those specified in 
12
section 201.327 of title 21, Code of Federal Regula-
13
tions. 
14
‘‘(3) CATEGORY III DRUGS SUBJECT TO A TEN-
15
TATIVE
FINAL
MONOGRAPH; CATEGORY
I
DRUGS 
16
SUBJECT TO PROPOSED MONOGRAPH OR ADVANCE 
17
NOTICE OF PROPOSED RULEMAKING.—A drug that 
18
is not described in paragraph (1), (2), or (4) is not 
19
required to be the subject of an application approved 
20
under section 505, and is not subject to section 
21
503(b)(1), if— 
22
‘‘(A) the drug is— 
23
‘‘(i) classified in category III for safe-
24
ty or effectiveness in the preamble of a 
25
04:12 Dec 12, 2019
H19
234 
•HR 19 IH
proposed rule establishing a tentative final 
1
monograph that is the most recently appli-
2
cable proposal or determination for such 
3
drug issued under part 330 of title 21, 
4
Code of Federal Regulations; 
5
‘‘(ii) in conformity with— 
6
‘‘(I) the conditions of use, includ-
7
ing indication and dosage strength, if 
8
any, described for such category III 
9
drug in such preamble or in an appli-
10
cable subsequent proposed rule; 
11
‘‘(II) the proposed requirements 
12
for drugs classified in such tentative 
13
final monograph in category I in the 
14
most recently proposed rule estab-
15
lishing requirements related to such 
16
tentative final monograph and in any 
17
final rule establishing requirements 
18
that are applicable to the drug; and 
19
‘‘(III) the general requirements 
20
for nonprescription drugs and condi-
21
tions or requirements under sub-
22
section (b) or (k); and 
23
‘‘(iii) in a dosage form that, imme-
24
diately prior to the date of the enactment 
25
04:12 Dec 12, 2019
H19
235 
•HR 19 IH
of this section, had been used to a material 
1
extent and for a material time under sec-
2
tion 201(p)(2); or 
3
‘‘(B) the drug is— 
4
‘‘(i) classified in category I for safety 
5
and effectiveness under a proposed mono-
6
graph or advance notice of proposed rule-
7
making that is the most recently applicable 
8
proposal or determination for such drug 
9
issued under part 330 of title 21, Code of 
10
Federal Regulations; 
11
‘‘(ii) in conformity with the require-
12
ments for nonprescription use of such pro-
13
posed monograph or advance notice of pro-
14
posed rulemaking, any applicable subse-
15
quent determination by the Secretary, the 
16
general requirements for nonprescription 
17
drugs, and conditions or requirements 
18
under subsection (b) or (k); and 
19
‘‘(iii) in a dosage form that, imme-
20
diately prior to the date of the enactment 
21
of this section, has been used to a material 
22
extent and for a material time under sec-
23
tion 201(p)(2). 
24
04:12 Dec 12, 2019
H19
236 
•HR 19 IH
‘‘(4) CATEGORY
II
DRUGS
DEEMED
NEW 
1
DRUGS.—A drug that is classified in category II for 
2
safety or effectiveness under a tentative final mono-
3
graph or that is subject to a determination to be not 
4
generally recognized as safe and effective in a pro-
5
posed rule that is the most recently applicable pro-
6
posal issued under part 330 of title 21, Code of Fed-
7
eral Regulations, shall be deemed to be a new drug 
8
under section 201(p), misbranded under section 
9
502(ee), and subject to the requirement for an ap-
10
proved new drug application under section 505 be-
11
ginning on the day that is 180 calendar days after 
12
the date of the enactment of this section, unless, be-
13
fore such day, the Secretary determines that it is in 
14
the interest of public health to extend the period 
15
during which the drug may be marketed without 
16
such an approved new drug application. 
17
‘‘(5) 
DRUGS
NOT
GRASE
DEEMED
NEW 
18
DRUGS.—A drug that the Secretary has determined 
19
not to be generally recognized as safe and effective 
20
under section 201(p)(1) under a final determination 
21
issued under part 330 of title 21, Code of Federal 
22
Regulations, shall be deemed to be a new drug under 
23
section 201(p), misbranded under section 502(ee), 
24
04:12 Dec 12, 2019
H19
237 
•HR 19 IH
and subject to the requirement for an approved new 
1
drug application under section 505. 
2
‘‘(6) OTHER DRUGS DEEMED NEW DRUGS.— 
3
Except as provided in subsection (m), a drug is 
4
deemed to be a new drug under section 201(p) and 
5
misbranded under section 502(ee) if the drug— 
6
‘‘(A) is not subject to section 503(b)(1); 
7
and 
8
‘‘(B) is not described in paragraph (1), 
9
(2), (3), (4), or (5), or subsection (b)(1)(B). 
10
‘‘(b) ADMINISTRATIVE ORDERS.— 
11
‘‘(1) IN GENERAL.— 
12
‘‘(A) 
DETERMINATION.—The 
Secretary 
13
may, on the initiative of the Secretary or at the 
14
request of one or more requestors, issue an ad-
15
ministrative order determining whether there 
16
are conditions under which a specific drug, a 
17
class of drugs, or a combination of drugs, is de-
18
termined to be— 
19
‘‘(i) not subject to section 503(b)(1); 
20
and 
21
‘‘(ii) generally recognized as safe and 
22
effective under section 201(p)(1). 
23
‘‘(B) EFFECT.—A drug or combination of 
24
drugs shall be deemed to not require approval 
25
04:12 Dec 12, 2019
H19
238 
•HR 19 IH
under section 505 if such drug or combination 
1
of drugs— 
2
‘‘(i) is determined by the Secretary to 
3
meet the conditions specified in clauses (i) 
4
and (ii) of subparagraph (A); 
5
‘‘(ii) is marketed in conformity with 
6
an administrative order under this sub-
7
section; 
8
‘‘(iii) meets the general requirements 
9
for nonprescription drugs; and 
10
‘‘(iv) meets the requirements under 
11
subsections (c) and (k). 
12
‘‘(C) STANDARD.—The Secretary shall find 
13
that a drug is not generally recognized as safe 
14
and effective under section 201(p)(1) if— 
15
‘‘(i) the evidence shows that the drug 
16
is not generally recognized as safe and ef-
17
fective under section 201(p)(1); or 
18
‘‘(ii) the evidence is inadequate to 
19
show that the drug is generally recognized 
20
as 
safe 
and 
effective 
under 
section 
21
201(p)(1). 
22
‘‘(2) ADMINISTRATIVE
ORDERS
INITIATED
BY 
23
THE SECRETARY.— 
24
04:12 Dec 12, 2019
H19
239 
•HR 19 IH
‘‘(A) IN GENERAL.—In issuing an adminis-
1
trative order under paragraph (1) upon the 
2
Secretary’s initiative, the Secretary shall— 
3
‘‘(i) make reasonable efforts to notify 
4
informally, not later than 2 business days 
5
before the issuance of the proposed order, 
6
the sponsors of drugs who have a listing in 
7
effect under section 510(j) for the drugs or 
8
combination of drugs that will be subject 
9
to the administrative order; 
10
‘‘(ii) after any such reasonable efforts 
11
of notification— 
12
‘‘(I) issue a proposed administra-
13
tive order by publishing it on the 
14
website of the Food and Drug Admin-
15
istration and include in such order the 
16
reasons for the issuance of such order; 
17
and 
18
‘‘(II) publish a notice of avail-
19
ability of such proposed order in the 
20
Federal Register; 
21
‘‘(iii) except as provided in subpara-
22
graph (B), provide for a public comment 
23
period with respect to such proposed order 
24
of not less than 45 calendar days; and 
25
04:12 Dec 12, 2019
H19
240 
•HR 19 IH
‘‘(iv) if, after completion of the pro-
1
ceedings specified in clauses (i) through 
2
(iii), the Secretary determines that it is ap-
3
propriate to issue a final administrative 
4
order— 
5
‘‘(I) issue the final administrative 
6
order, together with a detailed state-
7
ment of reasons, which order shall not 
8
take effect until the time for request-
9
ing judicial review under paragraph 
10
(3)(D)(ii) has expired; 
11
‘‘(II) publish a notice of such 
12
final administrative order in the Fed-
13
eral Register; 
14
‘‘(III) afford requestors of drugs 
15
that will be subject to such order the 
16
opportunity for formal dispute resolu-
17
tion up to the level of the Director of 
18
the Center for Drug Evaluation and 
19
Research, which initially must be re-
20
quested within 45 calendar days of 
21
the issuance of the order, and, for 
22
subsequent levels of appeal, within 30 
23
calendar days of the prior decision; 
24
and 
25
04:12 Dec 12, 2019
H19
241 
•HR 19 IH
‘‘(IV) except with respect to 
1
drugs described in paragraph (3)(B), 
2
upon completion of the formal dispute 
3
resolution procedure, inform the per-
4
sons which sought such dispute reso-
5
lution of their right to request a hear-
6
ing. 
7
‘‘(B) EXCEPTIONS.—When issuing an ad-
8
ministrative order under paragraph (1) on the 
9
Secretary’s initiative proposing to determine 
10
that a drug described in subsection (a)(3) is not 
11
generally recognized as safe and effective under 
12
section 201(p)(1), the Secretary shall follow the 
13
procedures in subparagraph (A), except that— 
14
‘‘(i) the proposed order shall include 
15
notice of— 
16
‘‘(I) the general categories of 
17
data the Secretary has determined 
18
necessary to establish that the drug is 
19
generally recognized as safe and effec-
20
tive under section 201(p)(1); and 
21
‘‘(II) the format for submissions 
22
by interested persons; 
23
‘‘(ii) the Secretary shall provide for a 
24
public comment period of no less than 180 
25
04:12 Dec 12, 2019
H19
242 
•HR 19 IH
calendar days with respect to such pro-
1
posed order, except when the Secretary de-
2
termines, for good cause, that a shorter pe-
3
riod is in the interest of public health; and 
4
‘‘(iii) any person who submits data in 
5
such comment period shall include a cer-
6
tification that the person has submitted all 
7
evidence created, obtained, or received by 
8
that person that is both within the cat-
9
egories of data identified in the proposed 
10
order and relevant to a determination as to 
11
whether the drug is generally recognized as 
12
safe and effective under section 201(p)(1). 
13
‘‘(3) HEARINGS; JUDICIAL REVIEW.— 
14
‘‘(A) IN
GENERAL.—Only a person who 
15
participated in each stage of formal dispute res-
16
olution under subclause (III) of paragraph 
17
(2)(A)(iv) of an administrative order with re-
18
spect to a drug may request a hearing con-
19
cerning a final administrative order issued 
20
under such paragraph with respect to such 
21
drug. If a hearing is sought, such person must 
22
submit a request for a hearing, which shall be 
23
based solely on information in the administra-
24
tive record, to the Secretary not later than 30 
25
04:12 Dec 12, 2019
H19
243 
•HR 19 IH
calendar days after receiving notice of the final 
1
decision of the formal dispute resolution proce-
2
dure. 
3
‘‘(B) NO
HEARING
REQUIRED
WITH
RE-
4
SPECT
TO
ORDERS
RELATING
TO
CERTAIN 
5
DRUGS.— 
6
‘‘(i) IN
GENERAL.—The Secretary 
7
shall not be required to provide notice and 
8
an opportunity for a hearing pursuant to 
9
paragraph (2)(A)(iv) if the final adminis-
10
trative order involved relates to a drug— 
11
‘‘(I) that is described in sub-
12
section (a)(3)(A); and 
13
‘‘(II) with respect to which no 
14
human or non-human data studies rel-
15
evant to the safety or effectiveness of 
16
such drug have been submitted to the 
17
administrative 
record 
since 
the 
18
issuance of the most recent tentative 
19
final monograph relating to such 
20
drug. 
21
‘‘(ii) HUMAN
DATA
STUDIES
AND 
22
NON-HUMAN DATA DEFINED.—In this sub-
23
paragraph: 
24
04:12 Dec 12, 2019
H19
244 
•HR 19 IH
‘‘(I) The term ‘human data stud-
1
ies’ means clinical trials of safety or 
2
effectiveness (including actual use 
3
studies), pharmacokinetics studies, or 
4
bioavailability studies. 
5
‘‘(II) The term ‘non-human data’ 
6
means data from testing other than 
7
with human subjects which provides 
8
information concerning safety or ef-
9
fectiveness. 
10
‘‘(C) HEARING PROCEDURES.— 
11
‘‘(i) DENIAL OF REQUEST FOR HEAR-
12
ING.—If the Secretary determines that in-
13
formation submitted in a request for a 
14
hearing under subparagraph (A) with re-
15
spect to a final administrative order issued 
16
under paragraph (2)(A)(iv) does not iden-
17
tify the existence of a genuine and sub-
18
stantial question of material fact, the Sec-
19
retary may deny such request. In making 
20
such a determination, the Secretary may 
21
consider only information and data that 
22
are based on relevant and reliable scientific 
23
principles and methodologies. 
24
04:12 Dec 12, 2019
H19
245 
•HR 19 IH
‘‘(ii) SINGLE HEARING FOR MULTIPLE 
1
RELATED
REQUESTS.—If more than one 
2
request for a hearing is submitted with re-
3
spect to the same administrative order 
4
under subparagraph (A), the Secretary 
5
may direct that a single hearing be con-
6
ducted in which all persons whose hearing 
7
requests were granted may participate. 
8
‘‘(iii) PRESIDING OFFICER.—The pre-
9
siding officer of a hearing requested under 
10
subparagraph (A) shall— 
11
‘‘(I) be designated by the Sec-
12
retary; 
13
‘‘(II) not be an employee of the 
14
Center for Drug Evaluation and Re-
15
search; and 
16
‘‘(III) not have been previously 
17
involved in the development of the ad-
18
ministrative order involved or pro-
19
ceedings relating to that administra-
20
tive order. 
21
‘‘(iv) RIGHTS OF PARTIES TO HEAR-
22
ING.—The parties to a hearing requested 
23
under subparagraph (A) shall have the 
24
right to present testimony, including testi-
25
04:12 Dec 12, 2019
H19
246 
•HR 19 IH
mony of expert witnesses, and to cross-ex-
1
amine witnesses presented by other parties. 
2
Where appropriate, the presiding officer 
3
may require that cross-examination by par-
4
ties representing substantially the same in-
5
terests be consolidated to promote effi-
6
ciency and avoid duplication. 
7
‘‘(v) FINAL DECISION.— 
8
‘‘(I) At the conclusion of a hear-
9
ing requested under subparagraph 
10
(A), the presiding officer of the hear-
11
ing shall issue a decision containing 
12
findings of fact and conclusions of 
13
law. The decision of the presiding offi-
14
cer shall be final. 
15
‘‘(II) The final decision may not 
16
take effect until the period under sub-
17
paragraph (D)(ii) for submitting a re-
18
quest for judicial review of such deci-
19
sion expires. 
20
‘‘(D) JUDICIAL REVIEW OF FINAL ADMIN-
21
ISTRATIVE ORDER.— 
22
‘‘(i) IN
GENERAL.—The procedures 
23
described in section 505(h) shall apply 
24
with respect to judicial review of final ad-
25
04:12 Dec 12, 2019
H19
247 
•HR 19 IH
ministrative orders issued under this sub-
1
section in the same manner and to the 
2
same extent as such section applies to an 
3
order described in such section except that 
4
the judicial review shall be taken by filing 
5
in an appropriate district court of the 
6
United States in lieu of the appellate 
7
courts specified in such section. 
8
‘‘(ii) PERIOD TO SUBMIT A REQUEST 
9
FOR JUDICIAL REVIEW.—A person eligible 
10
to request a hearing under this paragraph 
11
and seeking judicial review of a final ad-
12
ministrative order issued under this sub-
13
section shall file such request for judicial 
14
review not later than 60 calendar days 
15
after the latest of— 
16
‘‘(I) the date on which notice of 
17
such order is published; 
18
‘‘(II) the date on which a hearing 
19
with respect to such order is denied 
20
under subparagraph (B) or (C)(i); 
21
‘‘(III) the date on which a final 
22
decision is made following a hearing 
23
under subparagraph (C)(v); or 
24
04:12 Dec 12, 2019
H19
248 
•HR 19 IH
‘‘(IV) if no hearing is requested, 
1
the date on which the time for re-
2
questing a hearing expires. 
3
‘‘(4) EXPEDITED PROCEDURE WITH RESPECT 
4
TO
ADMINISTRATIVE
ORDERS
INITIATED
BY
THE 
5
SECRETARY.— 
6
‘‘(A) IMMINENT HAZARD TO THE PUBLIC 
7
HEALTH.— 
8
‘‘(i) IN GENERAL.—In the case of a 
9
determination by the Secretary that a 
10
drug, class of drugs, or combination of 
11
drugs subject to this section poses an im-
12
minent hazard to the public health, the 
13
Secretary, after first making reasonable ef-
14
forts to notify, not later than 48 hours be-
15
fore issuance of such order under this sub-
16
paragraph, sponsors who have a listing in 
17
effect under section 510(j) for such drug 
18
or combination of drugs— 
19
‘‘(I) may issue an interim final 
20
administrative order for such drug, 
21
class of drugs, or combination of 
22
drugs under paragraph (1), together 
23
with a detailed statement of the rea-
24
sons for such order; 
25
04:12 Dec 12, 2019
H19
249 
•HR 19 IH
‘‘(II) shall publish in the Federal 
1
Register a notice of availability of any 
2
such order; and 
3
‘‘(III) shall provide for a public 
4
comment period of at least 45 cal-
5
endar days with respect to such in-
6
terim final order. 
7
‘‘(ii) 
NONDELEGATION.—The 
Sec-
8
retary may not delegate the authority to 
9
issue an interim final administrative order 
10
under this subparagraph. 
11
‘‘(B) SAFETY LABELING CHANGES.— 
12
‘‘(i) IN GENERAL.—In the case of a 
13
determination by the Secretary that a 
14
change in the labeling of a drug, class of 
15
drugs, or combination of drugs subject to 
16
this section is reasonably expected to miti-
17
gate a significant or unreasonable risk of 
18
a serious adverse event associated with use 
19
of the drug, the Secretary may— 
20
‘‘(I) make reasonable efforts to 
21
notify informally, not later than 48 
22
hours before the issuance of the in-
23
terim final order, the sponsors of 
24
drugs who have a listing in effect 
25
04:12 Dec 12, 2019
H19
250 
•HR 19 IH
under section 510(j) for such drug or 
1
combination of drugs; 
2
‘‘(II) after reasonable efforts of 
3
notification, issue an interim final ad-
4
ministrative order in accordance with 
5
paragraph (1) to require such change, 
6
together with a detailed statement of 
7
the reasons for such order; 
8
‘‘(III) publish in the Federal 
9
Register a notice of availability of 
10
such order; and 
11
‘‘(IV) provide for a public com-
12
ment period of at least 45 calendar 
13
days with respect to such interim final 
14
order. 
15
‘‘(ii) CONTENT
OF
ORDER.—An in-
16
terim final order issued under this sub-
17
paragraph with respect to the labeling of a 
18
drug may provide for new warnings and 
19
other information required for safe use of 
20
the drug. 
21
‘‘(C) EFFECTIVE DATE.—An order under 
22
subparagraph (A) or (B) shall take effect on a 
23
date specified by the Secretary. 
24
04:12 Dec 12, 2019
H19
251 
•HR 19 IH
‘‘(D) FINAL ORDER.—After the completion 
1
of the proceedings in subparagraph (A) or (B), 
2
the Secretary shall— 
3
‘‘(i) issue a final order in accordance 
4
with paragraph (1); 
5
‘‘(ii) publish a notice of availability of 
6
such final administrative order in the Fed-
7
eral Register; and 
8
‘‘(iii) afford sponsors of such drugs 
9
that will be subject to such an order the 
10
opportunity for formal dispute resolution 
11
up to the level of the Director of the Cen-
12
ter for Drug Evaluation and Research, 
13
which must initially be within 45 calendar 
14
days of the issuance of the order, and for 
15
subsequent levels of appeal, within 30 cal-
16
endar days of the prior decision. 
17
‘‘(E) HEARINGS.—A sponsor of a drug 
18
subject to a final order issued under subpara-
19
graph (D) and that participated in each stage 
20
of formal dispute resolution under clause (iii) of 
21
such subparagraph may request a hearing on 
22
such order. The provisions of subparagraphs 
23
(A), (B), and (C) of paragraph (3), other than 
24
paragraph (3)(C)(v)(II), shall apply with re-
25
04:12 Dec 12, 2019
H19
252 
•HR 19 IH
spect to a hearing on such order in the same 
1
manner and to the same extent as such provi-
2
sions apply with respect to a hearing on an ad-
3
ministrative order issued under paragraph 
4
(2)(A)(iv). 
5
‘‘(F) TIMING.— 
6
‘‘(i) FINAL ORDER AND HEARING.— 
7
The Secretary shall— 
8
‘‘(I) not later than 6 months 
9
after the date on which the comment 
10
period closes under subparagraph (A) 
11
or (B), issue a final order in accord-
12
ance with paragraph (1); and 
13
‘‘(II) not later than 12 months 
14
after the date on which such final 
15
order is issued, complete any hearing 
16
under subparagraph (E). 
17
‘‘(ii) 
DISPUTE
RESOLUTION
RE-
18
QUEST.—The Secretary shall specify in an 
19
interim final order issued under subpara-
20
graph (A) or (B) such shorter periods for 
21
requesting dispute resolution under sub-
22
paragraph (D)(iii) as are necessary to 
23
meet the requirements of this subpara-
24
graph. 
25
04:12 Dec 12, 2019
H19
253 
•HR 19 IH
‘‘(G) JUDICIAL
REVIEW.—A final order 
1
issued pursuant to subparagraph (F) shall be 
2
subject to judicial review in accordance with 
3
paragraph (3)(D). 
4
‘‘(5) ADMINISTRATIVE
ORDER
INITIATED
AT 
5
THE REQUEST OF A REQUESTOR.— 
6
‘‘(A) IN GENERAL.—In issuing an adminis-
7
trative order under paragraph (1) at the re-
8
quest of a requestor with respect to certain 
9
drugs, classes of drugs, or combinations of 
10
drugs— 
11
‘‘(i) the Secretary shall, after receiv-
12
ing a request under this subparagraph, de-
13
termine whether the request is sufficiently 
14
complete and formatted to permit a sub-
15
stantive review; 
16
‘‘(ii) if the Secretary determines that 
17
the request is sufficiently complete and for-
18
matted to permit a substantive review, the 
19
Secretary shall— 
20
‘‘(I) file the request; and 
21
‘‘(II) initiate proceedings with re-
22
spect to issuing an administrative 
23
order in accordance with paragraphs 
24
(2) and (3); and 
25
04:12 Dec 12, 2019
H19
254 
•HR 19 IH
‘‘(iii) except as provided in paragraph 
1
(6), if the Secretary determines that a re-
2
quest does not meet the requirements for 
3
filing or is not sufficiently complete and 
4
formatted to permit a substantive review, 
5
the requestor may demand that the request 
6
be filed over protest, and the Secretary 
7
shall initiate proceedings to review the re-
8
quest in accordance with paragraph (2)(A). 
9
‘‘(B) 
REQUEST
TO
INITIATE
PRO-
10
CEEDINGS.— 
11
‘‘(i) IN GENERAL.—A requestor seek-
12
ing an administrative order under para-
13
graph (1) with respect to certain drugs, 
14
classes of drugs, or combinations of drugs, 
15
shall submit to the Secretary a request to 
16
initiate proceedings for such order in the 
17
form and manner as specified by the Sec-
18
retary. Such requestor may submit a re-
19
quest under this subparagraph for the 
20
issuance of an administrative order— 
21
‘‘(I) determining whether a drug 
22
is generally recognized as safe and ef-
23
fective under section 201(p)(1), ex-
24
empt from section 503(b)(1), and not 
25
04:12 Dec 12, 2019
H19
255 
•HR 19 IH
required to be the subject of an ap-
1
proved application under section 505; 
2
or 
3
‘‘(II) 
determining 
whether 
a 
4
change to a condition of use of a drug 
5
is generally recognized as safe and ef-
6
fective under section 201(p)(1), ex-
7
empt from section 503(b)(1), and not 
8
required to be the subject of an ap-
9
proved application under section 505, 
10
if, absent such a changed condition of 
11
use, such drug is— 
12
‘‘(aa) generally recognized 
13
as safe and effective under sec-
14
tion 201(p)(1) in accordance with 
15
subsection (a)(1), (a)(2), or an 
16
order under this subsection; or 
17
‘‘(bb) subject to subsection 
18
(a)(3), but only if such requestor 
19
initiates such request in conjunc-
20
tion with a request for the Sec-
21
retary to determine whether such 
22
drug is generally recognized as 
23
safe and effective under section 
24
201(p)(1), which is filed by the 
25
04:12 Dec 12, 2019
H19
256 
•HR 19 IH
Secretary under subparagraph 
1
(A)(ii). 
2
‘‘(ii) EXCEPTION.—The Secretary is 
3
not required to complete review of a re-
4
quest for a change described in clause 
5
(i)(II) if the Secretary determines that 
6
there is an inadequate basis to find the 
7
drug is generally recognized as safe and ef-
8
fective under section 201(p)(1) under para-
9
graph (1) and issues a final order an-
10
nouncing that determination. 
11
‘‘(iii) WITHDRAWAL.—The requestor 
12
may withdraw a request under this para-
13
graph, according to the procedures set 
14
forth pursuant to subsection (d)(2)(B). 
15
Notwithstanding any other provision of 
16
this section, if such request is withdrawn, 
17
the Secretary may cease proceedings under 
18
this subparagraph. 
19
‘‘(C) EXCLUSIVITY.— 
20
‘‘(i) IN GENERAL.—A final adminis-
21
trative order issued in response to a re-
22
quest under this section shall have the ef-
23
fect of authorizing solely the order re-
24
questor (or the licensees, assignees, or suc-
25
04:12 Dec 12, 2019
H19
257 
•HR 19 IH
cessors in interest of such requestor with 
1
respect to the subject of such order), for a 
2
period of 18 months following the effective 
3
date of such final order and beginning on 
4
the date the requestor may lawfully market 
5
such drugs pursuant to the order, to mar-
6
ket drugs— 
7
‘‘(I) incorporating changes de-
8
scribed in clause (ii); and 
9
‘‘(II) subject to the limitations 
10
under clause (iv). 
11
‘‘(ii) 
CHANGES
DESCRIBED.—A 
12
change described in this clause is a change 
13
subject to an order specified in clause (i), 
14
which— 
15
‘‘(I) provides for a drug to con-
16
tain an active ingredient (including 
17
any ester or salt of the active ingre-
18
dient) not previously incorporated in a 
19
drug described in clause (iii); or 
20
‘‘(II) provides for a change in the 
21
conditions of use of a drug, for which 
22
new human data studies conducted or 
23
sponsored by the requestor (or for 
24
which the requestor has an exclusive 
25
04:12 Dec 12, 2019
H19
258 
•HR 19 IH
right of reference) were essential to 
1
the issuance of such order. 
2
‘‘(iii) DRUGS DESCRIBED.—The drugs 
3
described in this clause are drugs— 
4
‘‘(I) 
specified 
in 
subsection 
5
(a)(1), (a)(2), or (a)(3); 
6
‘‘(II) subject to a final order 
7
issued under this section; 
8
‘‘(III) subject to a final sun-
9
screen order (as defined in section 
10
586(2)(A)); or 
11
‘‘(IV) described in subsection 
12
(m)(1), other than drugs subject to an 
13
active enforcement action under chap-
14
ter III of this Act. 
15
‘‘(iv) 
LIMITATIONS
ON
EXCLU-
16
SIVITY.— 
17
‘‘(I) IN GENERAL.—Only one 18- 
18
month period under this subpara-
19
graph shall be granted, under each 
20
order described in clause (i), with re-
21
spect to changes (to the drug subject 
22
to such order) which are either— 
23
04:12 Dec 12, 2019
H19
259 
•HR 19 IH
‘‘(aa) changes described in 
1
clause (ii)(I), relating to active 
2
ingredients; or 
3
‘‘(bb) changes described in 
4
clause (ii)(II), relating to condi-
5
tions of use. 
6
‘‘(II) 
NO
EXCLUSIVITY
AL-
7
LOWED.—No exclusivity shall apply to 
8
changes to a drug which are— 
9
‘‘(aa) the subject of a Tier 2 
10
OTC monograph order request 
11
(as defined in section 744L); 
12
‘‘(bb) safety-related changes, 
13
as defined by the Secretary, or 
14
any other changes the Secretary 
15
considers necessary to assure 
16
safe use; or 
17
‘‘(cc) changes related to 
18
methods of testing safety or effi-
19
cacy. 
20
‘‘(v) NEW HUMAN DATA STUDIES DE-
21
FINED.—In this subparagraph, the term 
22
‘new human data studies’ means clinical 
23
trials of safety or effectiveness (including 
24
actual use studies), pharmacokinetics stud-
25
04:12 Dec 12, 2019
H19
260 
•HR 19 IH
ies, or bioavailability studies, the results of 
1
which— 
2
‘‘(I) have not been relied on by 
3
the Secretary to support— 
4
‘‘(aa) a proposed or final de-
5
termination that a drug described 
6
in subclause (I), (II), or (III) of 
7
clause (iii) is generally recognized 
8
as safe and effective under sec-
9
tion 201(p)(1); or 
10
‘‘(bb) approval of a drug 
11
that was approved under section 
12
505; and 
13
‘‘(II) do not duplicate the results 
14
of another study that was relied on by 
15
the Secretary to support— 
16
‘‘(aa) a proposed or final de-
17
termination that a drug described 
18
in subclause (I), (II), or (III) of 
19
clause (iii) is generally recognized 
20
as safe and effective under sec-
21
tion 201(p)(1); or 
22
‘‘(bb) approval of a drug 
23
that was approved under section 
24
505. 
25
04:12 Dec 12, 2019
H19
261 
•HR 19 IH
‘‘(6) INFORMATION
REGARDING
SAFE
NON-
1
PRESCRIPTION MARKETING AND USE AS CONDITION 
2
FOR FILING A GENERALLY RECOGNIZED AS SAFE 
3
AND EFFECTIVE REQUEST.— 
4
‘‘(A) IN GENERAL.—In response to a re-
5
quest under this section that a drug described 
6
in subparagraph (B) be generally recognized as 
7
safe and effective, the Secretary— 
8
‘‘(i) may file such request, if the re-
9
quest includes information specified under 
10
subparagraph (C) with respect to safe non-
11
prescription marketing and use of such 
12
drug; or 
13
‘‘(ii) if the request fails to include in-
14
formation specified under subparagraph 
15
(C), shall refuse to file such request and 
16
require that nonprescription marketing of 
17
the drug be pursuant to a new drug appli-
18
cation as described in subparagraph (D). 
19
‘‘(B) DRUG
DESCRIBED.—A drug de-
20
scribed in this subparagraph is a nonprescrip-
21
tion drug which contains an active ingredient 
22
not previously incorporated in a drug— 
23
‘‘(i) specified in subsection (a)(1), 
24
(a)(2), or (a)(3); 
25
04:12 Dec 12, 2019
H19
262 
•HR 19 IH
‘‘(ii) subject to a final order under 
1
this section; or 
2
‘‘(iii) subject to a final sunscreen 
3
order (as defined in section 586(2)(A)). 
4
‘‘(C) 
INFORMATION
DEMONSTRATING 
5
PRIMA
FACIE
SAFE
NONPRESCRIPTION
MAR-
6
KETING
AND
USE.—Information specified in 
7
this subparagraph, with respect to a request de-
8
scribed in subparagraph (A)(i), is— 
9
‘‘(i) information sufficient for a prima 
10
facie demonstration that the drug subject 
11
to such request has a verifiable history of 
12
being marketed and safely used by con-
13
sumers in the United States as a non-
14
prescription drug under comparable condi-
15
tions of use; 
16
‘‘(ii) if the drug has not been pre-
17
viously marketed in the United States as a 
18
nonprescription drug, information suffi-
19
cient for a prima facie demonstration that 
20
the drug was marketed and safely used 
21
under comparable conditions of marketing 
22
and use in a country listed in section 
23
802(b)(1)(A) or designated by the Sec-
24
04:12 Dec 12, 2019
H19
263 
•HR 19 IH
retary 
in 
accordance 
with 
section 
1
802(b)(1)(B)— 
2
‘‘(I) for such period as needed to 
3
provide reasonable assurances con-
4
cerning the safe nonprescription use 
5
of the drug; and 
6
‘‘(II) during such time was sub-
7
ject to sufficient monitoring by a reg-
8
ulatory body considered acceptable by 
9
the Secretary for such monitoring 
10
purposes, including for adverse events 
11
associated with nonprescription use of 
12
the drug; or 
13
‘‘(iii) if the Secretary determines that 
14
information described in clause (i) or (ii) is 
15
not needed to provide a prima facie dem-
16
onstration that the drug can be safely mar-
17
keted and used as a nonprescription drug, 
18
such other information the Secretary deter-
19
mines is sufficient for such purposes. 
20
‘‘(D) MARKETING
PURSUANT
TO
NEW 
21
DRUG APPLICATION.—In the case of a request 
22
described in subparagraph (A)(ii), the drug 
23
subject to such request may be resubmitted for 
24
filing only if— 
25
04:12 Dec 12, 2019
H19
264 
•HR 19 IH
‘‘(i) the drug is marketed as a non-
1
prescription drug, under conditions of use 
2
comparable to the conditions specified in 
3
the request, for such period as the Sec-
4
retary determines appropriate (not to ex-
5
ceed 5 consecutive years) pursuant to an 
6
application approved under section 505; 
7
and 
8
‘‘(ii) during such period, 1,000,000 
9
retail packages of the drug, or an equiva-
10
lent quantity as determined by the Sec-
11
retary, were distributed for retail sale, as 
12
determined in such manner as the Sec-
13
retary finds appropriate. 
14
‘‘(E) RULE OF APPLICATION.—Except in 
15
the case of a request involving a drug described 
16
in section 586(9), as in effect on January 1, 
17
2017, if the Secretary refuses to file a request 
18
under this paragraph, the requestor may not 
19
file such request over protest under paragraph 
20
(5)(A)(iii). 
21
‘‘(7) PACKAGING.—An administrative order 
22
issued under paragraph (2), (4)(A), or (5) may in-
23
clude requirements for the packaging of a drug to 
24
encourage use in accordance with labeling. Such re-
25
04:12 Dec 12, 2019
H19
265 
•HR 19 IH
quirements may include unit dose packaging, re-
1
quirements for products intended for use by pedi-
2
atric populations, requirements to reduce risk of 
3
harm from unsupervised ingestion, and other appro-
4
priate requirements. This paragraph does not au-
5
thorize the Food and Drug Administration to re-
6
quire standards or testing procedures as described in 
7
part 1700 of title 16, Code of Federal Regulations. 
8
‘‘(8) FINAL
AND
TENTATIVE
FINAL
MONO-
9
GRAPHS FOR CATEGORY I DRUGS DEEMED FINAL 
10
ADMINISTRATIVE ORDERS.— 
11
‘‘(A) IN GENERAL.—A final monograph or 
12
tentative final monograph described in subpara-
13
graph (B) shall be deemed to be a final admin-
14
istrative order under this subsection and may 
15
be amended, revoked, or otherwise modified in 
16
accordance with the procedures of this sub-
17
section. 
18
‘‘(B) MONOGRAPHS DESCRIBED.—For pur-
19
poses of subparagraph (A), a final monograph 
20
or tentative final monograph is described in this 
21
subparagraph if it— 
22
‘‘(i) establishes conditions of use for a 
23
drug described in paragraph (1) or (2) of 
24
subsection (a); and 
25
04:12 Dec 12, 2019
H19
266 
•HR 19 IH
‘‘(ii) represents the most recently pro-
1
mulgated version of such conditions, in-
2
cluding as modified, in whole or in part, by 
3
any proposed or final rule. 
4
‘‘(C) DEEMED ORDERS INCLUDE HARMO-
5
NIZING
TECHNICAL
AMENDMENTS.—The 
6
deemed establishment of a final administrative 
7
order under subparagraph (A) shall be con-
8
strued to include any technical amendments to 
9
such order as the Secretary determines nec-
10
essary to ensure that such order is appro-
11
priately harmonized, in terms of terminology or 
12
cross-references, with the applicable provisions 
13
of this Act (and regulations thereunder) and 
14
any other orders issued under this section. 
15
‘‘(c) PROCEDURE FOR MINOR CHANGES.— 
16
‘‘(1) IN GENERAL.—Minor changes in the dos-
17
age form of a drug that is described in paragraph 
18
(1) or (2) of subsection (a) or the subject of an 
19
order issued under subsection (b) may be made by 
20
a requestor without the issuance of an order under 
21
subsection (b) if— 
22
‘‘(A) the requestor maintains such infor-
23
mation as is necessary to demonstrate that the 
24
change— 
25
04:12 Dec 12, 2019
H19
267 
•HR 19 IH
‘‘(i) will not affect the safety or effec-
1
tiveness of the drug; and 
2
‘‘(ii) will not materially affect the ex-
3
tent of absorption or other exposure to the 
4
active ingredient in comparison to a suit-
5
able reference product; and 
6
‘‘(B) the change is in conformity with the 
7
requirements of an applicable administrative 
8
order issued by the Secretary under paragraph 
9
(3). 
10
‘‘(2) ADDITIONAL INFORMATION.— 
11
‘‘(A) ACCESS
TO
RECORDS.—A sponsor 
12
shall submit records requested by the Secretary 
13
relating to such a minor change under section 
14
704(a)(4), within 15 business days of receiving 
15
such a request, or such longer period as the 
16
Secretary may provide. 
17
‘‘(B) INSUFFICIENT INFORMATION.—If the 
18
Secretary determines that the information con-
19
tained in such records is not sufficient to dem-
20
onstrate that the change does not affect the 
21
safety or effectiveness of the drug or materially 
22
affect the extent of absorption or other expo-
23
sure to the active ingredient, the Secretary— 
24
04:12 Dec 12, 2019
H19
268 
•HR 19 IH
‘‘(i) may so inform the sponsor of the 
1
drug in writing; and 
2
‘‘(ii) if the Secretary so informs the 
3
sponsor, shall provide the sponsor of the 
4
drug with a reasonable opportunity to pro-
5
vide additional information. 
6
‘‘(C) FAILURE TO SUBMIT SUFFICIENT IN-
7
FORMATION.—If the sponsor fails to provide 
8
such additional information within a time pre-
9
scribed by the Secretary, or if the Secretary de-
10
termines that such additional information does 
11
not demonstrate that the change does not— 
12
‘‘(i) affect the safety or effectiveness 
13
of the drug; or 
14
‘‘(ii) materially affect the extent of 
15
absorption or other exposure to the active 
16
ingredient in comparison to a suitable ref-
17
erence product, 
18
the drug as modified is a new drug under sec-
19
tion 201(p) and shall be deemed to be mis-
20
branded under section 502(ee). 
21
‘‘(3) DETERMINING WHETHER A CHANGE WILL 
22
AFFECT SAFETY OR EFFECTIVENESS.— 
23
‘‘(A) IN
GENERAL.—The Secretary shall 
24
issue one or more administrative orders speci-
25
04:12 Dec 12, 2019
H19
269 
•HR 19 IH
fying requirements for determining whether a 
1
minor change made by a sponsor pursuant to 
2
this subsection will affect the safety or effective-
3
ness of a drug or materially affect the extent of 
4
absorption or other exposure to an active ingre-
5
dient in the drug in comparison to a suitable 
6
reference product, together with guidance for 
7
applying those orders to specific dosage forms. 
8
‘‘(B) STANDARD PRACTICES.—The orders 
9
and guidance issued by the Secretary under 
10
subparagraph (A) shall take into account rel-
11
evant public standards and standard practices 
12
for evaluating the quality of drugs, and may 
13
take into account the special needs of popu-
14
lations, including children. 
15
‘‘(d) CONFIDENTIALITY
OF
INFORMATION
SUB-
16
MITTED TO THE SECRETARY.— 
17
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
18
any information, including reports of testing con-
19
ducted on the drug or drugs involved, that is sub-
20
mitted by a requestor in connection with proceedings 
21
on an order under this section (including any minor 
22
change under subsection (c)) and is a trade secret 
23
or confidential information subject to section 
24
552(b)(4) of title 5, United States Code, or section 
25
04:12 Dec 12, 2019
H19
270 
•HR 19 IH
1905 of title 18, United States Code, shall not be 
1
disclosed to the public unless the requestor consents 
2
to that disclosure. 
3
‘‘(2) PUBLIC AVAILABILITY.— 
4
‘‘(A) IN GENERAL.—Except as provided in 
5
subparagraph (B), the Secretary shall— 
6
‘‘(i) make any information submitted 
7
by a requestor in support of a request 
8
under subsection (b)(5)(A) available to the 
9
public not later than the date on which the 
10
proposed order is issued; and 
11
‘‘(ii) make any information submitted 
12
by any other person with respect to an 
13
order requested (or initiated by the Sec-
14
retary) under subsection (b), available to 
15
the public upon such submission. 
16
‘‘(B) LIMITATIONS
ON
PUBLIC
AVAIL-
17
ABILITY.—Information described in subpara-
18
graph (A) shall not be made public if— 
19
‘‘(i) the information pertains to phar-
20
maceutical quality information, unless such 
21
information is necessary to establish stand-
22
ards under which a drug is generally rec-
23
ognized as safe and effective under section 
24
201(p)(1); 
25
04:12 Dec 12, 2019
H19
271 
•HR 19 IH
‘‘(ii) the information is submitted in a 
1
requestor-initiated request, but the re-
2
questor withdraws such request, in accord-
3
ance with withdrawal procedures estab-
4
lished by the Secretary, before the Sec-
5
retary issues the proposed order; 
6
‘‘(iii) the Secretary requests and ob-
7
tains the information under subsection (c) 
8
and such information is not submitted in 
9
relation to an order under subsection (b); 
10
or 
11
‘‘(iv) the information is of the type 
12
contained in raw datasets. 
13
‘‘(e) UPDATES TO DRUG LISTING INFORMATION.— 
14
A sponsor who makes a change to a drug subject to this 
15
section shall submit updated drug listing information for 
16
the drug in accordance with section 510(j) within 30 cal-
17
endar days of the date when the drug is first commercially 
18
marketed, except that a sponsor who was the order re-
19
questor with respect to an order subject to subsection 
20
(b)(5)(C) (or a licensee, assignee, or successor in interest 
21
of such requestor) shall submit updated drug listing infor-
22
mation on or before the date when the drug is first com-
23
mercially marketed. 
24
04:12 Dec 12, 2019
H19
272 
•HR 19 IH
‘‘(f) APPROVALS UNDER SECTION 505.—The provi-
1
sions of this section shall not be construed to preclude a 
2
person from seeking or maintaining the approval of an ap-
3
plication for a drug under sections 505(b)(1), 505(b)(2), 
4
and 505(j). A determination under this section that a drug 
5
is not subject to section 503(b)(1), is generally recognized 
6
as safe and effective under section 201(p)(1), and is not 
7
a new drug under section 201(p) shall constitute a finding 
8
that the drug is safe and effective that may be relied upon 
9
for purposes of an application under section 505(b)(2), so 
10
that the applicant shall be required to submit for purposes 
11
of such application only information needed to support any 
12
modification of the drug that is not covered by such deter-
13
mination under this section. 
14
‘‘(g) PUBLIC AVAILABILITY OF ADMINISTRATIVE OR-
15
DERS.—The Secretary shall establish, maintain, update 
16
(as determined necessary by the Secretary but no less fre-
17
quently than annually), and make publicly available, with 
18
respect to orders issued under this section— 
19
‘‘(1) a repository of each final order and in-
20
terim final order in effect, including the complete 
21
text of the order; and 
22
‘‘(2) a listing of all orders proposed and under 
23
development under subsection (b)(2), including— 
24
04:12 Dec 12, 2019
H19
273 
•HR 19 IH
‘‘(A) a brief description of each such order; 
1
and 
2
‘‘(B) the Secretary’s expectations, if re-
3
sources permit, for issuance of proposed orders 
4
over a 3-year period. 
5
‘‘(h) DEVELOPMENT ADVICE TO SPONSORS OR RE-
6
QUESTORS.—The Secretary shall establish procedures 
7
under which sponsors or requestors may meet with appro-
8
priate officials of the Food and Drug Administration to 
9
obtain advice on the studies and other information nec-
10
essary to support submissions under this section and other 
11
matters relevant to the regulation of nonprescription 
12
drugs and the development of new nonprescription drugs 
13
under this section. 
14
‘‘(i) PARTICIPATION OF MULTIPLE SPONSORS OR RE-
15
QUESTORS.—The Secretary shall establish procedures to 
16
facilitate efficient participation by multiple sponsors or re-
17
questors in proceedings under this section, including provi-
18
sion for joint meetings with multiple sponsors or reques-
19
tors or with organizations nominated by sponsors or re-
20
questors to represent their interests in a proceeding. 
21
‘‘(j) ELECTRONIC FORMAT.—All submissions under 
22
this section shall be in electronic format. 
23
‘‘(k) EFFECT
ON EXISTING REGULATIONS GOV-
24
ERNING NONPRESCRIPTION DRUGS.— 
25
04:12 Dec 12, 2019
H19
274 
•HR 19 IH
‘‘(1) REGULATIONS
OF
GENERAL
APPLICA-
1
BILITY
TO
NONPRESCRIPTION
DRUGS.—Except as 
2
provided in this subsection, nothing in this section 
3
supersedes regulations establishing general require-
4
ments for nonprescription drugs, including regula-
5
tions of general applicability contained in parts 201, 
6
250, and 330 of title 21, Code of Federal Regula-
7
tions, or any successor regulations. The Secretary 
8
shall establish or modify such regulations by means 
9
of rulemaking in accordance with section 553 of title 
10
5, United States Code. 
11
‘‘(2) REGULATIONS
ESTABLISHING
REQUIRE-
12
MENTS FOR SPECIFIC NONPRESCRIPTION DRUGS.— 
13
‘‘(A) The provisions of section 310.545 of 
14
title 21, Code of Federal Regulations, as in ef-
15
fect on the day before the date of the enact-
16
ment of this section, shall be deemed to be a 
17
final order under subsection (b). 
18
‘‘(B) Regulations in effect on the day be-
19
fore the date of the enactment of this section, 
20
establishing requirements for specific non-
21
prescription drugs marketed pursuant to this 
22
section (including such requirements in parts 
23
201 and 250 of title 21, Code of Federal Regu-
24
lations), shall be deemed to be final orders 
25
04:12 Dec 12, 2019
H19
275 
•HR 19 IH
under subsection (b), only as they apply to 
1
drugs— 
2
‘‘(i) subject to paragraph (1), (2), (3), 
3
or (4) of subsection (a); or 
4
‘‘(ii) otherwise subject to an order 
5
under this section. 
6
‘‘(3) WITHDRAWAL
OF
REGULATIONS.—The 
7
Secretary shall withdraw regulations establishing 
8
final monographs and the procedures governing the 
9
over-the-counter drug review under part 330 and 
10
other relevant parts of title 21, Code of Federal 
11
Regulations (as in effect on the day before the date 
12
of the enactment of this section), or make technical 
13
changes to such regulations to ensure conformity 
14
with appropriate terminology and cross references. 
15
Notwithstanding subchapter II of chapter 5 of title 
16
5, United States Code, any such withdrawal or tech-
17
nical changes shall be made without public notice 
18
and comment and shall be effective upon publication 
19
through notice in the Federal Register (or upon such 
20
date as specified in such notice). 
21
‘‘(l) GUIDANCE.—The Secretary shall issue guidance 
22
that specifies— 
23
04:12 Dec 12, 2019
H19
276 
•HR 19 IH
‘‘(1) the procedures and principles for formal 
1
meetings between the Secretary and sponsors or re-
2
questors for drugs subject to this section; 
3
‘‘(2) the format and content of data submis-
4
sions to the Secretary under this section; 
5
‘‘(3) the format of electronic submissions to the 
6
Secretary under this section; 
7
‘‘(4) consolidated proceedings for appeal and 
8
the procedures for such proceedings where appro-
9
priate; and 
10
‘‘(5) for minor changes in drugs, recommenda-
11
tions on how to comply with the requirements in or-
12
ders issued under subsection (c)(3). 
13
‘‘(m) RULE OF CONSTRUCTION.— 
14
‘‘(1) IN GENERAL.—This section shall not af-
15
fect the treatment or status of a nonprescription 
16
drug— 
17
‘‘(A) that is marketed without an applica-
18
tion approved under section 505 as of the date 
19
of the enactment of this section; 
20
‘‘(B) that is not subject to an order issued 
21
under this section; and 
22
‘‘(C) to which paragraphs (1), (2), (3), (4), 
23
or (5) of subsection (a) do not apply. 
24
04:12 Dec 12, 2019
H19
277 
•HR 19 IH
‘‘(2) TREATMENT
OF
PRODUCTS
PREVIOUSLY 
1
FOUND TO BE SUBJECT TO TIME AND EXTENT RE-
2
QUIREMENTS.— 
3
‘‘(A) Notwithstanding subsection (a), a 
4
drug described in subparagraph (B) may only 
5
be lawfully marketed, without an application 
6
approved under section 505, pursuant to an 
7
order issued under this section. 
8
‘‘(B) A drug described in this subpara-
9
graph is a drug which, prior to the date of the 
10
enactment of this section, the Secretary deter-
11
mined in a proposed or final rule to be ineligible 
12
for review under the OTC drug review (as such 
13
phrase ‘OTC drug review’ was used in section 
14
330.14 of title 21, Code of Federal Regulations, 
15
as in effect on the day before the date of the 
16
enactment of this section). 
17
‘‘(3) PRESERVATION OF AUTHORITY.— 
18
‘‘(A) Nothing in paragraph (1) shall be 
19
construed to preclude or limit the applicability 
20
of any provision of this Act other than this sec-
21
tion. 
22
‘‘(B) Nothing in subsection (a) shall be 
23
construed to prohibit the Secretary from issuing 
24
an order under this section finding a drug to be 
25
04:12 Dec 12, 2019
H19
278 
•HR 19 IH
not generally recognized as safe and effective 
1
under section 201(p)(1), as the Secretary deter-
2
mines appropriate. 
3
‘‘(n) INVESTIGATIONAL NEW DRUGS.—A drug is not 
4
subject to this section if an exemption for investigational 
5
use under section 505(i) is in effect for such drug. 
6
‘‘(o) INAPPLICABILITY OF PAPERWORK REDUCTION 
7
ACT.—Chapter 35 of title 44, United States Code, shall 
8
not apply to collections of information made under this 
9
section. 
10
‘‘(p) INAPPLICABILITY OF NOTICE AND COMMENT 
11
RULEMAKING
AND OTHER REQUIREMENTS.—The re-
12
quirements of subsection (b) shall apply with respect to 
13
orders issued under this section instead of the require-
14
ments of subchapter II of chapter 5 of title 5, United 
15
States Code. 
16
‘‘(q) DEFINITIONS.—In this section: 
17
‘‘(1) The term ‘nonprescription drug’ refers to 
18
a drug not subject to the requirements of section 
19
503(b)(1). 
20
‘‘(2) The term ‘sponsor’ refers to any person 
21
marketing, manufacturing, or processing a drug 
22
that— 
23
‘‘(A) is listed pursuant to section 510(j); 
24
and 
25
04:12 Dec 12, 2019
H19
279 
•HR 19 IH
‘‘(B) is or will be subject to an administra-
1
tive order under this section of the Food and 
2
Drug Administration. 
3
‘‘(3) The term ‘requestor’ refers to any person 
4
or group of persons marketing, manufacturing, proc-
5
essing, or developing a drug.’’. 
6
(b) GAO STUDY.—Not later than 4 years after the 
7
date of enactment of this Act, the Comptroller General 
8
of the United States shall submit a study to the Com-
9
mittee on Energy and Commerce of the House of Rep-
10
resentatives and the Committee on Health, Education, 
11
Labor, and Pensions of the Senate addressing the effec-
12
tiveness and overall impact of exclusivity under section 
13
505G of the Federal Food, Drug, and Cosmetic Act, as 
14
added by subsection (a), and section 586C of such Act 
15
(21 U.S.C. 360fff–3), including the impact of such exclu-
16
sivity on consumer access. Such study shall include— 
17
(1) an analysis of the impact of exclusivity 
18
under such section 505G for nonprescription drug 
19
products, including— 
20
(A) the number of nonprescription drug 
21
products that were granted exclusivity and the 
22
indication for which the nonprescription drug 
23
products were determined to be generally recog-
24
nized as safe and effective; 
25
04:12 Dec 12, 2019
H19
280 
•HR 19 IH
(B) whether the exclusivity for such drug 
1
products was granted for— 
2
(i) a new active ingredient (including 
3
any ester or salt of the active ingredient); 
4
or 
5
(ii) changes in the conditions of use of 
6
a drug, for which new human data studies 
7
conducted or sponsored by the requestor 
8
were essential; 
9
(C) whether, and to what extent, the exclu-
10
sivity impacted the requestor’s or sponsor’s de-
11
cision to develop the drug product; 
12
(D) an analysis of the implementation of 
13
the exclusivity provision in such section 505G, 
14
including— 
15
(i) the resources used by the Food 
16
and Drug Administration; 
17
(ii) the impact of such provision on 
18
innovation, as well as research and devel-
19
opment in the nonprescription drug mar-
20
ket; 
21
(iii) the impact of such provision on 
22
competition in the nonprescription drug 
23
market; 
24
04:12 Dec 12, 2019
H19
281 
•HR 19 IH
(iv) the impact of such provision on 
1
consumer access to nonprescription drug 
2
products; 
3
(v) the impact of such provision on 
4
the prices of nonprescription drug prod-
5
ucts; and 
6
(vi) whether the administrative orders 
7
initiated by requestors under such section 
8
505G have been sufficient to encourage the 
9
development of nonprescription drug prod-
10
ucts that would likely not be otherwise de-
11
veloped, or developed in as timely a man-
12
ner; and 
13
(E) whether the administrative orders ini-
14
tiated by requestors under such section 505G 
15
have been sufficient incentive to encourage in-
16
novation in the nonprescription drug market; 
17
and 
18
(2) an analysis of the impact of exclusivity 
19
under such section 586C for sunscreen ingredients, 
20
including— 
21
(A) the number of sunscreen ingredients 
22
that were granted exclusivity and the specific 
23
ingredient that was determined to be generally 
24
recognized as safe and effective; 
25
04:12 Dec 12, 2019
H19
282 
•HR 19 IH
(B) whether, and to what extent, the exclu-
1
sivity impacted the requestor’s or sponsor’s de-
2
cision to develop the sunscreen ingredient; 
3
(C) whether, and to what extent, the sun-
4
screen ingredient granted exclusivity had pre-
5
viously been available outside of the United 
6
States; 
7
(D) an analysis of the implementation of 
8
the exclusivity provision in such section 586C, 
9
including— 
10
(i) the resources used by the Food 
11
and Drug Administration; 
12
(ii) the impact of such provision on 
13
innovation, as well as research and devel-
14
opment in the sunscreen market; 
15
(iii) the impact of such provision on 
16
competition in the sunscreen market; 
17
(iv) the impact of such provision on 
18
consumer access to sunscreen products; 
19
(v) the impact of such provision on 
20
the prices of sunscreen products; and 
21
(vi) whether the administrative orders 
22
initiated by requestors under such section 
23
505G have been utilized by sunscreen in-
24
gredient sponsors and whether such proc-
25
04:12 Dec 12, 2019
H19
283 
•HR 19 IH
ess has been sufficient to encourage the 
1
development of sunscreen ingredients that 
2
would likely not be otherwise developed, or 
3
developed in as timely a manner; and 
4
(E) whether the administrative orders ini-
5
tiated by requestors under such section 586C 
6
have been sufficient incentive to encourage in-
7
novation in the sunscreen market. 
8
(c) CONFORMING AMENDMENT.—Section 751(d)(1) 
9
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
10
379r(d)(1)) is amended— 
11
(1) in the matter preceding subparagraph (A)— 
12
(A) by striking ‘‘final regulation promul-
13
gated’’ and inserting ‘‘final order under section 
14
505G’’; and 
15
(B) by striking ‘‘and not misbranded’’; and 
16
(2) in subparagraph (A), by striking ‘‘regula-
17
tion in effect’’ and inserting ‘‘regulation or order in 
18
effect’’. 
19
SEC. 372. MISBRANDING. 
20
Section 502 of the Federal Food, Drug, and Cosmetic 
21
Act (21 U.S.C. 352) is amended by adding at the end the 
22
following: 
23
‘‘(ee) If it is a nonprescription drug that is subject 
24
to section 505G, is not the subject of an application ap-
25
04:12 Dec 12, 2019
H19
284 
•HR 19 IH
proved under section 505, and does not comply with the 
1
requirements under section 505G. 
2
‘‘(ff) If it is a drug and it was manufactured, pre-
3
pared, propagated, compounded, or processed in a facility 
4
for which fees have not been paid as required by section 
5
744M.’’. 
6
SEC. 
373. 
DRUGS 
EXCLUDED 
FROM 
THE 
OVER-THE- 
7
COUNTER DRUG REVIEW. 
8
(a) IN GENERAL.—Nothing in this Act (or the 
9
amendments made by this Act) shall apply to any non-
10
prescription drug (as defined in section 505G(q) of the 
11
Federal Food, Drug, and Cosmetic Act, as added by sec-
12
tion 1001 of this Act) which was excluded by the Food 
13
and Drug Administration from the Over-the-Counter 
14
Drug Review in accordance with the paragraph numbered 
15
25 on page 9466 of volume 37 of the Federal Register, 
16
published on May 11, 1972. 
17
(b) RULE OF CONSTRUCTION.—Nothing in this sec-
18
tion shall be construed to preclude or limit the applica-
19
bility of any other provision of the Federal Food, Drug, 
20
and Cosmetic Act (21 U.S.C. 301 et seq.). 
21
SEC. 374. TREATMENT OF SUNSCREEN INNOVATION ACT. 
22
(a) REVIEW OF NONPRESCRIPTION SUNSCREEN AC-
23
TIVE INGREDIENTS.— 
24
04:12 Dec 12, 2019
H19
285 
•HR 19 IH
(1) APPLICABILITY
OF
SECTION
505G
FOR 
1
PENDING SUBMISSIONS.— 
2
(A) IN GENERAL.—A sponsor of a non-
3
prescription sunscreen active ingredient or com-
4
bination of nonprescription sunscreen active in-
5
gredients that, as of the date of enactment of 
6
this Act, is subject to a proposed sunscreen 
7
order under section 586C of the Federal Food, 
8
Drug, and Cosmetic Act (21 U.S.C. 360fff–3) 
9
may elect, by means of giving written notifica-
10
tion to the Secretary of Health and Human 
11
Services within 180 calendar days of the enact-
12
ment of this Act, to transition into the review 
13
of such ingredient or combination of ingredients 
14
pursuant to the process set out in section 505G 
15
of the Federal Food, Drug, and Cosmetic Act, 
16
as added by section 1001 of this Act. 
17
(B) ELECTION EXERCISED.—Upon receipt 
18
by the Secretary of Health and Human Services 
19
of a timely notification under subparagraph 
20
(A)— 
21
(i) the proposed sunscreen order in-
22
volved is deemed to be a request for an 
23
order under subsection (b) of section 505G 
24
of the Federal Food, Drug, and Cosmetic 
25
04:12 Dec 12, 2019
H19
286 
•HR 19 IH
Act, as added by section 1001 of this Act; 
1
and 
2
(ii) such order is deemed to have been 
3
accepted 
for 
filing 
under 
subsection 
4
(b)(6)(A)(i) of such section 505G. 
5
(C) ELECTION NOT EXERCISED.—If a noti-
6
fication under subparagraph (A) is not received 
7
by the Secretary of Health and Human Services 
8
within 180 calendar days of the date of enact-
9
ment of this Act, the review of the proposed 
10
sunscreen order described in subparagraph 
11
(A)— 
12
(i) shall continue under section 586C 
13
of the Federal Food, Drug, and Cosmetic 
14
Act (21 U.S.C. 360fff–3); and 
15
(ii) shall not be eligible for review 
16
under section 505G, added by section 1001 
17
of this Act. 
18
(2) DEFINITIONS.—In this subsection, the 
19
terms ‘‘sponsor’’, ‘‘nonprescription’’, ‘‘sunscreen ac-
20
tive ingredient’’, and ‘‘proposed sunscreen order’’ 
21
have the meanings given to those terms in section 
22
586 of the Federal Food, Drug, and Cosmetic Act 
23
(21 U.S.C. 360fff). 
24
(b) AMENDMENTS TO SUNSCREEN PROVISIONS.— 
25
04:12 Dec 12, 2019
H19
287 
•HR 19 IH
(1) FINAL
SUNSCREEN
ORDERS.—Paragraph 
1
(3) of section 586C(e) of the Federal Food, Drug, 
2
and Cosmetic Act (21 U.S.C. 360fff–3(e)) is amend-
3
ed to read as follows: 
4
‘‘(3) RELATIONSHIP TO ORDERS UNDER SEC-
5
TION 505G.—A final sunscreen order shall be deemed 
6
to be a final order under section 505G.’’. 
7
(2) MEETINGS.—Paragraph (7) of section 
8
586C(b) of the Federal Food, Drug, and Cosmetic 
9
Act (21 U.S.C. 360fff–3(b)) is amended— 
10
(A) by striking ‘‘A sponsor may request’’ 
11
and inserting the following: 
12
‘‘(A) IN
GENERAL.—A sponsor may re-
13
quest’’; and 
14
(B) by adding at the end the following: 
15
‘‘(B) CONFIDENTIAL MEETINGS.—A spon-
16
sor may request one or more confidential meet-
17
ings with respect to a proposed sunscreen order, 
18
including a letter deemed to be a proposed sun-
19
screen order under paragraph (3), to discuss 
20
matters relating to data requirements to sup-
21
port a general recognition of safety and effec-
22
tiveness involving confidential information and 
23
public information related to such proposed 
24
sunscreen order, as appropriate. The Secretary 
25
04:12 Dec 12, 2019
H19
288 
•HR 19 IH
shall convene a confidential meeting with such 
1
sponsor in a reasonable time period. If a spon-
2
sor requests more than one confidential meeting 
3
for the same proposed sunscreen order, the Sec-
4
retary may refuse to grant an additional con-
5
fidential meeting request if the Secretary deter-
6
mines that such additional confidential meeting 
7
is not reasonably necessary for the sponsor to 
8
advance its proposed sunscreen order, or if the 
9
request for a confidential meeting fails to in-
10
clude sufficient information upon which to base 
11
a substantive discussion. The Secretary shall 
12
publish a post-meeting summary of each con-
13
fidential meeting under this subparagraph that 
14
does not disclose confidential commercial infor-
15
mation or trade secrets. This subparagraph 
16
does not authorize the disclosure of confidential 
17
commercial information or trade secrets subject 
18
to 552(b)(4) of title 5, United States Code, or 
19
section 1905 of title 18, United States Code.’’. 
20
(3) EXCLUSIVITY.—Section 586C of the Fed-
21
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
22
360fff–3) is amended by adding at the end the fol-
23
lowing: 
24
‘‘(f) EXCLUSIVITY.— 
25
04:12 Dec 12, 2019
H19
289 
•HR 19 IH
‘‘(1) IN
GENERAL.—A final sunscreen order 
1
shall have the effect of authorizing solely the order 
2
requestor (or the licensees, assignees, or successors 
3
in interest of such requestor with respect to the sub-
4
ject of such request and listed under paragraph (5)) 
5
for a period of 18 months, to market a sunscreen in-
6
gredient under this section incorporating changes 
7
described in paragraph (2) subject to the limitations 
8
under paragraph (4), beginning on the date the re-
9
questor (or any licensees, assignees, or successors in 
10
interest of such requestor with respect to the subject 
11
of such request and listed under paragraph (5)) may 
12
lawfully market such sunscreen ingredient pursuant 
13
to the order. 
14
‘‘(2) CHANGES
DESCRIBED.—A change de-
15
scribed in this paragraph is a change subject to an 
16
order specified in paragraph (1) that permits a sun-
17
screen to contain an active sunscreen ingredient not 
18
previously incorporated in a marketed sunscreen list-
19
ed in paragraph (3). 
20
‘‘(3) MARKETED
SUNSCREEN.—The marketed 
21
sunscreen ingredients described in this paragraph 
22
are sunscreen ingredients— 
23
‘‘(A) marketed in accordance with a final 
24
monograph for sunscreen drug products set 
25
04:12 Dec 12, 2019
H19
290 
•HR 19 IH
forth at part 352 of title 21, Code of Federal 
1
Regulations (as published at 64 Fed. Reg. 
2
27687); or 
3
‘‘(B) marketed in accordance with a final 
4
order issued under this section. 
5
‘‘(4) LIMITATIONS ON EXCLUSIVITY.—Only one 
6
18-month period may be granted per ingredient 
7
under paragraph (1). 
8
‘‘(5) LISTING OF LICENSEES, ASSIGNEES, OR 
9
SUCCESSORS IN INTEREST.—Requestors shall submit 
10
to the Secretary at the time when a drug subject to 
11
such request is introduced or delivered for introduc-
12
tion into interstate commerce, a list of licensees, as-
13
signees, or successors in interest under paragraph 
14
(1).’’. 
15
(4) SUNSET PROVISION.—Subchapter I of chap-
16
ter V of the Federal Food, Drug, and Cosmetic Act 
17
(21 U.S.C. 360fff et seq.) is amended by adding at 
18
the end the following: 
19
‘‘SEC. 586H. SUNSET. 
20
‘‘This subchapter shall cease to be effective at the end 
21
of fiscal year 2022.’’. 
22
(5) 
TREATMENT
OF
FINAL
SUNSCREEN 
23
ORDER.—The Federal Food, Drug, and Cosmetic 
24
04:12 Dec 12, 2019
H19
291 
•HR 19 IH
Act is amended by striking section 586E of such Act 
1
(21 U.S.C. 360fff–5). 
2
(c) TREATMENT OF AUTHORITY REGARDING FINAL-
3
IZATION OF SUNSCREEN MONOGRAPH.— 
4
(1) IN GENERAL.— 
5
(A) REVISION
OF
FINAL
SUNSCREEN 
6
ORDER.—Not later than November 26, 2019, 
7
the Secretary of Health and Human Services 
8
(referred to in this subsection as the ‘‘Sec-
9
retary’’) shall amend and revise the final ad-
10
ministrative order concerning nonprescription 
11
sunscreen (referred to in this subsection as the 
12
‘‘sunscreen order’’) for which the content, prior 
13
to the date of enactment of this Act, was rep-
14
resented by the final monograph for sunscreen 
15
drug products set forth in part 352 of title 21, 
16
Code of Federal Regulations (as in effect on 
17
May 21, 1999). 
18
(B) ISSUANCE
OF
REVISED
SUNSCREEN 
19
ORDER; EFFECTIVE DATE.—A revised sunscreen 
20
order described in subparagraph (A) shall be— 
21
(i) issued in accordance with the pro-
22
cedures described in section 505G(c)(2) of 
23
the Federal Food, Drug, and Cosmetic 
24
Act; 
25
04:12 Dec 12, 2019
H19
292 
•HR 19 IH
(ii) issued in proposed form not later 
1
than May 28, 2019; 
2
(iii) effective not later than November 
3
26, 2020; and 
4
(iv) issued by the Secretary at least 1 
5
year prior to the effective date of the re-
6
vised order. 
7
(2) REPORTS.—If a revised sunscreen order 
8
issued under paragraph (1) does not include provi-
9
sions related to the effectiveness of various sun pro-
10
tection factor levels, and does not address all dosage 
11
forms known to the Secretary to be used in sun-
12
screens marketed in the United States without a 
13
new drug application approved under section 505 of 
14
the Federal Food, Drug, and Cosmetic Act (21 
15
U.S.C. 355), the Secretary shall submit a report to 
16
the Committee on Energy and Commerce of the 
17
House of Representatives and the Committee on 
18
Health, Education, Labor, and Pensions of the Sen-
19
ate on the rationale for omission of such provisions 
20
from such order, and a plan and timeline to compile 
21
any information necessary to address such provisions 
22
through such order. 
23
(d) TREATMENT OF NON-SUNSCREEN TIME AND EX-
24
TENT APPLICATIONS.— 
25
04:12 Dec 12, 2019
H19
293 
•HR 19 IH
(1) IN GENERAL.—Any application described in 
1
section 586F of the Federal Food, Drug, and Cos-
2
metic Act (21 U.S.C. 360fff–6) that was submitted 
3
to the Secretary pursuant to section 330.14 of title 
4
21, Code of Federal Regulations, as such provisions 
5
were in effect immediately prior to the date of enact-
6
ment date of this Act, shall be extinguished as of 
7
such date of enactment, subject to paragraph (2). 
8
(2) ORDER REQUEST.—Nothing in paragraph 
9
(1) precludes the submission of an order request 
10
under section 505G(b) of the Federal Food, Drug, 
11
and Cosmetic Act, as added by section 1001 of this 
12
Act, with respect to a drug that was the subject of 
13
an application extinguished under paragraph (1). 
14
SEC. 375. ANNUAL UPDATE TO CONGRESS ON APPRO-
15
PRIATE PEDIATRIC INDICATION FOR CER-
16
TAIN OTC COUGH AND COLD DRUGS. 
17
(a) IN GENERAL.—Subject to subsection (c), the Sec-
18
retary of Health and Human Services shall, beginning not 
19
later than 1 year after the date of enactment of this Act, 
20
annually submit to the Committee on Energy and Com-
21
merce of the House of Representatives and the Committee 
22
on Health, Education, Labor, and Pensions of the Senate 
23
a letter describing the progress of the Food and Drug Ad-
24
ministration— 
25
04:12 Dec 12, 2019
H19
294 
•HR 19 IH
(1) in evaluating the cough and cold monograph 
1
described in subsection (b) with respect to children 
2
under age 6; and 
3
(2) as appropriate, revising such cough and cold 
4
monograph to address such children through the 
5
order process under section 505G(b) of the Federal 
6
Food, Drug, and Cosmetic Act, as added by section 
7
1001 of this Act. 
8
(b) COUGH AND COLD MONOGRAPH DESCRIBED.— 
9
The cough and cold monograph described in this sub-
10
section consists of the conditions under which nonprescrip-
11
tion drugs containing antitussive, expectorant, nasal de-
12
congestant, or antihistamine active ingredients (or com-
13
binations thereof) are generally recognized as safe and ef-
14
fective, as specified in part 341 of title 21, Code of Federal 
15
Regulations (as in effect immediately prior to the date of 
16
enactment of this Act), and included in an order deemed 
17
to be established under section 505G(b) of the Federal 
18
Food, Drug, and Cosmetic Act, as added by section 1001 
19
of this Act. 
20
(c) DURATION
OF AUTHORITY.—The requirement 
21
under subsection (a) shall terminate as of the date of a 
22
letter submitted by the Secretary of Health and Human 
23
Services pursuant to such subsection in which the Sec-
24
retary indicates that the Food and Drug Administration 
25
04:12 Dec 12, 2019
H19
295 
•HR 19 IH
has completed its evaluation and revised, in a final order, 
1
as applicable, the cough and cold monograph as described 
2
in subsection (a)(2). 
3
SEC. 376. TECHNICAL CORRECTIONS. 
4
(a) 
IMPORTS
AND
EXPORTS.—Section 
5
801(e)(4)(E)(iii) of the Federal Food, Drug, and Cosmetic 
6
Act (21 U.S.C. 381(e)(4)(E)(iii)) is amended by striking 
7
‘‘subparagraph’’ each place such term appears and insert-
8
ing ‘‘paragraph’’. 
9
(b) FDA REAUTHORIZATION ACT OF 2017.— 
10
(1) IN
GENERAL.—Section 905(b)(4) of the 
11
FDA Reauthorization Act of 2017 (Public Law 115– 
12
52) is amended by striking ‘‘Section 744H(e)(2)(B)’’ 
13
and inserting ‘‘Section 744H(f)(2)(B)’’. 
14
(2) EFFECTIVE DATE.—The amendment made 
15
by paragraph (1) shall take effect as of the enact-
16
ment of the FDA Reauthorization Act of 2017 
17
(Public Law 115–52). 
18
PART 2—USER FEES 
19
SEC. 381. SHORT TITLE; FINDING. 
20
(a) SHORT TITLE.—This part may be cited as the 
21
‘‘Over-the-Counter Monograph User Fee Act of 2019’’. 
22
(b) FINDING.—The Congress finds that the fees au-
23
thorized by the amendments made in this part will be dedi-
24
cated to OTC monograph drug activities, as set forth in 
25
04:12 Dec 12, 2019
H19
296 
•HR 19 IH
the goals identified for purposes of part 10 of subchapter 
1
C of chapter VII of the Federal Food, Drug, and Cosmetic 
2
Act, in the letters from the Secretary of Health and 
3
Human Services to the Chairman of the Committee on 
4
Health, Education, Labor, and Pensions of the Senate and 
5
the Chairman of the Committee on Energy and Commerce 
6
of the House of Representatives, as set forth in the Con-
7
gressional Record. 
8
SEC. 382. FEES RELATING TO OVER-THE-COUNTER DRUGS. 
9
Subchapter C of chapter VII of the Federal Food, 
10
Drug, and Cosmetic Act (21 U.S.C. 379f et seq.) is 
11
amended by inserting after part 9 the following: 
12
‘‘PART 10—FEES RELATING TO OVER-THE- 
13
COUNTER DRUGS 
14
‘‘SEC. 744L. DEFINITIONS. 
15
‘‘In this part: 
16
‘‘(1) The term ‘affiliate’ means a business enti-
17
ty that has a relationship with a second business en-
18
tity if, directly or indirectly— 
19
‘‘(A) one business entity controls, or has 
20
the power to control, the other business entity; 
21
or 
22
‘‘(B) a third party controls, or has power 
23
to control, both of the business entities. 
24
04:12 Dec 12, 2019
H19
297 
•HR 19 IH
‘‘(2) The term ‘contract manufacturing organi-
1
zation facility’ means an OTC monograph drug facil-
2
ity where neither the owner of such manufacturing 
3
facility nor any affiliate of such owner or facility 
4
sells the OTC monograph drug produced at such fa-
5
cility directly to wholesalers, retailers, or consumers 
6
in the United States. 
7
‘‘(3) The term ‘costs of resources allocated for 
8
OTC monograph drug activities’ means the expenses 
9
in connection with OTC monograph drug activities 
10
for— 
11
‘‘(A) officers and employees of the Food 
12
and Drug Administration, contractors of the 
13
Food and Drug Administration, advisory com-
14
mittees, and costs related to such officers, em-
15
ployees, and committees and costs related to 
16
contracts with such contractors; 
17
‘‘(B) management of information, and the 
18
acquisition, maintenance, and repair of com-
19
puter resources; 
20
‘‘(C) leasing, maintenance, renovation, and 
21
repair of facilities and acquisition, maintenance, 
22
and repair of fixtures, furniture, scientific 
23
equipment, and other necessary materials and 
24
supplies; and 
25
04:12 Dec 12, 2019
H19
298 
•HR 19 IH
‘‘(D) collecting fees under section 744M 
1
and accounting for resources allocated for OTC 
2
monograph drug activities. 
3
‘‘(4) The term ‘FDA establishment identifier’ is 
4
the unique number automatically generated by Food 
5
and Drug Administration’s Field Accomplishments 
6
and Compliance Tracking System (FACTS) (or any 
7
successor system). 
8
‘‘(5) The term ‘OTC monograph drug’ means a 
9
nonprescription drug without an approved new drug 
10
application which is governed by the provisions of 
11
section 505G. 
12
‘‘(6) The term ‘OTC monograph drug activities’ 
13
means activities of the Secretary associated with 
14
OTC monograph drugs and inspection of facilities 
15
associated with such products, including the fol-
16
lowing activities: 
17
‘‘(A) The activities necessary for review 
18
and evaluation of OTC monographs and OTC 
19
monograph order requests, including— 
20
‘‘(i) orders proposing or finalizing ap-
21
plicable conditions of use for OTC mono-
22
graph drugs; 
23
‘‘(ii) orders affecting status regarding 
24
general recognition of safety and effective-
25
04:12 Dec 12, 2019
H19
299 
•HR 19 IH
ness of an OTC monograph ingredient or 
1
combination of ingredients under specified 
2
conditions of use; 
3
‘‘(iii) all OTC monograph drug devel-
4
opment and review activities, including 
5
intra-agency collaboration; 
6
‘‘(iv) regulation and policy develop-
7
ment activities related to OTC monograph 
8
drugs; 
9
‘‘(v) development of product standards 
10
for products subject to review and evalua-
11
tion; 
12
‘‘(vi) meetings referred to in section 
13
505G(i); 
14
‘‘(vii) review of labeling prior to 
15
issuance of orders related to OTC mono-
16
graph drugs or conditions of use; and 
17
‘‘(viii) regulatory science activities re-
18
lated to OTC monograph drugs. 
19
‘‘(B) Inspections related to OTC mono-
20
graph drugs. 
21
‘‘(C) Monitoring of clinical and other re-
22
search conducted in connection with OTC 
23
monograph drugs. 
24
04:12 Dec 12, 2019
H19
300 
•HR 19 IH
‘‘(D) Safety activities with respect to OTC 
1
monograph drugs, including— 
2
‘‘(i) collecting, developing, and review-
3
ing safety information on OTC monograph 
4
drugs, including adverse event reports; 
5
‘‘(ii) developing and using improved 
6
adverse event data-collection systems, in-
7
cluding information technology systems; 
8
and 
9
‘‘(iii) developing and using improved 
10
analytical tools to assess potential safety 
11
risks, including access to external data-
12
bases. 
13
‘‘(E) Other activities necessary for imple-
14
mentation of section 505G. 
15
‘‘(7) The term ‘OTC monograph order request’ 
16
means a request for an order submitted under sec-
17
tion 505G(b)(5). 
18
‘‘(8) The term ‘Tier 1 OTC monograph order 
19
request’ means any OTC monograph order request 
20
not determined to be a Tier 2 OTC monograph 
21
order request. 
22
‘‘(9)(A) The term ‘Tier 2 OTC monograph 
23
order request’ means, subject to subparagraph (B), 
24
an OTC monograph order request for— 
25
04:12 Dec 12, 2019
H19
301 
•HR 19 IH
‘‘(i) the reordering of existing information 
1
in the drug facts label of an OTC monograph 
2
drug; 
3
‘‘(ii) the addition of information to the 
4
other information section of the drug facts label 
5
of an OTC monograph drug, as limited by sec-
6
tion 201.66(c)(7) of title 21, Code of Federal 
7
Regulations (or any successor regulations); 
8
‘‘(iii) modification to the directions for use 
9
section of the drug facts label of an OTC mono-
10
graph drug, if such changes conform to changes 
11
made pursuant to section 505G(c)(3)(A); 
12
‘‘(iv) the standardization of the concentra-
13
tion or dose of a specific finalized ingredient 
14
within a particular finalized monograph; 
15
‘‘(v) a change to ingredient nomenclature 
16
to align with nomenclature of a standards-set-
17
ting organization; or 
18
‘‘(vi) addition of an interchangeable term 
19
in accordance with section 330.1 of title 21, 
20
Code of Federal Regulations (or any successor 
21
regulations). 
22
‘‘(B) The Secretary may, based on program im-
23
plementation experience or other factors found ap-
24
propriate by the Secretary, characterize any OTC 
25
04:12 Dec 12, 2019
H19
302 
•HR 19 IH
monograph order request as a Tier 2 OTC mono-
1
graph order request (including recharacterizing a re-
2
quest from Tier 1 to Tier 2) and publish such deter-
3
mination in a proposed order issued pursuant to sec-
4
tion 505G. 
5
‘‘(10)(A) The term ‘OTC monograph drug facil-
6
ity’ means a foreign or domestic business or other 
7
entity that— 
8
‘‘(i) is— 
9
‘‘(I) under one management, either di-
10
rect or indirect; and 
11
‘‘(II) at one geographic location or ad-
12
dress engaged in manufacturing or proc-
13
essing the finished dosage form of an OTC 
14
monograph drug; 
15
‘‘(ii) includes a finished dosage form man-
16
ufacturer facility in a contractual relationship 
17
with the sponsor of one or more OTC mono-
18
graph drugs to manufacture or process such 
19
drugs; and 
20
‘‘(iii) does not include a business or other 
21
entity whose only manufacturing or processing 
22
activities are one or more of the following: pro-
23
duction of clinical research supplies, testing, or 
24
placement of outer packaging on packages con-
25
04:12 Dec 12, 2019
H19
303 
•HR 19 IH
taining multiple products, for such purposes as 
1
creating multipacks, when each monograph 
2
drug product contained within the overpack-
3
aging is already in a final packaged form prior 
4
to placement in the outer overpackaging. 
5
‘‘(B) For purposes of subparagraph (A)(i)(II), 
6
separate buildings or locations within close proximity 
7
are considered to be at one geographic location or 
8
address if the activities conducted in such buildings 
9
or locations are— 
10
‘‘(i) closely related to the same business 
11
enterprise; 
12
‘‘(ii) under the supervision of the same 
13
local management; and 
14
‘‘(iii) under a single FDA establishment 
15
identifier and capable of being inspected by the 
16
Food and Drug Administration during a single 
17
inspection. 
18
‘‘(C) If a business or other entity would meet 
19
criteria specified in subparagraph (A), but for being 
20
under multiple management, the business or other 
21
entity is deemed to constitute multiple facilities, one 
22
per management entity, for purposes of this para-
23
graph. 
24
04:12 Dec 12, 2019
H19
304 
•HR 19 IH
‘‘(11) The term ‘OTC monograph drug meet-
1
ing’ means any meeting regarding the content of a 
2
proposed OTC monograph order request. 
3
‘‘(12) The term ‘person’ includes an affiliate of 
4
a person. 
5
‘‘(13) The terms ‘requestor’ and ‘sponsor’ have 
6
the meanings given such terms in section 505G. 
7
‘‘SEC. 744M. AUTHORITY TO ASSESS AND USE OTC MONO-
8
GRAPH FEES. 
9
‘‘(a) TYPES OF FEES.—Beginning with fiscal year 
10
2019, the Secretary shall assess and collect fees in accord-
11
ance with this section as follows: 
12
‘‘(1) FACILITY FEE.— 
13
‘‘(A) IN
GENERAL.—Each person that 
14
owns a facility identified as an OTC monograph 
15
drug facility on December 31 of the fiscal year 
16
or at any time during the preceding 12-month 
17
period shall be assessed an annual fee for each 
18
such facility as determined under subsection 
19
(c). 
20
‘‘(B) EXCEPTIONS.— 
21
‘‘(i) A fee shall not be assessed under 
22
subparagraph (A) if the identified OTC 
23
monograph drug facility— 
24
04:12 Dec 12, 2019
H19
305 
•HR 19 IH
‘‘(I) has ceased all activities re-
1
lated to OTC monograph drugs prior 
2
to January 31, 2019, for the first pro-
3
gram year, and December 31 of the 
4
fiscal year for subsequent fiscal years; 
5
and 
6
‘‘(II) has updated its registration 
7
to reflect such change under the re-
8
quirements for drug establishment 
9
registration set forth in section 510. 
10
‘‘(ii) The amount of the fee for a con-
11
tract manufacturing organization facility 
12
shall be equal to two-thirds of the amount 
13
of the fee for an OTC monograph drug fa-
14
cility that is not a contract manufacturing 
15
organization facility. 
16
‘‘(C) AMOUNT.—The amount of fees estab-
17
lished under subparagraph (A) shall be estab-
18
lished under subsection (c). 
19
‘‘(D) DUE DATE.— 
20
‘‘(i) FOR FIRST PROGRAM YEAR.—For 
21
fiscal year 2019, the facility fees required 
22
under subparagraph (A) shall be due 45 
23
calendar days after publication of the Fed-
24
04:12 Dec 12, 2019
H19
306 
•HR 19 IH
eral Register notice provided for under 
1
subsection (c)(4)(A). 
2
‘‘(ii) SUBSEQUENT
FISCAL
YEARS.— 
3
For each fiscal year after fiscal year 2019, 
4
the facility fees required under subpara-
5
graph (A) shall be due on the later of— 
6
‘‘(I) the first business day of 
7
June of such year; or 
8
‘‘(II) the first business day after 
9
the enactment of an appropriations 
10
Act providing for the collection and 
11
obligation of fees under this section 
12
for such year. 
13
‘‘(2) 
OTC 
MONOGRAPH
ORDER
REQUEST 
14
FEE.— 
15
‘‘(A) IN GENERAL.—Each person that sub-
16
mits an OTC monograph order request shall be 
17
subject to a fee for an OTC monograph order 
18
request. The amount of such fee shall be— 
19
‘‘(i) for a Tier 1 OTC monograph 
20
order request, $500,000, adjusted for in-
21
flation for the fiscal year (as determined 
22
under subsection (c)(1)(B)); and 
23
‘‘(ii) for a Tier 2 OTC monograph 
24
order request, $100,000 adjusted for infla-
25
04:12 Dec 12, 2019
H19
307 
•HR 19 IH
tion for the fiscal year (as determined 
1
under subsection (c)(1)(B)). 
2
‘‘(B) DUE
DATE.—The OTC monograph 
3
order request fees required under subparagraph 
4
(A) shall be due on the date of submission of 
5
the OTC monograph order request. 
6
‘‘(C) EXCEPTION
FOR
CERTAIN
SAFETY 
7
CHANGES.—A person who is named as the re-
8
questor in an OTC monograph order shall not 
9
be subject to a fee under subparagraph (A) if 
10
the Secretary finds that the OTC monograph 
11
order request seeks to change the drug facts la-
12
beling of an OTC monograph drug in a way 
13
that would add to or strengthen— 
14
‘‘(i) a contraindication, warning, or 
15
precaution; 
16
‘‘(ii) a statement about risk associated 
17
with misuse or abuse; or 
18
‘‘(iii) an instruction about dosage and 
19
administration that is intended to increase 
20
the safe use of the OTC monograph drug. 
21
‘‘(D) REFUND OF FEE IF ORDER REQUEST 
22
IS RECATEGORIZED AS A TIER 2 OTC MONO-
23
GRAPH ORDER REQUEST.—If the Secretary de-
24
termines that an OTC monograph request ini-
25
04:12 Dec 12, 2019
H19
308 
•HR 19 IH
tially characterized as Tier 1 shall be re-charac-
1
terized as a Tier 2 OTC monograph order re-
2
quest, and the requestor has paid a Tier 1 fee 
3
in accordance with subparagraph (A)(i), the 
4
Secretary shall refund the requestor the dif-
5
ference between the Tier 1 and Tier 2 fees de-
6
termined under subparagraphs (A)(i) and 
7
(A)(ii), respectively. 
8
‘‘(E) REFUND OF FEE IF ORDER REQUEST 
9
REFUSED FOR FILING OR WITHDRAWN BEFORE 
10
FILING.—The Secretary shall refund 75 percent 
11
of the fee paid under subparagraph (B) for any 
12
order request which is refused for filing or was 
13
withdrawn before being accepted or refused for 
14
filing. 
15
‘‘(F) FEES
FOR
ORDER
REQUESTS
PRE-
16
VIOUSLY REFUSED FOR FILING OR WITHDRAWN 
17
BEFORE
FILING.—An OTC monograph order 
18
request that was submitted but was refused for 
19
filing, or was withdrawn before being accepted 
20
or refused for filing, shall be subject to the full 
21
fee under subparagraph (A) upon being resub-
22
mitted or filed over protest. 
23
‘‘(G) REFUND OF FEE IF ORDER REQUEST 
24
WITHDRAWN.—If an order request is withdrawn 
25
04:12 Dec 12, 2019
H19
309 
•HR 19 IH
after the order request was filed, the Secretary 
1
may refund the fee or a portion of the fee if no 
2
substantial work was performed on the order 
3
request after the application was filed. The Sec-
4
retary shall have the sole discretion to refund a 
5
fee or a portion of the fee under this subpara-
6
graph. A determination by the Secretary con-
7
cerning a refund under this subparagraph shall 
8
not be reviewable. 
9
‘‘(3) REFUNDS.— 
10
‘‘(A) IN
GENERAL.—Other than refunds 
11
provided pursuant to any of subparagraphs (D) 
12
through (G) of paragraph (2), the Secretary 
13
shall not refund any fee paid under paragraph 
14
(1) except as provided in subparagraph (B). 
15
‘‘(B) DISPUTES
CONCERNING
FEES.—To 
16
qualify for the return of a fee claimed to have 
17
been paid in error under paragraph (1) or (2), 
18
a person shall submit to the Secretary a written 
19
request justifying such return within 180 cal-
20
endar days after such fee was paid. 
21
‘‘(4) NOTICE.—Within the timeframe specified 
22
in subsection (c), the Secretary shall publish in the 
23
Federal Register the amount of the fees under para-
24
graph (1) for such fiscal year. 
25
04:12 Dec 12, 2019
H19
310 
•HR 19 IH
‘‘(b) FEE REVENUE AMOUNTS.— 
1
‘‘(1) FISCAL YEAR 2019.—For fiscal year 2019, 
2
fees under subsection (a)(1) shall be established to 
3
generate a total facility fee revenue amount equal to 
4
the sum of— 
5
‘‘(A) the annual base revenue for fiscal 
6
year 2019 (as determined under paragraph 
7
(3)); 
8
‘‘(B) the dollar amount equal to the oper-
9
ating reserve adjustment for the fiscal year, if 
10
applicable (as determined under subsection 
11
(c)(2)); and 
12
‘‘(C) additional direct cost adjustments (as 
13
determined under subsection (c)(3)). 
14
‘‘(2) SUBSEQUENT FISCAL YEARS.—For each of 
15
the fiscal years 2020 through 2023, fees under sub-
16
section (a)(1) shall be established to generate a total 
17
facility fee revenue amount equal to the sum of— 
18
‘‘(A) the annual base revenue for the fiscal 
19
year (as determined under paragraph (3)); 
20
‘‘(B) the dollar amount equal to the infla-
21
tion adjustment for the fiscal year (as deter-
22
mined under subsection (c)(1)); 
23
‘‘(C) the dollar amount equal to the oper-
24
ating reserve adjustment for the fiscal year, if 
25
04:12 Dec 12, 2019
H19
311 
•HR 19 IH
applicable (as determined under subsection 
1
(c)(2)); 
2
‘‘(D) additional direct cost adjustments (as 
3
determined under subsection (c)(3)); and 
4
‘‘(E) additional dollar amounts for each 
5
fiscal year as follows: 
6
‘‘(i) $7,000,000 for fiscal year 2020. 
7
‘‘(ii) $6,000,000 for fiscal year 2021. 
8
‘‘(iii) $7,000,000 for fiscal year 2022. 
9
‘‘(iv) $3,000,000 for fiscal year 2023. 
10
‘‘(3) ANNUAL BASE REVENUE.—For purposes 
11
of paragraphs (1)(A) and (2)(A), the dollar amount 
12
of the annual base revenue for a fiscal year shall 
13
be— 
14
‘‘(A) for fiscal year 2019, $8,000,000; and 
15
‘‘(B) for fiscal years 2020 through 2023, 
16
the dollar amount of the total revenue amount 
17
established under this subsection for the pre-
18
vious fiscal year, not including any adjustments 
19
made under subsection (c)(2) or (c)(3). 
20
‘‘(c) ADJUSTMENTS; ANNUAL FEE SETTING.— 
21
‘‘(1) INFLATION ADJUSTMENT.— 
22
‘‘(A) IN GENERAL.—For purposes of sub-
23
section (b)(2)(B), the dollar amount of the in-
24
flation adjustment to the annual base revenue 
25
04:12 Dec 12, 2019
H19
312 
•HR 19 IH
for fiscal year 2020 and each subsequent fiscal 
1
year shall be equal to the product of— 
2
‘‘(i) such annual base revenue for the 
3
fiscal year under subsection (b)(2); and 
4
‘‘(ii) the inflation adjustment percent-
5
age under subparagraph (C). 
6
‘‘(B) OTC MONOGRAPH ORDER REQUEST 
7
FEES.—For purposes of subsection (a)(2), the 
8
dollar amount of the inflation adjustment to the 
9
fee for OTC monograph order requests for fis-
10
cal year 2020 and each subsequent fiscal year 
11
shall be equal to the product of— 
12
‘‘(i) the applicable fee under sub-
13
section (a)(2) for the preceding fiscal year; 
14
and 
15
‘‘(ii) the inflation adjustment percent-
16
age under subparagraph (C). 
17
‘‘(C) INFLATION
ADJUSTMENT
PERCENT-
18
AGE.—The inflation adjustment percentage 
19
under this subparagraph for a fiscal year is 
20
equal to— 
21
‘‘(i) for each of fiscal years 2020 and 
22
2021, the average annual percent change 
23
that occurred in the Consumer Price Index 
24
for urban consumers (Washington-Balti-
25
04:12 Dec 12, 2019
H19
313 
•HR 19 IH
more, DC–MD–VA–WV; Not Seasonally 
1
Adjusted; All items; Annual Index) for the 
2
first 3 years of the preceding 4 years of 
3
available data; and 
4
‘‘(ii) for each of fiscal years 2022 and 
5
2023, the sum of— 
6
‘‘(I) the average annual percent 
7
change in the cost, per full-time equiv-
8
alent position of the Food and Drug 
9
Administration, of all personnel com-
10
pensation and benefits paid with re-
11
spect to such positions for the first 3 
12
years of the preceding 4 fiscal years, 
13
multiplied by the proportion of per-
14
sonnel 
compensation 
and 
benefits 
15
costs to total costs of OTC mono-
16
graph drug activities for the first 3 
17
years of the preceding 4 fiscal years; 
18
and 
19
‘‘(II) the average annual percent 
20
change that occurred in the Consumer 
21
Price Index for urban consumers 
22
(Washington-Baltimore, DC–MD–VA– 
23
WV; Not Seasonally Adjusted; All 
24
items; Annual Index) for the first 3 
25
04:12 Dec 12, 2019
H19
314 
•HR 19 IH
years of the preceding 4 years of 
1
available data multiplied by the pro-
2
portion of all costs other than per-
3
sonnel 
compensation 
and 
benefits 
4
costs to total costs of OTC mono-
5
graph drug activities for the first 3 
6
years of the preceding 4 fiscal years. 
7
‘‘(2) OPERATING RESERVE ADJUSTMENT.— 
8
‘‘(A) IN GENERAL.—For fiscal year 2019 
9
and subsequent fiscal years, for purposes of 
10
subsections (b)(1)(B) and (b)(2)(C), the Sec-
11
retary may, in addition to adjustments under 
12
paragraph (1), further increase the fee revenue 
13
and fees if such an adjustment is necessary to 
14
provide operating reserves of carryover user 
15
fees for OTC monograph drug activities for not 
16
more than the number of weeks specified in 
17
subparagraph (B). 
18
‘‘(B) NUMBER OF WEEKS.—The number of 
19
weeks specified in this subparagraph is— 
20
‘‘(i) 3 weeks for fiscal year 2019; 
21
‘‘(ii) 7 weeks for fiscal year 2020; 
22
‘‘(iii) 10 weeks for fiscal year 2021; 
23
‘‘(iv) 10 weeks for fiscal year 2022; 
24
and 
25
04:12 Dec 12, 2019
H19
315 
•HR 19 IH
‘‘(v) 10 weeks for fiscal year 2023. 
1
‘‘(C) DECREASE.—If the Secretary has 
2
carryover balances for such process in excess of 
3
10 weeks of the operating reserves referred to 
4
in subparagraph (A), the Secretary shall de-
5
crease the fee revenue and fees referred to in 
6
such subparagraph to provide for not more than 
7
10 weeks of such operating reserves. 
8
‘‘(D) RATIONALE
FOR
ADJUSTMENT.—If 
9
an adjustment under this paragraph is made, 
10
the rationale for the amount of the increase or 
11
decrease (as applicable) in fee revenue and fees 
12
shall be contained in the annual Federal Reg-
13
ister notice under paragraph (4) establishing 
14
fee revenue and fees for the fiscal year involved. 
15
‘‘(3) 
ADDITIONAL
DIRECT
COST
ADJUST-
16
MENT.—The Secretary shall, in addition to adjust-
17
ments under paragraphs (1) and (2), further in-
18
crease the fee revenue and fees for purposes of sub-
19
section (b)(2)(D) by an amount equal to— 
20
‘‘(A) $14,000,000 for fiscal year 2019; 
21
‘‘(B) $7,000,000 for fiscal year 2020; 
22
‘‘(C) $4,000,000 for fiscal year 2021; 
23
‘‘(D) $3,000,000 for fiscal year 2022; and 
24
‘‘(E) $3,000,000 for fiscal year 2023. 
25
04:12 Dec 12, 2019
H19
316 
•HR 19 IH
‘‘(4) ANNUAL FEE SETTING.— 
1
‘‘(A) FISCAL
YEAR
2019.—The Secretary 
2
shall, not later than the second Monday in 
3
March of 2019— 
4
‘‘(i) establish OTC monograph drug 
5
facility fees for fiscal year 2019 under sub-
6
section (a), based on the revenue amount 
7
for such year under subsection (b) and the 
8
adjustments provided under this sub-
9
section; and 
10
‘‘(ii) publish fee revenue, facility fees, 
11
and OTC monograph order requests in the 
12
Federal Register. 
13
‘‘(B) SUBSEQUENT
FISCAL
YEARS.—The 
14
Secretary shall, not later than the second Mon-
15
day in March of each fiscal year that begins 
16
after September 30, 2019— 
17
‘‘(i) establish for each such fiscal 
18
year, based on the revenue amounts under 
19
subsection (b) and the adjustments pro-
20
vided under this subsection— 
21
‘‘(I) OTC monograph drug facil-
22
ity fees under subsection (a)(1); and 
23
04:12 Dec 12, 2019
H19
317 
•HR 19 IH
‘‘(II) OTC monograph order re-
1
quest fees under subsection (a)(2); 
2
and 
3
‘‘(ii) 
publish 
such 
fee 
revenue 
4
amounts, facility fees, and OTC mono-
5
graph order request fees in the Federal 
6
Register. 
7
‘‘(d) IDENTIFICATION OF FACILITIES.—Each person 
8
that owns an OTC monograph drug facility shall submit 
9
to the Secretary the information required under this sub-
10
section each year. Such information shall, for each fiscal 
11
year— 
12
‘‘(1) be submitted as part of the requirements 
13
for drug establishment registration set forth in sec-
14
tion 510; and 
15
‘‘(2) include for each such facility, at a min-
16
imum, identification of the facility’s business oper-
17
ation as that of an OTC monograph drug facility. 
18
‘‘(e) EFFECT OF FAILURE TO PAY FEES.— 
19
‘‘(1) OTC MONOGRAPH DRUG FACILITY FEE.— 
20
‘‘(A) IN GENERAL.—Failure to pay the fee 
21
under subsection (a)(1) within 20 calendar days 
22
of the due date as specified in subparagraph 
23
(D) of such subsection shall result in the fol-
24
lowing: 
25
04:12 Dec 12, 2019
H19
318 
•HR 19 IH
‘‘(i) The Secretary shall place the fa-
1
cility on a publicly available arrears list. 
2
‘‘(ii) All OTC monograph drugs man-
3
ufactured in such a facility or containing 
4
an ingredient manufactured in such a facil-
5
ity shall be deemed misbranded under sec-
6
tion 502(ff). 
7
‘‘(B) APPLICATION
OF
PENALTIES.—The 
8
penalties under this paragraph shall apply until 
9
the fee established by subsection (a)(1) is paid. 
10
‘‘(2) ORDER REQUESTS.—An OTC monograph 
11
order request submitted by a person subject to fees 
12
under subsection (a) shall be considered incomplete 
13
and shall not be accepted for filing by the Secretary 
14
until all fees owed by such person under this section 
15
have been paid. 
16
‘‘(3) MEETINGS.—A person subject to fees 
17
under this section shall be considered ineligible for 
18
OTC monograph drug meetings until all such fees 
19
owed by such person have been paid. 
20
‘‘(f) CREDITING AND AVAILABILITY OF FEES.— 
21
‘‘(1) IN GENERAL.—Fees authorized under sub-
22
section (a) shall be collected and available for obliga-
23
tion only to the extent and in the amount provided 
24
in advance in appropriations Acts. Such fees are au-
25
04:12 Dec 12, 2019
H19
319 
•HR 19 IH
thorized to remain available until expended. Such 
1
sums as may be necessary may be transferred from 
2
the Food and Drug Administration salaries and ex-
3
penses appropriation account without fiscal year lim-
4
itation to such appropriation account for salaries 
5
and expenses with such fiscal year limitation. The 
6
sums transferred shall be available solely for OTC 
7
monograph drug activities. 
8
‘‘(2) 
COLLECTIONS
AND
APPROPRIATION 
9
ACTS.— 
10
‘‘(A) IN
GENERAL.—Subject to subpara-
11
graph (C), the fees authorized by this section 
12
shall be collected and available in each fiscal 
13
year in an amount not to exceed the amount 
14
specified in appropriation Acts, or otherwise 
15
made available for obligation, for such fiscal 
16
year. 
17
‘‘(B) USE
OF
FEES
AND
LIMITATION.— 
18
The fees authorized by this section shall be 
19
available to defray increases in the costs of the 
20
resources allocated for OTC monograph drug 
21
activities (including increases in such costs for 
22
an additional number of full-time equivalent po-
23
sitions in the Department of Health and 
24
Human Services to be engaged in such activi-
25
04:12 Dec 12, 2019
H19
320 
•HR 19 IH
ties), only if the Secretary allocates for such 
1
purpose an amount for such fiscal year (exclud-
2
ing amounts from fees collected under this sec-
3
tion) no less than $12,000,000, multiplied by 
4
the adjustment factor applicable to the fiscal 
5
year involved under subsection (c)(1). 
6
‘‘(C) COMPLIANCE.—The Secretary shall 
7
be considered to have met the requirements of 
8
subparagraph (B) in any fiscal year if the costs 
9
funded by appropriations and allocated for OTC 
10
monograph drug activities are not more than 15 
11
percent below the level specified in such sub-
12
paragraph. 
13
‘‘(D) PROVISION FOR EARLY PAYMENTS IN 
14
SUBSEQUENT YEARS.—Payment of fees author-
15
ized under this section for a fiscal year (after 
16
fiscal year 2019), prior to the due date for such 
17
fees, may be accepted by the Secretary in ac-
18
cordance with authority provided in advance in 
19
a prior year appropriations Act. 
20
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
21
For each of the fiscal years 2019 through 2023, 
22
there is authorized to be appropriated for fees under 
23
this section an amount equal to the total amount of 
24
fees assessed for such fiscal year under this section. 
25
04:12 Dec 12, 2019
H19
321 
•HR 19 IH
‘‘(g) COLLECTION OF UNPAID FEES.—In any case 
1
where the Secretary does not receive payment of a fee as-
2
sessed under subsection (a) within 30 calendar days after 
3
it is due, such fee shall be treated as a claim of the United 
4
States Government subject to subchapter II of chapter 37 
5
of title 31, United States Code. 
6
‘‘(h) CONSTRUCTION.—This section may not be con-
7
strued to require that the number of full-time equivalent 
8
positions in the Department of Health and Human Serv-
9
ices, for officers, employers, and advisory committees not 
10
engaged in OTC monograph drug activities, be reduced 
11
to offset the number of officers, employees, and advisory 
12
committees so engaged. 
13
‘‘SEC. 744N. REAUTHORIZATION; REPORTING REQUIRE-
14
MENTS. 
15
‘‘(a) PERFORMANCE REPORT.—Beginning with fiscal 
16
year 2019, and not later than 120 calendar days after the 
17
end of each fiscal year thereafter for which fees are col-
18
lected under this part, the Secretary shall prepare and 
19
submit to the Committee on Energy and Commerce of the 
20
House of Representatives and the Committee on Health, 
21
Education, Labor, and Pensions of the Senate a report 
22
concerning the progress of the Food and Drug Adminis-
23
tration in achieving the goals identified in the letters de-
24
scribed in section 2001(b) of the Over-the-Counter Mono-
25
04:12 Dec 12, 2019
H19
322 
•HR 19 IH
graph Safety, Innovation, and Reform Act of 2019 during 
1
such fiscal year and the future plans of the Food and 
2
Drug Administration for meeting such goals. 
3
‘‘(b) FISCAL REPORT.—Not later than 120 calendar 
4
days after the end of fiscal year 2019 and each subsequent 
5
fiscal year for which fees are collected under this part, 
6
the Secretary shall prepare and submit to the Committee 
7
on Energy and Commerce of the House of Representatives 
8
and the Committee on Health, Education, Labor, and 
9
Pensions of the Senate a report on the implementation 
10
of the authority for such fees during such fiscal year and 
11
the use, by the Food and Drug Administration, of the fees 
12
collected for such fiscal year. 
13
‘‘(c) PUBLIC AVAILABILITY.—The Secretary shall 
14
make the reports required under subsections (a) and (b) 
15
available to the public on the internet website of the Food 
16
and Drug Administration. 
17
‘‘(d) REAUTHORIZATION.— 
18
‘‘(1) 
CONSULTATION.—In 
developing 
rec-
19
ommendations to present to the Congress with re-
20
spect to the goals described in subsection (a), and 
21
plans for meeting the goals, for OTC monograph 
22
drug activities for the first 5 fiscal years after fiscal 
23
year 2023, and for the reauthorization of this part 
24
04:12 Dec 12, 2019
H19
323 
•HR 19 IH
for such fiscal years, the Secretary shall consult 
1
with— 
2
‘‘(A) the Committee on Energy and Com-
3
merce of the House of Representatives; 
4
‘‘(B) the Committee on Health, Education, 
5
Labor, and Pensions of the Senate; 
6
‘‘(C) scientific and academic experts; 
7
‘‘(D) health care professionals; 
8
‘‘(E) representatives of patient and con-
9
sumer advocacy groups; and 
10
‘‘(F) the regulated industry. 
11
‘‘(2) 
PUBLIC
REVIEW
OF
RECOMMENDA-
12
TIONS.—After negotiations with the regulated indus-
13
try, the Secretary shall— 
14
‘‘(A) present the recommendations devel-
15
oped under paragraph (1) to the congressional 
16
committees specified in such paragraph; 
17
‘‘(B) publish such recommendations in the 
18
Federal Register; 
19
‘‘(C) provide for a period of 30 calendar 
20
days for the public to provide written comments 
21
on such recommendations; 
22
‘‘(D) hold a meeting at which the public 
23
may present its views on such recommenda-
24
tions; and 
25
04:12 Dec 12, 2019
H19
324 
•HR 19 IH
‘‘(E) after consideration of such public 
1
views and comments, revise such recommenda-
2
tions as necessary. 
3
‘‘(3) TRANSMITTAL OF RECOMMENDATIONS.— 
4
Not later than January 15, 2023, the Secretary 
5
shall transmit to the Congress the revised rec-
6
ommendations under paragraph (2), a summary of 
7
the views and comments received under such para-
8
graph, and any changes made to the recommenda-
9
tions in response to such views and comments.’’. 
10
Subtitle I—Other Provisions 
11
SEC. 391. PROTECTING ACCESS TO BIOLOGICAL PRODUCTS. 
12
Section 351(k)(7) of the Public Health Service Act 
13
(42 U.S.C. 262(k)(7)) is amended by adding at the end 
14
the following: 
15
‘‘(D) DEEMED LICENSES.— 
16
‘‘(i) NO
ADDITIONAL
EXCLUSIVITY 
17
THROUGH DEEMING.—An approved appli-
18
cation that is deemed to be a license for a 
19
biological product under this section pursu-
20
ant to section 7002(e)(4) of the Biologics 
21
Price Competition and Innovation Act of 
22
2009 shall not be treated as having been 
23
first licensed under subsection (a) for pur-
24
poses of subparagraphs (A) and (B). 
25
04:12 Dec 12, 2019
H19
325 
•HR 19 IH
‘‘(ii) APPLICATION
OF
LIMITATIONS 
1
ON EXCLUSIVITY.—Subparagraph (C) shall 
2
apply with respect to a reference product 
3
referred to in such subparagraph that was 
4
the subject of an approved application that 
5
was deemed to be a license pursuant to 
6
section 7002(e)(4) of the Biologics Price 
7
Competition and Innovation Act of 2009. 
8
‘‘(iii) 
APPLICABILITY.—The 
exclu-
9
sivity periods described in section 527, sec-
10
tion 
505A(b)(1)(A)(ii), 
and 
section 
11
505A(c)(1)(A)(ii) of the Federal Food, 
12
Drug, and Cosmetic Act shall continue to 
13
apply to a biological product after an ap-
14
proved application for the biological prod-
15
uct is deemed to be a license for the bio-
16
logical product under subsection (a) pursu-
17
ant to section 7002(e)(4) of the Biologics 
18
Price Competition and Innovation Act of 
19
2009.’’. 
20
SEC. 392. ORPHAN DRUG CLARIFICATION. 
21
Section 527(c) of the Federal Food, Drug, and Cos-
22
metic Act (21 U.S.C. 360cc(c)) is amended by adding at 
23
the end the following: 
24
04:12 Dec 12, 2019
H19
326 
•HR 19 IH
‘‘(3) APPLICABILITY.—This subsection applies 
1
to any drug designated under section 526 for which 
2
an application was approved under section 505 of 
3
this Act or licensed under section 351 of the Public 
4
Health Service Act after the date of enactment of 
5
the FDA Reauthorization Act of 2017, regardless of 
6
the date on which such drug was designated under 
7
section 526.’’. 
8
SEC. 393. CONDITIONS OF USE FOR BIOSIMILAR BIOLOGI-
9
CAL PRODUCTS. 
10
Section 351(k)(2)(A)(iii) of the Public Health Service 
11
Act (42 U.S.C. 262(k)(2)(A)(iii)) is amended— 
12
(1) in subclause (I), by striking ‘‘; and’’ and in-
13
serting a semicolon; 
14
(2) in subclause (II), by striking the period and 
15
inserting ‘‘; and’’; and 
16
(3) by adding at the end the following: 
17
‘‘(III) may include information to 
18
show that the conditions of use pre-
19
scribed, recommended, or suggested in 
20
the labeling proposed for the biological 
21
product have been previously approved 
22
for the reference product.’’. 
23
04:12 Dec 12, 2019
H19
327 
•HR 19 IH
SEC. 394. CLARIFYING THE MEANING OF NEW CHEMICAL 
1
ENTITY. 
2
Chapter V of the Federal Food, Drug, and Cosmetic 
3
Act is amended— 
4
(1) in section 505 (21 U.S.C. 355)— 
5
(A) in subsection (c)(3)(E)— 
6
(i) in clause (ii), by striking ‘‘active 
7
ingredient (including any ester or salt of 
8
the active ingredient)’’ and inserting ‘‘ac-
9
tive moiety (as defined by the Secretary in 
10
section 314.3 of title 21, Code of Federal 
11
Regulations (or any successor regula-
12
tions))’’; and 
13
(ii) in clause (iii), by striking ‘‘active 
14
ingredient (including any ester or salt of 
15
the active ingredient)’’ and inserting ‘‘ac-
16
tive moiety (as defined by the Secretary in 
17
section 314.3 of title 21, Code of Federal 
18
Regulations (or any successor regula-
19
tions))’’; 
20
(B) in subsection (j)(5)(F)— 
21
(i) in clause (ii), by striking ‘‘active 
22
ingredient (including any ester or salt of 
23
the active ingredient)’’ and inserting ‘‘ac-
24
tive moiety (as defined by the Secretary in 
25
section 314.3 of title 21, Code of Federal 
26
04:12 Dec 12, 2019
H19
328 
•HR 19 IH
Regulations (or any successor regula-
1
tions))’’; and 
2
(ii) in clause (iii), by striking ‘‘active 
3
ingredient (including any ester or salt of 
4
the active ingredient)’’ and inserting ‘‘ac-
5
tive moiety (as defined by the Secretary in 
6
section 314.3 of title 21, Code of Federal 
7
Regulations (or any successor regula-
8
tions))’’; 
9
(C) in subsection (l)(2)(A)(i), by striking 
10
‘‘active ingredient (including any ester or salt of 
11
the active ingredient)’’ and inserting ‘‘active 
12
moiety (as defined by the Secretary in section 
13
314.3 of title 21, Code of Federal Regulations 
14
(or any successor regulations))’’; 
15
(D) in subsection (s), in the matter pre-
16
ceding paragraph (1), by striking ‘‘active ingre-
17
dient (including any ester or salt of the active 
18
ingredient)’’ and inserting ‘‘active moiety (as 
19
defined by the Secretary in section 314.3 of 
20
title 21, Code of Federal Regulations (or any 
21
successor regulations))’’; and 
22
(E) in subsection (u)(1), in the matter pre-
23
ceding subparagraph (A)— 
24
04:12 Dec 12, 2019
H19
329 
•HR 19 IH
(i) by striking ‘‘active ingredient (in-
1
cluding any ester or salt of the active in-
2
gredient)’’ and inserting ‘‘active moiety (as 
3
defined by the Secretary in section 314.3 
4
of title 21, Code of Federal Regulations (or 
5
any successor regulations))’’; and 
6
(ii) by striking ‘‘same active ingre-
7
dient’’ and inserting ‘‘same active moiety’’; 
8
(2) 
in 
section 
512(c)(2)(F) 
(21 
U.S.C. 
9
360b(c)(2)(F))— 
10
(A) in clause (i), by striking ‘‘active ingre-
11
dient (including any ester or salt of the active 
12
ingredient)’’ and inserting ‘‘active moiety (as 
13
defined by the Secretary in section 314.3 of 
14
title 21, Code of Federal Regulations (or any 
15
successor regulations))’’; 
16
(B) in clause (ii), by striking ‘‘active ingre-
17
dient (including any ester or salt of the active 
18
ingredient)’’ and inserting ‘‘active moiety (as 
19
defined by the Secretary in section 314.3 of 
20
title 21, Code of Federal Regulations (or any 
21
successor regulations))’’; and 
22
(C) in clause (v), by striking ‘‘active ingre-
23
dient (including any ester or salt of the active 
24
ingredient)’’ and inserting ‘‘active moiety (as 
25
04:12 Dec 12, 2019
H19
330 
•HR 19 IH
defined by the Secretary in section 314.3 of 
1
title 21, Code of Federal Regulations (or any 
2
successor regulations))’’; 
3
(3) 
in 
section 
524(a)(4)(C) 
(21 
U.S.C. 
4
360n(a)(4)(C)), by striking ‘‘active ingredient (in-
5
cluding any ester or salt of the active ingredient)’’ 
6
and inserting ‘‘active moiety (as defined by the Sec-
7
retary in section 314.3 of title 21, Code of Federal 
8
Regulations (or any successor regulations))’’; 
9
(4) in section 529(a)(4)(A)(ii) (21 U.S.C. 
10
360ff(a)(4)(A)(ii)), by striking ‘‘active ingredient 
11
(including any ester or salt of the active ingredient)’’ 
12
and inserting ‘‘active moiety (as defined by the Sec-
13
retary in section 314.3 of title 21, Code of Federal 
14
Regulations (or any successor regulations))’’; and 
15
(5) in section 565A(a)(4)(D) (21 U.S.C. 
16
360bbb–4a(a)(4)(D)), by striking ‘‘active ingredient 
17
(including any ester or salt of the active ingredient)’’ 
18
and inserting ‘‘active moiety (as defined by the Sec-
19
retary in section 314.3 of title 21, Code of Federal 
20
Regulations (or any successor regulations))’’. 
21
04:12 Dec 12, 2019
H19
331 
•HR 19 IH
TITLE IV—REVENUE 
1
PROVISIONS 
2
SEC. 401. PERMANENT EXTENSION OF REDUCTION IN MED-
3
ICAL EXPENSE DEDUCTION FLOOR. 
4
(a) IN GENERAL.—Section 213(a) of the Internal 
5
Revenue Code of 1986 is amended by striking ‘‘10 per-
6
cent’’ and inserting ‘‘7.5 percent’’. 
7
(b) CONFORMING AMENDMENTS.— 
8
(1) Section 213 of such Code is amended by 
9
striking subsection (f). 
10
(2) Section 56(b)(1) of such Code is amended 
11
by striking subparagraph (B) and by redesignating 
12
subparagraphs (C), (D), (E), and (F), as subpara-
13
graphs (B), (C), (D), and (E), respectively. 
14
(c) EFFECTIVE DATE.—The amendment made by 
15
this section shall apply to taxable years ending after De-
16
cember 31, 2019. 
17
SEC. 402. SAFE HARBOR FOR HIGH DEDUCTIBLE HEALTH 
18
PLANS WITHOUT DEDUCTIBLE FOR INSULIN. 
19
(a) IN GENERAL.—Section 223(c)(2)(C) of the Inter-
20
nal Revenue Code of 1986 is amended by inserting ‘‘or 
21
for insulin or any device for the delivery of insulin’’ before 
22
the period at the end. 
23
04:12 Dec 12, 2019
H19
332 
•HR 19 IH
(b) EFFECTIVE DATE.—The amendment made by 
1
this section shall apply to months beginning after the date 
2
of the enactment of this Act. 
3
SEC. 403. INCLUSION OF CERTAIN OVER-THE-COUNTER 
4
MEDICAL PRODUCTS AS QUALIFIED MEDICAL 
5
EXPENSES. 
6
(a) HSAS.—Section 223(d)(2) of the Internal Rev-
7
enue Code of 1986 is amended— 
8
(1) by striking the last sentence of subpara-
9
graph (A) and inserting the following: ‘‘For pur-
10
poses of this subparagraph, amounts paid for men-
11
strual care products shall be treated as paid for 
12
medical care.’’; and 
13
(2) by adding at the end the following new sub-
14
paragraph: 
15
‘‘(D) MENSTRUAL
CARE
PRODUCT.—For 
16
purposes of this paragraph, the term ‘menstrual 
17
care product’ means a tampon, pad, liner, cup, 
18
sponge, or similar product used by individuals 
19
with respect to menstruation or other genital- 
20
tract secretions.’’. 
21
(b) ARCHER MSAS.—Section 220(d)(2)(A) of such 
22
Code is amended by striking the last sentence and insert-
23
ing the following: ‘‘For purposes of this subparagraph, 
24
amounts paid for menstrual care products (as defined in 
25
04:12 Dec 12, 2019
H19
333 
•HR 19 IH
section 223(d)(2)(D)) shall be treated as paid for medical 
1
care.’’. 
2
(c) HEALTH FLEXIBLE SPENDING ARRANGEMENTS 
3
AND HEALTH REIMBURSEMENT ARRANGEMENTS.—Sec-
4
tion 106 of such Code is amended by striking subsection 
5
(f) and inserting the following new subsection: 
6
‘‘(f) REIMBURSEMENTS
FOR
MENSTRUAL
CARE 
7
PRODUCTS.—For purposes of this section and section 
8
105, expenses incurred for menstrual care products (as 
9
defined in section 223(d)(2)(D)) shall be treated as in-
10
curred for medical care.’’. 
11
(d) EFFECTIVE DATES.— 
12
(1) 
DISTRIBUTIONS
FROM
SAVINGS
AC-
13
COUNTS.—The amendment made by subsections (a) 
14
and (b) shall apply to amounts paid after December 
15
31, 2019. 
16
(2) REIMBURSEMENTS.—The amendment made 
17
by subsection (c) shall apply to expenses incurred 
18
after December 31, 2019. 
19
TITLE V—MISCELLANEOUS 
20
SEC. 501. PAYMENT FOR BIOSIMILAR BIOLOGICAL PROD-
21
UCTS DURING INITIAL PERIOD. 
22
Section 1847A(c)(4) of the Social Security Act (42 
23
U.S.C. 1395w–3a(c)(4)) is amended— 
24
04:12 Dec 12, 2019
H19
334 
•HR 19 IH
(1) in each of subparagraphs (A) and (B), by 
1
redesignating clauses (i) and (ii) as subclauses (I) 
2
and (II), respectively, and moving such subclauses 2 
3
ems to the right; 
4
(2) by redesignating subparagraphs (A) and 
5
(B) as clauses (i) and (ii) and moving such clauses 
6
2 ems to the right; 
7
(3) by striking ‘‘UNAVAILABLE.—In the case’’ 
8
and inserting ‘‘UNAVAILABLE.— 
9
‘‘(A) IN
GENERAL.—Subject to subpara-
10
graph (B), in the case’’; and 
11
(4) by adding at the end the following new sub-
12
paragraph: 
13
‘‘(B) LIMITATION
ON
PAYMENT
AMOUNT 
14
FOR BIOSIMILAR BIOLOGICAL PRODUCTS DUR-
15
ING
INITIAL
PERIOD.—In the case of a bio-
16
similar biological product furnished on or after 
17
July 1, 2020, in lieu of applying subparagraph 
18
(A) during the initial period described in such 
19
subparagraph with respect to the biosimilar bio-
20
logical product, the amount payable under this 
21
section for the biosimilar biological product is 
22
the lesser of the following: 
23
04:12 Dec 12, 2019
H19
335 
•HR 19 IH
‘‘(i) The amount determined under 
1
clause (ii) of such subparagraph for the 
2
biosimilar biological product. 
3
‘‘(ii) The amount determined under 
4
subsection (b)(1)(B) for the reference bio-
5
logical product.’’. 
6
SEC. 502. GAO STUDY AND REPORT ON AVERAGE SALES 
7
PRICE. 
8
(a) STUDY.— 
9
(1) IN GENERAL.—The Comptroller General of 
10
the United States (in this section referred to as the 
11
‘‘Comptroller General’’) shall conduct a study on 
12
spending for applicable drugs under part B of title 
13
XVIII of the Social Security Act. 
14
(2) APPLICABLE DRUGS DEFINED.—In this sec-
15
tion, the term ‘‘applicable drugs’’ means drugs and 
16
biologicals— 
17
(A) for which reimbursement under such 
18
part B is based on the average sales price of 
19
the drug or biological; and 
20
(B) that account for the largest percentage 
21
of total spending on drugs and biologicals under 
22
such part B (as determined by the Comptroller 
23
General, but in no case less than 25 drugs or 
24
biologicals). 
25
04:12 Dec 12, 2019
H19
336 
•HR 19 IH
(3) REQUIREMENTS.—The study under para-
1
graph (1) shall include an analysis of the following: 
2
(A) The extent to which each applicable 
3
drug is paid for— 
4
(i) under such part B for Medicare 
5
beneficiaries; or 
6
(ii) by private payers in the commer-
7
cial market. 
8
(B) Any change in Medicare spending or 
9
Medicare beneficiary cost-sharing that would 
10
occur if the average sales price of an applicable 
11
drug was based solely on payments by private 
12
payers in the commercial market. 
13
(C) The extent to which drug manufactur-
14
ers provide rebates, discounts, or other price 
15
concessions to private payers in the commercial 
16
market for applicable drugs, which the manu-
17
facturer includes in its average sales price cal-
18
culation, for— 
19
(i) formulary placement; 
20
(ii) utilization management consider-
21
ations; or 
22
(iii) other purposes. 
23
04:12 Dec 12, 2019
H19
337 
•HR 19 IH
(D) Barriers to drug manufacturers pro-
1
viding such price concessions for applicable 
2
drugs. 
3
(E) Other areas determined appropriate by 
4
the Comptroller General. 
5
(b) REPORT.—Not later than 2 years after the date 
6
of the enactment of this Act, the Comptroller General shall 
7
submit to Congress a report on the study conducted under 
8
subsection (a), together with recommendations for such 
9
legislation and administrative action as the Secretary de-
10
termines appropriate. 
11
SEC. 503. REQUIRING PRESCRIPTION DRUG PLANS AND 
12
MA–PD 
PLANS 
TO 
REPORT 
13
FRAUD, WASTE, AND ABUSE TO THE SEC-
14
RETARY OF HHS. 
15
Section 1860D–4 of the Social Security Act (42 
16
U.S.C. 1395w–104) is amended by adding at the end the 
17
following new subsection: 
18
‘‘(p) REPORTING POTENTIAL FRAUD, WASTE, AND 
19
ABUSE.—Beginning January 1, 2021, the PDP sponsor 
20
of a prescription drug plan shall report to the Secretary, 
21
as specified by the Secretary— 
22
‘‘(1) any substantiated or suspicious activities 
23
(as defined by the Secretary) with respect to the 
24
04:12 Dec 12, 2019
H19
338 
•HR 19 IH
program under this part as it relates to fraud, 
1
waste, and abuse; and 
2
‘‘(2) any steps made by the PDP sponsor after 
3
identifying such activities to take corrective ac-
4
tions.’’. 
5
SEC. 504. ESTABLISHMENT OF PHARMACY QUALITY MEAS-
6
URES UNDER MEDICARE PART D. 
7
Section 1860D–4(c) of the Social Security Act (42 
8
U.S.C. 1395w–104(c)) is amended by adding at the end 
9
the following new paragraph: 
10
‘‘(8) APPLICATION
OF
PHARMACY
QUALITY 
11
MEASURES.— 
12
‘‘(A) IN GENERAL.—A PDP sponsor that 
13
implements incentive payments to a pharmacy 
14
or price concessions paid by a pharmacy based 
15
on quality measures shall use measures estab-
16
lished or approved by the Secretary under sub-
17
paragraph (B) with respect to payment for cov-
18
ered part D drugs dispensed by such pharmacy. 
19
‘‘(B) 
STANDARD
PHARMACY
QUALITY 
20
MEASURES.—The Secretary shall establish or 
21
approve standard quality measures from a con-
22
sensus and evidence-based organization for pay-
23
ments described in subparagraph (A). Such 
24
measures shall focus on patient health outcomes 
25
04:12 Dec 12, 2019
H19
339 
•HR 19 IH
and be based on proven criteria measuring 
1
pharmacy performance. 
2
‘‘(C) EFFECTIVE DATE.—The requirement 
3
under subparagraph (A) shall take effect for 
4
plan years beginning on or after January 1, 
5
2023, or such earlier date specified by the Sec-
6
retary if the Secretary determines there are suf-
7
ficient measures established or approved under 
8
subparagraph (B) to meet the requirement 
9
under subparagraph (A).’’. 
10
SEC. 505. IMPROVING COORDINATION BETWEEN THE FOOD 
11
AND DRUG ADMINISTRATION AND THE CEN-
12
TERS FOR MEDICARE & MEDICAID SERVICES. 
13
(a) IN GENERAL.— 
14
(1) PUBLIC MEETING.— 
15
(A) IN
GENERAL.—Not later than 12 
16
months after the date of the enactment of this 
17
Act, the Secretary of Health and Human Serv-
18
ices (referred to in this section as the ‘‘Sec-
19
retary’’) shall convene a public meeting for the 
20
purposes of discussing and providing input on 
21
improvements to coordination between the Food 
22
and Drug Administration and the Centers for 
23
Medicare & Medicaid Services in preparing for 
24
the availability of novel medical products de-
25
04:12 Dec 12, 2019
H19
340 
•HR 19 IH
scribed in subsection (c) on the market in the 
1
United States. 
2
(B) ATTENDEES.—The public meeting 
3
shall include— 
4
(i) representatives of relevant Federal 
5
agencies, including representatives from 
6
each of the medical product centers within 
7
the Food and Drug Administration and 
8
representatives from the coding, coverage, 
9
and payment offices within the Centers for 
10
Medicare & Medicaid Services; 
11
(ii) stakeholders with expertise in the 
12
research and development of novel medical 
13
products, including manufacturers of such 
14
products; 
15
(iii) representatives of commercial 
16
health insurance payers; 
17
(iv) stakeholders with expertise in the 
18
administration and use of novel medical 
19
products, including physicians; and 
20
(v) stakeholders representing patients 
21
and with expertise in the utilization of pa-
22
tient experience data in medical product 
23
development. 
24
04:12 Dec 12, 2019
H19
341 
•HR 19 IH
(C) TOPICS.—The public meeting shall in-
1
clude a discussion of— 
2
(i) the status of the drug and medical 
3
device development pipeline related to the 
4
availability of novel medical products; 
5
(ii) the anticipated expertise necessary 
6
to review the safety and effectiveness of 
7
such products at the Food and Drug Ad-
8
ministration and current gaps in such ex-
9
pertise, if any; 
10
(iii) the expertise necessary to make 
11
coding, coverage, and payment decisions 
12
with respect to such products within the 
13
Centers for Medicare & Medicaid Services, 
14
and current gaps in such expertise, if any; 
15
(iv) trends in the differences in the 
16
data necessary to determine the safety and 
17
effectiveness of a novel medical product 
18
and the data necessary to determine 
19
whether a novel medical product meets the 
20
reasonable and necessary requirements for 
21
coverage and payment under title XVIII of 
22
the Social Security Act pursuant to section 
23
1862(a)(1)(A) of such Act (42 U.S.C. 
24
1395y(a)(1)(A)); 
25
04:12 Dec 12, 2019
H19
342 
•HR 19 IH
(v) the availability of information for 
1
sponsors of such novel medical products to 
2
meet each of those requirements; and 
3
(vi) the coordination of information 
4
related to significant clinical improvement 
5
over existing therapies for patients between 
6
the Food and Drug Administration and the 
7
Centers for Medicare & Medicaid Services 
8
with respect to novel medical products. 
9
(D) TRADE SECRETS AND CONFIDENTIAL 
10
INFORMATION.—No information discussed as a 
11
part of the public meeting under this paragraph 
12
shall be construed as authorizing the Secretary 
13
to disclose any information that is a trade se-
14
cret or confidential information subject to sec-
15
tion 552(b)(4) of title 5, United States Code. 
16
(2) IMPROVING
TRANSPARENCY
OF
CRITERIA 
17
FOR MEDICARE COVERAGE.— 
18
(A) DRAFT GUIDANCE.—Not later than 18 
19
months after the public meeting under para-
20
graph (1), the Secretary shall update the final 
21
guidance titled ‘‘National Coverage Determina-
22
tions with Data Collection as a Condition of 
23
Coverage: Coverage with Evidence Develop-
24
ment’’ to address any opportunities to improve 
25
04:12 Dec 12, 2019
H19
343 
•HR 19 IH
the availability and coordination of information 
1
as described in clauses (iv) through (vi) of para-
2
graph (1)(C). 
3
(B) FINAL GUIDANCE.—Not later than 12 
4
months after issuing draft guidance under sub-
5
paragraph (A), the Secretary shall finalize the 
6
updated guidance to address any such opportu-
7
nities. 
8
(b) REPORT ON CODING, COVERAGE, AND PAYMENT 
9
PROCESSES UNDER MEDICARE
FOR NOVEL MEDICAL 
10
PRODUCTS.—Not later than 12 months after the date of 
11
the enactment of this Act, the Secretary shall publish a 
12
report on the Internet website of the Department of 
13
Health and Human Services regarding processes under 
14
the Medicare program under title XVIII of the Social Se-
15
curity Act (42 U.S.C. 1395 et seq.) with respect to the 
16
coding, coverage, and payment of novel medical products 
17
described in subsection (c). Such report shall include the 
18
following: 
19
(1) A description of challenges in the coding, 
20
coverage, and payment processes under the Medicare 
21
program for novel medical products. 
22
(2) Recommendations to— 
23
(A) incorporate patient experience data 
24
(such as the impact of a disease or condition on 
25
04:12 Dec 12, 2019
H19
344 
•HR 19 IH
the lives of patients and patient treatment pref-
1
erences) into the coverage and payment proc-
2
esses within the Centers for Medicare & Med-
3
icaid Services; 
4
(B) decrease the length of time to make 
5
national and local coverage determinations 
6
under the Medicare program (as those terms 
7
are defined in subparagraph (A) and (B), re-
8
spectively, of section 1862(l)(6) of the Social 
9
Security Act (42 U.S.C. 1395y(l)(6))); 
10
(C) streamline the coverage process under 
11
the Medicare program and incorporate input 
12
from relevant stakeholders into such coverage 
13
determinations; and 
14
(D) identify potential mechanisms to incor-
15
porate novel payment designs similar to those 
16
in development in commercial insurance plans 
17
and State plans under title XIX of such Act 
18
(42 U.S.C. 1396 et seq.) into the Medicare pro-
19
gram. 
20
(c) NOVEL MEDICAL PRODUCTS DESCRIBED.—For 
21
purposes of this section, a novel medical product described 
22
in this subsection is a medical product, including a drug, 
23
biological (including gene and cell therapy), or medical de-
24
vice, that has been designated as a breakthrough therapy 
25
04:12 Dec 12, 2019
H19
345 
•HR 19 IH
under section 506(a) of the Federal Food, Drug, and Cos-
1
metic Act (21 U.S.C. 356(a)), a breakthrough device 
2
under section 515B of such Act (21 U.S.C. 360e–3), or 
3
a regenerative advanced therapy under section 506(g) of 
4
such Act (21 U.S.C. 356(g)). 
5
SEC. 506. PATIENT CONSULTATION IN MEDICARE NA-
6
TIONAL AND LOCAL COVERAGE DETERMINA-
7
TIONS IN ORDER TO MITIGATE BARRIERS TO 
8
INCLUSION OF SUCH PERSPECTIVES. 
9
Section 1862(l) of the Social Security Act (42 U.S.C. 
10
1395y(l)) is amended by adding at the end the following 
11
new paragraph: 
12
‘‘(7) PATIENT
CONSULTATION
IN
NATIONAL 
13
AND LOCAL COVERAGE DETERMINATIONS.—The Sec-
14
retary may consult with patients and organizations 
15
representing patients in making national and local 
16
coverage determinations.’’. 
17
SEC. 507. MEDPAC REPORT ON SHIFTING COVERAGE OF 
18
CERTAIN MEDICARE PART B DRUGS TO MEDI-
19
CARE PART D. 
20
(a) STUDY.—The Medicare Payment Advisory Com-
21
mission (in this section referred to as the ‘‘Commission’’) 
22
shall conduct a study on shifting coverage of certain drugs 
23
and biologicals for which payment is currently made under 
24
part B of title XVIII of the Social Security Act (42 U.S.C. 
25
04:12 Dec 12, 2019
H19
346 
•HR 19 IH
1395j et seq.) to part D of such title (42 U.S.C. 1395w– 
1
21 et seq.). Such study shall include an analysis of— 
2
(1) differences in program structures and pay-
3
ment methods for drugs and biologicals covered 
4
under such parts B and D, including effects of such 
5
a shift on program spending, beneficiary cost-shar-
6
ing liability, and utilization management techniques 
7
for such drugs and biologicals; and 
8
(2) the feasibility and policy implications of 
9
shifting coverage of drugs and biologicals for which 
10
payment is currently made under such part B to 
11
such part D. 
12
(b) REPORT.— 
13
(1) IN
GENERAL.—Not later than June 30, 
14
2021, the Commission shall submit to Congress a re-
15
port containing the results of the study conducted 
16
under subsection (a). 
17
(2) CONTENTS.—The report under paragraph 
18
(1) shall include information, and recommendations 
19
as the Commission deems appropriate, regarding— 
20
(A) formulary design under such part D; 
21
(B) the ability of the benefit structure 
22
under such part D to control total spending on 
23
drugs and biologicals for which payment is cur-
24
rently made under such part B; 
25
04:12 Dec 12, 2019
H19
347 
•HR 19 IH
(C) changes to the bid process under such 
1
part D, if any, that may be necessary to inte-
2
grate coverage of such drugs and biologicals 
3
into such part D; 
4
(D) any other changes to the program that 
5
Congress should consider in determining wheth-
6
er to shift coverage of such drugs and 
7
biologicals from such part B to such part D; 
8
and 
9
(E) the feasibility and policy implications 
10
of creating a methodology to preserve the 
11
healthcare provider’s ability to take title of the 
12
drug, including a methodology under which— 
13
(i) prescription drug plans negotiate 
14
reimbursement rates and other arrange-
15
ments with drug manufacturers on behalf 
16
of a wholesaler; 
17
(ii) wholesalers purchase the drugs 
18
from the manufacturers at the negotiated 
19
rate and ship them through distributors to 
20
physicians to administer to patients; 
21
(iii) physicians and hospitals purchase 
22
the drug from the wholesaler via the dis-
23
tributor; 
24
04:12 Dec 12, 2019
H19
348 
•HR 19 IH
(iv) after administering the drug, the 
1
physician submits a claim to the MAC for 
2
their drug administration fee; 
3
(v) to be reimbursed for the purchase 
4
of the drug from the distributor, the physi-
5
cian furnishes the claim for the drug itself 
6
to the wholesaler and the wholesaler would 
7
refund the cost of the drug to the physi-
8
cian; and 
9
(vi) the wholesaler passes this claim to 
10
the PDP to receive reimbursement. 
11
SEC. 508. REQUIREMENT THAT DIRECT-TO-CONSUMER AD-
12
VERTISEMENTS FOR PRESCRIPTION DRUGS 
13
AND 
BIOLOGICAL 
PRODUCTS 
INCLUDE 
14
TRUTHFUL AND NON-MISLEADING PRICING 
15
INFORMATION. 
16
Part A of title XI of the Social Security Act is 
17
amended by adding at the end the following new section: 
18
‘‘SEC. 1150C. REQUIREMENT THAT DIRECT-TO-CONSUMER 
19
ADVERTISEMENTS 
FOR 
PRESCRIPTION 
20
DRUGS 
AND 
BIOLOGICAL 
PRODUCTS 
IN-
21
CLUDE 
TRUTHFUL 
AND 
NON-MISLEADING 
22
PRICING INFORMATION. 
23
‘‘(a) IN GENERAL.—The Secretary shall require that 
24
each direct-to-consumer advertisement for a prescription 
25
04:12 Dec 12, 2019
H19
349 
•HR 19 IH
drug or biological product for which payment is available 
1
under title XVIII or XIX includes an appropriate disclo-
2
sure of truthful and non-misleading pricing information 
3
with respect to the drug or product. 
4
‘‘(b) DETERMINATION BY CMS.—The Secretary, act-
5
ing through the Administrator of the Centers for Medicare 
6
& Medicaid Services, shall determine the components of 
7
the requirement under subsection (a), such as the forms 
8
of advertising, the manner of disclosure, the price point 
9
listing, and the price information for disclosure.’’. 
10
SEC. 509. CHIEF PHARMACEUTICAL NEGOTIATOR AT THE 
11
OFFICE OF THE UNITED STATES TRADE REP-
12
RESENTATIVE. 
13
(a) IN GENERAL.—Section 141 of the Trade Act of 
14
1974 (19 U.S.C. 2171) is amended— 
15
(1) in subsection (b)(2)— 
16
(A) by striking ‘‘and one Chief Innovation 
17
and Intellectual Property Negotiator’’ and in-
18
serting ‘‘one Chief Innovation and Intellectual 
19
Property Negotiator, and one Chief Pharma-
20
ceutical Negotiator’’; 
21
(B) by striking ‘‘or the Chief Innovation 
22
and Intellectual Property Negotiator’’ and in-
23
serting ‘‘the Chief Innovation and Intellectual 
24
04:12 Dec 12, 2019
H19
350 
•HR 19 IH
Property Negotiator, or the Chief Pharma-
1
ceutical Negotiator’’; and 
2
(C) by striking ‘‘and the Chief Innovation 
3
and Intellectual Property Negotiator’’ and in-
4
serting ‘‘the Chief Innovation and Intellectual 
5
Property Negotiator, and the Chief Pharma-
6
ceutical Negotiator’’; and 
7
(2) in subsection (c), by adding at the end the 
8
following new paragraph: 
9
‘‘(7) The principal function of the Chief Phar-
10
maceutical Negotiator shall be to conduct trade ne-
11
gotiations and to enforce trade agreements relating 
12
to United States pharmaceutical products and serv-
13
ices. The Chief Pharmaceutical Negotiator shall be 
14
a vigorous advocate on behalf of United States phar-
15
maceutical interests. The Chief Pharmaceutical Ne-
16
gotiator shall perform such other functions as the 
17
United States Trade Representative may direct.’’. 
18
(b) COMPENSATION.—Section 5314 of title 5, United 
19
States Code, is amended by striking ‘‘Chief Innovation 
20
and Intellectual Property Negotiator, Office of the United 
21
States Trade Representative.’’ and inserting the following: 
22
‘‘Chief Innovation and Intellectual Property Ne-
23
gotiator, Office of the United States Trade Rep-
24
resentative. 
25
04:12 Dec 12, 2019
H19
351 
•HR 19 IH
‘‘Chief Pharmaceutical Negotiator, Office of the 
1
United States Trade Representative.’’. 
2
(c) REPORT REQUIRED.—Not later than the date 
3
that is one year after the appointment of the first Chief 
4
Pharmaceutical Negotiator pursuant to paragraph (2) of 
5
section 141(b) of the Trade Act of 1974, as amended by 
6
subsection (a), and annually thereafter, the United States 
7
Trade Representative shall submit to the Committee on 
8
Finance of the Senate and the Committee on Ways and 
9
Means of the House of Representatives a report describing 
10
in detail— 
11
(1) enforcement actions taken by the United 
12
States Trade Representative during the one-year pe-
13
riod preceding the submission of the report to en-
14
sure the protection of United States pharmaceutical 
15
products and services; and 
16
(2) other actions taken by the United States 
17
Trade Representative to advance United States 
18
pharmaceutical products and services. 
19
SEC. 
510. 
WAIVING 
MEDICARE 
COINSURANCE 
FOR 
20
COLORECTAL CANCER SCREENING TESTS. 
21
Section 1833(a) of the Social Security Act (42 U.S.C. 
22
1395l(a)) is amended— 
23
(1) by moving the flush text following para-
24
graph (9) 2 ems to the left; and 
25
04:12 Dec 12, 2019
H19
352 
•HR 19 IH
(2) by adding at the end of such flush text the 
1
following new sentence: ‘‘For items and services fur-
2
nished on or after January 1, 2021, paragraph 
3
(1)(Y) shall apply with respect to a colorectal cancer 
4
screening test regardless of the code that is billed 
5
for the establishment of a diagnosis as a result of 
6
the test, or for the removal of tissue or other matter 
7
or other procedure that is furnished in connection 
8
with, as a result of, and in the same clinical encoun-
9
ter as the screening test.’’. 
10
Æ 
04:12 Dec 12, 2019
H19
